{"c6ce214454ba61aecdede0c5c9f721dd8425375e": [["Abstract: (max 250 words) 26Influenza is a major global public health threat as a result of its highly pathogenic variants, large 27 zoonotic reservoir, and pandemic potential.", [["26Influenza", "CHEMICAL", 26, 37], ["pandemic", "DISEASE", 157, 165], ["large", "OBSERVATION_MODIFIER", 124, 129]]], ["Metagenomic viral sequencing offers the potential of 28 a diagnostic test for influenza which also provides insights on transmission, evolution and drug 29 resistance, and simultaneously detects other viruses.", [["influenza", "DISEASE", 78, 87], ["Metagenomic viral sequencing", "TEST", 0, 28], ["a diagnostic test", "TEST", 56, 73], ["influenza", "PROBLEM", 78, 87], ["viruses", "OBSERVATION", 201, 208]]], ["We therefore set out to apply Oxford 30 Nanopore Technology to metagenomic sequencing of respiratory samples.", [["respiratory samples", "ANATOMY", 89, 108], ["respiratory samples", "TEST", 89, 108], ["respiratory", "ANATOMY", 89, 100]]], ["We generated 31 influenza reads down to a limit of detection of 10 2 -10 3 genome copies/ml in pooled samples, 32 observing a strong relationship between the viral titre and the proportion of influenza reads (p = 33 4.7x10 -5 ).", [["samples", "ANATOMY", 102, 109], ["influenza", "DISEASE", 192, 201], ["influenza reads", "TEST", 16, 31], ["pooled samples", "TEST", 95, 109], ["the viral titre", "TEST", 154, 169], ["influenza reads", "TEST", 192, 207], ["viral titre", "OBSERVATION", 158, 169]]], ["Applying our methods to clinical throat swabs, we generated influenza reads for 27/27 34 samples with high-to-mid viral titres (Cycle threshold (Ct) values <30) and 6/13 samples with low 35 viral titres (Ct values 30-40).", [["throat swabs", "ANATOMY", 33, 45], ["samples", "ANATOMY", 89, 96], ["samples", "ANATOMY", 170, 177], ["samples", "CANCER", 170, 177], ["clinical throat swabs", "TEST", 24, 45], ["influenza reads", "TEST", 60, 75], ["mid viral titres", "TEST", 110, 126], ["Cycle threshold", "TEST", 128, 143], ["Ct) values", "TEST", 145, 155], ["samples", "TEST", 170, 177], ["viral titres", "TEST", 190, 202], ["Ct values", "TEST", 204, 213]]], ["No false positive reads were generated from 10 influenza-negative 36 samples.", [["samples", "ANATOMY", 69, 76], ["false positive reads", "PROBLEM", 3, 23], ["influenza", "TEST", 47, 56], ["false", "OBSERVATION", 3, 8], ["positive reads", "OBSERVATION", 9, 23]]], ["Thus Nanopore sequencing operated with 83% sensitivity (95% CI 67-93%) and 100% 37 specificity (95% CI 69-100%) compared to the current diagnostic standard.", [["CI", "TEST", 60, 62], ["specificity", "TEST", 83, 94], ["CI", "TEST", 100, 102]]], ["Coverage of full 38 length virus was dependent on sample composition, being negatively influenced by increased 39 host and bacterial reads.", [["sample", "ANATOMY", 50, 56], ["full 38 length virus", "TREATMENT", 12, 32], ["sample composition", "TEST", 50, 68], ["bacterial reads", "TEST", 123, 138], ["38 length", "OBSERVATION_MODIFIER", 17, 26]]], ["However, at high influenza titres, we were able to reconstruct >99% 40 complete sequence for all eight gene segments.", [["high influenza titres", "PROBLEM", 12, 33]]], ["We also detected Human Coronavirus and 41 generated a near complete Human Metapneumovirus genome from clinical samples.", [["samples", "ANATOMY", 111, 118], ["Human", "ORGANISM", 17, 22], ["Human", "ORGANISM", 68, 73], ["samples", "CANCER", 111, 118], ["Human Metapneumovirus genome", "DNA", 68, 96], ["Human", "SPECIES", 17, 22], ["Human", "SPECIES", 68, 73], ["Human Coronavirus", "SPECIES", 17, 34], ["Human Metapneumovirus", "SPECIES", 68, 89], ["Human Coronavirus", "PROBLEM", 17, 34], ["a near complete Human Metapneumovirus genome", "PROBLEM", 52, 96], ["clinical samples", "TEST", 102, 118], ["Metapneumovirus genome", "OBSERVATION", 74, 96]]], ["While 42 further optimisation is required to improve sensitivity, this approach shows promise for the 43 Introduction 47 Influenza A is an RNA Orthomyxovirus of approximately 13Kb length, with an eight-segment 48 genome.", [["eight-segment 48 genome", "DNA", 196, 219], ["Influenza", "PROBLEM", 121, 130], ["an RNA Orthomyxovirus", "TEST", 136, 157], ["segment", "ANATOMY_MODIFIER", 202, 209], ["48 genome", "OBSERVATION", 210, 219]]], ["It is typically classified on the basis of Haemagglutinin (HA) and Neuraminidase (NA), 49 of which there are 16 and 9 main variants respectively [1] .", [["Haemagglutinin", "CHEMICAL", 43, 57], ["Haemagglutinin", "GENE_OR_GENE_PRODUCT", 43, 57], ["HA", "GENE_OR_GENE_PRODUCT", 59, 61], ["Neuraminidase", "GENE_OR_GENE_PRODUCT", 67, 80], ["Haemagglutinin", "PROTEIN", 43, 57], ["Neuraminidase", "PROTEIN", 67, 80], ["Haemagglutinin (HA", "TREATMENT", 43, 61], ["Neuraminidase (NA)", "TEST", 67, 85]]], ["Genetic reassortment underpins the 50 potential for transmission between different host species [2] , and for the evolution of highly 51 pathogenic variants [3] [4] [5] [6] , recognised in the WHO list of 'ten threats to global health' [7] .", [["Genetic reassortment", "TREATMENT", 0, 20], ["transmission between different host species", "PROBLEM", 52, 95], ["highly 51 pathogenic variants", "PROBLEM", 127, 156]]], ["52Abstract: (max 250 words) 26Seasonal influenza causes an estimated 650,000 deaths globally each year, and H3N2 alone 53 kills 35,000 each year in the USA [1, 8] .", [["influenza", "DISEASE", 39, 48], ["deaths", "DISEASE", 77, 83], ["influenza", "PROBLEM", 39, 48], ["H3N2", "PROBLEM", 108, 112]]], ["Certain groups are particularly at risk, including older 54 adults, infants and young children, pregnant women, those with underlying lung disease, and 55 the immunocompromised [9] .", [["lung", "ANATOMY", 134, 138], ["lung disease", "DISEASE", 134, 146], ["infants", "ORGANISM", 68, 75], ["children", "ORGANISM", 86, 94], ["women", "ORGANISM", 105, 110], ["lung", "ORGAN", 134, 138], ["infants", "SPECIES", 68, 75], ["children", "SPECIES", 86, 94], ["women", "SPECIES", 105, 110], ["underlying lung disease", "PROBLEM", 123, 146], ["lung", "ANATOMY", 134, 138], ["disease", "OBSERVATION", 139, 146]]], ["The burden of disease disproportionately affects low/middle 56 income settings [10] .", [["disease", "PROBLEM", 14, 21], ["burden", "OBSERVATION_MODIFIER", 4, 10], ["disease", "OBSERVATION", 14, 21], ["middle", "ANATOMY_MODIFIER", 53, 59]]], ["Influenza diagnostics and surveillance are fundamental to identify the 57 emergence of novel strains, to improve prediction of potential epidemics and pandemics [4, 11] , 58 and to inform vaccine strategy [12] .", [["Influenza diagnostics", "TEST", 0, 21], ["surveillance", "TEST", 26, 38], ["novel strains", "PROBLEM", 87, 100], ["potential epidemics", "PROBLEM", 127, 146], ["pandemics", "PROBLEM", 151, 160]]], ["Diagnostic data facilitate real-time surveillance, can 59 underpin infection control interventions [13, 14] and inform the prescription of Neuraminidase 60 Inhibitors (NAI) [9] .", [["infection", "DISEASE", 67, 76], ["Neuraminidase 60 Inhibitors", "CHEMICAL", 139, 166], ["Neuraminidase 60 Inhibitors", "SIMPLE_CHEMICAL", 139, 166], ["Diagnostic data", "TEST", 0, 15], ["infection control interventions", "TREATMENT", 67, 98], ["Neuraminidase 60 Inhibitors", "TREATMENT", 139, 166]]], ["61 62 Currently, most clinical diagnostic tests for influenza depend on detecting viral antigen, or PCR 63 amplification of viral nucleic acid derived from respiratory samples [15] .", [["respiratory samples", "ANATOMY", 156, 175], ["influenza", "DISEASE", 52, 61], ["nucleic acid", "CHEMICAL", 130, 142], ["viral antigen", "PROTEIN", 82, 95], ["clinical diagnostic tests", "TEST", 22, 47], ["influenza", "PROBLEM", 52, 61], ["viral antigen", "TEST", 82, 95], ["PCR", "TEST", 100, 103], ["viral nucleic acid", "TEST", 124, 142], ["respiratory samples", "TEST", 156, 175]]], ["These two approaches 64 offer trade-offs in benefits: antigen tests (including point-of-care tests (POCT)) are typically rapid 65 but low sensitivity [16-18], while PCR is more time-consuming but more sensitive [9] .", [["antigen tests", "TEST", 54, 67], ["low sensitivity", "PROBLEM", 134, 149], ["PCR", "TEST", 165, 168]]], ["66Abstract: (max 250 words) 26Irrespective of test used, most clinical diagnostic facilities report a non-quantitative (binary) 67 diagnostic result, and the data generated for influenza have limited capacity to inform insights 68 into epidemiological linkage, vaccine efficacy or anti-viral susceptibility.", [["influenza", "DISEASE", 177, 186], ["the data", "TEST", 154, 162], ["influenza", "PROBLEM", 177, 186], ["limited capacity", "PROBLEM", 192, 208], ["anti-viral susceptibility", "PROBLEM", 281, 306], ["anti-viral susceptibility", "OBSERVATION", 281, 306]]], ["Given We therefore aimed to optimise a metagenomic protocol for detecting influenza viruses directly 84 from clinical samples using Nanopore sequencing.", [["samples", "ANATOMY", 118, 125], ["influenza viruses", "DISEASE", 74, 91], ["samples", "CANCER", 118, 125], ["a metagenomic protocol", "TREATMENT", 37, 59], ["influenza viruses", "PROBLEM", 74, 91], ["Nanopore sequencing", "TREATMENT", 132, 151]]], ["We determine its sensitivity compared to 85 existing diagnostic methods and its accuracy compared to short-read (Illumina) sequencing, 86 using clinical samples from hospital patients during an influenza season, and samples from a 87 laboratory controlled infection in ferrets.", [["samples", "ANATOMY", 216, 223], ["infection", "DISEASE", 256, 265], ["patients", "ORGANISM", 175, 183], ["ferrets", "ORGANISM", 269, 276], ["patients", "SPECIES", 175, 183], ["ferrets", "SPECIES", 269, 276], ["ferrets", "SPECIES", 269, 276], ["diagnostic methods", "TEST", 53, 71], ["its accuracy", "TEST", 76, 88], ["an influenza season", "PROBLEM", 191, 210], ["a 87 laboratory controlled infection in ferrets", "PROBLEM", 229, 276], ["infection", "OBSERVATION", 256, 265]]], ["88Method optimisation to increase proportion of viral reads derived from throat swabs 90We first sequenced five influenza A positive and five influenza-negative throat swabs, each 91 spiked with Hazara virus control at 10 4 genome copies/ml.", [["throat swabs", "ANATOMY", 161, 173], ["throat", "ORGANISM", 161, 167], ["Hazara virus", "SPECIES", 195, 207], ["viral reads", "PROBLEM", 48, 59], ["throat swabs", "TEST", 73, 85], ["five influenza A positive", "PROBLEM", 107, 132], ["five influenza", "TEST", 137, 151], ["throat swabs", "TEST", 161, 173], ["Hazara virus control", "TREATMENT", 195, 215]]], ["Using the SISPA approach [21] 92 followed by Nanopore sequencing, we produced metagenomic data dominated by reads that 93 were bacterial in origin, with extremely few viral reads detected.", [["the SISPA approach", "TREATMENT", 6, 24], ["Nanopore sequencing", "TEST", 45, 64], ["metagenomic data", "TEST", 78, 94], ["bacterial in origin", "PROBLEM", 127, 146], ["extremely few viral reads", "PROBLEM", 153, 178], ["few", "OBSERVATION_MODIFIER", 163, 166], ["viral reads", "OBSERVATION", 167, 178]]], ["Passing the sample through a 94 0.4 \u00b5m filter prior to nucleic acid extraction increased the detection of viral reads by several 95 orders of magnitude ( Fig S1) .", [["sample", "ANATOMY", 12, 18], ["nucleic acid", "CHEMICAL", 55, 67], ["nucleic acid", "SIMPLE_CHEMICAL", 55, 67], ["a 94 0.4 \u00b5m filter", "TREATMENT", 27, 45], ["nucleic acid extraction", "TREATMENT", 55, 78]]], ["Filtration is relatively expensive, so we also assessed the 96 alternative approach of adding a rapid centrifugation step to pellet bacterial and human cells, 97 followed by nucleic acid extraction from the supernatant.", [["cells", "ANATOMY", 152, 157], ["supernatant", "ANATOMY", 207, 218], ["nucleic acid", "CHEMICAL", 174, 186], ["human", "ORGANISM", 146, 151], ["cells", "CELL", 152, 157], ["nucleic acid", "SIMPLE_CHEMICAL", 174, 186], ["human cells", "CELL_TYPE", 146, 157], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 146, 151], ["a rapid centrifugation step", "TREATMENT", 94, 121], ["pellet bacterial and human cells", "PROBLEM", 125, 157], ["nucleic acid extraction", "TREATMENT", 174, 197]]], ["We used a pooled set of influenza A 98 positive samples (concentration 10 6 genome copies/ml), to provide a large enough sample to 99 assess reproducibility, with the Hazara control spiked in at 10 4 genome copies/ml.", [["samples", "ANATOMY", 48, 55], ["influenza A 98", "SPECIES", 24, 38], ["influenza", "PROBLEM", 24, 33], ["the Hazara control", "TREATMENT", 163, 181]]], ["Enrichment 100 for influenza and Hazara was similar for filtration vs centrifugation, based on reads mapping to 101 the viral genome ( Fig S2) .", [["influenza", "DISEASE", 19, 28], ["viral genome", "DNA", 120, 132], ["Enrichment", "TEST", 0, 10], ["influenza", "PROBLEM", 19, 28], ["Hazara", "PROBLEM", 33, 39], ["filtration vs centrifugation", "TREATMENT", 56, 84], ["reads mapping", "TEST", 95, 108], ["viral genome", "OBSERVATION", 120, 132]]], ["As centrifugation is simpler and cheaper, we selected this approach 102 for all further testing.", [["this approach", "TEST", 54, 67], ["all further testing", "TEST", 76, 95]]], ["103 104 Method optimisation to reduce time for cDNA synthesis 105Method optimisation to increase proportion of viral reads derived from throat swabs 90Synthesis of tagged, randomly primed cDNA and its subsequent amplification via SISPA [21] 106 required lengthy reverse transcription and PCR steps (1h and 3h 45min) respectively.", [["tagged, randomly primed cDNA", "DNA", 164, 192], ["SISPA [21] 106", "DNA", 230, 244], ["Method optimisation", "TREATMENT", 8, 27], ["cDNA synthesis", "TREATMENT", 47, 61], ["Method optimisation", "TREATMENT", 65, 84], ["viral reads", "PROBLEM", 111, 122], ["throat swabs", "TEST", 136, 148]]], ["107Method optimisation to increase proportion of viral reads derived from throat swabs 90Optimising these stages upgraded the reverse transcriptase from SuperScriptIII to 108 SuperScriptIV (ThermoFisher), reduced incubation time to 10min (processing time reduction of 109 50min) and reduced the PCR extension time within each cycle from 5min to 2min (1h 30min 110 processing time reduction).", [["reverse transcriptase", "PROTEIN", 126, 147], ["Method optimisation", "TREATMENT", 3, 22], ["viral reads", "PROBLEM", 49, 60], ["throat swabs", "TEST", 74, 86], ["SuperScriptIII", "TREATMENT", 153, 167], ["viral reads", "OBSERVATION", 49, 60]]], ["Comparing this final method with our original protocol, using 111 triplicate extractions from the pooled set of influenza A positive samples, demonstrated no 112 significant loss in performance in the more rapid protocol ( Fig S3) and we adopted this 113 approach as our routine protocol.", [["samples", "ANATOMY", 133, 140], ["111 triplicate extractions", "TREATMENT", 62, 88], ["influenza A positive samples", "PROBLEM", 112, 140], ["112 significant loss in performance", "PROBLEM", 158, 193], ["our routine protocol", "TREATMENT", 267, 287], ["significant", "OBSERVATION_MODIFIER", 162, 173], ["loss", "OBSERVATION", 174, 178]]], ["114 115Consistent retrieval of Hazara virus by Nanopore sequencing 116Starting with an influenza A positive sample pool (10 6 genome copies/ml), we made three 117 volumetric dilution series using three independent influenza-negative pools (Fig 1) .", [["sample", "ANATOMY", 108, 114], ["Hazara virus", "ORGANISM", 31, 43], ["Hazara virus", "SPECIES", 31, 43], ["Hazara virus", "PROBLEM", 31, 43], ["Nanopore sequencing", "TEST", 47, 66], ["an influenza A positive sample pool", "PROBLEM", 84, 119]]], ["The total 118 quantity of cDNA after preparation for sequencing was consistently higher in all samples using 119 negative pool-3 as diluent (Fig 2A) , indicating the presence of a higher concentration of non-120 viral RNA within pool-3.", [["samples", "ANATOMY", 95, 102], ["cDNA", "DNA", 26, 30], ["non-120 viral RNA", "RNA", 204, 221], ["sequencing", "TEST", 53, 63], ["viral RNA", "OBSERVATION", 212, 221]]], ["This is likely due to host cell lysis or higher bacterial presence, and 121 demonstrates the variable nature of throat swab samples.", [["cell", "ANATOMY", 27, 31], ["throat swab samples", "ANATOMY", 112, 131], ["cell", "CELL", 27, 31], ["throat swab samples", "ORGANISM_SUBSTANCE", 112, 131], ["host cell lysis", "TREATMENT", 22, 37], ["higher bacterial presence", "PROBLEM", 41, 66], ["throat swab samples", "TEST", 112, 131], ["likely due to", "UNCERTAINTY", 8, 21], ["host cell lysis", "OBSERVATION", 22, 37]]], ["122123We consistently retrieved Hazara virus reads from all three dilution series by Nanopore 124 sequencing, independently of influenza virus titre in the sample (Fig 2B) .", [["sample", "ANATOMY", 156, 162], ["Nanopore 124", "CHEMICAL", 85, 97], ["influenza virus", "ORGANISM", 127, 142], ["Hazara virus", "SPECIES", 32, 44], ["influenza virus", "SPECIES", 127, 142], ["influenza virus titre", "PROBLEM", 127, 148]]], ["Sequencing from 125 dilution series 1 and 2 gave a consistent proportion of total reads mapping to the Hazara 126 genome, across dilutions and between the first two pools with mean values per pool of 1.4x10 3 127 \u00b1660 RPM (reads per million (of total reads) \u00b1 standard deviation) and 1.2x10 3 \u00b1350 RPM 128 respectively.", [["Hazara 126 genome", "DNA", 103, 120], ["Sequencing from 125 dilution series", "TEST", 0, 35], ["mean values", "TEST", 176, 187]]], ["The pool-3 dilution series generated 260 \u00b1340 RPM Hazara reads across samples, 129 and showed a decreasing trend associated with increased dilution factor, as increasingly more 130 non-viral RNA was introduced from this high-background pool.", [["samples", "ANATOMY", 70, 77], ["130 non-viral RNA", "RNA", 177, 194], ["a decreasing trend", "PROBLEM", 94, 112], ["increased dilution factor", "PROBLEM", 129, 154], ["decreasing", "OBSERVATION_MODIFIER", 96, 106]]], ["131 132 Limit of influenza virus detection by Nanopore from pooled samples 133 Nanopore sequencing of the triplicate SISPA preparations of the influenza A positive pool 134 produced mean 5.3x10 4 \u00b13.6x10 4 RPM mapping to the influenza A genome (Fig 2B) .", [["influenza A genome", "DNA", 225, 243], ["influenza virus detection", "PROBLEM", 17, 42], ["pooled samples", "TEST", 60, 74], ["Nanopore sequencing", "TEST", 79, 98], ["the triplicate SISPA preparations", "TREATMENT", 102, 135], ["the influenza", "TEST", 139, 152], ["mean", "TEST", 182, 186], ["RPM mapping", "TEST", 206, 217]]], ["Across the 135 dilution series, the proportion of influenza reads was strongly associated with influenza virus 136 titre (p-value = 4.7x10 -5 ), but was also influenced by which negative pool was used for dilution, 137 consistent with the pattern observed for the Hazara control.", [["influenza", "DISEASE", 50, 59], ["influenza virus 136", "ORGANISM", 95, 114], ["influenza virus", "SPECIES", 95, 110], ["influenza virus", "SPECIES", 95, 110], ["Across the 135 dilution series", "TEST", 0, 30], ["influenza reads", "PROBLEM", 50, 65], ["influenza virus", "PROBLEM", 95, 110], ["p-value", "TEST", 122, 129], ["dilution", "TEST", 205, 213], ["the Hazara control", "TREATMENT", 260, 278]]], ["Sequencing the negative controls 138 (pools with no influenza virus spike) generated no reads mapping to influenza.", [["influenza", "DISEASE", 105, 114], ["Sequencing the negative controls", "TEST", 0, 32], ["influenza virus spike", "PROBLEM", 52, 73], ["influenza", "PROBLEM", 105, 114]]], ["At influenza virus 139 titres <10 3 copies/ml, influenza reads were inconsistently detected across the samples (Fig 2B) , 140 suggesting the limit of detection is between 10 2 -10 3 influenza copies/ml.", [["samples", "ANATOMY", 103, 110], ["influenza virus", "ORGANISM", 3, 18], ["influenza virus", "SPECIES", 3, 18], ["influenza virus", "TEST", 3, 18], ["influenza reads", "TEST", 47, 62]]], ["141 142Retrieval and reconstruction of complete influenza genomes from pooled/spiked samples 143For the Hazara virus control (10 4 genome copies/ml spike), genome coverage was 81.4-99.4% 144 (at 1x depth) for pools 1 and 2.", [["samples", "ANATOMY", 85, 92], ["influenza genomes", "DNA", 48, 65], ["Hazara virus", "SPECIES", 104, 116], ["Retrieval", "TREATMENT", 7, 16], ["reconstruction", "TREATMENT", 21, 35], ["complete influenza genomes", "PROBLEM", 39, 65], ["pooled/spiked samples", "TEST", 71, 92], ["the Hazara virus control", "TREATMENT", 100, 124], ["genome coverage", "TEST", 156, 171], ["influenza genomes", "OBSERVATION", 48, 65]]], ["Coverage in the high-background pool 3 was more variable 145 (21.5-96.5%; Fig 3A) .", [["Coverage", "TEST", 0, 8]]], ["Influenza A genome coverage at 10 6 copies/ml was \u226599.3% for each 146 segment in all samples (Fig 3A) .", [["samples", "ANATOMY", 85, 92], ["Influenza A", "SPECIES", 0, 11], ["Influenza A genome coverage", "TREATMENT", 0, 27]]], ["At 10 4 genome copies/ml of influenza, mean 1x coverage per 147 segment was 90.3% for pools 1 and 2, but was substantially reduced in the high-background 148 pool 3 to 5.7% (Fig 3A) .", [["influenza", "DISEASE", 28, 37], ["influenza", "PROBLEM", 28, 37], ["mean", "TEST", 39, 43], ["pools", "TEST", 86, 91], ["reduced", "OBSERVATION_MODIFIER", 123, 130]]], ["At influenza titres <10 4 copies/ ml, coverage was highly variable across 149 genome segments.", [["149 genome segments", "DNA", 74, 93], ["influenza titres", "TEST", 3, 19], ["coverage", "TREATMENT", 38, 46]]], ["However, when present at 10 3 copies/ml, 2/3 pools had sufficient data for 150 correct subtyping as H3N2 (Table 1) total reads generated was 1.0x10 5 to 2.4x10 6 (median 3.8x10 5 ) (Table S1) .", [["H3N2", "PROBLEM", 100, 104], ["total reads", "TEST", 115, 126]]], ["GeneXpert-negative samples (Table S1 ).", [["samples", "ANATOMY", 19, 26], ["GeneXpert", "TEST", 0, 9]]], ["Based on this small dataset, sensitivity is 83% and 167 specificity 100% (95% CI 67-93% and 69-100%, respectively).", [["sensitivity", "TEST", 29, 40], ["specificity", "TEST", 56, 67], ["CI", "TEST", 78, 80]]], ["There was a strong correlation 168 between Ct value and both reads per sample classified as influenza (R-squared =0.604) and 169 number of influenza reads per million reads (R-squared =0.623) (Fig 4) .", [["influenza", "DISEASE", 92, 101], ["Ct value", "TEST", 43, 51], ["influenza", "TEST", 92, 101]]], ["170 171Detection of Hazara virus internal control 172Detection of the control virus (Hazara at 10 4 genome copies/ml) was highly variable, 173 demonstrating that levels of background non-target RNA are a major source of inter-sample 174 variation.", [["Hazara virus", "ORGANISM", 20, 32], ["non-target RNA", "RNA", 183, 197], ["Hazara virus", "SPECIES", 20, 32], ["Hazara virus internal control", "TREATMENT", 20, 49], ["the control virus (Hazara", "TREATMENT", 66, 91], ["background non-target RNA", "PROBLEM", 172, 197]]], ["Hazara reads per sample ranged from 0 to 13.5x10 3 (0-3.5x10 4 RPM) with a median 175 of 70 (160 RPM) and mean of 706 (1.7x10 3 RPM) (Table S1) to simplify and accelerate the protocol if it is to become viable as a near-to-patient test.", [["patient", "ORGANISM", 223, 230], ["patient", "SPECIES", 223, 230], ["mean", "TEST", 106, 110], ["the protocol", "TREATMENT", 171, 183], ["patient test", "TEST", 223, 235]]], ["High 230 error rates are a recognised concern in Nanopore sequence data, and cross-barcode 231 contamination can create challenges when low and high titre samples are batched together [22] .", [["samples", "ANATOMY", 155, 162], ["Nanopore sequence data", "TEST", 49, 71], ["cross-barcode", "TREATMENT", 77, 90], ["high titre samples", "TREATMENT", 144, 162]]], ["232Detection of Hazara virus internal control 172To avoid these problems, we batched samples according to Ct value, and applied stringent 233 barcode demultiplexing criteria; however, this reduces the total data available for analysis [22] . in the clinical diagnostic laboratory to provide a large enough sample to assess 309 reproducibility ( Fig 1B) ; 310Detection of Hazara virus internal control 172\u2022 Negative pools: we generated three pools of throat swab samples that had tested", [["samples", "ANATOMY", 85, 92], ["throat swab samples", "ANATOMY", 450, 469], ["Hazara virus", "ORGANISM", 16, 28], ["Hazara virus", "SPECIES", 16, 28], ["Hazara virus", "SPECIES", 371, 383], ["Hazara virus internal control", "TREATMENT", 16, 45], ["these problems", "PROBLEM", 58, 72], ["Ct value", "TEST", 106, 114], ["analysis", "TEST", 226, 234], ["reproducibility", "TEST", 327, 342], ["Hazara virus internal control", "TREATMENT", 371, 400], ["throat swab samples", "TEST", 450, 469]]]], "PMC7122443": [["IntroductionAging is accompanied by profound morphological and physiological alterations.", [["profound morphological and physiological alterations", "PROBLEM", 36, 88], ["profound", "OBSERVATION_MODIFIER", 36, 44], ["physiological alterations", "OBSERVATION", 63, 88]]], ["In particular, the immune system undergoes a complex series of remodeling/restructuring events, involving almost all compartments, both cell-mediated immunity and humoral immune responses.IntroductionThis process termed immunosenescence or immune dysregulation, together changes in lung function who occur with advancing age, play a critical role in the manifestation of age-related pulmonary diseases such as infections (i.e., pneumonia), chronic obstructive pulmonary disease (COPD), and increased the risk for develop sepsis [1].IntroductionRespiratory failure is not a disease per se but a consequence of the problems that interfere with the ability to breathe.", [["immune system", "ANATOMY", 19, 32], ["compartments", "ANATOMY", 117, 129], ["cell", "ANATOMY", 136, 140], ["lung", "ANATOMY", 282, 286], ["pulmonary", "ANATOMY", 383, 392], ["pulmonary", "ANATOMY", 460, 469], ["pulmonary diseases", "DISEASE", 383, 401], ["infections", "DISEASE", 410, 420], ["pneumonia", "DISEASE", 428, 437], ["chronic obstructive pulmonary disease", "DISEASE", 440, 477], ["COPD", "DISEASE", 479, 483], ["sepsis", "DISEASE", 521, 527], ["IntroductionRespiratory failure", "DISEASE", 532, 563], ["cell", "CELL", 136, 140], ["lung", "ORGAN", 282, 286], ["pulmonary", "ORGAN", 383, 392], ["pulmonary", "ORGAN", 460, 469], ["remodeling/restructuring events", "PROBLEM", 63, 94], ["immune dysregulation", "PROBLEM", 240, 260], ["changes in lung function", "PROBLEM", 271, 295], ["pulmonary diseases", "PROBLEM", 383, 401], ["infections", "PROBLEM", 410, 420], ["pneumonia", "PROBLEM", 428, 437], ["chronic obstructive pulmonary disease", "PROBLEM", 440, 477], ["COPD", "PROBLEM", 479, 483], ["sepsis", "PROBLEM", 521, 527], ["IntroductionRespiratory failure", "PROBLEM", 532, 563], ["a disease", "PROBLEM", 571, 580], ["the problems", "PROBLEM", 609, 621], ["immune dysregulation", "OBSERVATION", 240, 260], ["lung", "ANATOMY", 282, 286], ["pulmonary", "ANATOMY", 383, 392], ["diseases", "OBSERVATION", 393, 401], ["infections", "OBSERVATION", 410, 420], ["pneumonia", "OBSERVATION", 428, 437], ["chronic", "OBSERVATION_MODIFIER", 440, 447], ["obstructive", "OBSERVATION_MODIFIER", 448, 459], ["pulmonary", "ANATOMY", 460, 469], ["disease", "OBSERVATION", 470, 477], ["COPD", "OBSERVATION", 479, 483], ["sepsis", "OBSERVATION", 521, 527], ["failure", "OBSERVATION", 556, 563]]], ["The term refers to the inability to perform adequately the fundamental functions of respiration: to deliver oxygen to the blood and to eliminate carbon dioxide from it.", [["blood", "ANATOMY", 122, 127], ["oxygen", "CHEMICAL", 108, 114], ["carbon dioxide", "CHEMICAL", 145, 159], ["oxygen", "CHEMICAL", 108, 114], ["carbon dioxide", "CHEMICAL", 145, 159], ["oxygen", "SIMPLE_CHEMICAL", 108, 114], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["carbon dioxide", "SIMPLE_CHEMICAL", 145, 159], ["oxygen", "TREATMENT", 108, 114], ["the blood", "TEST", 118, 127], ["carbon dioxide", "TREATMENT", 145, 159]]], ["Respiratory failure has many causes and can come on abruptly (acute respiratory failure), when the underlying cause progresses rapidly, or slowly (chronic respiratory failure), when it is associated over months or even years with a progressive underlying process.", [["Respiratory", "ANATOMY", 0, 11], ["respiratory", "ANATOMY", 68, 79], ["respiratory", "ANATOMY", 155, 166], ["Respiratory failure", "DISEASE", 0, 19], ["acute respiratory failure", "DISEASE", 62, 87], ["chronic respiratory failure", "DISEASE", 147, 174], ["Respiratory failure", "PROBLEM", 0, 19], ["acute respiratory failure", "PROBLEM", 62, 87], ["chronic respiratory failure", "PROBLEM", 147, 174], ["a progressive underlying process", "PROBLEM", 230, 262], ["failure", "OBSERVATION", 12, 19], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["respiratory failure", "OBSERVATION", 68, 87], ["chronic", "OBSERVATION_MODIFIER", 147, 154], ["respiratory failure", "OBSERVATION", 155, 174], ["progressive", "OBSERVATION_MODIFIER", 232, 243]]], ["Triggering causes of ARF in advanced aged patients are especially acute heart decompensation, severe community-acquired pneumonia (CAP), acute exacerbations of COPD (AECOPD), and pulmonary embolism.", [["heart", "ANATOMY", 72, 77], ["pulmonary", "ANATOMY", 179, 188], ["ARF", "DISEASE", 21, 24], ["heart decompensation", "DISEASE", 72, 92], ["community-acquired pneumonia", "DISEASE", 101, 129], ["CAP", "DISEASE", 131, 134], ["COPD", "DISEASE", 160, 164], ["AECOPD", "DISEASE", 166, 172], ["pulmonary embolism", "DISEASE", 179, 197], ["ARF", "GENE_OR_GENE_PRODUCT", 21, 24], ["patients", "ORGANISM", 42, 50], ["heart", "ORGAN", 72, 77], ["pulmonary", "ORGAN", 179, 188], ["patients", "SPECIES", 42, 50], ["ARF", "PROBLEM", 21, 24], ["acute heart decompensation", "PROBLEM", 66, 92], ["severe community-acquired pneumonia (CAP)", "PROBLEM", 94, 135], ["acute exacerbations", "PROBLEM", 137, 156], ["COPD", "PROBLEM", 160, 164], ["AECOPD", "PROBLEM", 166, 172], ["pulmonary embolism", "PROBLEM", 179, 197], ["ARF", "OBSERVATION", 21, 24], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["heart", "ANATOMY", 72, 77], ["decompensation", "OBSERVATION", 78, 92], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["pneumonia", "OBSERVATION", 120, 129], ["CAP", "OBSERVATION_MODIFIER", 131, 134], ["acute", "OBSERVATION_MODIFIER", 137, 142], ["exacerbations", "OBSERVATION", 143, 156], ["COPD", "OBSERVATION", 160, 164], ["AECOPD", "OBSERVATION", 166, 172], ["pulmonary", "ANATOMY", 179, 188], ["embolism", "OBSERVATION", 189, 197]]], ["Pneumothorax, lung cancer, severe sepsis, and acute asthma were less frequent (<5%) [2].IntroductionAcute respiratory failure is a condition in which the respiratory system fails in one or both of its gas functions, i.e., oxygenation (PaO2<60 mmHg) of and/or elimination of carbon dioxide (arterial carbon dioxide tension (PaCO2) >45 mmHg).", [["lung cancer", "ANATOMY", 14, 25], ["respiratory", "ANATOMY", 106, 117], ["respiratory system", "ANATOMY", 154, 172], ["arterial", "ANATOMY", 290, 298], ["Pneumothorax", "DISEASE", 0, 12], ["lung cancer", "DISEASE", 14, 25], ["sepsis", "DISEASE", 34, 40], ["asthma", "DISEASE", 52, 58], ["respiratory failure", "DISEASE", 106, 125], ["carbon dioxide", "CHEMICAL", 274, 288], ["carbon dioxide", "CHEMICAL", 299, 313], ["carbon dioxide", "CHEMICAL", 274, 288], ["carbon dioxide", "CHEMICAL", 299, 313], ["lung cancer", "CANCER", 14, 25], ["carbon dioxide", "SIMPLE_CHEMICAL", 274, 288], ["arterial", "MULTI-TISSUE_STRUCTURE", 290, 298], ["Pneumothorax", "PROBLEM", 0, 12], ["lung cancer", "PROBLEM", 14, 25], ["severe sepsis", "PROBLEM", 27, 40], ["acute asthma", "PROBLEM", 46, 58], ["Acute respiratory failure", "PROBLEM", 100, 125], ["its gas functions", "TEST", 197, 214], ["oxygenation", "TEST", 222, 233], ["PaO2", "TEST", 235, 239], ["carbon dioxide (arterial carbon dioxide tension", "TREATMENT", 274, 321], ["PaCO2", "TEST", 323, 328], ["lung", "ANATOMY", 14, 18], ["cancer", "OBSERVATION", 19, 25], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["sepsis", "OBSERVATION", 34, 40], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["asthma", "OBSERVATION", 52, 58], ["Acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory failure", "OBSERVATION", 106, 125], ["respiratory system", "ANATOMY", 154, 172]]], ["In practice, it may be classified as either hypoxemic or hypercapnic.", [["hypoxemic", "DISEASE", 44, 53], ["hypoxemic", "PROBLEM", 44, 53], ["hypercapnic", "PROBLEM", 57, 68], ["hypoxemic", "OBSERVATION", 44, 53], ["hypercapnic", "OBSERVATION", 57, 68]]], ["Hypoxemic respiratory failure (type I) is characterized by an arterial oxygen tension (PaO2) lower than 60 mm Hg with a normal or low arterial carbon dioxide tension (PaCO2).", [["respiratory", "ANATOMY", 10, 21], ["arterial", "ANATOMY", 62, 70], ["arterial", "ANATOMY", 134, 142], ["Hypoxemic respiratory failure", "DISEASE", 0, 29], ["oxygen", "CHEMICAL", 71, 77], ["carbon dioxide", "CHEMICAL", 143, 157], ["oxygen", "CHEMICAL", 71, 77], ["Hg", "CHEMICAL", 110, 112], ["carbon dioxide", "CHEMICAL", 143, 157], ["arterial", "MULTI-TISSUE_STRUCTURE", 62, 70], ["oxygen", "SIMPLE_CHEMICAL", 71, 77], ["arterial", "MULTI-TISSUE_STRUCTURE", 134, 142], ["Hypoxemic respiratory failure", "PROBLEM", 0, 29], ["an arterial oxygen tension", "PROBLEM", 59, 85], ["PaO2", "TEST", 87, 91], ["low arterial carbon dioxide tension", "PROBLEM", 130, 165], ["PaCO2", "TEST", 167, 172], ["respiratory failure", "OBSERVATION", 10, 29], ["arterial", "ANATOMY_MODIFIER", 62, 70], ["oxygen tension", "OBSERVATION", 71, 85], ["normal", "OBSERVATION", 120, 126], ["dioxide tension", "OBSERVATION", 150, 165]]], ["This is the most common form of respiratory failure, and it can be associated with virtually all acute diseases of the lung, which generally involve fluid filling or collapse of alveolar units.IntroductionThe four pathophysiological mechanisms related to hypoxemic ARF are [3, 4]:Ventilation/perfusion inequality which is the main mechanisms in an emergency setting (congestive heart failure or pneumonia)Increased shunt (acute respiratory distress syndrome)Alveolar hypoventilation (chronic obstructive pulmonary disease)Diffusion impairment (pulmonary fibrosis)", [["respiratory", "ANATOMY", 32, 43], ["lung", "ANATOMY", 119, 123], ["fluid", "ANATOMY", 149, 154], ["alveolar", "ANATOMY", 178, 186], ["heart", "ANATOMY", 378, 383], ["respiratory", "ANATOMY", 428, 439], ["Alveolar", "ANATOMY", 458, 466], ["pulmonary", "ANATOMY", 504, 513], ["pulmonary", "ANATOMY", 544, 553], ["respiratory failure", "DISEASE", 32, 51], ["ARF", "DISEASE", 265, 268], ["congestive heart failure", "DISEASE", 367, 391], ["pneumonia", "DISEASE", 395, 404], ["acute respiratory distress syndrome", "DISEASE", 422, 457], ["hypoventilation", "DISEASE", 467, 482], ["chronic obstructive pulmonary disease", "DISEASE", 484, 521], ["Diffusion impairment", "DISEASE", 522, 542], ["pulmonary fibrosis", "DISEASE", 544, 562], ["lung", "ORGAN", 119, 123], ["fluid", "ORGANISM_SUBSTANCE", 149, 154], ["alveolar units", "MULTI-TISSUE_STRUCTURE", 178, 192], ["[3, 4", "SIMPLE_CHEMICAL", 273, 278], ["heart", "ORGAN", 378, 383], ["pulmonary", "ORGAN", 504, 513], ["pulmonary", "ORGAN", 544, 553], ["respiratory failure", "PROBLEM", 32, 51], ["virtually all acute diseases of the lung", "PROBLEM", 83, 123], ["fluid filling", "PROBLEM", 149, 162], ["collapse of alveolar units", "PROBLEM", 166, 192], ["hypoxemic ARF", "PROBLEM", 255, 268], ["Ventilation", "TREATMENT", 280, 291], ["perfusion inequality", "PROBLEM", 292, 312], ["congestive heart failure", "PROBLEM", 367, 391], ["pneumonia", "PROBLEM", 395, 404], ["Increased shunt (acute respiratory distress syndrome", "PROBLEM", 405, 457], ["Alveolar hypoventilation", "PROBLEM", 458, 482], ["chronic obstructive pulmonary disease)", "PROBLEM", 484, 522], ["Diffusion impairment (pulmonary fibrosis)", "PROBLEM", 522, 563], ["most common", "OBSERVATION_MODIFIER", 12, 23], ["respiratory failure", "OBSERVATION", 32, 51], ["all", "OBSERVATION_MODIFIER", 93, 96], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["diseases", "OBSERVATION", 103, 111], ["lung", "ANATOMY", 119, 123], ["fluid filling", "OBSERVATION", 149, 162], ["collapse", "OBSERVATION", 166, 174], ["alveolar units", "OBSERVATION", 178, 192], ["hypoxemic", "OBSERVATION_MODIFIER", 255, 264], ["ARF", "OBSERVATION", 265, 268], ["perfusion inequality", "OBSERVATION", 292, 312], ["main", "OBSERVATION_MODIFIER", 326, 330], ["congestive", "OBSERVATION_MODIFIER", 367, 377], ["heart", "ANATOMY", 378, 383], ["failure", "OBSERVATION", 384, 391], ["pneumonia", "OBSERVATION", 395, 404], ["shunt", "OBSERVATION", 415, 420], ["acute", "OBSERVATION_MODIFIER", 422, 427], ["respiratory distress", "OBSERVATION", 428, 448], ["Alveolar hypoventilation", "OBSERVATION", 458, 482], ["chronic", "OBSERVATION_MODIFIER", 484, 491], ["obstructive", "OBSERVATION_MODIFIER", 492, 503], ["pulmonary", "ANATOMY", 504, 513], ["disease", "OBSERVATION", 514, 521], ["pulmonary", "ANATOMY", 544, 553], ["fibrosis", "OBSERVATION", 554, 562]]]], "83c19dc558bd57cea69b6c3913b3dc9fa2f7fa19": [["IntroductionGraphene is the fundamental building element of many carbon allotropes including graphite, charcoals, carbon nanotubes (CNTs) and bucky balls.", [["graphite", "CHEMICAL", 93, 101], ["carbon nanotubes", "CHEMICAL", 114, 130], ["CNTs", "CHEMICAL", 132, 136], ["carbon", "CHEMICAL", 65, 71], ["graphite", "CHEMICAL", 93, 101], ["carbon", "CHEMICAL", 114, 120], ["carbon allotropes", "SIMPLE_CHEMICAL", 65, 82], ["graphite", "SIMPLE_CHEMICAL", 93, 101], ["charcoals", "SIMPLE_CHEMICAL", 103, 112], ["carbon nanotubes", "SIMPLE_CHEMICAL", 114, 130], ["IntroductionGraphene", "TREATMENT", 0, 20], ["many carbon allotropes", "TREATMENT", 60, 82], ["graphite, charcoals", "TREATMENT", 93, 112], ["carbon nanotubes (CNTs", "TREATMENT", 114, 136], ["carbon allotropes", "OBSERVATION", 65, 82], ["carbon nanotubes", "OBSERVATION", 114, 130], ["bucky balls", "OBSERVATION", 142, 153]]], ["Since its discovery in 2004 [1] , graphene has rapidly emerged as a family of highly promising nanomaterials with unique electronic, optical and catalytic properties that can be exploited for numerous applications in energy, environment, and biomedicine.", [["graphene", "CHEMICAL", 34, 42], ["graphene", "CHEMICAL", 34, 42], ["graphene", "SIMPLE_CHEMICAL", 34, 42], ["optical and catalytic properties", "TREATMENT", 133, 165]]], ["In particular, the coupling of graphene with biology brings exciting research focuses.", [["graphene", "CHEMICAL", 31, 39], ["graphene", "CHEMICAL", 31, 39]]], ["Due to their large surface areas, superior physical and chemical properties, graphene-based nanomaterials has emerged as an attractive candidate to act as nanoscale building blocks for biological researches.", [["surface", "ANATOMY", 19, 26], ["graphene", "CHEMICAL", 77, 85], ["graphene", "CHEMICAL", 77, 85], ["graphene", "SIMPLE_CHEMICAL", 77, 85], ["their large surface areas", "PROBLEM", 7, 32], ["large", "OBSERVATION_MODIFIER", 13, 18], ["surface", "OBSERVATION_MODIFIER", 19, 26], ["areas", "OBSERVATION", 27, 32], ["chemical properties", "OBSERVATION", 56, 75]]], ["The strong van der Waals force between graphene nanosheets facilitate incorporating molecules or nanomaterials (e.g., polymer or nanoparticles) to form multifunctional nanocomposites, which is effective to improve their properties and enhance their performance toward biosystems.", [["graphene", "CHEMICAL", 39, 47], ["graphene", "CHEMICAL", 39, 47], ["graphene nanosheets", "SIMPLE_CHEMICAL", 39, 58], ["The strong van der Waals force between graphene nanosheets", "TREATMENT", 0, 58], ["nanomaterials (e.g., polymer or nanoparticles", "TREATMENT", 97, 142], ["multifunctional nanocomposites", "TREATMENT", 152, 182]]], ["In addition, based on their inherent antibacterial properties, graphene can be used as a new effective and green antibacterial agent with a severe cell inactivation toward bacteria.", [["cell", "ANATOMY", 147, 151], ["graphene", "CHEMICAL", 63, 71], ["graphene", "CHEMICAL", 63, 71], ["graphene", "SIMPLE_CHEMICAL", 63, 71], ["cell", "CELL", 147, 151], ["their inherent antibacterial properties", "TREATMENT", 22, 61], ["graphene", "TREATMENT", 63, 71], ["green antibacterial agent", "TREATMENT", 107, 132], ["a severe cell inactivation", "PROBLEM", 138, 164], ["bacteria", "PROBLEM", 172, 180], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["cell inactivation", "OBSERVATION", 147, 164]]], ["Also importantly, graphenebased nanomaterial is renewable and easy to fabricate with low cost and fast preparation techniques, compared to traditional metals and metal oxides.", [["metal oxides", "CHEMICAL", 162, 174], ["metal oxides", "SIMPLE_CHEMICAL", 162, 174], ["low cost and fast preparation techniques", "TREATMENT", 85, 125], ["traditional metals and metal oxides", "TREATMENT", 139, 174], ["metal oxides", "OBSERVATION", 162, 174]]], ["The research ranges from fundamental studies on the interactions between graphene and biomolecules to various graphenebased practical applications including antibacterial materials, cell culture substrates, biosensors and drug delivery carriers.", [["cell", "ANATOMY", 182, 186], ["graphene", "CHEMICAL", 73, 81], ["graphene", "SIMPLE_CHEMICAL", 73, 81], ["cell", "CELL", 182, 186], ["fundamental studies", "TEST", 25, 44], ["graphene", "TREATMENT", 73, 81], ["biomolecules", "TREATMENT", 86, 98], ["various graphenebased practical applications", "TREATMENT", 102, 146], ["antibacterial materials", "TREATMENT", 157, 180], ["cell culture substrates", "TREATMENT", 182, 205], ["biosensors", "TREATMENT", 207, 217], ["drug delivery carriers", "TREATMENT", 222, 244], ["antibacterial materials", "OBSERVATION", 157, 180]]], ["While several excellent reviews have appeared with the focus on some of these topics [2] [3] [4] [5] , there has not been a comprehensive review that summarizes the research progress in graphene-based nanomaterials in biosystems.IntroductionIn this review, we summarize recent advances in the biocompatibility, toxicology and applications of graphene-based nanomaterials in biosystems (Fig. 1) .", [["graphene", "CHEMICAL", 186, 194], ["graphene", "CHEMICAL", 342, 350], ["graphene", "CHEMICAL", 186, 194], ["graphene", "CHEMICAL", 342, 350], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 85, 100], ["graphene", "SIMPLE_CHEMICAL", 186, 194], ["graphene", "SIMPLE_CHEMICAL", 342, 350], ["graphene-based nanomaterials", "TREATMENT", 342, 370]]], ["We first briefly describe the structures, properties and synthesis of graphene, graphene derivatives, and graphene-based composites.", [["graphene", "CHEMICAL", 70, 78], ["graphene", "CHEMICAL", 80, 88], ["graphene", "CHEMICAL", 106, 114], ["graphene", "CHEMICAL", 70, 78], ["graphene", "CHEMICAL", 80, 88], ["graphene", "CHEMICAL", 106, 114], ["graphene", "SIMPLE_CHEMICAL", 70, 78], ["graphene derivatives", "SIMPLE_CHEMICAL", 80, 100], ["graphene", "SIMPLE_CHEMICAL", 106, 114], ["synthesis of graphene, graphene derivatives", "TREATMENT", 57, 100], ["graphene-based composites", "TREATMENT", 106, 131]]], ["Sequentially, we focus on the recent advances in the toxicology and biocompatibility of graphene in biosystems, including the extracellular interactions between graphene and biomacromolecules (e.g., nucleic acids, proteins, and peptides), the way of graphene influences on the biological responses of viruses and cellular metabolism, how graphene enters cells, in vivo toxicological effects of graphene on animals and plants, and toxicological concerns regarding its potential applications.", [["extracellular", "ANATOMY", 126, 139], ["cellular", "ANATOMY", 313, 321], ["cells", "ANATOMY", 354, 359], ["graphene", "CHEMICAL", 88, 96], ["graphene", "CHEMICAL", 161, 169], ["nucleic acids", "CHEMICAL", 199, 212], ["graphene", "CHEMICAL", 338, 346], ["graphene", "CHEMICAL", 394, 402], ["graphene", "CHEMICAL", 88, 96], ["graphene", "CHEMICAL", 161, 169], ["graphene", "CHEMICAL", 250, 258], ["graphene", "CHEMICAL", 338, 346], ["graphene", "CHEMICAL", 394, 402], ["graphene", "SIMPLE_CHEMICAL", 88, 96], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 126, 139], ["graphene", "SIMPLE_CHEMICAL", 161, 169], ["biomacromolecules", "SIMPLE_CHEMICAL", 174, 191], ["nucleic acids", "SIMPLE_CHEMICAL", 199, 212], ["cellular", "CELL", 313, 321], ["cells", "CELL", 354, 359], ["graphene", "SIMPLE_CHEMICAL", 394, 402], ["biocompatibility of graphene in biosystems", "TREATMENT", 68, 110], ["graphene and biomacromolecules", "TREATMENT", 161, 191], ["nucleic acids", "TEST", 199, 212], ["graphene influences", "PROBLEM", 250, 269], ["viruses", "PROBLEM", 301, 308], ["cellular metabolism", "PROBLEM", 313, 332], ["viruses", "OBSERVATION", 301, 308], ["cellular metabolism", "OBSERVATION", 313, 332]]], ["Next, we summarize the recent achievements and advancements in the antibacterial activities of graphene, its derivatives and graphene-based nanocomposites, the mechanisms of graphene-mediated antibacterial properties, and other applications in wound addressing, drug delivery, and water purification.", [["wound", "ANATOMY", 244, 249], ["graphene", "CHEMICAL", 95, 103], ["graphene", "CHEMICAL", 125, 133], ["graphene", "CHEMICAL", 174, 182], ["graphene", "CHEMICAL", 95, 103], ["graphene", "CHEMICAL", 125, 133], ["graphene", "CHEMICAL", 174, 182], ["graphene", "SIMPLE_CHEMICAL", 95, 103], ["graphene", "SIMPLE_CHEMICAL", 125, 133], ["graphene", "SIMPLE_CHEMICAL", 174, 182], ["wound", "PATHOLOGICAL_FORMATION", 244, 249], ["the antibacterial activities of graphene", "TREATMENT", 63, 103], ["its derivatives", "TREATMENT", 105, 120], ["graphene-based nanocomposites", "TREATMENT", 125, 154], ["graphene-mediated antibacterial properties", "TREATMENT", 174, 216], ["other applications", "TREATMENT", 222, 240], ["wound addressing", "TREATMENT", 244, 260], ["drug delivery", "TREATMENT", 262, 275], ["water purification", "TREATMENT", 281, 299], ["antibacterial properties", "OBSERVATION", 192, 216], ["wound", "OBSERVATION", 244, 249]]], ["Finally, we suggest some significant prospects, further developments and opportunities in this emerging and promising field.Graphene and graphene derivativesGraphene, a two-dimensional layer of sp 2 -hybridized single-atomscale carbon, has caught appreciable attention due to its extraordinary intrinsic strength, high surface area, fast electron mobility, high thermal conductivity, and strong Young's modulus.", [["surface", "ANATOMY", 319, 326], ["Graphene", "CHEMICAL", 124, 132], ["graphene derivatives", "CHEMICAL", 137, 157], ["Graphene", "CHEMICAL", 157, 165], ["Graphene", "CHEMICAL", 124, 132], ["graphene", "CHEMICAL", 137, 145], ["Graphene", "CHEMICAL", 157, 165], ["carbon", "CHEMICAL", 228, 234], ["Graphene", "SIMPLE_CHEMICAL", 124, 132], ["graphene derivatives", "SIMPLE_CHEMICAL", 137, 157], ["Graphene", "SIMPLE_CHEMICAL", 157, 165], ["single-atomscale carbon", "SIMPLE_CHEMICAL", 211, 234], ["electron", "SIMPLE_CHEMICAL", 338, 346], ["Graphene and graphene derivatives", "TREATMENT", 124, 157], ["Graphene", "TEST", 157, 165], ["hybridized single-atomscale carbon", "TREATMENT", 200, 234], ["high surface area", "PROBLEM", 314, 331], ["fast electron mobility", "PROBLEM", 333, 355], ["high thermal conductivity", "PROBLEM", 357, 382], ["strong Young's modulus", "PROBLEM", 388, 410], ["graphene derivatives", "OBSERVATION", 137, 157], ["strength", "OBSERVATION", 304, 312], ["high", "OBSERVATION_MODIFIER", 314, 318], ["surface", "OBSERVATION_MODIFIER", 319, 326], ["high", "OBSERVATION_MODIFIER", 357, 361], ["thermal conductivity", "OBSERVATION_MODIFIER", 362, 382], ["strong", "OBSERVATION_MODIFIER", 388, 394]]], ["Each carbon atom in the lattice has the s, px, and py atomic orbitals that hybridize to form covalent sp 2 bonds, which gives rise to C-C-C bond angles of 120\u00b0 and the chicken-wire-like layers.", [["carbon atom", "CHEMICAL", 5, 16], ["carbon", "CHEMICAL", 5, 11], ["C-C-C", "CHEMICAL", 134, 139], ["carbon atom", "SIMPLE_CHEMICAL", 5, 16], ["sp 2 bonds", "SIMPLE_CHEMICAL", 102, 112], ["C-C-C", "SIMPLE_CHEMICAL", 134, 139], ["C", "TEST", 134, 135], ["the chicken-wire", "TREATMENT", 164, 180], ["carbon atom", "OBSERVATION", 5, 16], ["wire", "OBSERVATION", 176, 180], ["layers", "OBSERVATION_MODIFIER", 186, 192]]], ["In the hexagonal ring, three valence electrons on each carbon in the lattice form the \u03c3 bond, which makes carbon atoms bonded together.", [["carbon", "CHEMICAL", 55, 61], ["carbon", "CHEMICAL", 55, 61], ["\u03c3", "CHEMICAL", 86, 87], ["carbon", "CHEMICAL", 106, 112], ["carbon", "SIMPLE_CHEMICAL", 55, 61], ["carbon atoms", "SIMPLE_CHEMICAL", 106, 118], ["hexagonal", "ANATOMY_MODIFIER", 7, 16], ["ring", "ANATOMY_MODIFIER", 17, 21], ["three", "OBSERVATION_MODIFIER", 23, 28], ["valence electrons", "OBSERVATION", 29, 46], ["carbon atoms", "OBSERVATION", 106, 118]]], ["A \u03c0 orbital known as the valence band, is formed by the remaining pz orbital on each carbon atom overlaps with its neighbors.", [["pz", "CHEMICAL", 66, 68], ["carbon", "CHEMICAL", 85, 91], ["carbon atom", "SIMPLE_CHEMICAL", 85, 96], ["orbital", "ANATOMY", 4, 11], ["pz", "ANATOMY_MODIFIER", 66, 68], ["orbital", "ANATOMY", 69, 76]]], ["The \u03c0 orbital is also called the conduction band that contributes to delocalized electrons.", [["the conduction band", "PROBLEM", 29, 48], ["delocalized electrons", "PROBLEM", 69, 90], ["orbital", "ANATOMY", 6, 13], ["conduction band", "OBSERVATION", 33, 48], ["delocalized electrons", "OBSERVATION", 69, 90]]], ["Graphene-based nanomaterials contain not only \"pristine\" graphene, but also chemical modified graphene as graphene derivatives that have been treated by chemical modifications [6] for covalent bonding with pendent groups, such as graphene oxide (GO) and reduced graphene oxide (rGO).", [["Graphene", "CHEMICAL", 0, 8], ["graphene", "CHEMICAL", 94, 102], ["graphene", "CHEMICAL", 106, 114], ["graphene oxide", "CHEMICAL", 230, 244], ["graphene oxide", "CHEMICAL", 262, 276], ["Graphene", "CHEMICAL", 0, 8], ["graphene", "CHEMICAL", 57, 65], ["graphene", "CHEMICAL", 94, 102], ["graphene", "CHEMICAL", 106, 114], ["graphene oxide", "CHEMICAL", 230, 244], ["reduced graphene oxide", "CHEMICAL", 254, 276], ["rGO", "CHEMICAL", 278, 281], ["graphene", "SIMPLE_CHEMICAL", 57, 65], ["graphene", "SIMPLE_CHEMICAL", 94, 102], ["graphene derivatives", "SIMPLE_CHEMICAL", 106, 126], ["graphene oxide", "SIMPLE_CHEMICAL", 230, 244], ["GO", "SIMPLE_CHEMICAL", 246, 248], ["reduced graphene oxide", "SIMPLE_CHEMICAL", 254, 276], ["rGO", "SIMPLE_CHEMICAL", 278, 281], ["Graphene-based nanomaterials", "TREATMENT", 0, 28], ["pristine\" graphene", "TREATMENT", 47, 65], ["chemical modified graphene as graphene derivatives", "TREATMENT", 76, 126], ["chemical modifications", "TREATMENT", 153, 175], ["covalent bonding with pendent groups", "TREATMENT", 184, 220], ["graphene oxide", "TREATMENT", 230, 244], ["reduced graphene oxide", "TREATMENT", 254, 276]]], ["GO contains epoxy and carbon radicals in the basal planes, while its edges are decorated with carboxyl and hydroxyl groups.", [["hydroxyl", "CHEMICAL", 107, 115], ["epoxy", "CHEMICAL", 12, 17], ["carbon", "CHEMICAL", 22, 28], ["carboxyl", "CHEMICAL", 94, 102], ["hydroxyl", "CHEMICAL", 107, 115], ["carbon radicals", "SIMPLE_CHEMICAL", 22, 37], ["hydroxyl", "SIMPLE_CHEMICAL", 107, 115], ["epoxy and carbon radicals in the basal planes", "TREATMENT", 12, 57], ["carboxyl and hydroxyl groups", "TREATMENT", 94, 122], ["epoxy", "OBSERVATION_MODIFIER", 12, 17], ["carbon radicals", "OBSERVATION", 22, 37], ["basal", "ANATOMY_MODIFIER", 45, 50], ["planes", "ANATOMY_MODIFIER", 51, 57], ["edges", "OBSERVATION_MODIFIER", 69, 74]]], ["The amount of oxygen groups depends significantly on the preparation approaches, including direct oxidation of graphite and subsequent exfoliation of carbon sheets that are deeply oxidized.", [["oxygen", "CHEMICAL", 14, 20], ["graphite", "CHEMICAL", 111, 119], ["oxygen", "CHEMICAL", 14, 20], ["graphite", "CHEMICAL", 111, 119], ["carbon", "CHEMICAL", 150, 156], ["oxygen", "SIMPLE_CHEMICAL", 14, 20], ["graphite", "SIMPLE_CHEMICAL", 111, 119], ["carbon sheets", "SIMPLE_CHEMICAL", 150, 163], ["direct oxidation of graphite", "TREATMENT", 91, 119], ["subsequent exfoliation of carbon sheets", "TREATMENT", 124, 163], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["oxygen groups", "OBSERVATION", 14, 27], ["carbon sheets", "OBSERVATION", 150, 163]]], ["The intrinsic properties of graphene make that GO can partly be reduced going toward graphene-like sheets, which is generally referred as rGO.", [["graphene", "CHEMICAL", 28, 36], ["graphene", "CHEMICAL", 85, 93], ["graphene", "CHEMICAL", 28, 36], ["graphene", "CHEMICAL", 85, 93], ["rGO", "CHEMICAL", 138, 141], ["graphene", "SIMPLE_CHEMICAL", 28, 36], ["rGO", "SIMPLE_CHEMICAL", 138, 141], ["rGO", "PROTEIN", 138, 141]]], ["Chemical doping is another effective approach to synthesize doped-graphene, which is used to tailor the nature of graphene.", [["doped-graphene", "CHEMICAL", 60, 74], ["graphene", "CHEMICAL", 114, 122], ["graphene", "CHEMICAL", 66, 74], ["graphene", "CHEMICAL", 114, 122], ["doped-graphene", "SIMPLE_CHEMICAL", 60, 74], ["graphene", "SIMPLE_CHEMICAL", 114, 122], ["Chemical doping", "TREATMENT", 0, 15], ["synthesize doped-graphene", "TREATMENT", 49, 74]]], ["In doped graphene, other elements, such as nitrogen atoms, boron atoms, and sulfur atoms, are introduced into the hexagonal lattice of graphene and replace the carbon atoms.", [["doped graphene", "CHEMICAL", 3, 17], ["nitrogen atoms", "CHEMICAL", 43, 57], ["boron atoms", "CHEMICAL", 59, 70], ["sulfur atoms", "CHEMICAL", 76, 88], ["graphene", "CHEMICAL", 135, 143], ["graphene", "CHEMICAL", 9, 17], ["nitrogen", "CHEMICAL", 43, 51], ["boron", "CHEMICAL", 59, 64], ["sulfur", "CHEMICAL", 76, 82], ["graphene", "CHEMICAL", 135, 143], ["carbon", "CHEMICAL", 160, 166], ["doped graphene", "SIMPLE_CHEMICAL", 3, 17], ["nitrogen atoms", "SIMPLE_CHEMICAL", 43, 57], ["boron atoms", "SIMPLE_CHEMICAL", 59, 70], ["sulfur atoms", "SIMPLE_CHEMICAL", 76, 88], ["graphene", "SIMPLE_CHEMICAL", 135, 143], ["carbon atoms", "SIMPLE_CHEMICAL", 160, 172], ["nitrogen atoms, boron atoms", "TREATMENT", 43, 70], ["sulfur atoms", "TREATMENT", 76, 88], ["the hexagonal lattice of graphene", "TREATMENT", 110, 143], ["the carbon atoms", "TREATMENT", 156, 172], ["doped graphene", "OBSERVATION", 3, 17], ["sulfur atoms", "OBSERVATION", 76, 88], ["carbon atoms", "OBSERVATION", 160, 172]]], ["Usually, the doped-atoms are under 10% of the whole system.", [["doped-atoms", "SIMPLE_CHEMICAL", 13, 24], ["the doped-atoms", "TREATMENT", 9, 24]]], ["Except modifying the natural properties of graphene, the morphologies can also be shaped, such as two-dimensional (2D) graphene nanosheets (GNSs) [1] , zero-dimensional (0D) graphene quantum dots (GQDs) [7] , and one-dimensional (1D) graphene nanoribbons (GNRs) [8] .Graphene and graphene derivativesUp to now, the synthesis procedures of graphene and its derivatives can be classified into two main categories: physical and chemical approaches.", [["graphene", "CHEMICAL", 43, 51], ["Graphene", "CHEMICAL", 267, 275], ["graphene derivatives", "CHEMICAL", 280, 300], ["graphene", "CHEMICAL", 339, 347], ["graphene", "CHEMICAL", 43, 51], ["graphene", "CHEMICAL", 119, 127], ["graphene", "CHEMICAL", 174, 182], ["graphene", "CHEMICAL", 234, 242], ["Graphene", "CHEMICAL", 267, 275], ["graphene", "CHEMICAL", 280, 288], ["graphene", "CHEMICAL", 339, 347], ["graphene", "SIMPLE_CHEMICAL", 43, 51], ["graphene nanosheets", "SIMPLE_CHEMICAL", 119, 138], ["GNSs) [1]", "SIMPLE_CHEMICAL", 140, 149], ["zero-dimensional (0D) graphene quantum dots", "SIMPLE_CHEMICAL", 152, 195], ["GQDs", "SIMPLE_CHEMICAL", 197, 201], ["1D) graphene nanoribbons", "SIMPLE_CHEMICAL", 230, 254], ["GNRs", "SIMPLE_CHEMICAL", 256, 260], ["Graphene", "SIMPLE_CHEMICAL", 267, 275], ["graphene derivatives", "SIMPLE_CHEMICAL", 280, 300], ["graphene", "SIMPLE_CHEMICAL", 339, 347], ["two-dimensional (2D) graphene nanosheets (GNSs)", "TREATMENT", 98, 145], ["zero-dimensional (0D) graphene quantum dots", "TREATMENT", 152, 195], ["one-dimensional (1D) graphene nanoribbons (GNRs)", "TEST", 213, 261], ["Graphene and graphene derivatives", "TREATMENT", 267, 300], ["the synthesis procedures of graphene", "TREATMENT", 311, 347], ["its derivatives", "TREATMENT", 352, 367], ["graphene derivatives", "OBSERVATION", 280, 300]]], ["Physical approaches utilize exfoliation of a graphene layer from bulk graphite by disrupting the van der Waals forces between the stacked sheets, including mechanical exfoliation, and direct liquid phase exfoliation.", [["graphite", "CHEMICAL", 70, 78], ["graphene", "CHEMICAL", 45, 53], ["graphite", "CHEMICAL", 70, 78], ["a graphene layer from bulk graphite", "TREATMENT", 43, 78], ["the van der Waals forces", "TREATMENT", 93, 117], ["the stacked sheets", "TREATMENT", 126, 144], ["mechanical exfoliation", "TREATMENT", 156, 178], ["direct liquid phase exfoliation", "TREATMENT", 184, 215], ["mechanical exfoliation", "OBSERVATION", 156, 178]]], ["Chemical approaches build up various graphene-based nanomaterials through chemical reaction, including epitaxial growth, chemical vapor deposition (CVD), chemical oxidation, chemical reduction, and so on.", [["graphene", "CHEMICAL", 37, 45], ["CVD", "DISEASE", 148, 151], ["graphene", "CHEMICAL", 37, 45], ["graphene", "SIMPLE_CHEMICAL", 37, 45], ["Chemical approaches", "TREATMENT", 0, 19], ["various graphene", "TREATMENT", 29, 45], ["chemical reaction", "PROBLEM", 74, 91], ["epitaxial growth", "PROBLEM", 103, 119], ["chemical vapor deposition", "TREATMENT", 121, 146], ["chemical oxidation", "TREATMENT", 154, 172], ["chemical reduction", "TREATMENT", 174, 192], ["chemical reaction", "OBSERVATION", 74, 91], ["vapor deposition", "OBSERVATION", 130, 146], ["chemical oxidation", "OBSERVATION", 154, 172], ["chemical reduction", "OBSERVATION", 174, 192]]], ["The structures of graphene, its derivatives, and graphene-based composites as well as their related prepared approaches are shown in Fig. 2 .Physically grown grapheneIn graphite, the interactions between adjacent graphene layers formed via van der Waals forces are extremely weak [9] .", [["graphene", "CHEMICAL", 18, 26], ["graphene", "CHEMICAL", 49, 57], ["graphene", "CHEMICAL", 158, 166], ["graphite", "CHEMICAL", 169, 177], ["graphene", "CHEMICAL", 18, 26], ["graphene", "CHEMICAL", 49, 57], ["graphene", "CHEMICAL", 158, 166], ["graphite", "CHEMICAL", 169, 177], ["graphene", "CHEMICAL", 213, 221], ["graphene", "SIMPLE_CHEMICAL", 18, 26], ["graphene", "SIMPLE_CHEMICAL", 49, 57], ["graphene", "SIMPLE_CHEMICAL", 158, 166], ["its derivatives", "TREATMENT", 28, 43], ["graphene-based composites", "TREATMENT", 49, 74], ["adjacent graphene layers", "TREATMENT", 204, 228], ["extremely weak", "PROBLEM", 265, 279], ["grown graphene", "OBSERVATION", 152, 166]]], ["This causes the delamination of bulk graphite into individual graphene sheets under mechanical forces.", [["graphene", "CHEMICAL", 62, 70], ["graphite", "CHEMICAL", 37, 45], ["graphene", "CHEMICAL", 62, 70], ["the delamination of bulk graphite into individual graphene sheets", "TREATMENT", 12, 77], ["delamination", "OBSERVATION_MODIFIER", 16, 28], ["bulk graphite", "OBSERVATION", 32, 45], ["graphene sheets", "OBSERVATION", 62, 77], ["mechanical forces", "OBSERVATION", 84, 101]]], ["Geim and his co-workers first mechanically exfoliated graphene by using adhesive tapes in 2004 [1] , which has been credited with the explosive growth of interest in graphene in recent years.", [["graphene", "CHEMICAL", 166, 174], ["graphene", "CHEMICAL", 54, 62], ["graphene", "CHEMICAL", 166, 174], ["graphene", "SIMPLE_CHEMICAL", 54, 62], ["graphene", "SIMPLE_CHEMICAL", 166, 174], ["adhesive tapes", "TREATMENT", 72, 86]]], ["This simple approach can keep the structural integrity of graphene; however, it has low efficiency, and the size and orientation of available graphene sheets are generally uncontrollable with the lateral size up to tens of microns.Physically grown grapheneLiquid-phase exfoliation is another typical physical synthesis approach, which is prepared by sonicating graphite in the presence of certain solvents.", [["grapheneLiquid", "CHEMICAL", 248, 262], ["graphite", "CHEMICAL", 361, 369], ["graphene", "CHEMICAL", 58, 66], ["graphene", "CHEMICAL", 142, 150], ["graphite", "CHEMICAL", 361, 369], ["graphene", "SIMPLE_CHEMICAL", 58, 66], ["This simple approach", "TREATMENT", 0, 20], ["low efficiency", "PROBLEM", 84, 98], ["available graphene sheets", "TEST", 132, 157], ["low efficiency", "OBSERVATION_MODIFIER", 84, 98], ["size", "OBSERVATION_MODIFIER", 108, 112], ["uncontrollable", "OBSERVATION_MODIFIER", 172, 186], ["lateral", "OBSERVATION_MODIFIER", 196, 203], ["size", "OBSERVATION_MODIFIER", 204, 208]]], ["This direct method is based on one-step physical process by using liquids as exfoliation media, such as organic solvents, ionic liquids, and surfactant solutions.", [["liquids as exfoliation media", "TREATMENT", 66, 94], ["organic solvents, ionic liquids", "TREATMENT", 104, 135], ["surfactant solutions", "TREATMENT", 141, 161]]], ["Coleman et al. [10] developed graphene dispersions in the forms of mono-and multilayered graphene sheets, which are free from oxides and defects.", [["graphene", "CHEMICAL", 30, 38], ["graphene", "CHEMICAL", 30, 38], ["graphene", "CHEMICAL", 89, 97], ["oxides", "CHEMICAL", 126, 132], ["graphene sheets", "SIMPLE_CHEMICAL", 89, 104], ["oxides", "SIMPLE_CHEMICAL", 126, 132], ["graphene dispersions", "TREATMENT", 30, 50], ["mono", "TEST", 67, 71], ["multilayered graphene sheets", "TREATMENT", 76, 104], ["defects", "PROBLEM", 137, 144], ["graphene sheets", "OBSERVATION", 89, 104], ["defects", "OBSERVATION", 137, 144]]], ["The yield of monolayer graphene in N-methyl pyrrolidone (NMP) dispersions was 28%, corresponding to an overall yield of approximately 1 wt.%.", [["graphene", "CHEMICAL", 23, 31], ["N-methyl pyrrolidone", "CHEMICAL", 35, 55], ["NMP", "CHEMICAL", 57, 60], ["graphene", "CHEMICAL", 23, 31], ["N-methyl pyrrolidone", "CHEMICAL", 35, 55], ["NMP", "CHEMICAL", 57, 60], ["monolayer graphene", "SIMPLE_CHEMICAL", 13, 31], ["N-methyl pyrrolidone", "SIMPLE_CHEMICAL", 35, 55], ["NMP", "SIMPLE_CHEMICAL", 57, 60], ["The yield of monolayer graphene", "TREATMENT", 0, 31], ["N-methyl pyrrolidone (NMP) dispersions", "TREATMENT", 35, 73]]], ["However, the low concentration of obtained graphene, which was below 0.01 mg\u00b7mL \u22121 , made it difficult to concentrate and isolate from the viscous solvents.Chemically produced grapheneCVD technique has been widely used to produce large-scale and high-quality graphene films with low/no oxygen content and defect-free hexagonal lattice.", [["graphene", "CHEMICAL", 43, 51], ["oxygen", "CHEMICAL", 286, 292], ["graphene", "CHEMICAL", 43, 51], ["graphene", "CHEMICAL", 259, 267], ["oxygen", "CHEMICAL", 286, 292], ["graphene", "SIMPLE_CHEMICAL", 43, 51], ["graphene films", "SIMPLE_CHEMICAL", 259, 273], ["oxygen", "SIMPLE_CHEMICAL", 286, 292], ["the viscous solvents", "TREATMENT", 135, 155], ["Chemically produced grapheneCVD technique", "TREATMENT", 156, 197], ["high-quality graphene films", "TEST", 246, 273], ["oxygen content", "PROBLEM", 286, 300], ["defect", "PROBLEM", 305, 311], ["low concentration", "OBSERVATION_MODIFIER", 13, 30], ["viscous solvents", "OBSERVATION", 139, 155], ["oxygen content", "OBSERVATION", 286, 300], ["defect", "OBSERVATION", 305, 311], ["free hexagonal lattice", "OBSERVATION", 312, 334]]], ["Hong, Choi and co-workers [11] used CVD technique to grow and transfer few-layer graphene films on a large scale on a ~ 300 nm-thick nickel layer on a SiO2/Si substrate.", [["CVD", "DISEASE", 36, 39], ["nickel", "CHEMICAL", 133, 139], ["SiO2", "CHEMICAL", 151, 155], ["graphene", "CHEMICAL", 81, 89], ["nickel", "CHEMICAL", 133, 139], ["SiO2", "CHEMICAL", 151, 155], ["Si", "CHEMICAL", 156, 158], ["SiO2/Si substrate", "SIMPLE_CHEMICAL", 151, 168], ["CVD technique", "TREATMENT", 36, 49], ["layer graphene films", "TEST", 75, 95], ["thick nickel layer", "PROBLEM", 127, 145], ["a SiO2/Si substrate", "TREATMENT", 149, 168]]], ["Besides nickel, copper (Cu) is another ideal metal in CVD synthesis.", [["nickel", "CHEMICAL", 8, 14], ["copper", "CHEMICAL", 16, 22], ["Cu", "CHEMICAL", 24, 26], ["CVD", "DISEASE", 54, 57], ["nickel", "CHEMICAL", 8, 14], ["copper", "CHEMICAL", 16, 22], ["Cu", "CHEMICAL", 24, 26], ["nickel", "SIMPLE_CHEMICAL", 8, 14], ["copper", "SIMPLE_CHEMICAL", 16, 22], ["Cu", "SIMPLE_CHEMICAL", 24, 26], ["CVD", "SIMPLE_CHEMICAL", 54, 57], ["another ideal metal in CVD synthesis", "PROBLEM", 31, 67]]], ["Bea et al. [12] developed the roll-to-roll production of monolayer 30-inch graphene films through CVD technique onto flexible and large copper substrates.", [["CVD", "DISEASE", 98, 101], ["copper", "CHEMICAL", 136, 142], ["graphene", "CHEMICAL", 75, 83], ["copper", "CHEMICAL", 136, 142], ["copper substrates", "SIMPLE_CHEMICAL", 136, 153], ["monolayer 30-inch graphene films through CVD technique", "TREATMENT", 57, 111], ["flexible and large copper substrates", "TREATMENT", 117, 153]]], ["The films presented low resistances of ~ 125 \u03a9\u00b7m \u22121 and 97.4% optical transmittance, which was superior to that grown on indium tin oxides.", [["indium tin oxides", "CHEMICAL", 121, 138], ["indium tin oxides", "CHEMICAL", 121, 138], ["indium tin oxides", "SIMPLE_CHEMICAL", 121, 138], ["The films", "TEST", 0, 9], ["indium tin oxides", "TREATMENT", 121, 138], ["low resistances", "OBSERVATION_MODIFIER", 20, 35]]], ["Recently, Chen et al. [13] found the lattice constant of monolayer graphene as-grown on Cu via CVD was expanded to around 7.5% of its relaxed value using electronic and lattice structure analysis.Chemically produced grapheneEpitaxial growth of graphene film formed by thermal decomposition and vacuum graphitization on insulating carbon-containing or metal substrate, has also been reported [14] [15] [16] .", [["graphene", "CHEMICAL", 67, 75], ["Cu", "CHEMICAL", 88, 90], ["CVD", "DISEASE", 95, 98], ["graphene", "CHEMICAL", 216, 224], ["graphene", "CHEMICAL", 244, 252], ["graphene", "CHEMICAL", 67, 75], ["Cu", "CHEMICAL", 88, 90], ["graphene", "CHEMICAL", 216, 224], ["graphene", "CHEMICAL", 244, 252], ["carbon", "CHEMICAL", 330, 336], ["monolayer graphene", "SIMPLE_CHEMICAL", 57, 75], ["Cu", "SIMPLE_CHEMICAL", 88, 90], ["graphene", "SIMPLE_CHEMICAL", 216, 224], ["graphene film", "SIMPLE_CHEMICAL", 244, 257], ["[14] [15] [16]", "SIMPLE_CHEMICAL", 391, 405], ["the lattice constant of monolayer graphene", "TREATMENT", 33, 75], ["electronic and lattice structure analysis", "TEST", 154, 195], ["Epitaxial growth of graphene film", "PROBLEM", 224, 257], ["thermal decomposition", "TREATMENT", 268, 289], ["vacuum graphitization on insulating carbon-containing or metal substrate", "TREATMENT", 294, 366], ["graphene", "OBSERVATION", 216, 224], ["growth", "OBSERVATION_MODIFIER", 234, 240], ["vacuum graphitization", "OBSERVATION", 294, 315]]], ["After Si atoms was evaporated from the substrate, uniform ordered graphene films in the size of few microns was produced on silicon carbide (SiC) surface through vacuum high-temperature annealing and carbon segregation.", [["Si atoms", "CHEMICAL", 6, 14], ["graphene", "CHEMICAL", 66, 74], ["silicon carbide", "CHEMICAL", 124, 139], ["carbon", "CHEMICAL", 200, 206], ["Si", "CHEMICAL", 6, 8], ["graphene", "CHEMICAL", 66, 74], ["silicon carbide", "CHEMICAL", 124, 139], ["SiC", "CHEMICAL", 141, 144], ["carbon", "CHEMICAL", 200, 206], ["Si atoms", "SIMPLE_CHEMICAL", 6, 14], ["graphene films", "SIMPLE_CHEMICAL", 66, 80], ["silicon carbide", "SIMPLE_CHEMICAL", 124, 139], ["carbon", "SIMPLE_CHEMICAL", 200, 206], ["uniform ordered graphene films", "TEST", 50, 80], ["silicon carbide (SiC) surface", "TREATMENT", 124, 153], ["vacuum high-temperature annealing", "TREATMENT", 162, 195], ["carbon segregation", "PROBLEM", 200, 218], ["size", "OBSERVATION_MODIFIER", 88, 92], ["carbon segregation", "OBSERVATION", 200, 218]]], ["This technique could obtain high-quality graphene films.", [["graphene", "CHEMICAL", 41, 49], ["graphene films", "SIMPLE_CHEMICAL", 41, 55], ["This technique", "TEST", 0, 14], ["high-quality graphene films", "TREATMENT", 28, 55]]], ["Unfortunately, it requires special conditions of high temperature and vacuum environment, and expensive costs for only small-size graphene film.Chemically produced grapheneThe most common way to prepare graphene for biological researches is chemical reduction of GO to rGO, involving deep oxidation of graphite, followed exfoliation of GO by sonication irritation, and reduction by chemical or thermal methods.", [["graphene", "CHEMICAL", 164, 172], ["graphene", "CHEMICAL", 203, 211], ["rGO", "CHEMICAL", 269, 272], ["graphite", "CHEMICAL", 302, 310], ["graphene", "CHEMICAL", 130, 138], ["graphene", "CHEMICAL", 164, 172], ["graphene", "CHEMICAL", 203, 211], ["rGO", "CHEMICAL", 269, 272], ["graphite", "CHEMICAL", 302, 310], ["graphene film", "SIMPLE_CHEMICAL", 130, 143], ["graphene", "SIMPLE_CHEMICAL", 164, 172], ["graphene", "SIMPLE_CHEMICAL", 203, 211], ["rGO", "SIMPLE_CHEMICAL", 269, 272], ["graphite", "SIMPLE_CHEMICAL", 302, 310], ["high temperature and vacuum environment", "TREATMENT", 49, 88], ["small-size graphene film", "TREATMENT", 119, 143], ["deep oxidation of graphite", "TREATMENT", 284, 310], ["sonication irritation", "PROBLEM", 342, 363], ["graphene", "OBSERVATION", 164, 172], ["irritation", "OBSERVATION", 353, 363]]], ["Currently, there are several improved techniques to Hummer oxidation by using different oxidizing agents/acids or under different reaction conditions.", [["Hummer", "SIMPLE_CHEMICAL", 52, 58], ["Hummer oxidation", "TREATMENT", 52, 68], ["different oxidizing agents", "TREATMENT", 78, 104], ["acids", "TREATMENT", 105, 110], ["several", "OBSERVATION_MODIFIER", 21, 28], ["improved", "OBSERVATION_MODIFIER", 29, 37]]], ["Ruoff et al. [18] prepared a free-standing GO paper by flow-directed assembly method, possessing higher tensile modulus and fracture strength than many other paper-like materials.", [["fracture", "DISEASE", 124, 132], ["possessing higher tensile modulus", "PROBLEM", 86, 119], ["fracture strength", "PROBLEM", 124, 141], ["higher", "OBSERVATION_MODIFIER", 97, 103], ["tensile modulus", "OBSERVATION", 104, 119], ["fracture strength", "OBSERVATION", 124, 141]]], ["Marcano et al. [19] improved Hummer's methods by elimination NaNO3, increasing the concentration of KMnO4, and using a mixture of H2SO4/H3PO4, which obtained a high oxidized GO with free generation of toxic gases (NOx). rGO can be obtained by chemical or thermal reduction treatments heated above 100 \u00b0C using reducing agents, such as hydrazine, hydrogen, etc. Li et al. [20] reduced GO dispersions to stable graphene colloids via hydrazine reduction under controlled conditions, which provided a simple method to prepare single-layer chemical converted graphene sheets with thickness of ~ 1 nm.", [["NaNO3", "CHEMICAL", 61, 66], ["KMnO4", "CHEMICAL", 100, 105], ["H2SO4/H3PO4", "CHEMICAL", 130, 141], ["NOx", "CHEMICAL", 214, 217], ["rGO", "CHEMICAL", 220, 223], ["hydrazine", "CHEMICAL", 335, 344], ["hydrogen", "CHEMICAL", 346, 354], ["Li", "CHEMICAL", 361, 363], ["graphene colloids", "CHEMICAL", 409, 426], ["hydrazine", "CHEMICAL", 431, 440], ["graphene", "CHEMICAL", 554, 562], ["NaNO3", "CHEMICAL", 61, 66], ["KMnO4", "CHEMICAL", 100, 105], ["H2SO4", "CHEMICAL", 130, 135], ["H3PO4", "CHEMICAL", 136, 141], ["NOx", "CHEMICAL", 214, 217], ["hydrazine", "CHEMICAL", 335, 344], ["hydrogen", "CHEMICAL", 346, 354], ["graphene", "CHEMICAL", 409, 417], ["hydrazine", "CHEMICAL", 431, 440], ["graphene", "CHEMICAL", 554, 562], ["NaNO3", "SIMPLE_CHEMICAL", 61, 66], ["KMnO4", "SIMPLE_CHEMICAL", 100, 105], ["H2SO4/H3PO4", "SIMPLE_CHEMICAL", 130, 141], ["NOx", "SIMPLE_CHEMICAL", 214, 217], ["rGO", "SIMPLE_CHEMICAL", 220, 223], ["hydrazine", "SIMPLE_CHEMICAL", 335, 344], ["hydrogen", "SIMPLE_CHEMICAL", 346, 354], ["graphene colloids", "SIMPLE_CHEMICAL", 409, 426], ["hydrazine", "SIMPLE_CHEMICAL", 431, 440], ["NaNO3", "TREATMENT", 61, 66], ["increasing the concentration of KMnO4", "TREATMENT", 68, 105], ["H2SO4/H3PO4", "TREATMENT", 130, 141], ["toxic gases", "TREATMENT", 201, 212], ["thermal reduction treatments", "TREATMENT", 255, 283], ["reducing agents", "TREATMENT", 310, 325], ["hydrazine", "TREATMENT", 335, 344], ["hydrogen", "TREATMENT", 346, 354], ["reduced GO dispersions", "TREATMENT", 376, 398], ["stable graphene colloids", "TREATMENT", 402, 426], ["hydrazine reduction", "TREATMENT", 431, 450], ["a simple method", "TREATMENT", 495, 510], ["single-layer chemical converted graphene sheets", "TREATMENT", 522, 569]]], ["Recently, Chhowalla's group [21] further simplified the method to reduce GO into rGO by using few seconds long microwave pulses.", [["rGO", "SIMPLE_CHEMICAL", 81, 84], ["long microwave pulses", "PROBLEM", 106, 127]]], ["The microwave-reduced GO showed CVD graphene-like Raman features, as well as atomic-scale highly ordered structures.Graphene-based compositesGraphene-based composites as filler materials where graphene is used as a base to disperse in or incorporation of other nanomaterials, such as metal nanostructures [22] [23] [24] , semiconductor nanostructures [25] [26] [27] , and polymers [28, 29] .", [["Graphene", "CHEMICAL", 116, 124], ["Graphene", "CHEMICAL", 141, 149], ["graphene", "CHEMICAL", 193, 201], ["[25] [26] [27]", "CHEMICAL", 351, 365], ["graphene", "CHEMICAL", 36, 44], ["Graphene", "CHEMICAL", 116, 124], ["Graphene", "CHEMICAL", 141, 149], ["graphene", "CHEMICAL", 193, 201], ["graphene", "SIMPLE_CHEMICAL", 193, 201], ["metal nanostructures [22] [23] [24]", "SIMPLE_CHEMICAL", 284, 319], ["semiconductor nanostructures [25] [26] [27]", "SIMPLE_CHEMICAL", 322, 365], ["The microwave", "TEST", 0, 13], ["CVD graphene-like Raman features", "PROBLEM", 32, 64], ["Graphene-based composites", "TREATMENT", 116, 141], ["Graphene-based composites as filler materials", "TREATMENT", 141, 186], ["other nanomaterials", "PROBLEM", 255, 274], ["metal nanostructures", "TEST", 284, 304], ["semiconductor nanostructures", "TEST", 322, 350], ["polymers", "TEST", 372, 380]]], ["Chemical reduction, hydrothermal method, microwave-assisted growth, solution mixing, in situ growth are often used to prepare graphene-based composites [30] .", [["graphene", "CHEMICAL", 126, 134], ["graphene", "CHEMICAL", 126, 134], ["graphene", "SIMPLE_CHEMICAL", 126, 134], ["Chemical reduction", "TREATMENT", 0, 18], ["hydrothermal method", "TREATMENT", 20, 39], ["microwave-assisted growth, solution mixing", "TREATMENT", 41, 83], ["reduction", "OBSERVATION_MODIFIER", 9, 18]]], ["Kamat et al. [31] first decorated gold nanoparticles (AuNPs) by chemical reduction of AuCl 4ions with NaBH4 on octadecylamine (ODA) modified graphene suspended in tetrahydrofuran (THF) medium.", [["gold nanoparticles", "CHEMICAL", 34, 52], ["AuNPs", "CHEMICAL", 54, 59], ["AuCl 4ions", "CHEMICAL", 86, 96], ["NaBH4", "CHEMICAL", 102, 107], ["octadecylamine", "CHEMICAL", 111, 125], ["ODA", "CHEMICAL", 127, 130], ["graphene", "CHEMICAL", 141, 149], ["THF", "CHEMICAL", 180, 183], ["AuCl 4ions", "CHEMICAL", 86, 96], ["NaBH4", "CHEMICAL", 102, 107], ["octadecylamine", "CHEMICAL", 111, 125], ["ODA", "CHEMICAL", 127, 130], ["graphene", "CHEMICAL", 141, 149], ["tetrahydrofuran", "CHEMICAL", 163, 178], ["THF", "CHEMICAL", 180, 183], ["gold nanoparticles", "SIMPLE_CHEMICAL", 34, 52], ["AuNPs", "SIMPLE_CHEMICAL", 54, 59], ["AuCl 4ions", "SIMPLE_CHEMICAL", 86, 96], ["NaBH4", "SIMPLE_CHEMICAL", 102, 107], ["octadecylamine", "SIMPLE_CHEMICAL", 111, 125], ["ODA", "SIMPLE_CHEMICAL", 127, 130], ["graphene", "SIMPLE_CHEMICAL", 141, 149], ["tetrahydrofuran", "SIMPLE_CHEMICAL", 163, 178], ["THF", "SIMPLE_CHEMICAL", 180, 183], ["first decorated gold nanoparticles (AuNPs", "TREATMENT", 18, 59], ["chemical reduction of AuCl 4ions", "TREATMENT", 64, 96], ["NaBH4", "TREATMENT", 102, 107], ["octadecylamine (ODA) modified graphene", "TREATMENT", 111, 149]]], ["Gao et al. [32] reported the preparation of a graphene-CdS QD composite using a one-pot process, where simultaneously brought about the reduction of GO and the formation of CdS on graphene.", [["graphene-CdS QD", "CHEMICAL", 46, 61], ["CdS", "CHEMICAL", 173, 176], ["graphene", "CHEMICAL", 180, 188], ["graphene", "CHEMICAL", 46, 54], ["CdS", "CHEMICAL", 55, 58], ["CdS", "CHEMICAL", 173, 176], ["graphene", "CHEMICAL", 180, 188], ["graphene-CdS QD", "SIMPLE_CHEMICAL", 46, 61], ["CdS", "SIMPLE_CHEMICAL", 173, 176], ["graphene", "SIMPLE_CHEMICAL", 180, 188], ["a graphene-CdS QD composite", "TREATMENT", 44, 71], ["CdS on graphene", "TREATMENT", 173, 188]]], ["Graphene-ploymer composites required polymer matrixes, such as poly-N-vinyl carbazole (PVK), poly(methyl methacrylate) (PMMA), Poly(L-lysine) (PLL), and polycaprolactone (PCL) [33] .Graphene in biosystems: toxicology and biocompatibilityIn this section, we first introduce studies on the interactions between graphene and biomacromolecules in extracellular environment.", [["extracellular", "ANATOMY", 343, 356], ["Graphene", "CHEMICAL", 0, 8], ["poly-N-vinyl carbazole", "CHEMICAL", 63, 85], ["PVK", "CHEMICAL", 87, 90], ["poly(methyl methacrylate", "CHEMICAL", 93, 117], ["PMMA", "CHEMICAL", 120, 124], ["Poly(L-lysine", "CHEMICAL", 127, 140], ["PLL", "CHEMICAL", 143, 146], ["polycaprolactone", "CHEMICAL", 153, 169], ["PCL", "CHEMICAL", 171, 174], ["Graphene", "CHEMICAL", 182, 190], ["graphene", "CHEMICAL", 309, 317], ["Graphene", "CHEMICAL", 0, 8], ["poly-N-vinyl carbazole", "CHEMICAL", 63, 85], ["PVK", "CHEMICAL", 87, 90], ["poly(methyl methacrylate)", "CHEMICAL", 93, 118], ["PMMA", "CHEMICAL", 120, 124], ["Poly(L-lysine)", "CHEMICAL", 127, 141], ["PLL", "CHEMICAL", 143, 146], ["polycaprolactone", "CHEMICAL", 153, 169], ["PCL", "CHEMICAL", 171, 174], ["Graphene", "CHEMICAL", 182, 190], ["graphene", "CHEMICAL", 309, 317], ["polymer matrixes", "SIMPLE_CHEMICAL", 37, 53], ["poly-N-vinyl carbazole", "SIMPLE_CHEMICAL", 63, 85], ["PVK", "SIMPLE_CHEMICAL", 87, 90], ["poly(methyl methacrylate)", "SIMPLE_CHEMICAL", 93, 118], ["PMMA", "SIMPLE_CHEMICAL", 120, 124], ["Poly(L-lysine)", "SIMPLE_CHEMICAL", 127, 141], ["PLL", "SIMPLE_CHEMICAL", 143, 146], ["polycaprolactone", "SIMPLE_CHEMICAL", 153, 169], ["Graphene", "SIMPLE_CHEMICAL", 182, 190], ["graphene", "SIMPLE_CHEMICAL", 309, 317], ["biomacromolecules", "SIMPLE_CHEMICAL", 322, 339], ["extracellular environment", "CELLULAR_COMPONENT", 343, 368], ["Graphene-ploymer composites", "TREATMENT", 0, 27], ["polymer matrixes", "TREATMENT", 37, 53], ["poly-N-vinyl carbazole (PVK)", "TREATMENT", 63, 91], ["poly(methyl methacrylate) (PMMA)", "TREATMENT", 93, 125], ["Poly(L-lysine) (PLL)", "TREATMENT", 127, 147], ["polycaprolactone (PCL)", "TREATMENT", 153, 175], ["graphene and biomacromolecules in extracellular environment", "TREATMENT", 309, 368], ["biocompatibility", "OBSERVATION", 221, 237], ["extracellular environment", "OBSERVATION", 343, 368]]], ["Then we summarize the progress on the cytotoxicity of graphene, how graphene enters cells, and how it affects cellular metabolism.", [["cells", "ANATOMY", 84, 89], ["cellular", "ANATOMY", 110, 118], ["graphene", "CHEMICAL", 54, 62], ["graphene", "CHEMICAL", 68, 76], ["graphene", "CHEMICAL", 54, 62], ["graphene", "CHEMICAL", 68, 76], ["graphene", "SIMPLE_CHEMICAL", 54, 62], ["graphene", "SIMPLE_CHEMICAL", 68, 76], ["cells", "CELL", 84, 89], ["cellular", "CELL", 110, 118], ["the cytotoxicity of graphene", "TREATMENT", 34, 62], ["cellular metabolism", "OBSERVATION", 110, 129]]], ["Furthermore, we describe the in-vivo toxicity of graphene in various organs and model animals by demonstrating biodistribution of graphene, and their toxicological effects.", [["organs", "ANATOMY", 69, 75], ["toxicity", "DISEASE", 37, 45], ["graphene", "CHEMICAL", 49, 57], ["graphene", "CHEMICAL", 130, 138], ["graphene", "CHEMICAL", 49, 57], ["graphene", "CHEMICAL", 130, 138], ["graphene", "SIMPLE_CHEMICAL", 49, 57], ["organs", "ORGAN", 69, 75], ["graphene", "SIMPLE_CHEMICAL", 130, 138], ["biodistribution of graphene", "TREATMENT", 111, 138]]], ["Finally, we bring about an overview on the toxicology of graphene, and how we could circumvent this problem to realize real-world applications.Interactions between graphene and nucleic acidsIt is well known that nucleic acids are essential in transmitting and expressing information through protein synthesis in living entities.", [["graphene", "CHEMICAL", 164, 172], ["nucleic acids", "CHEMICAL", 177, 190], ["nucleic acids", "CHEMICAL", 212, 225], ["graphene", "CHEMICAL", 57, 65], ["graphene", "CHEMICAL", 164, 172], ["graphene", "SIMPLE_CHEMICAL", 57, 65], ["graphene", "SIMPLE_CHEMICAL", 164, 172], ["nucleic acids", "SIMPLE_CHEMICAL", 177, 190], ["nucleic acids", "SIMPLE_CHEMICAL", 212, 225], ["nucleic acids", "TEST", 177, 190], ["nucleic acids", "TREATMENT", 212, 225], ["protein synthesis", "TREATMENT", 291, 308]]], ["Recently, a series of functional nucleic acids [34] are produced by a combinatorial method called in-vitro selection or systematic evolution of ligands by exponential enrichment (SELEX), functioning beyond the conventional genetic roles.", [["nucleic acids", "CHEMICAL", 33, 46], ["functional nucleic acids", "TEST", 22, 46], ["systematic evolution of ligands", "PROBLEM", 120, 151], ["exponential enrichment (SELEX", "TREATMENT", 155, 184]]], ["The programmable pairing of DNA single strands into precisely engineered, connecting double helices make it an ideal material for assemblage of nano-architectures [35] [36] [37] [38] [39] , such as DNA nanotube/nanowire [40] , DNA array [41] and DNA origami [42] [43] [44] , for advancing bioimaging [45] [46] [47] [48] , biomedicine [49, 50] , and biomolecular sensing [51] [52] [53] .", [["DNA", "CELLULAR_COMPONENT", 28, 31], ["nano-architectures [35] [36] [37] [38] [39]", "SIMPLE_CHEMICAL", 144, 187], ["DNA", "CELLULAR_COMPONENT", 198, 201], ["nanowire [40]", "SIMPLE_CHEMICAL", 211, 224], ["DNA", "CELLULAR_COMPONENT", 227, 230], ["[41]", "SIMPLE_CHEMICAL", 237, 241], ["DNA origami [42] [43] [44]", "SIMPLE_CHEMICAL", 246, 272], ["[45] [46] [47] [48]", "SIMPLE_CHEMICAL", 300, 319], ["[51] [52] [53]", "SIMPLE_CHEMICAL", 370, 384], ["The programmable pairing of DNA single strands", "TREATMENT", 0, 46], ["connecting double helices", "TREATMENT", 74, 99], ["nano-architectures", "TEST", 144, 162], ["DNA nanotube/nanowire", "TREATMENT", 198, 219], ["DNA array", "TEST", 227, 236], ["DNA origami", "TEST", 246, 257], ["advancing bioimaging", "TEST", 279, 299], ["biomolecular sensing", "TEST", 349, 369]]], ["Thus, the study of interaction between graphene and nucleic acids is well appealing towards biomedical applications.Interactions between graphene and nucleic acidsUp until now, some experimental studies regarding the absorption and desorption mechanisms between graphene and nucleic acids have been reported.", [["graphene", "CHEMICAL", 39, 47], ["nucleic acids", "CHEMICAL", 52, 65], ["graphene", "CHEMICAL", 137, 145], ["nucleic acids", "CHEMICAL", 150, 163], ["graphene", "CHEMICAL", 262, 270], ["nucleic acids", "CHEMICAL", 275, 288], ["graphene", "CHEMICAL", 39, 47], ["graphene", "CHEMICAL", 137, 145], ["graphene", "CHEMICAL", 262, 270], ["graphene", "SIMPLE_CHEMICAL", 39, 47], ["nucleic acids", "SIMPLE_CHEMICAL", 52, 65], ["graphene", "SIMPLE_CHEMICAL", 137, 145], ["nucleic acids", "SIMPLE_CHEMICAL", 150, 163], ["graphene", "SIMPLE_CHEMICAL", 262, 270], ["nucleic acids", "SIMPLE_CHEMICAL", 275, 288], ["the study", "TEST", 6, 15], ["graphene and nucleic acids", "TREATMENT", 39, 65], ["biomedical applications", "TREATMENT", 92, 115], ["nucleic acids", "TEST", 150, 163], ["some experimental studies", "TEST", 177, 202], ["the absorption", "PROBLEM", 213, 227], ["graphene", "TREATMENT", 262, 270], ["nucleic acids", "TEST", 275, 288]]], ["Mann and co-workers [54] reported a method of utilizing single-stranded DNA (ssDNA) to prepare stable aqueous graphene suspensions sheets, which proposed a surface binding model for ssDNA/graphene interactions via non-covalent hydrophobic and electrostatic/hydrogen bonding between purine/pyrimidine bases of ssDNA and the carboxylic and phenolic groups of graphene.", [["surface", "ANATOMY", 156, 163], ["graphene", "CHEMICAL", 110, 118], ["graphene", "CHEMICAL", 188, 196], ["purine", "CHEMICAL", 282, 288], ["pyrimidine", "CHEMICAL", 289, 299], ["graphene", "CHEMICAL", 357, 365], ["graphene", "CHEMICAL", 110, 118], ["graphene", "CHEMICAL", 188, 196], ["hydrogen", "CHEMICAL", 257, 265], ["purine", "CHEMICAL", 282, 288], ["pyrimidine", "CHEMICAL", 289, 299], ["carboxylic", "CHEMICAL", 323, 333], ["phenolic", "CHEMICAL", 338, 346], ["graphene", "CHEMICAL", 357, 365], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["ssDNA", "CELLULAR_COMPONENT", 77, 82], ["ssDNA", "SIMPLE_CHEMICAL", 182, 187], ["graphene", "SIMPLE_CHEMICAL", 188, 196], ["purine", "SIMPLE_CHEMICAL", 282, 288], ["pyrimidine", "SIMPLE_CHEMICAL", 289, 299], ["ssDNA", "SIMPLE_CHEMICAL", 309, 314], ["carboxylic", "SIMPLE_CHEMICAL", 323, 333], ["graphene", "SIMPLE_CHEMICAL", 357, 365], ["single-stranded DNA", "DNA", 56, 75], ["single-stranded DNA (ssDNA)", "TREATMENT", 56, 83], ["stable aqueous graphene suspensions sheets", "TREATMENT", 95, 137], ["a surface binding model", "TREATMENT", 154, 177], ["ssDNA/graphene interactions", "TREATMENT", 182, 209], ["non-covalent hydrophobic and electrostatic/hydrogen bonding", "TREATMENT", 214, 273], ["purine/pyrimidine bases of ssDNA", "TREATMENT", 282, 314], ["the carboxylic and phenolic groups of graphene", "TREATMENT", 319, 365]]], ["In general, the binding affinity between graphene and ssDNA via noncovalent interactions (i.e., \u03c0-\u03c0 stacking interactions and hydrophobic forces) is much higher than those between graphene and double-stranded DNA (dsDNA) or tertiary DNA structures.", [["graphene", "CHEMICAL", 41, 49], ["graphene", "CHEMICAL", 180, 188], ["graphene", "CHEMICAL", 41, 49], ["graphene", "CHEMICAL", 180, 188], ["graphene", "SIMPLE_CHEMICAL", 41, 49], ["ssDNA", "CELLULAR_COMPONENT", 54, 59], ["graphene", "SIMPLE_CHEMICAL", 180, 188], ["DNA", "CELLULAR_COMPONENT", 209, 212], ["dsDNA", "CELLULAR_COMPONENT", 214, 219], ["DNA", "CELLULAR_COMPONENT", 233, 236], ["graphene", "TREATMENT", 180, 188], ["double-stranded DNA (dsDNA", "TREATMENT", 193, 219], ["tertiary DNA structures", "PROBLEM", 224, 247]]], ["Chen and co-workers [55] demonstrated that GO could bind dyelabeled ssDNA and quench its fluorescence, where GO has lower affinity for dsDNA than for ssDNA.", [["ssDNA", "CELLULAR_COMPONENT", 68, 73], ["dsDNA", "CELLULAR_COMPONENT", 135, 140], ["ssDNA", "CELLULAR_COMPONENT", 150, 155], ["ssDNA", "PROBLEM", 150, 155]]], ["Fan et al. [56] developed a GO-based multicolor fluorescent DNA analysis and performed a molecular dynamic (MD) simulation to study the interaction differences between ssDNA and dsDNA with GO.", [["DNA", "CELLULAR_COMPONENT", 60, 63], ["ssDNA", "CELLULAR_COMPONENT", 168, 173], ["dsDNA", "CELLULAR_COMPONENT", 178, 183], ["multicolor fluorescent DNA analysis", "TEST", 37, 72], ["ssDNA and dsDNA", "TREATMENT", 168, 183]]], ["As a result, the nucleobases of ssDNA lay nearly flat on the GO surface that led to the strong absorption by GO.", [["GO surface", "ANATOMY", 61, 71], ["nucleobases", "CHEMICAL", 17, 28], ["ssDNA", "CELLULAR_COMPONENT", 32, 37], ["the nucleobases of ssDNA", "PROBLEM", 13, 37]]], ["Such interaction was ascribed to the \u03c0-\u03c0 stacking interactions between its nucleobases and hexagonal rings of GO.", [["nucleobases", "CHEMICAL", 75, 86]]], ["Whereas, the nucleobases of dsDNA in helical structure were shielded, so that GO could not stably adsorb it ( Fig. 3(a) ).", [["dsDNA", "CELLULAR_COMPONENT", 28, 33], ["dsDNA", "PROBLEM", 28, 33], ["dsDNA", "OBSERVATION", 28, 33]]], ["Li's group [57] constructed graphene-based fluorescence resonance energy transfer (FRET) aptasensor for detection of thrombin by assembling FAM-labeled aptamer on graphene.", [["Li", "CHEMICAL", 0, 2], ["graphene", "CHEMICAL", 28, 36], ["FAM", "CHEMICAL", 140, 143], ["graphene", "CHEMICAL", 163, 171], ["Li", "CHEMICAL", 0, 2], ["graphene", "CHEMICAL", 28, 36], ["graphene", "CHEMICAL", 163, 171], ["thrombin", "GENE_OR_GENE_PRODUCT", 117, 125], ["FAM", "SIMPLE_CHEMICAL", 140, 143], ["graphene", "SIMPLE_CHEMICAL", 163, 171], ["thrombin", "PROTEIN", 117, 125], ["Li's group", "TEST", 0, 10], ["constructed graphene", "TEST", 16, 36], ["thrombin", "TREATMENT", 117, 125]]], ["When thrombin was introduced, it caused the conformational change of aptamer that induced the recovery of fluorescence ( Fig. 3(b) ).", [["thrombin", "GENE_OR_GENE_PRODUCT", 5, 13], ["thrombin", "PROTEIN", 5, 13], ["thrombin", "TREATMENT", 5, 13], ["the conformational change of aptamer", "PROBLEM", 40, 76]]], ["Liu and Maheshwari et al. [58] reported the binding efficiency of DNA to GO surface depends on DNA length, salt, pH, solvent, and temperature.", [["surface", "ANATOMY", 76, 83], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["salt", "SIMPLE_CHEMICAL", 107, 111], ["the binding efficiency of DNA", "PROBLEM", 40, 69], ["DNA length", "TEST", 95, 105]]], ["As reported, short DNA strands usually had faster kinetics and higher adsorption efficiency than long DNA strands.", [["DNA", "CELLULAR_COMPONENT", 19, 22], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["short DNA strands", "DNA", 13, 30], ["long DNA strands", "DNA", 97, 113], ["short DNA strands", "PROBLEM", 13, 30], ["faster kinetics", "PROBLEM", 43, 58], ["higher adsorption efficiency", "PROBLEM", 63, 91], ["long DNA strands", "PROBLEM", 97, 113], ["higher", "OBSERVATION_MODIFIER", 63, 69], ["adsorption efficiency", "OBSERVATION", 70, 91]]], ["Also, higher salt concentration, lower pH value, and additional organic solvent facilitated the absorption of DNA on GO.Interactions between graphene and nucleic acidsKumar et al. [59] compared the interactions of DNA, polyamide (PNA) and polycarbamatenucleic acid (PCNA) oligomers with GO.", [["salt", "CHEMICAL", 13, 17], ["graphene", "CHEMICAL", 141, 149], ["polyamide", "CHEMICAL", 219, 228], ["PNA", "CHEMICAL", 230, 233], ["polycarbamatenucleic acid", "CHEMICAL", 239, 264], ["graphene", "CHEMICAL", 141, 149], ["polyamide", "CHEMICAL", 219, 228], ["PNA", "CHEMICAL", 230, 233], ["polycarbamatenucleic acid", "CHEMICAL", 239, 264], ["PCNA", "CHEMICAL", 266, 270], ["salt", "SIMPLE_CHEMICAL", 13, 17], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["graphene", "SIMPLE_CHEMICAL", 141, 149], ["DNA", "CELLULAR_COMPONENT", 214, 217], ["polyamide", "SIMPLE_CHEMICAL", 219, 228], ["PNA", "SIMPLE_CHEMICAL", 230, 233], ["polycarbamatenucleic acid", "SIMPLE_CHEMICAL", 239, 264], ["PCNA", "SIMPLE_CHEMICAL", 266, 270], ["PCNA", "PROTEIN", 266, 270], ["higher salt concentration", "PROBLEM", 6, 31], ["lower pH value", "PROBLEM", 33, 47], ["additional organic solvent", "TREATMENT", 53, 79], ["DNA", "TREATMENT", 214, 217], ["polyamide (PNA)", "TREATMENT", 219, 234], ["polycarbamatenucleic acid (PCNA) oligomers", "TREATMENT", 239, 281], ["higher", "OBSERVATION_MODIFIER", 6, 12], ["salt concentration", "OBSERVATION", 13, 31]]], ["They claimed that PNA and D-/L-PCNA possessed higher quenching efficiencies than that of DNA due to no generation of electrostatic charge repulsions.", [["L-PCNA", "CHEMICAL", 29, 35], ["PNA", "SIMPLE_CHEMICAL", 18, 21], ["D-/L-PCNA", "SIMPLE_CHEMICAL", 26, 35], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["PNA", "PROBLEM", 18, 21], ["D-/L-PCNA", "PROBLEM", 26, 35], ["higher quenching efficiencies", "PROBLEM", 46, 75], ["DNA", "PROBLEM", 89, 92], ["electrostatic charge repulsions", "PROBLEM", 117, 148], ["PNA", "OBSERVATION", 18, 21], ["quenching efficiencies", "OBSERVATION", 53, 75], ["electrostatic", "OBSERVATION", 117, 130], ["charge repulsions", "OBSERVATION", 131, 148]]], ["Yang et al. [60] reported that ssRNA showed similar adsorption and desorption abilities towards GO to ssDNA, as well as effective protection from enzymatic cleavage.", [["ssDNA", "CELLULAR_COMPONENT", 102, 107], ["ssRNA", "PROBLEM", 31, 36], ["enzymatic cleavage", "TREATMENT", 146, 164], ["enzymatic cleavage", "OBSERVATION", 146, 164]]], ["Huang and co-workers [61] explored the size effect of nGO on ssDNA binding.", [["nGO", "CHEMICAL", 54, 57], ["nGO", "CHEMICAL", 54, 57], ["nGO", "SIMPLE_CHEMICAL", 54, 57], ["ssDNA", "CELLULAR_COMPONENT", 61, 66], ["nGO", "PROTEIN", 54, 57]]], ["They found that nGO sheets with ~ 200 nm lateral dimensions had the highest quenching efficiency, while nGO sheets of ~ 40 nm exhibited much weaker quenching efficiency (Fig. 3(c) ).Interactions between graphene and nucleic acidsBased upon the above findings, nucleic acid/graphene complexes have been used for DNA hybridization [62] , DNA sequencing [63] , protein identification [64] , and cancer cell realization [65] .", [["nGO sheets", "ANATOMY", 16, 26], ["cancer cell", "ANATOMY", 392, 403], ["graphene", "CHEMICAL", 203, 211], ["nucleic acids", "CHEMICAL", 216, 229], ["nucleic acid", "CHEMICAL", 260, 272], ["graphene", "CHEMICAL", 273, 281], ["cancer", "DISEASE", 392, 398], ["graphene", "CHEMICAL", 203, 211], ["graphene", "CHEMICAL", 273, 281], ["graphene", "SIMPLE_CHEMICAL", 203, 211], ["nucleic acids", "SIMPLE_CHEMICAL", 216, 229], ["nucleic acid", "SIMPLE_CHEMICAL", 260, 272], ["DNA", "CELLULAR_COMPONENT", 311, 314], ["DNA", "CELLULAR_COMPONENT", 336, 339], ["cancer cell", "CELL", 392, 403], ["nucleic acid/graphene complexes", "PROTEIN", 260, 291], ["nGO sheets", "TEST", 16, 26], ["the highest quenching efficiency", "PROBLEM", 64, 96], ["nGO sheets", "TEST", 104, 114], ["much weaker quenching efficiency", "PROBLEM", 136, 168], ["nucleic acids", "TREATMENT", 216, 229], ["the above findings", "TEST", 240, 258], ["nucleic acid/graphene complexes", "TREATMENT", 260, 291], ["DNA hybridization", "TEST", 311, 328], ["DNA sequencing", "TEST", 336, 350], ["protein identification", "TEST", 358, 380], ["cancer cell realization", "PROBLEM", 392, 415], ["highest", "OBSERVATION_MODIFIER", 68, 75], ["quenching efficiency", "OBSERVATION", 76, 96], ["quenching efficiency", "OBSERVATION", 148, 168], ["cancer cell", "OBSERVATION", 392, 403]]], ["Fan and Hu et al. [64] used different DNA elements with high-precision identification for given analytes to set a small library of \"ensemble aptamers\" possessing \"lock-and-key\" recognition with molecular or cellular targets.", [["cellular", "ANATOMY", 207, 215], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["cellular", "CELL", 207, 215], ["DNA elements", "DNA", 38, 50], ["different DNA elements", "TREATMENT", 28, 50], ["cellular targets", "OBSERVATION", 207, 223]]], ["Wang and Zhou et al. [62] determined the binding kinetics and affinity of DNA hybridization in real-time based on multi-channel graphene field-effect transistor (FET) sensors, where an analytical model was described for the evaluation of probe density, hybridization efficiency, and the maximum signal response.Interactions between graphene and nucleic acidsIn addition, some signal amplification strategies, such as rolling circulation amplification (RCA) [66, 67] , hybridization chain reaction (HCR) [68] , exonuclease III (Exo III)-triggered recycling of the targets [69, 70] , have also been coupled to improve the properties of graphene/nucleic acids complexes.", [["graphene", "CHEMICAL", 332, 340], ["nucleic acids", "CHEMICAL", 345, 358], ["graphene", "CHEMICAL", 634, 642], ["nucleic acids", "CHEMICAL", 643, 656], ["graphene", "CHEMICAL", 128, 136], ["graphene", "CHEMICAL", 332, 340], ["graphene", "CHEMICAL", 634, 642], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["graphene", "SIMPLE_CHEMICAL", 332, 340], ["nucleic acids", "SIMPLE_CHEMICAL", 345, 358], ["exonuclease III", "GENE_OR_GENE_PRODUCT", 510, 525], ["Exo III", "GENE_OR_GENE_PRODUCT", 527, 534], ["graphene/nucleic acids", "SIMPLE_CHEMICAL", 634, 656], ["exonuclease III", "PROTEIN", 510, 525], ["Exo III", "PROTEIN", 527, 534], ["graphene/nucleic acids complexes", "PROTEIN", 634, 666], ["the binding kinetics", "PROBLEM", 37, 57], ["DNA hybridization", "TREATMENT", 74, 91], ["multi-channel graphene field", "TREATMENT", 114, 142], ["transistor (FET) sensors", "TREATMENT", 150, 174], ["the evaluation", "TEST", 220, 234], ["hybridization efficiency", "PROBLEM", 253, 277], ["nucleic acids", "TEST", 345, 358], ["some signal amplification strategies", "PROBLEM", 371, 407], ["hybridization chain reaction", "TEST", 468, 496], ["HCR", "TEST", 498, 501], ["exonuclease III", "TEST", 510, 525], ["graphene/nucleic acids complexes", "TREATMENT", 634, 666], ["amplification strategies", "OBSERVATION", 383, 407]]], ["For example, Li's group [66] developed a graphene-based biosensing platform for ultrasensitive detection of thrombin and ATP based on rGO and rolling circulation amplification (RCA) (Fig. 3(d) ).", [["Li", "CHEMICAL", 13, 15], ["graphene", "CHEMICAL", 41, 49], ["ATP", "CHEMICAL", 121, 124], ["Li", "CHEMICAL", 13, 15], ["graphene", "CHEMICAL", 41, 49], ["ATP", "CHEMICAL", 121, 124], ["graphene", "SIMPLE_CHEMICAL", 41, 49], ["thrombin", "GENE_OR_GENE_PRODUCT", 108, 116], ["ATP", "SIMPLE_CHEMICAL", 121, 124], ["rGO", "SIMPLE_CHEMICAL", 134, 137], ["thrombin", "PROTEIN", 108, 116], ["a graphene", "TREATMENT", 39, 49], ["thrombin", "PROBLEM", 108, 116], ["ATP", "PROBLEM", 121, 124], ["rGO and rolling circulation amplification (RCA", "TREATMENT", 134, 180], ["thrombin", "OBSERVATION", 108, 116], ["RCA", "ANATOMY", 177, 180]]], ["Fan's group [68] utilized GO as nanoprobes to investigate the interactions between GO and different DNA structures and real-time monitor HCR and RCA amplification process (Fig. 3(e) ).Interactions between graphene and nucleic acidsApart from experimental studies, some theoretical researches have also been carried out regarding the binding mechanisms between graphene and nucleic acids.", [["graphene", "CHEMICAL", 205, 213], ["nucleic acids", "CHEMICAL", 218, 231], ["graphene", "CHEMICAL", 360, 368], ["nucleic acids", "CHEMICAL", 373, 386], ["graphene", "CHEMICAL", 205, 213], ["graphene", "CHEMICAL", 360, 368], ["DNA", "CELLULAR_COMPONENT", 100, 103], ["graphene", "SIMPLE_CHEMICAL", 205, 213], ["nucleic acids", "SIMPLE_CHEMICAL", 218, 231], ["graphene", "SIMPLE_CHEMICAL", 360, 368], ["nucleic acids", "SIMPLE_CHEMICAL", 373, 386], ["RCA", "PROTEIN", 145, 148], ["nanoprobes", "TREATMENT", 32, 42], ["different DNA structures", "PROBLEM", 90, 114], ["HCR", "TEST", 137, 140], ["RCA amplification process", "TREATMENT", 145, 170], ["nucleic acids", "TEST", 218, 231], ["experimental studies", "TEST", 242, 262], ["graphene and nucleic acids", "TREATMENT", 360, 386], ["RCA", "ANATOMY", 145, 148]]], ["Gowtham et al. [71] investigated the interaction of nucleobases with graphene using density-functional theory (DFT) framework, finding the calculated binding energy in the order as G > A \u2248 T \u2248 C > U. Rao and co-workers [72] optimized the structures of nucleobase/graphene and calculated binding energies following the sequence of G > A > T > C by using the Jaguar computational package.", [["graphene", "CHEMICAL", 69, 77], ["nucleobase", "CHEMICAL", 252, 262], ["graphene", "CHEMICAL", 263, 271], ["nucleobases", "CHEMICAL", 52, 63], ["graphene", "CHEMICAL", 69, 77], ["nucleobase", "CHEMICAL", 252, 262], ["graphene", "CHEMICAL", 263, 271], ["graphene", "SIMPLE_CHEMICAL", 69, 77], ["graphene", "SIMPLE_CHEMICAL", 263, 271], ["nucleobase/graphene", "TREATMENT", 252, 271], ["calculated binding energies", "PROBLEM", 276, 303], ["the sequence", "TEST", 314, 326], ["G", "TEST", 330, 331], ["the Jaguar computational package", "TREATMENT", 353, 385]]], ["Bhattacharyya et al. [73] reported ab initio quantum chemical calculations of graphene/nucleobase complexes by dispersion corrected DFT.", [["graphene", "CHEMICAL", 78, 86], ["nucleobase", "CHEMICAL", 87, 97], ["graphene", "CHEMICAL", 78, 86], ["nucleobase", "CHEMICAL", 87, 97], ["graphene/nucleobase complexes", "SIMPLE_CHEMICAL", 78, 107], ["ab initio quantum chemical calculations of graphene/nucleobase complexes", "TREATMENT", 35, 107], ["nucleobase complexes", "OBSERVATION", 87, 107]]], ["It was found that large graphene sheets with curvatures might be more stable for nucleobase binding.Interactions between graphene and proteinsProteins are fundamental elements in all living organisms, which has physiological activities within cells.", [["cells", "ANATOMY", 243, 248], ["graphene", "CHEMICAL", 24, 32], ["nucleobase", "CHEMICAL", 81, 91], ["graphene", "CHEMICAL", 24, 32], ["nucleobase", "CHEMICAL", 81, 91], ["graphene", "CHEMICAL", 121, 129], ["nucleobase", "SIMPLE_CHEMICAL", 81, 91], ["cells", "CELL", 243, 248], ["large graphene sheets with curvatures", "PROBLEM", 18, 55], ["nucleobase binding", "PROBLEM", 81, 99], ["fundamental elements", "PROBLEM", 155, 175], ["all living organisms", "PROBLEM", 179, 199], ["large", "OBSERVATION_MODIFIER", 18, 23], ["graphene sheets", "OBSERVATION", 24, 39], ["fundamental elements", "OBSERVATION", 155, 175]]], ["For nanomaterials to enter biological mediums, the first thing to encounter are the interaction with proteins (i.e., proteins, lipids, enzymes) [74] [75] [76] .", [["lipids", "SIMPLE_CHEMICAL", 127, 133], ["enzymes", "PROTEIN", 135, 142], ["enzymes", "TEST", 135, 142]]], ["Therefore, investigations of the interactions between graphene and proteins are essential for study the cellular uptake and biological toxicity of graphene.Interactions between graphene and proteinsSeo et al. [77] explored the adsorption topography on the surface of GO by atomic force microscopy (AFM).", [["cellular", "ANATOMY", 104, 112], ["surface", "ANATOMY", 256, 263], ["toxicity", "DISEASE", 135, 143], ["graphene", "CHEMICAL", 147, 155], ["graphene", "CHEMICAL", 177, 185], ["graphene", "CHEMICAL", 54, 62], ["graphene", "CHEMICAL", 147, 155], ["graphene", "CHEMICAL", 177, 185], ["graphene", "SIMPLE_CHEMICAL", 54, 62], ["cellular", "CELL", 104, 112], ["graphene", "SIMPLE_CHEMICAL", 147, 155], ["graphene", "SIMPLE_CHEMICAL", 177, 185], ["surface", "CELLULAR_COMPONENT", 256, 263], ["the interactions between graphene and proteins", "TEST", 29, 75], ["the cellular uptake", "PROBLEM", 100, 119], ["biological toxicity of graphene", "PROBLEM", 124, 155], ["the adsorption topography", "TEST", 223, 248], ["atomic force microscopy", "TEST", 273, 296]]], ["The antibody was particularly linked on the edges and folded structures of GO where were rich of carboxylic acid groups.", [["carboxylic acid", "CHEMICAL", 97, 112], ["carboxylic acid", "CHEMICAL", 97, 112], ["carboxylic acid", "SIMPLE_CHEMICAL", 97, 112], ["The antibody", "TEST", 0, 12], ["carboxylic acid groups", "TREATMENT", 97, 119], ["carboxylic acid", "OBSERVATION", 97, 112]]], ["Fan and Liu et al. [78] found that GO was an efficient quencher for fluorescent conjugated oligomer FBT with extensive \u03b1-mannose side.", [["\u03b1-mannose", "CHEMICAL", 119, 128], ["FBT", "CHEMICAL", 100, 103], ["\u03b1-mannose", "CHEMICAL", 119, 128], ["FBT", "SIMPLE_CHEMICAL", 100, 103], ["an efficient quencher", "TREATMENT", 42, 63], ["fluorescent conjugated oligomer FBT", "TREATMENT", 68, 103], ["extensive \u03b1-mannose side", "TREATMENT", 109, 133]]], ["In the presence of concanavalin A (ConA), the specific binding between FBT and ConA prevented GO/FBT interact which led to light-up sensing of lectin and Escherichia Coli (E. coli) (Fig. 3(f) ).", [["concanavalin A", "CHEMICAL", 19, 33], ["FBT", "CHEMICAL", 71, 74], ["FBT", "CHEMICAL", 97, 100], ["concanavalin A", "SIMPLE_CHEMICAL", 19, 33], ["ConA", "GENE_OR_GENE_PRODUCT", 35, 39], ["FBT", "GENE_OR_GENE_PRODUCT", 71, 74], ["ConA", "SIMPLE_CHEMICAL", 79, 83], ["FBT", "GENE_OR_GENE_PRODUCT", 97, 100], ["lectin", "GENE_OR_GENE_PRODUCT", 143, 149], ["Escherichia Coli", "ORGANISM", 154, 170], ["E. coli", "ORGANISM", 172, 179], ["concanavalin A", "PROTEIN", 19, 33], ["ConA", "PROTEIN", 35, 39], ["FBT", "PROTEIN", 71, 74], ["ConA", "PROTEIN", 79, 83], ["FBT", "PROTEIN", 97, 100], ["lectin", "PROTEIN", 143, 149], ["Escherichia Coli", "SPECIES", 154, 170], ["E. coli", "SPECIES", 172, 179], ["Escherichia Coli", "SPECIES", 154, 170], ["E. coli", "SPECIES", 172, 179], ["ConA prevented GO/FBT", "TREATMENT", 79, 100], ["Escherichia Coli (E. coli", "PROBLEM", 154, 179], ["Escherichia Coli", "OBSERVATION", 154, 170], ["E. coli", "OBSERVATION_MODIFIER", 172, 179]]], ["Dravid et al. [79] used nGO with 20 nm lateral dimensions as artificial receptor to identify 48 unknown proteins at concentrations of 100 and 10 nM.", [["20 nm lateral dimensions", "TREATMENT", 33, 57], ["artificial receptor", "TREATMENT", 61, 80]]], ["Liu and Peng et al. [80] studied the effects of PEGylation on serum behaviors of GO by using LC-MS/MS and Western blot analysis.", [["serum", "ANATOMY", 62, 67], ["serum", "ORGANISM_SUBSTANCE", 62, 67], ["PEGylation", "TREATMENT", 48, 58], ["MS", "PROBLEM", 99, 101], ["Western blot analysis", "TEST", 106, 127]]], ["They found PEGylated nGO (PEG-nGO) generated a nanointerface that significantly reduced serum protein binding and complement C3 activation.", [["serum", "ANATOMY", 88, 93], ["PEG-nGO", "CHEMICAL", 26, 33], ["nGO", "CHEMICAL", 21, 24], ["PEG-nGO", "CHEMICAL", 26, 33], ["PEGylated nGO", "SIMPLE_CHEMICAL", 11, 24], ["PEG-nGO", "SIMPLE_CHEMICAL", 26, 33], ["serum", "ORGANISM_SUBSTANCE", 88, 93], ["complement C3", "GENE_OR_GENE_PRODUCT", 114, 127], ["nGO", "PROTEIN", 30, 33], ["serum protein", "PROTEIN", 88, 101], ["complement C3", "PROTEIN", 114, 127], ["PEGylated nGO (PEG", "TREATMENT", 11, 29], ["significantly reduced serum protein binding", "PROBLEM", 66, 109], ["complement C3 activation", "PROBLEM", 114, 138], ["PEGylated", "OBSERVATION_MODIFIER", 11, 20], ["protein binding", "OBSERVATION", 94, 109], ["C3 activation", "OBSERVATION", 125, 138]]], ["Niu and Chi et al. [81] investigated the interactions between stabilized chemical converted graphene (sCCG) and blood proteins.", [["blood", "ANATOMY", 112, 117], ["graphene", "CHEMICAL", 92, 100], ["sCCG", "CHEMICAL", 102, 106], ["graphene", "CHEMICAL", 92, 100], ["sCCG", "CHEMICAL", 102, 106], ["graphene", "SIMPLE_CHEMICAL", 92, 100], ["sCCG", "SIMPLE_CHEMICAL", 102, 106], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["chemical converted graphene (sCCG) and blood proteins", "PROTEIN", 73, 126], ["blood proteins", "TEST", 112, 126]]], ["It is revealed that the sCCG/protein binds via the \u03c0-\u03c0 interactions.Interactions between graphene and proteinsInvestigation of the peptide-graphene interactions can be useful for understanding the protein functions within cells [82] [83] [84] .", [["cells", "ANATOMY", 222, 227], ["graphene", "CHEMICAL", 89, 97], ["graphene", "CHEMICAL", 89, 97], ["graphene", "CHEMICAL", 139, 147], ["sCCG", "GENE_OR_GENE_PRODUCT", 24, 28], ["\u03c0-\u03c0", "GENE_OR_GENE_PRODUCT", 51, 54], ["graphene", "SIMPLE_CHEMICAL", 89, 97], ["cells", "CELL", 222, 227], ["sCCG", "PROTEIN", 24, 28], ["the sCCG/protein binds", "TREATMENT", 20, 42], ["the peptide-graphene interactions", "TREATMENT", 127, 160]]], ["Huang et al. [82] developed a GO-based fluorescence resonance energy transfer (FRET)-biosensor using fluoresce in isothiocyanate (FITC)labeled octreotide (FOC) ( Fig. 3(g) ).", [["octreotide", "CHEMICAL", 143, 153], ["isothiocyanate", "CHEMICAL", 114, 128], ["FITC", "CHEMICAL", 130, 134], ["octreotide", "CHEMICAL", 143, 153], ["fluoresce in isothiocyanate", "SIMPLE_CHEMICAL", 101, 128], ["FITC", "SIMPLE_CHEMICAL", 130, 134], ["octreotide", "SIMPLE_CHEMICAL", 143, 153], ["FOC", "SIMPLE_CHEMICAL", 155, 158], ["fluoresce in isothiocyanate (FITC)labeled octreotide (FOC)", "TREATMENT", 101, 159]]], ["As a result, FOC showed a high absorption affinity and high kinetics for GO via electrostatic forces and \u03c0-\u03c0 interactions, but a lower quenching efficiency of 78% than that for ssDNA.", [["FOC", "CHEMICAL", 13, 16], ["FOC", "SIMPLE_CHEMICAL", 13, 16], ["\u03c0-\u03c0", "SIMPLE_CHEMICAL", 105, 108], ["ssDNA", "CELLULAR_COMPONENT", 177, 182], ["a high absorption affinity", "PROBLEM", 24, 50], ["high kinetics", "PROBLEM", 55, 68], ["a lower quenching efficiency", "PROBLEM", 127, 155], ["ssDNA", "PROBLEM", 177, 182], ["electrostatic forces", "OBSERVATION", 80, 100]]], ["Very recently, Chen et al. [83] experimentally and theoretically studied the interactions between two peptides (cecropin P1 and MSI-78(C1)) and graphene via sum frequency generation vibrational spectroscopy and MD simulation ( Fig. 3(h) ).", [["graphene", "CHEMICAL", 144, 152], ["graphene", "CHEMICAL", 144, 152], ["graphene", "SIMPLE_CHEMICAL", 144, 152], ["two peptides (cecropin P1", "TREATMENT", 98, 123], ["MSI", "TEST", 128, 131], ["graphene", "TREATMENT", 144, 152], ["vibrational spectroscopy", "TEST", 182, 206]]], ["They found that the competition between planar and charged hydrophilic residues significantly affected the peptide-graphene interactions.Graphene and virusesSome global infectious diseases that threat to human health have been caused by emerging and reemerging viruses, like Ebola, Zika, MERS-CoV and avian influenza virus.", [["Graphene", "CHEMICAL", 137, 145], ["infectious diseases", "DISEASE", 169, 188], ["Ebola", "DISEASE", 275, 280], ["avian influenza virus", "DISEASE", 301, 322], ["graphene", "CHEMICAL", 115, 123], ["Graphene", "CHEMICAL", 137, 145], ["graphene", "SIMPLE_CHEMICAL", 115, 123], ["human", "ORGANISM", 204, 209], ["Ebola", "ORGANISM", 275, 280], ["Zika", "ORGANISM", 282, 286], ["MERS-CoV", "ORGANISM", 288, 296], ["avian influenza virus", "ORGANISM", 301, 322], ["human", "SPECIES", 204, 209], ["Ebola", "SPECIES", 275, 280], ["MERS-CoV", "SPECIES", 288, 296], ["avian influenza virus", "SPECIES", 301, 322], ["human", "SPECIES", 204, 209], ["MERS-CoV", "SPECIES", 288, 296], ["the competition between planar and charged hydrophilic residues", "PROBLEM", 16, 79], ["the peptide-graphene interactions", "TREATMENT", 103, 136], ["Graphene", "TREATMENT", 137, 145], ["Some global infectious diseases", "PROBLEM", 157, 188], ["Ebola", "PROBLEM", 275, 280], ["Zika", "PROBLEM", 282, 286], ["CoV", "PROBLEM", 293, 296], ["avian influenza virus", "PROBLEM", 301, 322], ["hydrophilic residues", "OBSERVATION", 59, 79], ["global", "OBSERVATION_MODIFIER", 162, 168], ["infectious", "OBSERVATION", 169, 179], ["influenza virus", "OBSERVATION", 307, 322]]], ["Owing to the superior physiochemical properties, graphene-based nanomaterials have been focused on the biological responses of viruses, including the capture and destruction, attachment inhibition, and detection of viruses.", [["graphene", "CHEMICAL", 49, 57], ["graphene", "CHEMICAL", 49, 57], ["graphene", "SIMPLE_CHEMICAL", 49, 57], ["viruses", "PROBLEM", 127, 134], ["destruction", "PROBLEM", 162, 173], ["viruses", "PROBLEM", 215, 222], ["viruses", "OBSERVATION", 127, 134], ["destruction", "OBSERVATION", 162, 173], ["viruses", "OBSERVATION", 215, 222]]], ["Min et al. [85] developed a multiplexed GO-based helicase assay (mGOHA) based on GO to screen viral enzymes: inhibitors of HCV NS3 helicase and severe acute respirator syndrome coronavirus (SARS CoV) helicase.", [["acute respirator syndrome coronavirus", "DISEASE", 151, 188], ["HCV NS3", "ORGANISM", 123, 130], ["SARS CoV", "ORGANISM", 190, 198], ["viral enzymes", "PROTEIN", 94, 107], ["HCV NS3 helicase", "PROTEIN", 123, 139], ["severe acute respirator syndrome coronavirus (SARS CoV) helicase", "PROTEIN", 144, 208], ["HCV", "SPECIES", 123, 126], ["acute respirator syndrome coronavirus", "SPECIES", 151, 188], ["SARS CoV", "SPECIES", 190, 198], ["a multiplexed GO-based helicase assay", "PROBLEM", 26, 63], ["viral enzymes", "TEST", 94, 107], ["inhibitors", "TREATMENT", 109, 119], ["HCV NS3 helicase", "TREATMENT", 123, 139], ["severe acute respirator syndrome coronavirus", "PROBLEM", 144, 188], ["helicase", "PROBLEM", 200, 208], ["severe", "OBSERVATION_MODIFIER", 144, 150], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["respirator syndrome", "OBSERVATION", 157, 176]]], ["As a result, 22 inhibitors of HCV NS3 helicase, 26 of SARS CoV helicase and 24 of both helicases was discovered from a 10,000 small molecule library.", [["HCV NS3", "ORGANISM", 30, 37], ["SARS CoV", "ORGANISM", 54, 62], ["HCV NS3 helicase", "PROTEIN", 30, 46], ["SARS CoV helicase", "PROTEIN", 54, 71], ["helicases", "PROTEIN", 87, 96], ["HCV", "SPECIES", 30, 33], ["SARS CoV", "SPECIES", 54, 62], ["22 inhibitors", "TREATMENT", 13, 26], ["HCV NS3 helicase", "TREATMENT", 30, 46], ["SARS CoV helicase", "TREATMENT", 54, 71]]], ["Wang and Tang et al. [86] demonstrated that GO could act as a label-free material for detection and disinfection of enteric viruses: EV71 and H9N2.", [["H9N2", "DISEASE", 142, 146], ["EV71", "ORGANISM", 133, 137], ["H9N2", "ORGANISM", 142, 146], ["H9N2", "SPECIES", 142, 146], ["EV71", "SPECIES", 133, 137], ["enteric viruses", "PROBLEM", 116, 131], ["EV71", "PROBLEM", 133, 137], ["H9N2", "TREATMENT", 142, 146], ["enteric", "ANATOMY", 116, 123], ["viruses", "OBSERVATION", 124, 131]]], ["GO can effectively interact with viruses, as well as significantly improve the destruction, removal and disinfection that achieved at least 6-log inactivation.", [["the destruction", "PROBLEM", 75, 90], ["removal", "TREATMENT", 92, 99], ["disinfection", "TREATMENT", 104, 116], ["destruction", "OBSERVATION", 79, 90]]], ["Gedanken and Sarid et al. [87] prepared sulfonated magnetic nanoparticles functionalized reduced graphene oxide (SMRGO) to capture and photothermally destroy herpes simplex virus type 1 (HSV-1).", [["graphene oxide", "CHEMICAL", 97, 111], ["SMRGO", "CHEMICAL", 113, 118], ["herpes simplex virus", "DISEASE", 158, 178], ["graphene oxide", "CHEMICAL", 97, 111], ["SMRGO", "CHEMICAL", 113, 118], ["sulfonated magnetic nanoparticles functionalized reduced graphene oxide", "SIMPLE_CHEMICAL", 40, 111], ["SMRGO", "SIMPLE_CHEMICAL", 113, 118], ["herpes simplex virus type 1", "ORGANISM", 158, 185], ["HSV-1", "ORGANISM", 187, 192], ["herpes simplex virus type 1", "SPECIES", 158, 185], ["HSV-1", "SPECIES", 187, 192], ["herpes simplex virus type 1", "SPECIES", 158, 185], ["HSV-1", "SPECIES", 187, 192], ["prepared sulfonated magnetic nanoparticles functionalized reduced graphene oxide (SMRGO)", "TREATMENT", 31, 119], ["photothermally destroy herpes simplex virus type", "PROBLEM", 135, 183], ["HSV", "TEST", 187, 190]]], ["They found that SMRGO could be served as an effective antiviral agent (~ 99.99%) with a short capture time of 7 min.", [["SMRGO", "CHEMICAL", 16, 21], ["SMRGO", "CHEMICAL", 16, 21], ["SMRGO", "SIMPLE_CHEMICAL", 16, 21], ["SMRGO", "PROBLEM", 16, 21], ["an effective antiviral agent", "TREATMENT", 41, 69]]], ["Gadanken et al. [88] reported that HSV-1 infections were inhibited by GO and partially reduced sulfonated GO (rGO-SO3) via a competitive inhibition mechanism.", [["infections", "DISEASE", 41, 51], ["rGO-SO3", "CHEMICAL", 110, 117], ["rGO-SO3", "CHEMICAL", 110, 117], ["HSV-1", "ORGANISM", 35, 40], ["sulfonated GO", "SIMPLE_CHEMICAL", 95, 108], ["rGO-SO3", "SIMPLE_CHEMICAL", 110, 117], ["HSV-1", "SPECIES", 35, 40], ["HSV", "PROBLEM", 35, 38], ["1 infections", "PROBLEM", 39, 51], ["partially reduced sulfonated GO (rGO-SO3", "TREATMENT", 77, 117], ["a competitive inhibition mechanism", "TREATMENT", 123, 157]]], ["Recently, Adeli and Haag et al. [89] synthesized highly active functionalized graphene sheets containing 6% graphene and 94% sulfated polyglycerol, which are able to trap 20 virions by individual sheets with the size of ~ 1 \uf06dm \u00d7 1 \uf06dm.Graphene and virusesMoreover, some graphene and its derivatives-based biosensing assays have been employed for analyzing viruses.", [["graphene", "CHEMICAL", 78, 86], ["graphene", "CHEMICAL", 108, 116], ["polyglycerol", "CHEMICAL", 134, 146], ["Graphene", "CHEMICAL", 234, 242], ["graphene", "CHEMICAL", 269, 277], ["graphene", "CHEMICAL", 78, 86], ["graphene", "CHEMICAL", 108, 116], ["polyglycerol", "CHEMICAL", 134, 146], ["Graphene", "CHEMICAL", 234, 242], ["graphene", "CHEMICAL", 269, 277], ["graphene", "SIMPLE_CHEMICAL", 108, 116], ["sulfated polyglycerol", "SIMPLE_CHEMICAL", 125, 146], ["graphene", "SIMPLE_CHEMICAL", 269, 277], ["synthesized highly active functionalized graphene sheets", "TREATMENT", 37, 93], ["6% graphene", "TREATMENT", 105, 116], ["94% sulfated polyglycerol", "TREATMENT", 121, 146], ["Graphene", "TREATMENT", 234, 242], ["viruses", "TREATMENT", 247, 254], ["some graphene", "TREATMENT", 264, 277], ["its derivatives", "TREATMENT", 282, 297], ["based biosensing assays", "TEST", 298, 321], ["analyzing viruses", "PROBLEM", 345, 362], ["size", "OBSERVATION_MODIFIER", 212, 216], ["viruses", "OBSERVATION", 247, 254]]], ["For instance, colorimetric analysis of respiratory syncytial virus (RSV) using AuNP-GO hybrids [90] , and graphene-FET biochip for Zika virus detection have been reported [91] .", [["respiratory syncytial virus", "DISEASE", 39, 66], ["AuNP", "CHEMICAL", 79, 83], ["graphene", "CHEMICAL", 106, 114], ["graphene", "CHEMICAL", 106, 114], ["respiratory syncytial virus", "ORGANISM", 39, 66], ["RSV", "ORGANISM", 68, 71], ["AuNP", "SIMPLE_CHEMICAL", 79, 83], ["graphene-FET", "SIMPLE_CHEMICAL", 106, 118], ["Zika virus", "ORGANISM", 131, 141], ["respiratory syncytial virus", "SPECIES", 39, 66], ["respiratory syncytial virus", "SPECIES", 39, 66], ["RSV", "SPECIES", 68, 71], ["Zika virus", "SPECIES", 131, 141], ["colorimetric analysis", "TEST", 14, 35], ["respiratory syncytial virus", "PROBLEM", 39, 66], ["AuNP-GO hybrids", "TREATMENT", 79, 94], ["graphene", "TREATMENT", 106, 114], ["FET biochip", "TEST", 115, 126], ["Zika virus detection", "PROBLEM", 131, 151], ["respiratory syncytial", "ANATOMY", 39, 60]]], ["To obtain mechanically reinforced ultrathin membranes, Yoo and co-workers [92] developed a novel method to unidirectionally align M13 viruses on GO sheets in large area (> 20 cm 2 ) by applying shear force, in which the engineered peptide of STB1 fused to the end of the virus through salt-bridge forces.", [["membranes", "ANATOMY", 44, 53], ["STB1", "CHEMICAL", 242, 246], ["STB1", "GENE_OR_GENE_PRODUCT", 242, 246], ["STB1", "PROTEIN", 242, 246], ["a novel method", "PROBLEM", 89, 103], ["unidirectionally align M13 viruses", "PROBLEM", 107, 141], ["STB1 fused", "PROBLEM", 242, 252], ["salt-bridge forces", "TREATMENT", 285, 303], ["large", "OBSERVATION_MODIFIER", 158, 163], ["area", "OBSERVATION_MODIFIER", 164, 168], ["bridge forces", "OBSERVATION", 290, 303]]], ["It was confirmed that the viral-nanomesh ultrathin membranes showed enhanced permeability and high size-selective exclusion.Graphene and mammalian cellsLike other carbon nanomaterials (i.e., CNTs), graphene-based nanomaterials could also influence cell morphology, adhesion, differentiation, migration, proliferation and cytoskeleton organization.", [["membranes", "ANATOMY", 51, 60], ["cell", "ANATOMY", 248, 252], ["cytoskeleton", "ANATOMY", 321, 333], ["Graphene", "CHEMICAL", 124, 132], ["graphene", "CHEMICAL", 198, 206], ["Graphene", "CHEMICAL", 124, 132], ["carbon", "CHEMICAL", 163, 169], ["graphene", "CHEMICAL", 198, 206], ["Graphene", "SIMPLE_CHEMICAL", 124, 132], ["carbon nanomaterials", "SIMPLE_CHEMICAL", 163, 183], ["graphene", "SIMPLE_CHEMICAL", 198, 206], ["cell", "CELL", 248, 252], ["cytoskeleton", "CELLULAR_COMPONENT", 321, 333], ["the viral-nanomesh ultrathin membranes", "TEST", 22, 60], ["enhanced permeability", "PROBLEM", 68, 89], ["Graphene", "TREATMENT", 124, 132], ["mammalian cellsLike other carbon nanomaterials", "TREATMENT", 137, 183], ["graphene-based nanomaterials", "TREATMENT", 198, 226], ["adhesion", "PROBLEM", 265, 273], ["proliferation and cytoskeleton organization", "PROBLEM", 303, 346], ["permeability", "OBSERVATION_MODIFIER", 77, 89], ["high", "OBSERVATION_MODIFIER", 94, 98], ["size", "OBSERVATION_MODIFIER", 99, 103], ["selective", "OBSERVATION_MODIFIER", 104, 113], ["exclusion", "OBSERVATION", 114, 123], ["carbon nanomaterials", "OBSERVATION", 163, 183], ["cell morphology", "OBSERVATION_MODIFIER", 248, 263], ["adhesion", "OBSERVATION_MODIFIER", 265, 273], ["migration", "OBSERVATION_MODIFIER", 292, 301], ["cytoskeleton organization", "OBSERVATION", 321, 346]]], ["Graphene paper have provided an ideal platform for the growth and proliferation of the mouse fibroblast cell line (L-929) [93] .", [["fibroblast cell line", "ANATOMY", 93, 113], ["Graphene", "CHEMICAL", 0, 8], ["mouse", "ORGANISM", 87, 92], ["fibroblast cell line", "CELL", 93, 113], ["L-929) [93]", "CELL", 115, 126], ["mouse fibroblast cell line", "CELL_LINE", 87, 113], ["L-929", "CELL_LINE", 115, 120], ["mouse", "SPECIES", 87, 92], ["mouse", "SPECIES", 87, 92], ["the growth", "PROBLEM", 51, 61], ["the mouse fibroblast cell line", "TEST", 83, 113], ["fibroblast cell line", "OBSERVATION", 93, 113]]], ["Likewise, graphene also serves as a preconcentration platform for osteogenic inducers for stem cell differentiation [94] .", [["stem cell", "ANATOMY", 90, 99], ["graphene", "CHEMICAL", 10, 18], ["graphene", "CHEMICAL", 10, 18], ["graphene", "SIMPLE_CHEMICAL", 10, 18], ["stem cell", "CELL", 90, 99], ["a preconcentration platform", "TREATMENT", 34, 61], ["osteogenic inducers", "TREATMENT", 66, 85], ["stem cell differentiation", "TEST", 90, 115], ["stem cell differentiation", "OBSERVATION", 90, 115]]], ["Studies also suggest that graphene-based nanomaterials treated by macromolecules exhibited good biocompatibility.", [["graphene", "CHEMICAL", 26, 34], ["graphene", "CHEMICAL", 26, 34], ["graphene", "SIMPLE_CHEMICAL", 26, 34], ["Studies", "TEST", 0, 7], ["graphene-based nanomaterials", "TREATMENT", 26, 54], ["good biocompatibility", "OBSERVATION", 91, 112]]], ["Recent study [95] revealed that pristine graphene improved cell adhesion and proliferation, but it exhibits no influence on cell stress for both nonneuronal and neuronal cells, such as the mitochondrial membrane potential (MMP), the morphology and the autophagy levels.", [["cell", "ANATOMY", 59, 63], ["cell", "ANATOMY", 124, 128], ["nonneuronal", "ANATOMY", 145, 156], ["neuronal cells", "ANATOMY", 161, 175], ["mitochondrial membrane", "ANATOMY", 189, 211], ["graphene", "CHEMICAL", 41, 49], ["graphene", "CHEMICAL", 41, 49], ["pristine graphene", "SIMPLE_CHEMICAL", 32, 49], ["cell", "CELL", 59, 63], ["cell", "CELL", 124, 128], ["nonneuronal", "CELL", 145, 156], ["neuronal cells", "CELL", 161, 175], ["mitochondrial membrane", "CELLULAR_COMPONENT", 189, 211], ["nonneuronal and neuronal cells", "CELL_TYPE", 145, 175], ["Recent study", "TEST", 0, 12], ["pristine graphene improved cell adhesion", "PROBLEM", 32, 72], ["proliferation", "PROBLEM", 77, 90], ["cell stress", "PROBLEM", 124, 135], ["both nonneuronal and neuronal cells", "PROBLEM", 140, 175], ["the autophagy levels", "TEST", 248, 268], ["pristine graphene", "OBSERVATION", 32, 49], ["improved cell adhesion", "OBSERVATION", 50, 72], ["proliferation", "OBSERVATION_MODIFIER", 77, 90], ["no", "UNCERTAINTY", 108, 110], ["neuronal cells", "OBSERVATION", 161, 175], ["autophagy levels", "OBSERVATION", 252, 268]]], ["The functionalization of artificial peroxidase and extracellular matrix protein on graphene surface could improve the adhesion/growth capability of MCF-7 cells [96] .", [["extracellular matrix", "ANATOMY", 51, 71], ["graphene surface", "ANATOMY", 83, 99], ["MCF-7 cells", "ANATOMY", 148, 159], ["graphene", "CHEMICAL", 83, 91], ["graphene", "CHEMICAL", 83, 91], ["peroxidase", "GENE_OR_GENE_PRODUCT", 36, 46], ["extracellular matrix", "CELLULAR_COMPONENT", 51, 71], ["MCF-7 cells", "CELL", 148, 159], ["artificial peroxidase", "PROTEIN", 25, 46], ["extracellular matrix protein", "PROTEIN", 51, 79], ["MCF-7 cells", "CELL_LINE", 148, 159], ["The functionalization of artificial peroxidase", "TREATMENT", 0, 46], ["extracellular matrix protein on graphene surface", "TREATMENT", 51, 99], ["MCF", "TEST", 148, 151], ["artificial peroxidase", "OBSERVATION", 25, 46]]], ["Both experimental observations and MD simulations showed that GO substrates treated by a mild thermal annealing process promoted the capture of Class II MHC-positive cell induced by oxygen clustering [97] .", [["cell", "ANATOMY", 166, 170], ["oxygen", "CHEMICAL", 182, 188], ["oxygen", "CHEMICAL", 182, 188], ["Class II MHC", "GENE_OR_GENE_PRODUCT", 144, 156], ["oxygen", "SIMPLE_CHEMICAL", 182, 188], ["Class II MHC", "PROTEIN", 144, 156], ["MD simulations", "TEST", 35, 49], ["a mild thermal annealing process", "PROBLEM", 87, 119], ["oxygen clustering", "TEST", 182, 199], ["positive cell", "OBSERVATION", 157, 170]]], ["Besides acting as a good substrate, graphene has been designed as hybrid scaffold for tissue engineering applications.", [["tissue", "ANATOMY", 86, 92], ["graphene", "CHEMICAL", 36, 44], ["graphene", "CHEMICAL", 36, 44], ["graphene", "SIMPLE_CHEMICAL", 36, 44], ["tissue", "TISSUE", 86, 92], ["hybrid scaffold", "TREATMENT", 66, 81], ["tissue engineering applications", "TREATMENT", 86, 117]]], ["Fox example, the graphene-nanofiber hybrid scaffold by coating different amount of GO on the polymeric nanofiber (polycaprol actone) could cause selective differentiation of neural stem cells (NSCs), wherein a higher amount of GO facilitated cell differentiation into mature oligodendrocytes ( Fig. 4(a) ) [98] .", [["neural stem cells", "ANATOMY", 174, 191], ["NSCs", "ANATOMY", 193, 197], ["cell", "ANATOMY", 242, 246], ["oligodendrocytes", "ANATOMY", 275, 291], ["graphene", "CHEMICAL", 17, 25], ["polycaprol actone", "CHEMICAL", 114, 131], ["graphene", "CHEMICAL", 17, 25], ["polycaprol actone", "CHEMICAL", 114, 131], ["polymeric nanofiber", "SIMPLE_CHEMICAL", 93, 112], ["polycaprol actone", "SIMPLE_CHEMICAL", 114, 131], ["neural stem cells", "CELL", 174, 191], ["NSCs", "CELL", 193, 197], ["cell", "CELL", 242, 246], ["oligodendrocytes", "CELL", 275, 291], ["neural stem cells", "CELL_TYPE", 174, 191], ["NSCs", "CELL_TYPE", 193, 197], ["mature oligodendrocytes", "CELL_TYPE", 268, 291], ["the graphene-nanofiber hybrid scaffold", "TREATMENT", 13, 51], ["the polymeric nanofiber (polycaprol actone", "TREATMENT", 89, 131], ["neural stem cells", "PROBLEM", 174, 191], ["neural stem cells", "OBSERVATION", 174, 191], ["cell differentiation", "OBSERVATION", 242, 262]]], ["Furthermore, a 3D GO/polymer hydrogel [99] served as an active cell scaffold for reversible cell capture triggered by near-infrared (NIR) light.", [["cell", "ANATOMY", 63, 67], ["cell", "ANATOMY", 92, 96], ["cell", "CELL", 63, 67], ["cell", "CELL", 92, 96], ["a 3D GO/polymer hydrogel", "TREATMENT", 13, 37], ["an active cell scaffold", "TREATMENT", 53, 76], ["reversible cell capture", "PROBLEM", 81, 104], ["active cell scaffold", "OBSERVATION", 56, 76], ["reversible cell capture", "OBSERVATION", 81, 104]]], ["Custom made 3D graphene micropatterns fabricated by a LightScribe DVD writer were used as scaffolds for guiding neuronal cell alignment [100] .Graphene and mammalian cellsTill now, there are conflicting conclusions on the cytotoxicity of graphene.", [["neuronal cell", "ANATOMY", 112, 125], ["mammalian cells", "ANATOMY", 156, 171], ["Graphene", "CHEMICAL", 143, 151], ["graphene", "CHEMICAL", 238, 246], ["graphene", "CHEMICAL", 15, 23], ["Graphene", "CHEMICAL", 143, 151], ["graphene", "CHEMICAL", 238, 246], ["neuronal cell", "CELL", 112, 125], ["mammalian cells", "CELL", 156, 171], ["graphene", "SIMPLE_CHEMICAL", 238, 246], ["mammalian cells", "CELL_TYPE", 156, 171], ["3D graphene micropatterns", "TREATMENT", 12, 37], ["a LightScribe DVD writer", "TREATMENT", 52, 76], ["guiding neuronal cell alignment", "TREATMENT", 104, 135], ["Graphene and mammalian cells", "TREATMENT", 143, 171], ["the cytotoxicity of graphene", "TREATMENT", 218, 246], ["mammalian cells", "OBSERVATION", 156, 171]]], ["Various cytotoxicity methods suggested GO could hardly enter A549 cells and has no obvious cytotoxicity in a dosedependent manner [101] .", [["A549 cells", "ANATOMY", 61, 71], ["A549 cells", "CELL", 61, 71], ["A549 cells", "CELL_LINE", 61, 71], ["Various cytotoxicity methods", "TEST", 0, 28], ["obvious cytotoxicity", "PROBLEM", 83, 103], ["cytotoxicity", "OBSERVATION", 8, 20], ["A549 cells", "OBSERVATION", 61, 71], ["no obvious", "UNCERTAINTY", 80, 90], ["cytotoxicity", "OBSERVATION_MODIFIER", 91, 103]]], ["In vitro experiments revealed that GQD showed no obvious cytotoxicity against Hela cells because of its ultra-small size and high oxygen content [102] .", [["Hela cells", "ANATOMY", 78, 88], ["GQD", "CHEMICAL", 35, 38], ["oxygen", "CHEMICAL", 130, 136], ["oxygen", "CHEMICAL", 130, 136], ["GQD", "SIMPLE_CHEMICAL", 35, 38], ["Hela cells", "CELL", 78, 88], ["oxygen", "SIMPLE_CHEMICAL", 130, 136], ["Hela cells", "CELL_LINE", 78, 88], ["vitro experiments", "TEST", 3, 20], ["obvious cytotoxicity", "PROBLEM", 49, 69], ["Hela cells", "PROBLEM", 78, 88], ["its ultra-small size", "PROBLEM", 100, 120], ["high oxygen content", "PROBLEM", 125, 144], ["no obvious", "UNCERTAINTY", 46, 56], ["ultra-small", "OBSERVATION_MODIFIER", 104, 115], ["size", "OBSERVATION_MODIFIER", 116, 120], ["high", "OBSERVATION_MODIFIER", 125, 129], ["oxygen content", "OBSERVATION", 130, 144]]], ["Compared to single-walled carbon nanotube (SWCNT), graphene exhibited a low cytotoxic effect on PC12 cells in concentration-and shape-dependent manner [103] .", [["PC12 cells", "ANATOMY", 96, 106], ["carbon nanotube", "CHEMICAL", 26, 41], ["SWCNT", "CHEMICAL", 43, 48], ["graphene", "CHEMICAL", 51, 59], ["PC12", "CHEMICAL", 96, 100], ["carbon", "CHEMICAL", 26, 32], ["graphene", "CHEMICAL", 51, 59], ["single-walled carbon nanotube", "SIMPLE_CHEMICAL", 12, 41], ["SWCNT", "SIMPLE_CHEMICAL", 43, 48], ["graphene", "SIMPLE_CHEMICAL", 51, 59], ["PC12 cells", "CELL", 96, 106], ["PC12 cells", "CELL_LINE", 96, 106], ["single-walled carbon nanotube (SWCNT)", "TREATMENT", 12, 49], ["a low cytotoxic effect", "PROBLEM", 70, 92], ["PC12 cells", "TREATMENT", 96, 106], ["low cytotoxic", "OBSERVATION_MODIFIER", 72, 85], ["PC12 cells", "OBSERVATION", 96, 106], ["shape", "OBSERVATION_MODIFIER", 128, 133], ["dependent", "OBSERVATION_MODIFIER", 134, 143]]], ["However, another study indicated that GO could induce cytotoxicity and apoptosis in human lung cancer cells (BEAS-2B cell lines) [104] .", [["lung cancer cells", "ANATOMY", 90, 107], ["BEAS-2B cell lines", "ANATOMY", 109, 127], ["GO", "CHEMICAL", 38, 40], ["lung cancer", "DISEASE", 90, 101], ["human", "ORGANISM", 84, 89], ["lung cancer cells", "CELL", 90, 107], ["BEAS-2B cell lines) [104]", "CELL", 109, 134], ["human lung cancer cells", "CELL_TYPE", 84, 107], ["BEAS-2B cell lines", "CELL_LINE", 109, 127], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["another study", "TEST", 9, 22], ["cytotoxicity", "PROBLEM", 54, 66], ["apoptosis in human lung cancer cells", "PROBLEM", 71, 107], ["BEAS", "TEST", 109, 113], ["lung", "ANATOMY", 90, 94], ["cancer", "OBSERVATION", 95, 101]]], ["Interestingly, when GO was coated with fetal bovine serum (FBS), it could greatly mitigate the cytotoxicity against A549 cells and eliminate cell membrane damage.", [["fetal bovine serum", "ANATOMY", 39, 57], ["FBS", "ANATOMY", 59, 62], ["A549 cells", "ANATOMY", 116, 126], ["cell membrane", "ANATOMY", 141, 154], ["bovine", "ORGANISM", 45, 51], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["FBS", "ORGANISM_SUBSTANCE", 59, 62], ["A549 cells", "CELL", 116, 126], ["cell membrane", "CELLULAR_COMPONENT", 141, 154], ["A549 cells", "CELL_LINE", 116, 126], ["bovine", "SPECIES", 45, 51], ["bovine", "SPECIES", 45, 51], ["fetal bovine serum (FBS", "TEST", 39, 62], ["the cytotoxicity", "TEST", 91, 107], ["A549 cells", "PROBLEM", 116, 126], ["cell membrane damage", "PROBLEM", 141, 161], ["A549 cells", "OBSERVATION", 116, 126], ["cell membrane damage", "OBSERVATION", 141, 161]]], ["It was also found that the cytotoxicity of FBS-coated GO showed little or no dependency on temperature ( Fig. 4(b) ) [105] .", [["FBS", "CHEMICAL", 43, 46], ["FBS", "ORGANISM_SUBSTANCE", 43, 46], ["the cytotoxicity", "TEST", 23, 39], ["FBS", "TEST", 43, 46], ["temperature", "TEST", 91, 102]]], ["Similarly, reducing cytotoxicity of GO/rGO mediated by blood proteins coating was also demonstrated by MD simulations [106] .Graphene and mammalian cellsThe cytotoxicity of graphene exhibits concentration, size, shape and time dependency.", [["blood", "ANATOMY", 55, 60], ["mammalian cells", "ANATOMY", 138, 153], ["Graphene", "CHEMICAL", 125, 133], ["graphene", "CHEMICAL", 173, 181], ["Graphene", "CHEMICAL", 125, 133], ["graphene", "CHEMICAL", 173, 181], ["rGO", "SIMPLE_CHEMICAL", 39, 42], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["mammalian cells", "CELL", 138, 153], ["graphene", "SIMPLE_CHEMICAL", 173, 181], ["rGO", "PROTEIN", 39, 42], ["blood proteins", "PROTEIN", 55, 69], ["mammalian cells", "CELL_TYPE", 138, 153], ["reducing cytotoxicity of GO/rGO", "PROBLEM", 11, 42], ["blood proteins coating", "TREATMENT", 55, 77], ["Graphene and mammalian cells", "TREATMENT", 125, 153], ["mammalian cells", "OBSERVATION", 138, 153], ["concentration", "OBSERVATION_MODIFIER", 191, 204], ["size", "OBSERVATION_MODIFIER", 206, 210], ["shape", "OBSERVATION_MODIFIER", 212, 217], ["time dependency", "OBSERVATION", 222, 237]]], ["The toxicity intensity was in accordance with increasing graphene concentration or incubation time [101, 103] .", [["toxicity", "DISEASE", 4, 12], ["graphene", "CHEMICAL", 57, 65], ["graphene", "CHEMICAL", 57, 65], ["graphene", "SIMPLE_CHEMICAL", 57, 65], ["The toxicity intensity", "PROBLEM", 0, 22], ["increasing graphene concentration", "TREATMENT", 46, 79], ["toxicity", "OBSERVATION_MODIFIER", 4, 12], ["intensity", "OBSERVATION_MODIFIER", 13, 22]]], ["Ultrasmall GO nanosheet with lateral size less than 50 nm displayed lower cytotoxicity and higher cellular uptake than large sized GO nanosheets [107] .", [["cellular", "ANATOMY", 98, 106], ["cellular", "CELL", 98, 106], ["Ultrasmall GO nanosheet", "TEST", 0, 23], ["lateral size", "TEST", 29, 41], ["lower cytotoxicity", "PROBLEM", 68, 86], ["higher cellular uptake than large sized GO nanosheets", "PROBLEM", 91, 144], ["lower cytotoxicity", "OBSERVATION_MODIFIER", 68, 86], ["higher", "OBSERVATION_MODIFIER", 91, 97], ["cellular uptake", "OBSERVATION", 98, 113]]], ["A comparative study [108] revealed that the cytotoxicity of graphene-based materials increased as the lateral size decreased and functional groups density increased, by assessing the interaction between GO, thermally rGO and chemically rGO and human lung cells (BEAS-2B and A549).", [["lung cells", "ANATOMY", 250, 260], ["BEAS-2B", "ANATOMY", 262, 269], ["A549", "ANATOMY", 274, 278], ["graphene", "CHEMICAL", 60, 68], ["graphene", "CHEMICAL", 60, 68], ["graphene", "SIMPLE_CHEMICAL", 60, 68], ["rGO", "SIMPLE_CHEMICAL", 217, 220], ["rGO", "CELL", 236, 239], ["human", "ORGANISM", 244, 249], ["lung cells", "CELL", 250, 260], ["BEAS-2B", "CELL", 262, 269], ["A549", "CELL", 274, 278], ["thermally rGO", "CELL_LINE", 207, 220], ["chemically rGO", "CELL_LINE", 225, 239], ["human lung cells", "CELL_TYPE", 244, 260], ["BEAS-2B", "CELL_LINE", 262, 269], ["A549", "CELL_LINE", 274, 278], ["human", "SPECIES", 244, 249], ["human", "SPECIES", 244, 249], ["A comparative study", "TEST", 0, 19], ["the cytotoxicity of graphene-based materials", "TREATMENT", 40, 84], ["functional groups density", "PROBLEM", 129, 154], ["thermally rGO and chemically rGO and human lung cells", "PROBLEM", 207, 260], ["BEAS", "TEST", 262, 266], ["increased", "OBSERVATION_MODIFIER", 85, 94], ["lateral", "OBSERVATION_MODIFIER", 102, 109], ["size", "OBSERVATION_MODIFIER", 110, 114], ["decreased", "OBSERVATION_MODIFIER", 115, 124], ["functional", "OBSERVATION_MODIFIER", 129, 139], ["groups", "OBSERVATION_MODIFIER", 140, 146], ["density", "OBSERVATION_MODIFIER", 147, 154], ["increased", "OBSERVATION_MODIFIER", 155, 164], ["lung", "ANATOMY", 250, 254]]], ["On the contrary, another recent study found that large GO with micrometer size was more likely to damage cell membrane and cause pro-inflammatory response than small GO with nanometer size [109] .", [["cell membrane", "ANATOMY", 105, 118], ["cell membrane", "CELLULAR_COMPONENT", 105, 118], ["another recent study", "TEST", 17, 37], ["large GO with micrometer size", "PROBLEM", 49, 78], ["damage cell membrane", "PROBLEM", 98, 118], ["pro-inflammatory response", "PROBLEM", 129, 154], ["nanometer size", "TEST", 174, 188], ["large", "OBSERVATION_MODIFIER", 49, 54], ["more likely to", "UNCERTAINTY", 83, 97], ["damage cell membrane", "OBSERVATION", 98, 118], ["pro-inflammatory response", "OBSERVATION", 129, 154], ["size", "OBSERVATION_MODIFIER", 184, 188]]], ["Besides that, surface oxidation state of graphene had a significant impact on the induction of cytotoxicity in mammalian cells and lung.", [["surface", "ANATOMY", 14, 21], ["mammalian cells", "ANATOMY", 111, 126], ["lung", "ANATOMY", 131, 135], ["graphene", "CHEMICAL", 41, 49], ["graphene", "CHEMICAL", 41, 49], ["graphene", "SIMPLE_CHEMICAL", 41, 49], ["mammalian cells", "CELL", 111, 126], ["lung", "ORGAN", 131, 135], ["mammalian cells", "CELL_TYPE", 111, 126], ["cytotoxicity in mammalian cells and lung", "PROBLEM", 95, 135], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["mammalian cells", "OBSERVATION", 111, 126], ["lung", "ANATOMY", 131, 135]]], ["Hydrated GO (hGO) with highest carbon radical led to much more lipid peroxidation and cell death in THP-1 and BEAS-2B cells.", [["cell", "ANATOMY", 86, 90], ["THP-1", "ANATOMY", 100, 105], ["BEAS-2B cells", "ANATOMY", 110, 123], ["hGO", "CHEMICAL", 13, 16], ["carbon", "CHEMICAL", 31, 37], ["death", "DISEASE", 91, 96], ["carbon", "CHEMICAL", 31, 37], ["hGO", "SIMPLE_CHEMICAL", 13, 16], ["carbon radical", "SIMPLE_CHEMICAL", 31, 45], ["lipid", "SIMPLE_CHEMICAL", 63, 68], ["cell", "CELL", 86, 90], ["THP-1", "CELL", 100, 105], ["BEAS-2B cells", "CELL", 110, 123], ["THP-1 and BEAS-2B cells", "CELL_LINE", 100, 123], ["highest carbon radical", "TREATMENT", 23, 45], ["cell death", "PROBLEM", 86, 96], ["THP", "TEST", 100, 103], ["BEAS", "TEST", 110, 114], ["lipid peroxidation", "OBSERVATION", 63, 81], ["cell death", "OBSERVATION", 86, 96], ["2B cells", "OBSERVATION", 115, 123]]], ["GO exhibited lesser effects, and rGO had minimal toxicity (Fig. 4(c) ) [110] .Signal pathways of graphene in cellsIt is revealed that the pristine graphene induced apoptosis in RAW 264.7 macrophages through the mitochondrial pathways [111] .", [["cells", "ANATOMY", 109, 114], ["RAW 264.7 macrophages", "ANATOMY", 177, 198], ["mitochondrial", "ANATOMY", 211, 224], ["rGO", "CHEMICAL", 33, 36], ["toxicity", "DISEASE", 49, 57], ["graphene", "CHEMICAL", 97, 105], ["graphene", "CHEMICAL", 147, 155], ["rGO", "CHEMICAL", 33, 36], ["graphene", "CHEMICAL", 97, 105], ["graphene", "CHEMICAL", 147, 155], ["rGO", "SIMPLE_CHEMICAL", 33, 36], ["cells", "CELL", 109, 114], ["graphene", "SIMPLE_CHEMICAL", 147, 155], ["RAW 264.7 macrophages", "CELL", 177, 198], ["mitochondrial", "CELLULAR_COMPONENT", 211, 224], ["RAW 264.7 macrophages", "CELL_LINE", 177, 198], ["minimal toxicity", "PROBLEM", 41, 57], ["Signal pathways of graphene in cells", "PROBLEM", 78, 114], ["the pristine graphene induced apoptosis", "TREATMENT", 134, 173], ["the mitochondrial pathways", "TEST", 207, 233], ["lesser", "OBSERVATION_MODIFIER", 13, 19], ["minimal", "OBSERVATION_MODIFIER", 41, 48], ["toxicity", "OBSERVATION", 49, 57], ["cells", "OBSERVATION", 109, 114], ["pristine graphene", "OBSERVATION", 138, 155], ["264.7 macrophages", "OBSERVATION", 181, 198]]], ["Graphene exposure caused the depletion of the MMP and the accumulation of intracellular reactive oxygen species (ROS), leading to the activation of MAPKs-and TGF-beta signaling pathways which triggered Bim and Bax.", [["intracellular", "ANATOMY", 74, 87], ["Graphene", "CHEMICAL", 0, 8], ["oxygen", "CHEMICAL", 97, 103], ["ROS", "CHEMICAL", 113, 116], ["Graphene", "CHEMICAL", 0, 8], ["oxygen", "CHEMICAL", 97, 103], ["Graphene", "SIMPLE_CHEMICAL", 0, 8], ["MMP", "GENE_OR_GENE_PRODUCT", 46, 49], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 74, 87], ["reactive oxygen species", "SIMPLE_CHEMICAL", 88, 111], ["ROS", "SIMPLE_CHEMICAL", 113, 116], ["MAPKs", "GENE_OR_GENE_PRODUCT", 148, 153], ["TGF-beta", "GENE_OR_GENE_PRODUCT", 158, 166], ["Bim", "GENE_OR_GENE_PRODUCT", 202, 205], ["Bax", "GENE_OR_GENE_PRODUCT", 210, 213], ["MMP", "PROTEIN", 46, 49], ["MAPKs", "PROTEIN", 148, 153], ["TGF-beta", "PROTEIN", 158, 166], ["Bim", "PROTEIN", 202, 205], ["Bax", "PROTEIN", 210, 213], ["Graphene exposure", "PROBLEM", 0, 17], ["the MMP", "PROBLEM", 42, 49], ["intracellular reactive oxygen species", "PROBLEM", 74, 111], ["MAPKs", "TEST", 148, 153], ["TGF", "TEST", 158, 161], ["beta signaling pathways", "PROBLEM", 162, 185], ["depletion", "OBSERVATION", 29, 38], ["accumulation", "OBSERVATION_MODIFIER", 58, 70], ["intracellular", "OBSERVATION_MODIFIER", 74, 87], ["reactive", "OBSERVATION_MODIFIER", 88, 96], ["oxygen species", "OBSERVATION", 97, 111]]], ["Consequently, the caspase 3 were activated and the apoptosis was initiated.", [["caspase 3", "GENE_OR_GENE_PRODUCT", 18, 27], ["caspase 3", "PROTEIN", 18, 27], ["the caspase 3", "TREATMENT", 14, 27], ["the apoptosis", "TREATMENT", 47, 60]]], ["In another study [112] , it was observed that GO treatment of cells simultaneously elicited autophagy [113] as well as TLR4/TLR9-regulated cytokine responses.", [["cells", "ANATOMY", 62, 67], ["cells", "CELL", 62, 67], ["TLR4", "GENE_OR_GENE_PRODUCT", 119, 123], ["TLR9", "GENE_OR_GENE_PRODUCT", 124, 128], ["TLR4", "PROTEIN", 119, 123], ["TLR9", "PROTEIN", 124, 128], ["cytokine", "PROTEIN", 139, 147], ["another study", "TEST", 3, 16], ["autophagy", "TEST", 92, 101], ["TLR4/TLR9", "TREATMENT", 119, 128]]], ["The GO-induced autophagy was regulated by the TLRs signaling pathway which was associated with downstream adaptor proteins MyD88, TRIF and TRAF6.", [["TLRs", "GENE_OR_GENE_PRODUCT", 46, 50], ["MyD88", "GENE_OR_GENE_PRODUCT", 123, 128], ["TRIF", "GENE_OR_GENE_PRODUCT", 130, 134], ["TRAF6", "GENE_OR_GENE_PRODUCT", 139, 144], ["TLRs", "PROTEIN", 46, 50], ["downstream adaptor proteins", "PROTEIN", 95, 122], ["MyD88", "PROTEIN", 123, 128], ["TRIF", "PROTEIN", 130, 134], ["TRAF6", "PROTEIN", 139, 144], ["downstream adaptor proteins MyD88", "TREATMENT", 95, 128], ["TRIF and TRAF6", "TREATMENT", 130, 144]]], ["Furthermore, Mokhir et al. [114] proposed that surface-bound endoperoxide groups defined the capability of GO to enhance oxidative stress and cytotoxicity in Hela cells.", [["surface", "ANATOMY", 47, 54], ["Hela cells", "ANATOMY", 158, 168], ["endoperoxide", "CHEMICAL", 61, 73], ["endoperoxide", "CHEMICAL", 61, 73], ["endoperoxide", "SIMPLE_CHEMICAL", 61, 73], ["Hela cells", "CELL", 158, 168], ["Hela cells", "CELL_LINE", 158, 168], ["bound endoperoxide groups", "TREATMENT", 55, 80], ["oxidative stress", "PROBLEM", 121, 137], ["cytotoxicity in Hela cells", "PROBLEM", 142, 168], ["Hela cells", "OBSERVATION", 158, 168]]], ["Liu et al. [115] found that GO could induce plasma damages and cytoskeletal impairments in J774A.1 macrophages and A549 cells.", [["plasma", "ANATOMY", 44, 50], ["cytoskeletal", "ANATOMY", 63, 75], ["J774A", "ANATOMY", 91, 96], ["1 macrophages", "ANATOMY", 97, 110], ["A549 cells", "ANATOMY", 115, 125], ["plasma damages", "DISEASE", 44, 58], ["plasma", "ORGANISM_SUBSTANCE", 44, 50], ["cytoskeletal", "CELLULAR_COMPONENT", 63, 75], ["1 macrophages", "CELL", 97, 110], ["A549 cells", "CELL", 115, 125], ["J774A", "CELL_LINE", 91, 96], ["macrophages", "CELL_TYPE", 99, 110], ["A549 cells", "CELL_LINE", 115, 125], ["plasma damages", "PROBLEM", 44, 58], ["cytoskeletal impairments", "PROBLEM", 63, 87], ["cytoskeletal impairments", "OBSERVATION", 63, 87], ["macrophages", "OBSERVATION", 99, 110], ["A549 cells", "OBSERVATION", 115, 125]]], ["Additionally, GO undermined the signaling transduction of integrin-FAK-Rho-ROCK pathway, resulting in plasma membrane perturbation.", [["plasma membrane", "ANATOMY", 102, 117], ["integrin-FAK-Rho-ROCK", "GENE_OR_GENE_PRODUCT", 58, 79], ["plasma membrane", "CELLULAR_COMPONENT", 102, 117], ["integrin-FAK", "PROTEIN", 58, 70], ["Rho", "PROTEIN", 71, 74], ["ROCK", "PROTEIN", 75, 79], ["integrin-FAK", "TEST", 58, 70], ["plasma membrane perturbation", "PROBLEM", 102, 130], ["plasma membrane perturbation", "OBSERVATION", 102, 130]]], ["GO also affects the gene expression signature that was responsible for membrane and cytoskeletal damages.Signal pathways of graphene in cellsA multiple-path mechanism has also been proposed to elucidate the stress-induced toxicity of GO/PP with Caenorhabditis elegans (C. elegans) [116] .", [["membrane", "ANATOMY", 71, 79], ["cytoskeletal", "ANATOMY", 84, 96], ["graphene", "CHEMICAL", 124, 132], ["toxicity", "DISEASE", 222, 230], ["graphene", "CHEMICAL", 124, 132], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["cytoskeletal", "CELLULAR_COMPONENT", 84, 96], ["graphene", "SIMPLE_CHEMICAL", 124, 132], ["Caenorhabditis elegans", "ORGANISM", 245, 267], ["C. elegans", "ORGANISM", 269, 279], ["Caenorhabditis elegans", "SPECIES", 245, 267], ["C. elegans", "SPECIES", 269, 279], ["Caenorhabditis elegans", "SPECIES", 245, 267], ["C. elegans", "SPECIES", 269, 279], ["the gene expression signature", "PROBLEM", 16, 45], ["membrane and cytoskeletal damages", "PROBLEM", 71, 104], ["Signal pathways of graphene in cellsA", "PROBLEM", 105, 142], ["the stress", "PROBLEM", 203, 213], ["Caenorhabditis elegans", "PROBLEM", 245, 267], ["cytoskeletal damages", "OBSERVATION", 84, 104]]], ["Under normal physiological conditions, cytochrome c (cyt c) was located on the inner membrane of mitochondria, and H2O2 was decomposed to \u00b7OH catalyzed by GO/PP to a minimum which exerted no harmful effects on C. elegans.", [["inner membrane", "ANATOMY", 79, 93], ["mitochondria", "ANATOMY", 97, 109], ["H2O2", "CHEMICAL", 115, 119], ["\u00b7OH", "CHEMICAL", 138, 141], ["H2O2", "CHEMICAL", 115, 119], ["\u00b7OH", "CHEMICAL", 138, 141], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 39, 51], ["cyt c", "GENE_OR_GENE_PRODUCT", 53, 58], ["inner membrane", "CELLULAR_COMPONENT", 79, 93], ["mitochondria", "CELLULAR_COMPONENT", 97, 109], ["H2O2", "SIMPLE_CHEMICAL", 115, 119], ["\u00b7OH", "SIMPLE_CHEMICAL", 138, 141], ["C. elegans", "ORGANISM", 210, 220], ["cytochrome c", "PROTEIN", 39, 51], ["cyt c", "PROTEIN", 53, 58], ["C. elegans", "SPECIES", 210, 220], ["C. elegans", "SPECIES", 210, 220], ["cytochrome c (cyt c)", "TREATMENT", 39, 59], ["H2O2", "TREATMENT", 115, 119], ["normal", "OBSERVATION", 6, 12], ["physiological conditions", "OBSERVATION", 13, 37], ["inner membrane", "ANATOMY", 79, 93], ["no", "UNCERTAINTY", 188, 190]]], ["Under stress conditions, GO-mediated production of \u00b7OH and cyt c/H2O2 electron transfer may occur simultaneously.", [["H2O2", "CHEMICAL", 65, 69], ["\u00b7OH", "CHEMICAL", 51, 54], ["H2O2", "CHEMICAL", 65, 69], ["\u00b7OH", "SIMPLE_CHEMICAL", 51, 54], ["cyt c", "GENE_OR_GENE_PRODUCT", 59, 64], ["H2O2 electron", "SIMPLE_CHEMICAL", 65, 78], ["cyt c", "PROTEIN", 59, 64], ["Under stress conditions", "PROBLEM", 0, 23], ["\u00b7OH", "PROBLEM", 51, 54], ["cyt c/H2O2 electron transfer", "TREATMENT", 59, 87]]], ["Since the over production of H2O2 was triggered by oxidative and thermal condition, the accelerating effects of GO/PP on \u00b7OH generation were significantly improved.", [["H2O2", "CHEMICAL", 29, 33], ["H2O2", "CHEMICAL", 29, 33], ["H2O2", "SIMPLE_CHEMICAL", 29, 33], ["PP", "SIMPLE_CHEMICAL", 115, 117], ["\u00b7OH", "SIMPLE_CHEMICAL", 121, 124], ["H2O2", "TREATMENT", 29, 33], ["GO/PP", "TREATMENT", 112, 117], ["improved", "OBSERVATION_MODIFIER", 155, 163]]], ["Moreover, cyt c provided chance for GO/PP to direct interact with it.", [["cyt c", "GENE_OR_GENE_PRODUCT", 10, 15], ["GO/PP", "GENE_OR_GENE_PRODUCT", 36, 41], ["cyt c", "PROTEIN", 10, 15]]], ["GO/PP elevated and accelerated the electron transfer between cyt c and H2O2, as well as destroyed the inherent antioxidant defense system, eventually leading to apparent toxicity to worms.Graphene in organsSome study [117] found that GO predominantly deposited in lung and induced pulmonary edema and granuloma formation after being injected intravenously at a high dosage of 10 mg\u00b7kg \u22121 body weight ( Fig. 5(a) ), which showed relative longer blood circulation half time and lower uptake in reticuloendothelial system (RES) than other carbon nanomaterials.", [["organs", "ANATOMY", 200, 206], ["lung", "ANATOMY", 264, 268], ["pulmonary", "ANATOMY", 281, 290], ["granuloma", "ANATOMY", 301, 310], ["intravenously", "ANATOMY", 342, 355], ["body", "ANATOMY", 388, 392], ["blood", "ANATOMY", 444, 449], ["reticuloendothelial system", "ANATOMY", 492, 518], ["H2O2", "CHEMICAL", 71, 75], ["toxicity", "DISEASE", 170, 178], ["Graphene", "CHEMICAL", 188, 196], ["pulmonary edema", "DISEASE", 281, 296], ["granuloma", "DISEASE", 301, 310], ["H2O2", "CHEMICAL", 71, 75], ["Graphene", "CHEMICAL", 188, 196], ["carbon", "CHEMICAL", 536, 542], ["electron", "SIMPLE_CHEMICAL", 35, 43], ["cyt c", "GENE_OR_GENE_PRODUCT", 61, 66], ["H2O2", "SIMPLE_CHEMICAL", 71, 75], ["organs", "ORGAN", 200, 206], ["lung", "ORGAN", 264, 268], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 281, 296], ["granuloma", "PATHOLOGICAL_FORMATION", 301, 310], ["body", "ORGANISM_SUBDIVISION", 388, 392], ["blood", "ORGANISM_SUBSTANCE", 444, 449], ["reticuloendothelial system", "MULTI-TISSUE_STRUCTURE", 492, 518], ["cyt c", "PROTEIN", 61, 66], ["worms", "SPECIES", 182, 187], ["PP elevated", "PROBLEM", 3, 14], ["cyt c and H2O2", "TREATMENT", 61, 75], ["apparent toxicity to worms", "PROBLEM", 161, 187], ["Some study", "TEST", 206, 216], ["pulmonary edema", "PROBLEM", 281, 296], ["granuloma formation", "PROBLEM", 301, 320], ["relative longer blood circulation half time", "PROBLEM", 428, 471], ["lower uptake in reticuloendothelial system", "PROBLEM", 476, 518], ["other carbon nanomaterials", "PROBLEM", 530, 556], ["elevated", "OBSERVATION", 6, 14], ["organs", "ANATOMY", 200, 206], ["predominantly", "OBSERVATION_MODIFIER", 237, 250], ["deposited", "OBSERVATION", 251, 260], ["lung", "ANATOMY", 264, 268], ["pulmonary", "ANATOMY", 281, 290], ["edema", "OBSERVATION", 291, 296], ["granuloma", "OBSERVATION", 301, 310], ["lower", "OBSERVATION_MODIFIER", 476, 481], ["uptake", "OBSERVATION", 482, 488], ["reticuloendothelial system", "ANATOMY", 492, 518]]], ["Surface modified graphene-based nanomaterials with improved dispersion and stability significantly mediated biodistribution and translocation of graphene in organs.", [["organs", "ANATOMY", 157, 163], ["graphene", "CHEMICAL", 17, 25], ["graphene", "CHEMICAL", 145, 153], ["graphene", "CHEMICAL", 17, 25], ["graphene", "CHEMICAL", 145, 153], ["graphene", "SIMPLE_CHEMICAL", 17, 25], ["graphene", "SIMPLE_CHEMICAL", 145, 153], ["organs", "ORGAN", 157, 163], ["Surface modified graphene", "TREATMENT", 0, 25], ["translocation of graphene in organs", "PROBLEM", 128, 163], ["improved dispersion", "OBSERVATION", 51, 70], ["stability", "OBSERVATION_MODIFIER", 75, 84], ["organs", "ANATOMY", 157, 163]]], ["For instance, PEGylated nGO mainly accumulated in liver and spleen that were excreted by renal and fecal clearance [118] , in which the PEG coating could decrease the retention of nGO in RES and promote the clearance of nGO from the organs [119] .", [["liver", "ANATOMY", 50, 55], ["spleen", "ANATOMY", 60, 66], ["renal", "ANATOMY", 89, 94], ["fecal", "ANATOMY", 99, 104], ["organs", "ANATOMY", 233, 239], ["nGO", "CHEMICAL", 24, 27], ["PEG", "CHEMICAL", 136, 139], ["PEG", "CHEMICAL", 136, 139], ["nGO", "CHEMICAL", 180, 183], ["RES", "CHEMICAL", 187, 190], ["nGO", "CHEMICAL", 220, 223], ["PEGylated nGO", "SIMPLE_CHEMICAL", 14, 27], ["liver", "ORGAN", 50, 55], ["spleen", "ORGAN", 60, 66], ["renal", "ORGAN", 89, 94], ["fecal", "ORGANISM_SUBSTANCE", 99, 104], ["PEG", "SIMPLE_CHEMICAL", 136, 139], ["nGO", "SIMPLE_CHEMICAL", 180, 183], ["RES", "SIMPLE_CHEMICAL", 187, 190], ["nGO", "SIMPLE_CHEMICAL", 220, 223], ["organs", "ORGAN", 233, 239], ["PEGylated nGO", "PROTEIN", 14, 27], ["nGO", "PROTEIN", 180, 183], ["nGO", "PROTEIN", 220, 223], ["PEGylated nGO", "TREATMENT", 14, 27], ["the PEG coating", "TREATMENT", 132, 147], ["the retention of nGO in RES", "TREATMENT", 163, 190], ["PEGylated", "OBSERVATION_MODIFIER", 14, 23], ["liver", "ANATOMY", 50, 55], ["spleen", "ANATOMY", 60, 66], ["renal", "ANATOMY", 89, 94], ["fecal", "ANATOMY", 99, 104], ["retention", "OBSERVATION_MODIFIER", 167, 176], ["organs", "ANATOMY", 233, 239]]], ["Similarly, GO-dextran (GO-DEX) conjugate was also trapped in RES organs including liver and spleen, which showed clearance from the blood without apparent short-term toxicity in treated mice [120] .", [["RES organs", "ANATOMY", 61, 71], ["liver", "ANATOMY", 82, 87], ["spleen", "ANATOMY", 92, 98], ["blood", "ANATOMY", 132, 137], ["GO-dextran", "CHEMICAL", 11, 21], ["GO", "CHEMICAL", 23, 25], ["DEX", "CHEMICAL", 26, 29], ["toxicity", "DISEASE", 166, 174], ["DEX", "CHEMICAL", 26, 29], ["RES", "CHEMICAL", 61, 64], ["GO-dextran", "SIMPLE_CHEMICAL", 11, 21], ["GO-DEX", "SIMPLE_CHEMICAL", 23, 29], ["RES organs", "MULTI-TISSUE_STRUCTURE", 61, 71], ["liver", "ORGAN", 82, 87], ["spleen", "ORGAN", 92, 98], ["blood", "ORGANISM_SUBSTANCE", 132, 137], ["mice", "ORGANISM", 186, 190], ["mice", "SPECIES", 186, 190], ["dextran (GO-DEX) conjugate", "TREATMENT", 14, 40], ["liver and spleen", "TEST", 82, 98], ["the blood", "TEST", 128, 137], ["apparent short-term toxicity", "PROBLEM", 146, 174], ["liver", "ANATOMY", 82, 87], ["spleen", "ANATOMY", 92, 98], ["short-term toxicity", "OBSERVATION_MODIFIER", 155, 174]]], ["PEGylated GO derivatives exhibited no clear tissue uptake via oral administration, but high accumulation in RES including liver and spleen after intraperitoneal injection [121] .", [["tissue", "ANATOMY", 44, 50], ["oral", "ANATOMY", 62, 66], ["liver", "ANATOMY", 122, 127], ["spleen", "ANATOMY", 132, 138], ["intraperitoneal", "ANATOMY", 145, 160], ["RES", "CHEMICAL", 108, 111], ["PEGylated GO derivatives", "SIMPLE_CHEMICAL", 0, 24], ["tissue", "TISSUE", 44, 50], ["oral", "ORGANISM_SUBDIVISION", 62, 66], ["RES", "SIMPLE_CHEMICAL", 108, 111], ["liver", "ORGAN", 122, 127], ["spleen", "ORGAN", 132, 138], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 145, 160], ["PEGylated GO derivatives", "TREATMENT", 0, 24], ["clear tissue uptake", "PROBLEM", 38, 57], ["oral administration", "TREATMENT", 62, 81], ["high accumulation in RES including liver and spleen", "PROBLEM", 87, 138], ["intraperitoneal injection", "TREATMENT", 145, 170], ["high accumulation", "OBSERVATION", 87, 104], ["liver", "ANATOMY", 122, 127], ["spleen", "ANATOMY", 132, 138], ["intraperitoneal", "ANATOMY", 145, 160]]], ["Unlike PEGylated GO, PEGylated rGO was distributed on major organs such as liver, spleen, kidney and brain after intraperitoneal and intravenous administration.", [["organs", "ANATOMY", 60, 66], ["liver", "ANATOMY", 75, 80], ["spleen", "ANATOMY", 82, 88], ["kidney", "ANATOMY", 90, 96], ["brain", "ANATOMY", 101, 106], ["intraperitoneal", "ANATOMY", 113, 128], ["intravenous", "ANATOMY", 133, 144], ["rGO", "CHEMICAL", 31, 34], ["PEGylated rGO", "SIMPLE_CHEMICAL", 21, 34], ["organs", "ORGAN", 60, 66], ["liver", "ORGAN", 75, 80], ["spleen", "ORGAN", 82, 88], ["kidney", "ORGAN", 90, 96], ["brain", "ORGAN", 101, 106], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 128], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 133, 144], ["PEGylated rGO", "PROTEIN", 21, 34], ["Unlike PEGylated GO", "PROBLEM", 0, 19], ["PEGylated rGO", "TREATMENT", 21, 34], ["intraperitoneal and intravenous administration", "TREATMENT", 113, 159], ["PEGylated", "OBSERVATION", 7, 16], ["liver", "ANATOMY", 75, 80], ["spleen", "ANATOMY", 82, 88], ["kidney", "ANATOMY", 90, 96], ["brain", "ANATOMY", 101, 106], ["intraperitoneal", "ANATOMY", 113, 128]]], ["Repeated administration of PEGylated rGO could cause severe liver injury, congestion in kidney and enhanced proliferation of splenocytes ( Fig. 5(b) ) [122] .", [["liver", "ANATOMY", 60, 65], ["kidney", "ANATOMY", 88, 94], ["splenocytes", "ANATOMY", 125, 136], ["rGO", "CHEMICAL", 37, 40], ["liver injury", "DISEASE", 60, 72], ["congestion", "DISEASE", 74, 84], ["PEGylated rGO", "SIMPLE_CHEMICAL", 27, 40], ["liver", "ORGAN", 60, 65], ["kidney", "ORGAN", 88, 94], ["splenocytes", "CELL", 125, 136], ["splenocytes", "CELL_TYPE", 125, 136], ["Repeated administration of PEGylated rGO", "TREATMENT", 0, 40], ["severe liver injury", "PROBLEM", 53, 72], ["congestion in kidney", "PROBLEM", 74, 94], ["enhanced proliferation of splenocytes", "PROBLEM", 99, 136], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["liver", "ANATOMY", 60, 65], ["injury", "OBSERVATION", 66, 72], ["congestion", "OBSERVATION", 74, 84], ["kidney", "ANATOMY", 88, 94], ["enhanced", "OBSERVATION_MODIFIER", 99, 107], ["proliferation", "OBSERVATION_MODIFIER", 108, 121], ["splenocytes", "ANATOMY", 125, 136]]], ["Moreover, a carboxylated photoluminescent GQD prepared from carbon fiber show no acute toxicity or morphological changes, most of which accumulated in liver, spleen, lung, kidney, and tumor sites at 24 h after intravenous injection [123] .", [["liver", "ANATOMY", 151, 156], ["spleen", "ANATOMY", 158, 164], ["lung", "ANATOMY", 166, 170], ["kidney", "ANATOMY", 172, 178], ["tumor sites", "ANATOMY", 184, 195], ["intravenous", "ANATOMY", 210, 221], ["carboxylated", "CHEMICAL", 12, 24], ["GQD", "CHEMICAL", 42, 45], ["toxicity", "DISEASE", 87, 95], ["tumor", "DISEASE", 184, 189], ["carbon", "CHEMICAL", 60, 66], ["GQD", "SIMPLE_CHEMICAL", 42, 45], ["carbon fiber", "SIMPLE_CHEMICAL", 60, 72], ["liver", "ORGAN", 151, 156], ["spleen", "ORGAN", 158, 164], ["lung", "ORGAN", 166, 170], ["kidney", "ORGAN", 172, 178], ["tumor sites", "MULTI-TISSUE_STRUCTURE", 184, 195], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 210, 221], ["a carboxylated photoluminescent GQD", "TREATMENT", 10, 45], ["carbon fiber", "TEST", 60, 72], ["acute toxicity", "PROBLEM", 81, 95], ["morphological changes", "PROBLEM", 99, 120], ["tumor sites", "PROBLEM", 184, 195], ["intravenous injection", "TREATMENT", 210, 231], ["no", "UNCERTAINTY", 78, 80], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["toxicity", "OBSERVATION", 87, 95], ["liver", "ANATOMY", 151, 156], ["spleen", "ANATOMY", 158, 164], ["lung", "ANATOMY", 166, 170], ["kidney", "ANATOMY", 172, 178], ["tumor", "OBSERVATION", 184, 189]]], ["Finally, GQDs did not induced accumulation in major organs possibly due to the metabolism through kidneys, as well as no obvious in vivo toxicities due to the ultrasmall size and high oxygen content of GQD [102] .Graphene in animalsThe toxic effects of graphene to animals have also been investigated [124] .", [["organs", "ANATOMY", 52, 58], ["kidneys", "ANATOMY", 98, 105], ["GQDs", "CHEMICAL", 9, 13], ["toxicities", "DISEASE", 137, 147], ["oxygen", "CHEMICAL", 184, 190], ["GQD", "CHEMICAL", 202, 205], ["Graphene", "CHEMICAL", 213, 221], ["graphene", "CHEMICAL", 253, 261], ["oxygen", "CHEMICAL", 184, 190], ["GQD [102]", "CHEMICAL", 202, 211], ["Graphene", "CHEMICAL", 213, 221], ["graphene", "CHEMICAL", 253, 261], ["GQDs", "SIMPLE_CHEMICAL", 9, 13], ["organs", "ORGAN", 52, 58], ["kidneys", "ORGAN", 98, 105], ["oxygen", "SIMPLE_CHEMICAL", 184, 190], ["graphene", "SIMPLE_CHEMICAL", 253, 261], ["accumulation in major organs", "PROBLEM", 30, 58], ["the metabolism through kidneys", "PROBLEM", 75, 105], ["vivo toxicities", "PROBLEM", 132, 147], ["the ultrasmall size", "PROBLEM", 155, 174], ["high oxygen content", "PROBLEM", 179, 198], ["Graphene", "TREATMENT", 213, 221], ["The toxic effects of graphene", "TREATMENT", 232, 261], ["kidneys", "ANATOMY", 98, 105], ["no obvious", "UNCERTAINTY", 118, 128], ["ultrasmall size", "OBSERVATION_MODIFIER", 159, 174], ["high", "OBSERVATION_MODIFIER", 179, 183], ["oxygen content", "OBSERVATION", 184, 198], ["toxic", "OBSERVATION_MODIFIER", 236, 241]]], ["In vivo toxicological study revealed that multifunctional graphene with fluorescence and magnetic properties did not cause any significant abnormalities nor influence the survival rate of zebrafish.", [["graphene", "CHEMICAL", 58, 66], ["graphene", "CHEMICAL", 58, 66], ["graphene", "SIMPLE_CHEMICAL", 58, 66], ["zebrafish", "ORGANISM", 188, 197], ["vivo toxicological study", "TEST", 3, 27], ["any significant abnormalities", "PROBLEM", 123, 152], ["significant", "OBSERVATION_MODIFIER", 127, 138], ["abnormalities", "OBSERVATION", 139, 152]]], ["In vivo whole-animal imaging confirmed that multifunctional graphene co-localized and evenly biodistributed from the head to tail in zebrafish [125] .", [["head", "ANATOMY", 117, 121], ["tail", "ANATOMY", 125, 129], ["graphene", "CHEMICAL", 60, 68], ["graphene", "CHEMICAL", 60, 68], ["head", "ORGANISM_SUBDIVISION", 117, 121], ["zebrafish", "ORGANISM", 133, 142], ["animal imaging", "TEST", 14, 28], ["multifunctional graphene co-localized", "PROBLEM", 44, 81], ["head", "ANATOMY", 117, 121], ["tail", "ANATOMY", 125, 129]]], ["The toxicity of GO and PEGylated poly-L-lysine (GO/PP) functionalized GO were explored under stress conditions using a simple animal model, C. elegans worm.", [["toxicity", "DISEASE", 4, 12], ["poly-L-lysine", "CHEMICAL", 33, 46], ["poly-L-lysine", "CHEMICAL", 33, 46], ["poly-L-lysine", "SIMPLE_CHEMICAL", 33, 46], ["GO/PP", "SIMPLE_CHEMICAL", 48, 53], ["C. elegans", "ORGANISM", 140, 150], ["worm", "ORGANISM", 151, 155], ["C. elegans", "SPECIES", 140, 150], ["C. elegans", "SPECIES", 140, 150], ["The toxicity of GO", "PROBLEM", 0, 18], ["PEGylated poly-L-lysine (GO/PP) functionalized", "TREATMENT", 23, 69], ["a simple animal model", "TREATMENT", 117, 138]]], ["The results showed that GO/PP facilitated the electron transfer that impaired the inherent antioxidant defense system, and eventually triggered nanotoxicity to worms [116] .", [["PP", "SIMPLE_CHEMICAL", 27, 29], ["electron", "SIMPLE_CHEMICAL", 46, 54], ["worms", "SPECIES", 160, 165], ["impaired the inherent antioxidant defense system", "PROBLEM", 69, 117]]], ["Graphene-TiO2 composite film could inactivate the C. elegans nematodes under solar light irradiation with concentration-dependency, implying the application in destruction of minuscule animals on biological environments [126] .", [["Graphene-TiO2", "CHEMICAL", 0, 13], ["Graphene", "CHEMICAL", 0, 8], ["TiO2", "CHEMICAL", 9, 13], ["Graphene", "SIMPLE_CHEMICAL", 0, 8], ["C. elegans", "ORGANISM", 50, 60], ["C. elegans", "SPECIES", 50, 60], ["C. elegans", "SPECIES", 50, 60], ["Graphene-TiO2 composite film", "TREATMENT", 0, 28], ["solar light irradiation", "TREATMENT", 77, 100]]], ["Long-term toxicity of rGO nanosheets on female mouse reproductive performance and offspring development was investigated [127] .", [["toxicity", "DISEASE", 10, 18], ["rGO nanosheets", "CHEMICAL", 22, 36], ["rGO", "CHEMICAL", 22, 25], ["rGO nanosheets", "SIMPLE_CHEMICAL", 22, 36], ["mouse", "ORGANISM", 47, 52], ["mouse", "SPECIES", 47, 52], ["mouse", "SPECIES", 47, 52], ["Long-term toxicity of rGO nanosheets", "TREATMENT", 0, 36]]], ["The results showed that rGO did not significantly change the sex hormone level of adult female mice.", [["rGO", "CHEMICAL", 24, 27], ["rGO", "CHEMICAL", 24, 27], ["rGO", "SIMPLE_CHEMICAL", 24, 27], ["mice", "ORGANISM", 95, 99], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99]]], ["After intravenous injection, mouse dams achieved normal pregnancies and produce healthy offsprings before pregnancy or at an early gestational stage, whereas all surviving mice had abortions if they were injected with low or medium doses at a late stage of gestational.", [["intravenous", "ANATOMY", 6, 17], ["abortions", "DISEASE", 181, 190], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 6, 17], ["mouse", "ORGANISM", 29, 34], ["dams", "ORGANISM", 35, 39], ["mice", "ORGANISM", 172, 176], ["mouse", "SPECIES", 29, 34], ["mice", "SPECIES", 172, 176], ["mouse", "SPECIES", 29, 34], ["mice", "SPECIES", 172, 176], ["intravenous injection", "TREATMENT", 6, 27]]], ["Besides toxic effects on animals, GO demonstrated lateral size-dependent effects in the induction of inflammatory responses in mice [128] .", [["mice", "ORGANISM", 127, 131], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 127, 131], ["toxic effects on animals", "PROBLEM", 8, 32], ["lateral size-dependent effects", "PROBLEM", 50, 80], ["inflammatory responses", "PROBLEM", 101, 123], ["toxic", "OBSERVATION_MODIFIER", 8, 13], ["lateral", "OBSERVATION_MODIFIER", 50, 57], ["size", "OBSERVATION_MODIFIER", 58, 62], ["dependent effects", "OBSERVATION_MODIFIER", 63, 80], ["inflammatory", "OBSERVATION_MODIFIER", 101, 113]]], ["Larger GO sheets showed a plasma membrane adsorption and gave more production of inflammatory cytokines and recruitment of immune cells, whereas smaller GO sheets were prone to be taken up by macrophages (Fig. 5(c) ).Graphene in plants-phytotoxicityGraphene showed toxic effects on terrestrial plants of cabbage, tomato, and red spinach in a concentration-dependent manner, resulting in significant growth inhibition and biomass decrease mediated by the overproduction of ROS [129] .", [["plasma membrane", "ANATOMY", 26, 41], ["immune cells", "ANATOMY", 123, 135], ["GO sheets", "ANATOMY", 153, 162], ["macrophages", "ANATOMY", 192, 203], ["cabbage", "ANATOMY", 304, 311], ["tomato", "ANATOMY", 313, 319], ["red spinach", "ANATOMY", 325, 336], ["Graphene", "CHEMICAL", 217, 225], ["Graphene", "CHEMICAL", 249, 257], ["ROS", "CHEMICAL", 472, 475], ["Graphene", "CHEMICAL", 217, 225], ["Graphene", "CHEMICAL", 249, 257], ["plasma membrane", "CELLULAR_COMPONENT", 26, 41], ["immune cells", "CELL", 123, 135], ["macrophages", "CELL", 192, 203], ["Graphene", "SIMPLE_CHEMICAL", 217, 225], ["Graphene", "SIMPLE_CHEMICAL", 249, 257], ["cabbage", "ORGANISM_SUBDIVISION", 304, 311], ["tomato", "ORGANISM_SUBDIVISION", 313, 319], ["red spinach", "ORGANISM", 325, 336], ["ROS", "SIMPLE_CHEMICAL", 472, 475], ["inflammatory cytokines", "PROTEIN", 81, 103], ["immune cells", "CELL_TYPE", 123, 135], ["macrophages", "CELL_TYPE", 192, 203], ["cabbage", "SPECIES", 304, 311], ["tomato", "SPECIES", 313, 319], ["cabbage", "SPECIES", 304, 311], ["tomato", "SPECIES", 313, 319], ["red spinach", "SPECIES", 325, 336], ["a plasma membrane adsorption", "TREATMENT", 24, 52], ["inflammatory cytokines", "PROBLEM", 81, 103], ["immune cells", "PROBLEM", 123, 135], ["smaller GO sheets", "PROBLEM", 145, 162], ["phytotoxicity", "PROBLEM", 236, 249], ["toxic effects", "PROBLEM", 265, 278], ["significant growth inhibition", "PROBLEM", 387, 416], ["inflammatory cytokines", "OBSERVATION", 81, 103], ["immune cells", "OBSERVATION", 123, 135], ["phytotoxicity", "OBSERVATION", 236, 249], ["toxic effects", "OBSERVATION", 265, 278], ["significant", "OBSERVATION_MODIFIER", 387, 398], ["growth inhibition", "OBSERVATION", 399, 416]]], ["Likewise, GO demonstrated negative effects on the growth of wheat plants, which significantly caused root elongation, impairment of hair production, inhibition of photosynthesis and imbalance of nutrient homeostasis after 30 days of culture [130] .", [["root", "ANATOMY", 101, 105], ["hair", "ANATOMY", 132, 136], ["wheat", "ORGANISM", 60, 65], ["root", "ORGAN", 101, 105], ["hair", "MULTI-TISSUE_STRUCTURE", 132, 136], ["wheat", "SPECIES", 60, 65], ["wheat", "SPECIES", 60, 65], ["wheat plants", "PROBLEM", 60, 72], ["root elongation", "PROBLEM", 101, 116], ["hair production", "PROBLEM", 132, 147], ["inhibition of photosynthesis", "TREATMENT", 149, 177], ["imbalance of nutrient homeostasis", "TREATMENT", 182, 215], ["culture", "TEST", 233, 240], ["negative", "OBSERVATION", 26, 34], ["root", "OBSERVATION_MODIFIER", 101, 105], ["elongation", "OBSERVATION_MODIFIER", 106, 116]]], ["Interestingly, under normal levels, GO exposure did not induce obvious toxicity on Arabidopsis plants in seed germination, shoot and root development of seedlings, and flowering time.", [["seed", "ANATOMY", 105, 109], ["shoot", "ANATOMY", 123, 128], ["root", "ANATOMY", 133, 137], ["seedlings", "ANATOMY", 153, 162], ["toxicity", "DISEASE", 71, 79], ["seed", "DEVELOPING_ANATOMICAL_STRUCTURE", 105, 109], ["root", "DEVELOPING_ANATOMICAL_STRUCTURE", 133, 137], ["Arabidopsis", "SPECIES", 83, 94], ["obvious toxicity", "PROBLEM", 63, 79], ["Arabidopsis plants", "TREATMENT", 83, 101], ["root", "OBSERVATION_MODIFIER", 133, 137]]], ["GO did not accumulated in mesophyll and parenchyma cells of lead or stem, but in root hair and parenchyma cells [131, 132] .", [["mesophyll", "ANATOMY", 26, 35], ["parenchyma cells", "ANATOMY", 40, 56], ["stem", "ANATOMY", 68, 72], ["root hair", "ANATOMY", 81, 90], ["parenchyma cells", "ANATOMY", 95, 111], ["mesophyll", "CELL", 26, 35], ["parenchyma cells", "CELL", 40, 56], ["stem", "CELL", 68, 72], ["root hair", "CELL", 81, 90], ["parenchyma cells", "CELL", 95, 111], ["mesophyll and parenchyma cells", "CELL_TYPE", 26, 56], ["parenchyma cells", "CELL_TYPE", 95, 111], ["parenchyma cells", "TEST", 95, 111], ["mesophyll", "ANATOMY_MODIFIER", 26, 35], ["parenchyma cells", "OBSERVATION", 40, 56], ["stem", "ANATOMY_MODIFIER", 68, 72], ["root hair", "ANATOMY", 81, 90], ["parenchyma", "ANATOMY_MODIFIER", 95, 105]]], ["However, under drought or salt stress conditions, it influenced the development of the seedlings, and induced the translocation of GO from the roots to the leaves [131] .", [["seedlings", "ANATOMY", 87, 96], ["roots", "ANATOMY", 143, 148], ["leaves", "ANATOMY", 156, 162], ["roots", "ORGAN", 143, 148], ["salt stress conditions", "PROBLEM", 26, 48], ["the seedlings", "PROBLEM", 83, 96]]], ["In another study, it was found that GO accumulated in the root at 112 g/g after 15 days using 13 C-stable labeling of the C-skeleton, which inhibited the growth of wheat, altered root structure and cellular ultrastructure [133] .Toxicological concerns of grapheneSimilar to other inorganic nanomaterials, graphene has also been challenged by toxicological concerns in regard to its potential biomedical applications.", [["root", "ANATOMY", 58, 62], ["root", "ANATOMY", 179, 183], ["cellular", "ANATOMY", 198, 206], ["graphene", "CHEMICAL", 305, 313], ["graphene", "CHEMICAL", 305, 313], ["root", "ORGAN", 58, 62], ["C-skeleton", "SIMPLE_CHEMICAL", 122, 132], ["root", "MULTI-TISSUE_STRUCTURE", 179, 183], ["cellular", "CELL", 198, 206], ["grapheneSimilar", "SIMPLE_CHEMICAL", 255, 270], ["graphene", "SIMPLE_CHEMICAL", 305, 313], ["wheat", "SPECIES", 164, 169], ["wheat", "SPECIES", 164, 169], ["another study", "TEST", 3, 16], ["altered root structure", "PROBLEM", 171, 193], ["grapheneSimilar to other inorganic nanomaterials", "PROBLEM", 255, 303], ["root", "ANATOMY", 58, 62], ["skeleton", "ANATOMY", 124, 132], ["growth", "OBSERVATION_MODIFIER", 154, 160], ["altered", "OBSERVATION_MODIFIER", 171, 178], ["root structure", "OBSERVATION", 179, 193], ["cellular ultrastructure", "OBSERVATION", 198, 221]]], ["There are several inevitable issues should be taken into account in graphene toxicology, such as valid amount, toxicity criteria, irreversible/reversible toxic effect, and joint toxicity.", [["joint", "ANATOMY", 172, 177], ["toxicity", "DISEASE", 111, 119], ["toxicity", "DISEASE", 178, 186], ["graphene", "CHEMICAL", 68, 76], ["graphene", "SIMPLE_CHEMICAL", 68, 76], ["joint", "ORGANISM_SUBDIVISION", 172, 177], ["several inevitable issues", "PROBLEM", 10, 35], ["toxicity criteria", "PROBLEM", 111, 128], ["irreversible/reversible toxic effect", "PROBLEM", 130, 166], ["joint toxicity", "PROBLEM", 172, 186], ["reversible", "OBSERVATION_MODIFIER", 143, 153], ["toxic effect", "OBSERVATION", 154, 166], ["joint", "ANATOMY", 172, 177]]], ["First of all, the target dose is a direct and valid concentration in the biological response studies in the detailed experiments; unfortunately, numerous studies have used exposure dose to represent concentration-bioresponse relationships, which resulted in a false relevance for cytotoxic effects.", [["numerous studies", "TEST", 145, 161], ["cytotoxic effects", "PROBLEM", 280, 297]]], ["On the other hand, current acceptance criteria for toxicity tests are unknown.", [["toxicity", "DISEASE", 51, 59], ["toxicity tests", "TEST", 51, 65]]], ["In spite of certain inconsistencies in some experimental results and hypotheses of the toxicity mechanisms, a wealth of reports agree that physicochemical properties of graphene-based nanomaterials significantly affect the toxicological responses, such as sizes, charges, coatings, and structural defects of graphene.", [["toxicity", "DISEASE", 87, 95], ["graphene", "CHEMICAL", 169, 177], ["graphene", "CHEMICAL", 308, 316], ["graphene", "CHEMICAL", 169, 177], ["graphene", "CHEMICAL", 308, 316], ["graphene", "SIMPLE_CHEMICAL", 169, 177], ["graphene", "SIMPLE_CHEMICAL", 308, 316], ["the toxicity mechanisms", "PROBLEM", 83, 106], ["coatings", "TREATMENT", 272, 280], ["structural defects of graphene", "PROBLEM", 286, 316], ["defects", "OBSERVATION", 297, 304]]], ["To compare the nanotoxicity obtained under different conditions, an acceptance criterion for toxicity tests, including choice of statistical assumptions, statistical procedures, or set of experimental conditions, is necessary.", [["toxicity", "DISEASE", 93, 101], ["toxicity tests", "TEST", 93, 107], ["statistical procedures", "TEST", 154, 176]]], ["Also, a long-term test upon multiple administrations to evaluate the risks of graphene is lacking.", [["graphene", "CHEMICAL", 78, 86], ["graphene", "CHEMICAL", 78, 86], ["graphene", "SIMPLE_CHEMICAL", 78, 86], ["a long-term test", "TEST", 6, 22], ["multiple administrations", "TREATMENT", 28, 52]]], ["Despite many studies reported in vivo behaviors, the irreversible/reversible toxic effects of graphene are unclear because the acute toxic assays often ignored the reversible or delayed effects upon target organs.", [["organs", "ANATOMY", 206, 212], ["graphene", "CHEMICAL", 94, 102], ["graphene", "CHEMICAL", 94, 102], ["graphene", "SIMPLE_CHEMICAL", 94, 102], ["organs", "ORGAN", 206, 212], ["many studies", "TEST", 8, 20], ["the irreversible/reversible toxic effects of graphene", "PROBLEM", 49, 102], ["the acute toxic assays", "PROBLEM", 123, 145], ["delayed effects upon target organs", "PROBLEM", 178, 212], ["irreversible", "OBSERVATION_MODIFIER", 53, 65], ["reversible", "OBSERVATION_MODIFIER", 66, 76], ["toxic effects", "OBSERVATION", 77, 90], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["toxic", "OBSERVATION_MODIFIER", 133, 138], ["reversible", "OBSERVATION_MODIFIER", 164, 174]]], ["Last but not least, the literatures have been reported that joint toxicity is greatly different from single toxicity [134, 135] .", [["joint", "ANATOMY", 60, 65], ["toxicity", "DISEASE", 66, 74], ["toxicity", "DISEASE", 108, 116], ["joint", "MULTI-TISSUE_STRUCTURE", 60, 65], ["joint toxicity", "PROBLEM", 60, 74], ["single toxicity", "PROBLEM", 101, 116], ["joint", "ANATOMY", 60, 65], ["toxicity", "OBSERVATION", 66, 74]]], ["Synergistic effects can occur between metal ions, organic materials, or biomolecules with graphene.", [["graphene", "CHEMICAL", 90, 98], ["graphene", "CHEMICAL", 90, 98], ["metal ions", "SIMPLE_CHEMICAL", 38, 48], ["graphene", "SIMPLE_CHEMICAL", 90, 98], ["Synergistic effects", "PROBLEM", 0, 19], ["organic materials", "TREATMENT", 50, 67], ["biomolecules with graphene", "TREATMENT", 72, 98]]], ["And so the concern of joint toxicity should be paid enough attention, avoiding overestimation or underestimation the graphene toxicity. whose antibacterial activities are caused by physical damages or chemical effects.", [["joint", "ANATOMY", 22, 27], ["toxicity", "DISEASE", 28, 36], ["graphene", "CHEMICAL", 117, 125], ["toxicity", "DISEASE", 126, 134], ["graphene", "CHEMICAL", 117, 125], ["joint", "MULTI-TISSUE_STRUCTURE", 22, 27], ["graphene", "SIMPLE_CHEMICAL", 117, 125], ["joint toxicity", "PROBLEM", 22, 36], ["the graphene toxicity", "PROBLEM", 113, 134], ["physical damages", "PROBLEM", 181, 197], ["joint", "ANATOMY", 22, 27], ["toxicity", "OBSERVATION", 28, 36]]], ["Huang and Fan et al. [136] first reported the antibacterial activity of GO and rGO nanosheets ( Fig. 6(a) ).", [["rGO", "CHEMICAL", 79, 82], ["rGO nanosheets", "SIMPLE_CHEMICAL", 79, 93], ["the antibacterial activity of GO and rGO nanosheets", "TREATMENT", 42, 93]]], ["After treatment with 85 g/mL GO/rGO for 2 h, the growth of E. coli was almost completely suppressed, with a viability loss up to > 90%.", [["rGO", "CHEMICAL", 32, 35], ["rGO", "SIMPLE_CHEMICAL", 32, 35], ["E. coli", "ORGANISM", 59, 66], ["E. coli", "SPECIES", 59, 66], ["E. coli", "SPECIES", 59, 66], ["treatment", "TREATMENT", 6, 15], ["rGO", "TREATMENT", 32, 35], ["E. coli", "PROBLEM", 59, 66], ["a viability loss", "PROBLEM", 106, 122], ["E. coli", "OBSERVATION", 59, 66], ["viability", "OBSERVATION_MODIFIER", 108, 117], ["loss", "OBSERVATION_MODIFIER", 118, 122]]], ["Moreover, macroscopic freestanding GO/rGO paper made by vacuum filtration also exhibited the superior antibacterial effect, which could open up new opportunities for developing antibacterial material.", [["macroscopic freestanding GO/rGO", "TREATMENT", 10, 41], ["vacuum filtration", "TREATMENT", 56, 73], ["the superior antibacterial effect", "PROBLEM", 89, 122], ["developing antibacterial material", "PROBLEM", 166, 199], ["superior", "OBSERVATION_MODIFIER", 93, 101], ["antibacterial effect", "OBSERVATION", 102, 122], ["antibacterial material", "OBSERVATION", 177, 199]]], ["Akhavan et al. [137] studied the bacterial toxicity of graphene nanowalls (GONWs) prepared by electrophoretic deposition (EPD) and reduced graphene nanowalls (RGNWs) obtained by hydrazine reduction.", [["toxicity", "DISEASE", 43, 51], ["graphene nanowalls", "CHEMICAL", 55, 73], ["GONWs", "CHEMICAL", 75, 80], ["graphene", "CHEMICAL", 139, 147], ["hydrazine", "CHEMICAL", 178, 187], ["graphene", "CHEMICAL", 55, 63], ["graphene", "CHEMICAL", 139, 147], ["hydrazine", "CHEMICAL", 178, 187], ["graphene nanowalls", "SIMPLE_CHEMICAL", 55, 73], ["GONWs", "SIMPLE_CHEMICAL", 75, 80], ["graphene nanowalls", "SIMPLE_CHEMICAL", 139, 157], ["RGNWs", "SIMPLE_CHEMICAL", 159, 164], ["hydrazine", "SIMPLE_CHEMICAL", 178, 187], ["the bacterial toxicity of graphene nanowalls", "PROBLEM", 29, 73], ["electrophoretic deposition (EPD)", "TREATMENT", 94, 126], ["reduced graphene nanowalls", "TREATMENT", 131, 157], ["hydrazine reduction", "TREATMENT", 178, 197]]], ["Both GONWs and RGNWs exhibited bacterial cytotoxicity to Gram-negative E. Coli bacteria and Gram-positive Staphylococcus aureus (S. aureus) bacteria.", [["RGNWs", "CHEMICAL", 15, 20], ["Gram-", "CHEMICAL", 57, 62], ["GONWs", "SIMPLE_CHEMICAL", 5, 10], ["RGNWs", "SIMPLE_CHEMICAL", 15, 20], ["Gram-", "GENE_OR_GENE_PRODUCT", 57, 62], ["E. Coli", "ORGANISM", 71, 78], ["Gram-positive Staphylococcus aureus", "ORGANISM", 92, 127], ["S. aureus", "ORGANISM", 129, 138], ["GONWs", "CELL_TYPE", 5, 10], ["E. Coli", "SPECIES", 71, 78], ["Staphylococcus aureus", "SPECIES", 106, 127], ["S. aureus", "SPECIES", 129, 138], ["E. Coli", "SPECIES", 71, 78], ["Staphylococcus aureus", "SPECIES", 106, 127], ["S. aureus", "SPECIES", 129, 138], ["bacterial cytotoxicity", "PROBLEM", 31, 53], ["Gram-negative E. Coli bacteria", "PROBLEM", 57, 87], ["Gram-positive Staphylococcus aureus (S. aureus) bacteria", "PROBLEM", 92, 148], ["bacterial cytotoxicity", "OBSERVATION", 31, 53], ["Coli bacteria", "OBSERVATION", 74, 87], ["positive Staphylococcus aureus", "OBSERVATION", 97, 127], ["aureus", "OBSERVATION_MODIFIER", 132, 138], ["bacteria", "OBSERVATION_MODIFIER", 140, 148]]], ["In particular, RGNWs exhibited higher antibacterial activity than GONW because of more sharp edges of the nanowalls leading to more cell membrane damage of the bacteria (Fig. 6(b) ).", [["cell membrane", "ANATOMY", 132, 145], ["RGNWs", "SIMPLE_CHEMICAL", 15, 20], ["GONW", "SIMPLE_CHEMICAL", 66, 70], ["cell membrane", "CELLULAR_COMPONENT", 132, 145], ["higher antibacterial activity", "PROBLEM", 31, 60], ["the nanowalls", "PROBLEM", 102, 115], ["more cell membrane damage of the bacteria", "PROBLEM", 127, 168], ["higher", "OBSERVATION_MODIFIER", 31, 37], ["antibacterial activity", "OBSERVATION", 38, 60], ["sharp", "OBSERVATION_MODIFIER", 87, 92], ["more cell membrane damage", "OBSERVATION", 127, 152], ["bacteria", "OBSERVATION_MODIFIER", 160, 168]]], ["Chen and co-workers [138] compared the bacterial toxicity of graphite (Gt), graphite oxide (GtO), GO and rGO using E. coli as a bacterial model.", [["toxicity", "DISEASE", 49, 57], ["graphite", "CHEMICAL", 61, 69], ["Gt", "CHEMICAL", 71, 73], ["graphite oxide", "CHEMICAL", 76, 90], ["GtO", "CHEMICAL", 92, 95], ["rGO", "CHEMICAL", 105, 108], ["graphite", "CHEMICAL", 61, 69], ["graphite oxide", "CHEMICAL", 76, 90], ["GtO", "CHEMICAL", 92, 95], ["graphite", "SIMPLE_CHEMICAL", 61, 69], ["Gt)", "SIMPLE_CHEMICAL", 71, 74], ["graphite oxide", "SIMPLE_CHEMICAL", 76, 90], ["GtO", "SIMPLE_CHEMICAL", 92, 95], ["rGO", "SIMPLE_CHEMICAL", 105, 108], ["E. coli", "ORGANISM", 115, 122], ["E. coli", "SPECIES", 115, 122], ["E. coli", "SPECIES", 115, 122], ["the bacterial toxicity", "PROBLEM", 35, 57], ["graphite (Gt), graphite oxide (GtO)", "TREATMENT", 61, 96], ["E. coli", "PROBLEM", 115, 122], ["a bacterial model", "PROBLEM", 126, 143], ["E. coli", "OBSERVATION", 115, 122], ["bacterial model", "OBSERVATION", 128, 143]]], ["Under the same conditions, GO exhibited the highest antibacterial activities, followed by rGO, graphite, and GtO (Fig. 6(c) ).", [["GO", "CHEMICAL", 27, 29], ["rGO, graphite", "CHEMICAL", 90, 103], ["GtO", "CHEMICAL", 109, 112], ["rGO", "CHEMICAL", 90, 93], ["graphite", "CHEMICAL", 95, 103], ["GtO", "CHEMICAL", 109, 112], ["rGO", "SIMPLE_CHEMICAL", 90, 93], ["graphite", "SIMPLE_CHEMICAL", 95, 103], ["GtO", "SIMPLE_CHEMICAL", 109, 112], ["Fig. 6(c)", "SIMPLE_CHEMICAL", 114, 123]]], ["Besides the antibacterial activities described above, the investigations of GO against dental pathogens has also been reported by Tang et al. [139] .", [["the antibacterial activities", "PROBLEM", 8, 36], ["the investigations", "TEST", 54, 72], ["dental pathogens", "PROBLEM", 87, 103], ["antibacterial activities", "OBSERVATION", 12, 36]]], ["Three typical dental bacterial, including S. mutans, P. gingivalis and F. nucleatum, were chosen to estimate the bacterial toxicity of nGO sheets.", [["toxicity", "DISEASE", 123, 131], ["S. mutans", "ORGANISM", 42, 51], ["P. gingivalis", "ORGANISM", 53, 66], ["F. nucleatum", "ORGANISM", 71, 83], ["S. mutans", "SPECIES", 42, 51], ["P. gingivalis", "SPECIES", 53, 66], ["F. nucleatum", "SPECIES", 71, 83], ["S. mutans", "SPECIES", 42, 51], ["P. gingivalis", "SPECIES", 53, 66], ["F. nucleatum", "SPECIES", 71, 83], ["Three typical dental bacterial", "PROBLEM", 0, 30], ["S. mutans", "PROBLEM", 42, 51], ["the bacterial toxicity of nGO sheets", "PROBLEM", 109, 145], ["dental bacterial", "OBSERVATION_MODIFIER", 14, 30], ["bacterial toxicity", "OBSERVATION", 113, 131]]], ["It was clearly confirmed that GO showed prominent antibacterial effect toward dental bacterial by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reduced assay, colony forming units [136] , [137] , [138] , [139] , [143] , and [153] , \u00a9 American Chemical Society 2010, 2010, 2011, 2015, 2016 and 2018, respectively.", [["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "CHEMICAL", 104, 165], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "CHEMICAL", 104, 165], ["MTT", "CHEMICAL", 167, 170], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "SIMPLE_CHEMICAL", 104, 165], ["MTT", "SIMPLE_CHEMICAL", 167, 170], ["prominent antibacterial effect", "PROBLEM", 40, 70], ["dimethylthiazol", "TREATMENT", 111, 126], ["diphenyl tetrazolium bromide", "TREATMENT", 137, 165], ["prominent", "OBSERVATION_MODIFIER", 40, 49], ["antibacterial effect", "OBSERVATION", 50, 70]]], ["(CFU) counting, growth curve observation, and fluorescent live/dead staining (Fig. 6(d) ).Toxicological concerns of grapheneMany factors related to the physiochemical properties of graphenebased material, such as lateral dimension, surface area, layer number, surface chemistry, and shape, can influence their antimicrobial effects.", [["surface area", "ANATOMY", 232, 244], ["surface", "ANATOMY", 260, 267], ["graphene", "CHEMICAL", 116, 124], ["graphene", "CHEMICAL", 116, 124], ["graphene", "SIMPLE_CHEMICAL", 116, 124], ["growth curve observation", "TEST", 16, 40], ["Many factors", "PROBLEM", 124, 136], ["graphenebased material", "PROBLEM", 181, 203], ["surface chemistry", "TEST", 260, 277], ["physiochemical properties", "OBSERVATION_MODIFIER", 152, 177], ["graphenebased material", "OBSERVATION", 181, 203], ["lateral", "OBSERVATION_MODIFIER", 213, 220], ["surface", "OBSERVATION_MODIFIER", 232, 239], ["area", "OBSERVATION_MODIFIER", 240, 244], ["layer", "OBSERVATION_MODIFIER", 246, 251], ["number", "OBSERVATION_MODIFIER", 252, 258], ["surface", "OBSERVATION_MODIFIER", 260, 267], ["shape", "OBSERVATION_MODIFIER", 283, 288], ["antimicrobial effects", "OBSERVATION", 310, 331]]], ["The size of GO sheet was a main factor influencing graphene's antibacterial activity.", [["graphene", "CHEMICAL", 51, 59], ["graphene", "CHEMICAL", 51, 59], ["graphene", "SIMPLE_CHEMICAL", 51, 59], ["size", "OBSERVATION_MODIFIER", 4, 8], ["antibacterial activity", "OBSERVATION", 62, 84]]], ["GO sheet with a larger size induced higher antibacterial activity than do smaller one [140, 141] , either induced by direct insertion or cutting [137, 141] or lipid extraction of phospholipids [141] on treatment with graphene nanosheets.", [["phospholipids [141", "CHEMICAL", 179, 197], ["graphene nanosheets", "CHEMICAL", 217, 236], ["graphene", "CHEMICAL", 217, 225], ["lipid", "SIMPLE_CHEMICAL", 159, 164], ["phospholipids [141]", "SIMPLE_CHEMICAL", 179, 198], ["graphene nanosheets", "SIMPLE_CHEMICAL", 217, 236], ["a larger size induced higher antibacterial activity", "TREATMENT", 14, 65], ["lipid extraction of phospholipids", "TREATMENT", 159, 192], ["treatment with graphene nanosheets", "TREATMENT", 202, 236], ["antibacterial activity", "OBSERVATION", 43, 65]]], ["On the contrary, Elimelech et al. found that the cell inactivation of GO with surface coatings increased by 4 times as the average area of GO decreased from 0.65 to 0.01 m 2 .", [["cell", "ANATOMY", 49, 53], ["surface", "ANATOMY", 78, 85], ["cell", "CELL", 49, 53], ["the cell inactivation", "PROBLEM", 45, 66], ["surface coatings", "TREATMENT", 78, 94], ["cell inactivation", "OBSERVATION", 49, 66]]], ["It was mediated via oxidative mechanisms because of intensive defects in smaller GO sheets [142] .", [["intensive defects", "PROBLEM", 52, 69], ["defects", "OBSERVATION", 62, 69], ["smaller", "OBSERVATION_MODIFIER", 73, 80]]], ["The source material and bacterial shape were also associated with antibacterial properties of graphene.", [["graphene", "CHEMICAL", 94, 102], ["graphene", "CHEMICAL", 94, 102], ["graphene", "SIMPLE_CHEMICAL", 94, 102], ["bacterial shape", "PROBLEM", 24, 39], ["antibacterial properties of graphene", "TREATMENT", 66, 102], ["source material", "OBSERVATION", 4, 19], ["bacterial shape", "OBSERVATION", 24, 39], ["antibacterial properties", "OBSERVATION", 66, 90]]], ["It was reported that [143] GQDs prepared from GO sheets (GO-GQDs) did not show antibacterial ability, whereas GQDs synthesized by rupturing C60 cage (C60-GQDs) could effectively eliminate S. aureus, but not other three bacteria, Bacillus subtilis (B. subtilis), E. coli, and Pseudomonas aeruginosa (P. aeruginosa).", [["[143] GQDs", "CHEMICAL", 21, 31], ["GQDs", "CHEMICAL", 110, 114], ["C60", "CHEMICAL", 140, 143], ["C60-GQDs", "CHEMICAL", 150, 158], ["[143] GQDs", "CHEMICAL", 21, 31], ["C60", "CHEMICAL", 140, 143], ["C60", "CHEMICAL", 150, 153], ["[143] GQDs", "SIMPLE_CHEMICAL", 21, 31], ["GO sheets", "SIMPLE_CHEMICAL", 46, 55], ["GO-GQDs", "SIMPLE_CHEMICAL", 57, 64], ["GQDs", "SIMPLE_CHEMICAL", 110, 114], ["C60 cage", "SIMPLE_CHEMICAL", 140, 148], ["C60-GQDs", "SIMPLE_CHEMICAL", 150, 158], ["S. aureus", "ORGANISM", 188, 197], ["Bacillus subtilis", "ORGANISM", 229, 246], ["B. subtilis)", "ORGANISM", 248, 260], ["E. coli", "ORGANISM", 262, 269], ["Pseudomonas aeruginosa", "ORGANISM", 275, 297], ["P. aeruginosa", "ORGANISM", 299, 312], ["S. aureus", "SPECIES", 188, 197], ["Bacillus subtilis", "SPECIES", 229, 246], ["B. subtilis", "SPECIES", 248, 259], ["E. coli", "SPECIES", 262, 269], ["Pseudomonas aeruginosa", "SPECIES", 275, 297], ["P. aeruginosa", "SPECIES", 299, 312], ["S. aureus", "SPECIES", 188, 197], ["Bacillus subtilis", "SPECIES", 229, 246], ["B. subtilis", "SPECIES", 248, 259], ["E. coli", "SPECIES", 262, 269], ["Pseudomonas aeruginosa", "SPECIES", 275, 297], ["P. aeruginosa", "SPECIES", 299, 312], ["antibacterial ability", "PROBLEM", 79, 100], ["rupturing C60 cage (C60-GQDs", "TEST", 130, 158], ["S. aureus", "PROBLEM", 188, 197], ["other three bacteria", "PROBLEM", 207, 227], ["Bacillus subtilis (B. subtilis", "TEST", 229, 259], ["E. coli", "PROBLEM", 262, 269], ["Pseudomonas aeruginosa (P. aeruginosa", "PROBLEM", 275, 312], ["aureus", "OBSERVATION", 191, 197]]], ["It seemed that surface Gaussian-curvature match between a GQD and a bacterium membrane might determine whether GQD cause the damaging the integrity of bacterial cell envelope (Fig. 6(e) ).", [["surface", "ANATOMY", 15, 22], ["membrane", "ANATOMY", 78, 86], ["cell", "ANATOMY", 161, 165], ["GQD", "CHEMICAL", 111, 114], ["GQD", "CHEMICAL", 111, 114], ["GQD", "SIMPLE_CHEMICAL", 58, 61], ["membrane", "CELLULAR_COMPONENT", 78, 86], ["GQD", "SIMPLE_CHEMICAL", 111, 114], ["a bacterium membrane", "TREATMENT", 66, 86], ["bacterial cell envelope", "TREATMENT", 151, 174], ["bacterial cell", "OBSERVATION", 151, 165]]], ["The doping of nitrogen (N) was considered to be a useful method to improve the properties of GQDs.", [["doping of nitrogen", "CHEMICAL", 4, 22], ["nitrogen", "CHEMICAL", 14, 22], ["N", "CHEMICAL", 24, 25], ["nitrogen", "SIMPLE_CHEMICAL", 14, 22], ["GQDs", "SIMPLE_CHEMICAL", 93, 97], ["nitrogen (N)", "TREATMENT", 14, 26]]], ["A recent study showed that N-doped GQD could generate more ROS than N-free GQD, implying enhanced antibacterial activities [144] .", [["N-doped", "CHEMICAL", 27, 34], ["GQD", "CHEMICAL", 35, 38], ["ROS", "CHEMICAL", 59, 62], ["GQD", "CHEMICAL", 75, 78], ["N", "CHEMICAL", 27, 28], ["GQD", "CHEMICAL", 35, 38], ["N", "CHEMICAL", 68, 69], ["GQD", "CHEMICAL", 75, 78], ["N-doped GQD", "SIMPLE_CHEMICAL", 27, 38], ["ROS", "SIMPLE_CHEMICAL", 59, 62], ["N-free GQD", "SIMPLE_CHEMICAL", 68, 78], ["A recent study", "TEST", 0, 14]]], ["Other than the intrinsic properties of graphene-based nanomaterials, studies also revealed GO killed bacteria in concentration-and time-dependent manners [140] .Antibacterial activities of graphene-based compositesIt is well known that silver acts as an effective antibacterial agent for centuries.", [["graphene", "CHEMICAL", 39, 47], ["graphene", "CHEMICAL", 189, 197], ["silver", "CHEMICAL", 236, 242], ["graphene", "CHEMICAL", 39, 47], ["graphene", "CHEMICAL", 189, 197], ["silver", "CHEMICAL", 236, 242], ["graphene", "SIMPLE_CHEMICAL", 39, 47], ["graphene", "SIMPLE_CHEMICAL", 189, 197], ["silver", "SIMPLE_CHEMICAL", 236, 242], ["GO killed bacteria in concentration", "PROBLEM", 91, 126], ["Antibacterial activities of graphene-based composites", "TREATMENT", 161, 214], ["silver acts", "TREATMENT", 236, 247], ["an effective antibacterial agent", "TREATMENT", 251, 283]]], ["Ag + treatment resulted in the detachment of cytoplasm membrane from the cell wall for E. coli and S. aureus and inactivated DNA replication and protein [145] .", [["cytoplasm membrane", "ANATOMY", 45, 63], ["cell wall", "ANATOMY", 73, 82], ["Ag", "CHEMICAL", 0, 2], ["Ag +", "CHEMICAL", 0, 4], ["Ag +", "SIMPLE_CHEMICAL", 0, 4], ["cytoplasm membrane", "CELLULAR_COMPONENT", 45, 63], ["cell wall", "CELLULAR_COMPONENT", 73, 82], ["E. coli", "ORGANISM", 87, 94], ["S. aureus", "ORGANISM", 99, 108], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["Ag", "PROTEIN", 0, 2], ["E. coli", "SPECIES", 87, 94], ["S. aureus", "SPECIES", 99, 108], ["E. coli", "SPECIES", 87, 94], ["S. aureus", "SPECIES", 99, 108], ["Ag + treatment", "TREATMENT", 0, 14], ["cytoplasm membrane", "PROBLEM", 45, 63], ["the cell wall", "TEST", 69, 82], ["E. coli", "PROBLEM", 87, 94], ["S. aureus", "PROBLEM", 99, 108], ["inactivated DNA replication", "PROBLEM", 113, 140], ["protein", "TEST", 145, 152], ["detachment", "OBSERVATION", 31, 41], ["cytoplasm membrane", "OBSERVATION", 45, 63], ["cell wall", "ANATOMY", 73, 82], ["E. coli", "OBSERVATION", 87, 94], ["aureus", "OBSERVATION", 102, 108]]], ["Gelatinous AgNPs with a diameter less than 10 nm effectively killed different Gram-positive and Gram-negative bacteria.", [["AgNPs", "CHEMICAL", 11, 16], ["AgNPs", "SIMPLE_CHEMICAL", 11, 16], ["Gram-positive", "GENE_OR_GENE_PRODUCT", 78, 91], ["Gram", "GENE_OR_GENE_PRODUCT", 96, 100], ["Gelatinous AgNPs", "PROBLEM", 0, 16], ["Gram-negative bacteria", "PROBLEM", 96, 118], ["AgNPs", "OBSERVATION", 11, 16], ["diameter", "OBSERVATION_MODIFIER", 24, 32], ["negative bacteria", "OBSERVATION", 101, 118]]], ["Unfortunately, bare AgNPs aggregated when they directly interact with bacteria.", [["AgNPs", "CHEMICAL", 20, 25], ["AgNPs", "SIMPLE_CHEMICAL", 20, 25], ["bacteria", "PROBLEM", 70, 78]]], ["To alleviate this issue, Ag-graphene nanocomposites have been synthesized via different reducing agents, like NaBH4 [146] , hydrazine [138] , and dopamine [147] , etc. As-prepared Ag-rGO nanohybrid displayed surface enhanced Raman scattering (SERS) and high disinfection activities [148, 149] .", [["Ag-graphene", "CHEMICAL", 25, 36], ["NaBH4 [146] , hydrazine [138]", "CHEMICAL", 110, 139], ["dopamine", "CHEMICAL", 146, 154], ["Ag", "CHEMICAL", 180, 182], ["rGO", "CHEMICAL", 183, 186], ["Ag", "CHEMICAL", 25, 27], ["graphene", "CHEMICAL", 28, 36], ["NaBH4", "CHEMICAL", 110, 115], ["hydrazine", "CHEMICAL", 124, 133], ["dopamine", "CHEMICAL", 146, 154], ["Ag", "CHEMICAL", 180, 182], ["rGO", "CHEMICAL", 183, 186], ["Ag-graphene nanocomposites", "SIMPLE_CHEMICAL", 25, 51], ["NaBH4 [146]", "SIMPLE_CHEMICAL", 110, 121], ["hydrazine [138]", "SIMPLE_CHEMICAL", 124, 139], ["dopamine [147]", "SIMPLE_CHEMICAL", 146, 160], ["Ag-rGO", "SIMPLE_CHEMICAL", 180, 186], ["Ag", "PROTEIN", 25, 27], ["Ag", "PROTEIN", 180, 182], ["this issue", "PROBLEM", 13, 23], ["Ag-graphene nanocomposites", "TREATMENT", 25, 51], ["different reducing agents", "TREATMENT", 78, 103], ["hydrazine", "TREATMENT", 124, 133], ["dopamine", "TREATMENT", 146, 154], ["high disinfection activities", "PROBLEM", 253, 281]]], ["Ag-rGO nanocomposites also could be prepared without additional reducing agents, which showed enhanced antibacterial ability likely caused by the synergistic effect of \"capturing-killing process\", but no tolerable edema and/or erythema in skin irritation test [150] .", [["edema", "ANATOMY", 214, 219], ["skin", "ANATOMY", 239, 243], ["Ag", "CHEMICAL", 0, 2], ["edema", "DISEASE", 214, 219], ["erythema", "DISEASE", 227, 235], ["Ag", "CHEMICAL", 0, 2], ["rGO", "CHEMICAL", 3, 6], ["Ag-rGO", "SIMPLE_CHEMICAL", 0, 6], ["edema", "PATHOLOGICAL_FORMATION", 214, 219], ["skin", "ORGAN", 239, 243], ["Ag", "PROTEIN", 0, 2], ["Ag-rGO nanocomposites", "TREATMENT", 0, 21], ["additional reducing agents", "TREATMENT", 53, 79], ["enhanced antibacterial ability", "PROBLEM", 94, 124], ["tolerable edema", "PROBLEM", 204, 219], ["erythema in skin irritation test", "PROBLEM", 227, 259], ["rGO nanocomposites", "OBSERVATION", 3, 21], ["no", "UNCERTAINTY", 201, 203], ["tolerable", "OBSERVATION_MODIFIER", 204, 213], ["edema", "OBSERVATION", 214, 219], ["erythema", "OBSERVATION", 227, 235], ["skin", "ANATOMY", 239, 243], ["irritation", "OBSERVATION", 244, 254]]], ["Tan et al. develop a new method by using DNA as a template to prepare metal NPs and GO composites with controllable size and shape [151, 152] .", [["DNA", "CELLULAR_COMPONENT", 41, 44], ["metal NPs", "SIMPLE_CHEMICAL", 70, 79], ["a new method", "TREATMENT", 19, 31], ["DNA", "TREATMENT", 41, 44], ["a template to prepare metal NPs and GO composites", "TREATMENT", 48, 97], ["new", "OBSERVATION_MODIFIER", 21, 24], ["size", "OBSERVATION_MODIFIER", 116, 120]]], ["Among the as-synthesized nanocomposites, 20 ppm Ag(18nm) and 16 ppm Ag(5nm) composites showed optimal antimicrobial capability towards a model plant bacterium Xanthomon asperforans due to the synergistic effect between AgNPs and GO [151] .", [["Ag", "CHEMICAL", 48, 50], ["Ag", "CHEMICAL", 68, 70], ["Xanthomon asperforans", "CHEMICAL", 159, 180], ["AgNPs", "CHEMICAL", 219, 224], ["Ag", "CHEMICAL", 48, 50], ["Ag", "CHEMICAL", 68, 70], ["Xanthomon asperforans", "ORGANISM", 159, 180], ["AgNPs", "SIMPLE_CHEMICAL", 219, 224], ["Xanthomon asperforans", "SPECIES", 159, 180], ["Xanthomon asperforans", "SPECIES", 159, 180], ["the as-synthesized nanocomposites", "TREATMENT", 6, 39], ["16 ppm Ag(5nm) composites", "TREATMENT", 61, 86], ["optimal antimicrobial capability", "PROBLEM", 94, 126], ["a model plant bacterium Xanthomon asperforans", "TREATMENT", 135, 180], ["the synergistic effect", "PROBLEM", 188, 210]]], ["He et al. prepared graphene-AgNPs-Si nanohybrids (G@AgNPs) as a multifunctional SERS platform, allowing for molecular to cellular detection.", [["cellular", "ANATOMY", 121, 129], ["graphene-AgNPs-Si", "CHEMICAL", 19, 36], ["G@AgNPs", "CHEMICAL", 50, 57], ["graphene", "CHEMICAL", 19, 27], ["Si", "CHEMICAL", 34, 36], ["graphene-AgNPs-Si nanohybrids", "SIMPLE_CHEMICAL", 19, 48], ["G@AgNPs", "SIMPLE_CHEMICAL", 50, 57], ["cellular", "CELL", 121, 129], ["Si nanohybrids (G@AgNPs", "TREATMENT", 34, 57], ["cellular detection", "TEST", 121, 139]]], ["In particular, it was utilized for capturing, discriminating, and inactivating of E. coli and S. aureus bacteria with strong antibacterial rate of ~ 93% after incubation for 24 h (Fig. 6(f) ) [153] .", [["E. coli", "ORGANISM", 82, 89], ["S. aureus bacteria", "ORGANISM", 94, 112], ["E. coli", "SPECIES", 82, 89], ["S. aureus", "SPECIES", 94, 103], ["E. coli", "SPECIES", 82, 89], ["S. aureus", "SPECIES", 94, 103], ["E. coli", "PROBLEM", 82, 89], ["S. aureus bacteria", "PROBLEM", 94, 112], ["strong antibacterial rate", "TEST", 118, 143], ["E. coli", "OBSERVATION", 82, 89]]], ["In addition, copper, gold and lanthanum has also been anchored on graphene to kill bacteria [154] [155] [156] .Antibacterial activities of graphene-based compositesTitanium oxide (TiO2) is an important and inexpensive photocatalytic material.", [["copper", "CHEMICAL", 13, 19], ["gold", "CHEMICAL", 21, 25], ["lanthanum", "CHEMICAL", 30, 39], ["graphene", "CHEMICAL", 139, 147], ["Titanium oxide", "CHEMICAL", 164, 178], ["TiO2", "CHEMICAL", 180, 184], ["copper", "CHEMICAL", 13, 19], ["lanthanum", "CHEMICAL", 30, 39], ["graphene", "CHEMICAL", 66, 74], ["graphene", "CHEMICAL", 139, 147], ["Titanium oxide", "CHEMICAL", 164, 178], ["TiO2", "CHEMICAL", 180, 184], ["copper", "SIMPLE_CHEMICAL", 13, 19], ["gold", "SIMPLE_CHEMICAL", 21, 25], ["lanthanum", "SIMPLE_CHEMICAL", 30, 39], ["graphene", "SIMPLE_CHEMICAL", 66, 74], ["graphene", "SIMPLE_CHEMICAL", 139, 147], ["Titanium oxide", "SIMPLE_CHEMICAL", 164, 178], ["TiO2", "SIMPLE_CHEMICAL", 180, 184], ["lanthanum", "TREATMENT", 30, 39], ["Antibacterial activities of graphene-based composites", "TREATMENT", 111, 164], ["Titanium oxide (TiO2", "TREATMENT", 164, 184], ["inexpensive photocatalytic material", "TREATMENT", 206, 241]]], ["The rGO/TiO2 thin films as photocatalysts degraded E. coli bacterial under solar light irradiation.", [["rGO", "CHEMICAL", 4, 7], ["TiO2", "CHEMICAL", 8, 12], ["rGO", "CHEMICAL", 4, 7], ["TiO2", "CHEMICAL", 8, 12], ["rGO", "SIMPLE_CHEMICAL", 4, 7], ["TiO2 thin films", "SIMPLE_CHEMICAL", 8, 23], ["E. coli", "ORGANISM", 51, 58], ["E. coli", "SPECIES", 51, 58], ["E. coli", "SPECIES", 51, 58], ["The rGO/TiO2 thin films", "TREATMENT", 0, 23], ["photocatalysts", "TREATMENT", 27, 41], ["E. coli bacterial", "PROBLEM", 51, 68], ["solar light irradiation", "TREATMENT", 75, 98], ["coli bacterial", "OBSERVATION", 54, 68], ["solar light irradiation", "OBSERVATION", 75, 98]]], ["The reduction of GO for 4h maximally improved the antibacterial effect of bare TiO2 films by approximate 7.5-fold [157] .", [["TiO2", "CHEMICAL", 79, 83], ["TiO2", "CHEMICAL", 79, 83], ["TiO2 films", "SIMPLE_CHEMICAL", 79, 89], ["bare TiO2 films", "TEST", 74, 89], ["reduction", "OBSERVATION_MODIFIER", 4, 13]]], ["GO-TiO2 nanorod composites (NRCs) on the gram scale exhibited higher antibacterial activities against E. coli under simulated solar light irradiation than that of TiO2 NRCs, which was ascribed to the anti-charge recombination and increased (101) facets [158] .", [["GO-TiO2", "CHEMICAL", 0, 7], ["NRCs", "CHEMICAL", 28, 32], ["TiO2", "CHEMICAL", 163, 167], ["TiO2", "CHEMICAL", 3, 7], ["TiO2", "CHEMICAL", 163, 167], ["E. coli", "ORGANISM", 102, 109], ["TiO2 NRCs", "SIMPLE_CHEMICAL", 163, 172], ["E. coli", "SPECIES", 102, 109], ["E. coli", "SPECIES", 102, 109], ["TiO2 nanorod composites", "TREATMENT", 3, 26], ["the gram scale", "TEST", 37, 51], ["higher antibacterial activities", "PROBLEM", 62, 93], ["E. coli", "PROBLEM", 102, 109], ["simulated solar light irradiation", "TREATMENT", 116, 149], ["TiO2 NRCs", "TEST", 163, 172], ["solar light irradiation", "OBSERVATION_MODIFIER", 126, 149]]], ["The flexible hybrid films comprising of free standing graphene strongly coupled with Ti nanosheets showed almost complete sterilization of E. coli within only 15 min [159] .Antibacterial activities of graphene-based compositesThe poor dispersibility and processability of graphene limit its application in bacteria disinfection.", [["graphene", "CHEMICAL", 54, 62], ["Ti nanosheets", "CHEMICAL", 85, 98], ["graphene", "CHEMICAL", 201, 209], ["graphene", "CHEMICAL", 272, 280], ["graphene", "CHEMICAL", 54, 62], ["Ti", "CHEMICAL", 85, 87], ["graphene", "CHEMICAL", 201, 209], ["graphene", "CHEMICAL", 272, 280], ["graphene", "SIMPLE_CHEMICAL", 54, 62], ["Ti nanosheets", "SIMPLE_CHEMICAL", 85, 98], ["E. coli", "ORGANISM", 139, 146], ["graphene", "SIMPLE_CHEMICAL", 201, 209], ["graphene", "SIMPLE_CHEMICAL", 272, 280], ["E. coli", "SPECIES", 139, 146], ["E. coli", "SPECIES", 139, 146], ["The flexible hybrid films", "TEST", 0, 25], ["free standing graphene", "TREATMENT", 40, 62], ["Ti nanosheets", "TREATMENT", 85, 98], ["E. coli", "PROBLEM", 139, 146], ["Antibacterial activities of graphene-based composites", "TREATMENT", 173, 226], ["The poor dispersibility", "PROBLEM", 226, 249], ["graphene", "TREATMENT", 272, 280], ["bacteria disinfection", "PROBLEM", 306, 327], ["sterilization", "OBSERVATION", 122, 135], ["E. coli", "OBSERVATION", 139, 146], ["poor dispersibility", "OBSERVATION_MODIFIER", 230, 249], ["bacteria disinfection", "OBSERVATION", 306, 327]]], ["To address these challenges, dispersible polymer-graphene hybrids have been formed via \u03c0-\u03c0 stacking interaction formed between them by embedding graphene into polymer matrix.", [["polymer-graphene", "CHEMICAL", 41, 57], ["graphene", "CHEMICAL", 145, 153], ["graphene", "CHEMICAL", 49, 57], ["\u03c0-\u03c0", "CHEMICAL", 87, 90], ["graphene", "CHEMICAL", 145, 153], ["polymer-graphene hybrids", "SIMPLE_CHEMICAL", 41, 65], ["\u03c0-\u03c0", "SIMPLE_CHEMICAL", 87, 90], ["graphene", "SIMPLE_CHEMICAL", 145, 153], ["matrix", "CELLULAR_COMPONENT", 167, 173], ["dispersible polymer-graphene hybrids", "CELL_LINE", 29, 65], ["these challenges", "TREATMENT", 11, 27], ["dispersible polymer-graphene hybrids", "TREATMENT", 29, 65]]], ["Rodrigues and co-workers [160] fabricated an antimicrobial film containing PVK polymer and GO on ITO surface.", [["PVK polymer", "CHEMICAL", 75, 86], ["ITO", "CHEMICAL", 97, 100], ["PVK polymer", "SIMPLE_CHEMICAL", 75, 86], ["an antimicrobial film", "TREATMENT", 42, 63], ["PVK polymer", "TREATMENT", 75, 86]]], ["The resulting film was 90% more effective in inactivating E. coli bacterial colonization, in which the inclusion of PVK led to the enhanced bacterial toxicity.", [["PVK", "CHEMICAL", 116, 119], ["toxicity", "DISEASE", 150, 158], ["PVK", "CHEMICAL", 116, 119], ["E. coli", "ORGANISM", 58, 65], ["PVK", "SIMPLE_CHEMICAL", 116, 119], ["E. coli", "SPECIES", 58, 65], ["E. coli", "SPECIES", 58, 65], ["The resulting film", "TEST", 0, 18], ["inactivating E. coli bacterial colonization", "PROBLEM", 45, 88], ["PVK", "PROBLEM", 116, 119], ["the enhanced bacterial toxicity", "PROBLEM", 127, 158], ["coli bacterial colonization", "OBSERVATION", 61, 88], ["enhanced", "OBSERVATION_MODIFIER", 131, 139], ["bacterial toxicity", "OBSERVATION", 140, 158]]], ["PLL as a polycationic homopolymer facilitates the attachment and immobilization cells on solid substrate.", [["cells", "ANATOMY", 80, 85], ["PLL", "CHEMICAL", 0, 3], ["PLL", "CHEMICAL", 0, 3], ["PLL", "SIMPLE_CHEMICAL", 0, 3], ["cells", "CELL", 80, 85], ["PLL", "TREATMENT", 0, 3], ["a polycationic homopolymer", "TREATMENT", 7, 33], ["the attachment and immobilization cells", "TREATMENT", 46, 85], ["solid substrate", "TREATMENT", 89, 104]]], ["Lee et al. [161] prepared various graphene-PLL composites through electrostatic interactions and covalent bonding between PLL and GO/rGO sheets.", [["graphene-PLL", "CHEMICAL", 34, 46], ["graphene", "CHEMICAL", 34, 42], ["PLL", "CHEMICAL", 43, 46], ["PLL", "CHEMICAL", 122, 125], ["graphene-PLL composites", "SIMPLE_CHEMICAL", 34, 57], ["PLL", "SIMPLE_CHEMICAL", 122, 125], ["various graphene-PLL composites", "TREATMENT", 26, 57], ["electrostatic interactions and covalent bonding between PLL and GO/rGO sheets", "TREATMENT", 66, 143]]], ["Among the as-prepared composites, graphene-DS-PLL composed of 4-carboxylic acid benzene diazonium salt (DS) showed the most effective antibacterial behavior given the production of carboxylic acid groups, while improving the growth of human cell.Mechanisms of antibacterial activities of graphene-based nanomaterialsDespite increasing number of experimental results, however, there is no identical mechanism on how graphene-based nanomaterials cause bacterial inactivation, which may be related to the inconsistent physicochemical properties of graphene-based nanomaterials and experimental surroundings.", [["cell", "ANATOMY", 241, 245], ["graphene-DS-PLL", "CHEMICAL", 34, 49], ["4-carboxylic acid benzene diazonium salt", "CHEMICAL", 62, 102], ["DS", "CHEMICAL", 104, 106], ["carboxylic acid", "CHEMICAL", 181, 196], ["graphene", "CHEMICAL", 288, 296], ["graphene", "CHEMICAL", 415, 423], ["graphene", "CHEMICAL", 545, 553], ["graphene", "CHEMICAL", 34, 42], ["PLL", "CHEMICAL", 46, 49], ["4-carboxylic acid benzene diazonium salt", "CHEMICAL", 62, 102], ["carboxylic acid", "CHEMICAL", 181, 196], ["graphene", "CHEMICAL", 288, 296], ["graphene", "CHEMICAL", 415, 423], ["graphene", "CHEMICAL", 545, 553], ["graphene-DS-PLL", "SIMPLE_CHEMICAL", 34, 49], ["4-carboxylic acid benzene diazonium salt", "SIMPLE_CHEMICAL", 62, 102], ["DS", "SIMPLE_CHEMICAL", 104, 106], ["carboxylic acid", "SIMPLE_CHEMICAL", 181, 196], ["human", "ORGANISM", 235, 240], ["cell", "CELL", 241, 245], ["graphene", "SIMPLE_CHEMICAL", 288, 296], ["graphene", "SIMPLE_CHEMICAL", 415, 423], ["graphene", "SIMPLE_CHEMICAL", 545, 553], ["human cell", "CELL_TYPE", 235, 245], ["human", "SPECIES", 235, 240], ["human", "SPECIES", 235, 240], ["the as-prepared composites", "TREATMENT", 6, 32], ["graphene", "TEST", 34, 42], ["DS", "TEST", 43, 45], ["PLL", "TREATMENT", 46, 49], ["4-carboxylic acid benzene diazonium salt (DS", "TREATMENT", 62, 106], ["the most effective antibacterial behavior", "PROBLEM", 115, 156], ["carboxylic acid groups", "TREATMENT", 181, 203], ["antibacterial activities of graphene", "PROBLEM", 260, 296], ["bacterial inactivation", "PROBLEM", 450, 472], ["human cell", "OBSERVATION", 235, 245], ["antibacterial activities", "OBSERVATION", 260, 284], ["increasing", "OBSERVATION_MODIFIER", 324, 334], ["no", "UNCERTAINTY", 385, 387], ["bacterial inactivation", "OBSERVATION", 450, 472], ["may be related to", "UNCERTAINTY", 480, 497]]], ["According to recent achievements, several predominant mechanisms have been proposed to explain the graphene-based nanomaterial's antimicrobial behavior, that is, the membrane damage hypothesis, the oxidative stress hypothesis, the wrapping or trapping hypothesis, and other mechanisms.Mechanisms of antibacterial activities of graphene-based nanomaterialsThe membrane damage hypothesis.", [["membrane", "ANATOMY", 166, 174], ["membrane", "ANATOMY", 359, 367], ["graphene", "CHEMICAL", 99, 107], ["graphene", "CHEMICAL", 327, 335], ["graphene", "CHEMICAL", 99, 107], ["graphene", "CHEMICAL", 327, 335], ["graphene", "SIMPLE_CHEMICAL", 99, 107], ["membrane", "CELLULAR_COMPONENT", 166, 174], ["graphene", "SIMPLE_CHEMICAL", 327, 335], ["membrane", "CELLULAR_COMPONENT", 359, 367], ["the graphene-based nanomaterial's antimicrobial behavior", "PROBLEM", 95, 151], ["the membrane damage hypothesis", "PROBLEM", 162, 192], ["the oxidative stress hypothesis", "PROBLEM", 194, 225], ["the wrapping", "TREATMENT", 227, 239], ["trapping hypothesis", "PROBLEM", 243, 262], ["antibacterial activities of graphene", "PROBLEM", 299, 335], ["The membrane damage hypothesis", "PROBLEM", 355, 385], ["antimicrobial behavior", "OBSERVATION", 129, 151], ["trapping hypothesis", "OBSERVATION", 243, 262], ["antibacterial activities", "OBSERVATION", 299, 323], ["membrane damage", "OBSERVATION", 359, 374]]], ["Several studies have demonstrated that the sharp edges of graphene-based nanomaterials, also called \"nano-knives\", \"cutters\", or \"blades\" could penetrate into and physically damage the cell membrane of bacteria, resulting in the leakage of intracellular materials and eventual cell death.", [["cell membrane", "ANATOMY", 185, 198], ["intracellular", "ANATOMY", 240, 253], ["cell", "ANATOMY", 277, 281], ["graphene", "CHEMICAL", 58, 66], ["death", "DISEASE", 282, 287], ["graphene", "CHEMICAL", 58, 66], ["graphene", "SIMPLE_CHEMICAL", 58, 66], ["cell membrane", "CELLULAR_COMPONENT", 185, 198], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 240, 253], ["cell", "CELL", 277, 281], ["Several studies", "TEST", 0, 15], ["bacteria", "PROBLEM", 202, 210], ["the leakage of intracellular materials", "PROBLEM", 225, 263], ["eventual cell death", "PROBLEM", 268, 287], ["cell membrane", "OBSERVATION", 185, 198], ["leakage", "OBSERVATION_MODIFIER", 229, 236], ["intracellular materials", "OBSERVATION", 240, 263], ["eventual cell death", "OBSERVATION", 268, 287]]], ["The mechanism is sometimes mentioned as insertion or penetration mode, which could induce membrane stress and thus inactive microorganisms documented in experimental studies and theoretical simulations.Mechanisms of antibacterial activities of graphene-based nanomaterialsAkhavan and Ghaderi [137] first proposed that the bacterial cell membrane was effectively damaged by direct contact interaction with extremely sharp edges of the NWs, and subsequently leading to leakage of RNA and losing of cell vitality.", [["membrane", "ANATOMY", 90, 98], ["cell membrane", "ANATOMY", 332, 345], ["cell", "ANATOMY", 496, 500], ["graphene", "CHEMICAL", 244, 252], ["graphene", "CHEMICAL", 244, 252], ["membrane", "CELLULAR_COMPONENT", 90, 98], ["graphene", "SIMPLE_CHEMICAL", 244, 252], ["Akhavan", "SIMPLE_CHEMICAL", 272, 279], ["cell membrane", "CELLULAR_COMPONENT", 332, 345], ["cell", "CELL", 496, 500], ["insertion or penetration mode", "TREATMENT", 40, 69], ["membrane stress", "PROBLEM", 90, 105], ["inactive microorganisms", "PROBLEM", 115, 138], ["experimental studies", "TEST", 153, 173], ["theoretical simulations", "PROBLEM", 178, 201], ["antibacterial activities of graphene", "PROBLEM", 216, 252], ["the bacterial cell membrane", "PROBLEM", 318, 345], ["leakage of RNA", "PROBLEM", 467, 481], ["antibacterial activities", "OBSERVATION", 216, 240], ["bacterial cell membrane", "OBSERVATION", 322, 345], ["leakage", "OBSERVATION", 467, 474], ["cell vitality", "OBSERVATION", 496, 509]]], ["Tu et al. [141] experimentally and theoretically studied how graphene and GO nanosheets cause the damage of E. coli within the outer and inner membranes.", [["outer", "ANATOMY", 127, 132], ["inner membranes", "ANATOMY", 137, 152], ["graphene", "CHEMICAL", 61, 69], ["graphene", "CHEMICAL", 61, 69], ["graphene", "SIMPLE_CHEMICAL", 61, 69], ["GO nanosheets", "SIMPLE_CHEMICAL", 74, 87], ["E. coli", "ORGANISM", 108, 115], ["outer", "TISSUE", 127, 132], ["inner membranes", "CELLULAR_COMPONENT", 137, 152], ["E. coli", "SPECIES", 108, 115], ["E. coli", "SPECIES", 108, 115], ["the damage of E. coli", "PROBLEM", 94, 115], ["damage", "OBSERVATION", 98, 104], ["E. coli", "OBSERVATION", 108, 115], ["outer", "ANATOMY_MODIFIER", 127, 132], ["inner membranes", "ANATOMY_MODIFIER", 137, 152]]], ["In the TEM experiments and MD simulations, it was both clearly observed two kinds of molecular mechanism: direct insertion/cutting mode and destructive lipid extraction mode (Fig. 7) .", [["direct insertion/cutting mode", "TREATMENT", 106, 135], ["destructive lipid extraction", "TREATMENT", 140, 168], ["destructive", "OBSERVATION_MODIFIER", 140, 151]]], ["The vigorous extraction of phospholipids from the lipid bilayers was first discovered in MD simulations, which was further verified by typical TEM images.", [["lipid bilayers", "ANATOMY", 50, 64], ["phospholipids", "CHEMICAL", 27, 40], ["phospholipids", "SIMPLE_CHEMICAL", 27, 40], ["The vigorous extraction of phospholipids", "TREATMENT", 0, 40], ["typical TEM images", "TEST", 135, 153], ["vigorous", "OBSERVATION_MODIFIER", 4, 12]]], ["The strong attraction between graphene and lipid molecules was mostly generated from unique 2D carbons with sp 2 -bonded structures, promoting unexpected strong dispersion interactions between them.", [["graphene", "CHEMICAL", 30, 38], ["graphene", "CHEMICAL", 30, 38], ["carbons", "CHEMICAL", 95, 102], ["graphene", "SIMPLE_CHEMICAL", 30, 38], ["lipid molecules", "SIMPLE_CHEMICAL", 43, 58], ["The strong attraction between graphene and lipid molecules", "TREATMENT", 0, 58], ["sp 2 -bonded structures", "TREATMENT", 108, 131], ["strong", "OBSERVATION_MODIFIER", 4, 10], ["attraction", "OBSERVATION", 11, 21], ["strong dispersion", "OBSERVATION", 154, 171]]], ["Both insertion and extraction could cause severe membrane stress, leading to the degradation of the bacterial membrane and then the reduction of bacterial viability.Mechanisms of antibacterial activities of graphene-based nanomaterialsSimilarly, the two basic modes of insertion/cutting and lipid extraction were induced by blade-like graphene-based nanomaterials, which were also observed in other studies.", [["membrane", "ANATOMY", 49, 57], ["membrane", "ANATOMY", 110, 118], ["graphene", "CHEMICAL", 207, 215], ["graphene", "CHEMICAL", 335, 343], ["graphene", "CHEMICAL", 207, 215], ["graphene", "CHEMICAL", 335, 343], ["membrane", "CELLULAR_COMPONENT", 49, 57], ["bacterial membrane", "CELLULAR_COMPONENT", 100, 118], ["graphene", "SIMPLE_CHEMICAL", 207, 215], ["lipid", "SIMPLE_CHEMICAL", 291, 296], ["Both insertion and extraction", "TREATMENT", 0, 29], ["severe membrane stress", "PROBLEM", 42, 64], ["the bacterial membrane", "PROBLEM", 96, 118], ["bacterial viability", "PROBLEM", 145, 164], ["antibacterial activities of graphene", "PROBLEM", 179, 215], ["insertion/cutting and lipid extraction", "TREATMENT", 269, 307], ["other studies", "TEST", 393, 406], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["membrane stress", "OBSERVATION", 49, 64], ["bacterial membrane", "OBSERVATION", 100, 118], ["bacterial viability", "OBSERVATION", 145, 164], ["antibacterial activities", "OBSERVATION", 179, 203], ["two", "OBSERVATION_MODIFIER", 250, 253], ["basic", "OBSERVATION_MODIFIER", 254, 259], ["modes", "OBSERVATION_MODIFIER", 260, 265], ["insertion", "OBSERVATION_MODIFIER", 269, 278], ["nanomaterials", "OBSERVATION", 350, 363]]], ["Liu et al. [138] presented that direct contact with graphene nanosheets could disrupt or damage cell membrane, where sharp edge of graphene sheets acted as \"cutters\" and caused membrane stress, previously applicable for SWCNTs.", [["cell membrane", "ANATOMY", 96, 109], ["membrane", "ANATOMY", 177, 185], ["graphene nanosheets", "CHEMICAL", 52, 71], ["SWCNTs", "CHEMICAL", 220, 226], ["graphene", "CHEMICAL", 52, 60], ["graphene", "CHEMICAL", 131, 139], ["graphene nanosheets", "SIMPLE_CHEMICAL", 52, 71], ["cell membrane", "CELLULAR_COMPONENT", 96, 109], ["membrane", "CELLULAR_COMPONENT", 177, 185], ["SWCNTs", "SIMPLE_CHEMICAL", 220, 226], ["graphene nanosheets", "TREATMENT", 52, 71], ["damage cell membrane", "PROBLEM", 89, 109], ["membrane stress", "PROBLEM", 177, 192], ["SWCNTs", "PROBLEM", 220, 226], ["damage cell membrane", "OBSERVATION", 89, 109], ["membrane stress", "OBSERVATION", 177, 192]]], ["Li et al. [162] revealed that few-layered graphene flake started with Brownian motion, followed by spontaneous piercing of the membrane with its sharp corners or protrusions at edges, eventually achieving complete penetration into the membranes.", [["membrane", "ANATOMY", 127, 135], ["membranes", "ANATOMY", 235, 244], ["Li", "CHEMICAL", 0, 2], ["graphene", "CHEMICAL", 42, 50], ["membrane", "CELLULAR_COMPONENT", 127, 135], ["membranes", "CELLULAR_COMPONENT", 235, 244], ["layered graphene flake", "PROBLEM", 34, 56], ["Brownian motion", "PROBLEM", 70, 85], ["protrusions at edges", "PROBLEM", 162, 182], ["few", "OBSERVATION_MODIFIER", 30, 33], ["graphene flake", "OBSERVATION", 42, 56], ["Brownian motion", "OBSERVATION", 70, 85], ["spontaneous", "OBSERVATION_MODIFIER", 99, 110], ["piercing", "OBSERVATION", 111, 119], ["sharp", "OBSERVATION_MODIFIER", 145, 150], ["protrusions", "OBSERVATION", 162, 173], ["penetration", "OBSERVATION", 214, 225]]], ["While the previous studies have revealed that graphene surfaces with an orientation of 90\u00b0 [136, 138, 140] were effective for cell inactivation, Pham et al. [163] found that graphene surfaces with a 37\u00b0 orientation has the best efficiency to kill bacteria.", [["cell", "ANATOMY", 126, 130], ["graphene", "CHEMICAL", 46, 54], ["graphene", "CHEMICAL", 174, 182], ["graphene", "CHEMICAL", 46, 54], ["graphene", "CHEMICAL", 174, 182], ["cell", "CELL", 126, 130], ["the previous studies", "TEST", 6, 26], ["graphene surfaces", "TEST", 46, 63], ["an orientation", "TEST", 69, 83], ["cell inactivation", "PROBLEM", 126, 143], ["graphene surfaces", "TEST", 174, 191], ["kill bacteria", "PROBLEM", 242, 255]]], ["It is also found that the density of graphene edges served as a crucial parameter in the determination of antimicrobial behavior.", [["graphene", "CHEMICAL", 37, 45], ["the density of graphene edges", "PROBLEM", 22, 51], ["antimicrobial behavior", "PROBLEM", 106, 128], ["density", "OBSERVATION", 26, 33], ["graphene edges", "OBSERVATION", 37, 51], ["antimicrobial behavior", "OBSERVATION", 106, 128]]], ["Moreover, some theoretical analysis has proposed the nearperpendicular penetration as another interaction mode between graphene and cell membrane.", [["cell membrane", "ANATOMY", 132, 145], ["graphene", "CHEMICAL", 119, 127], ["graphene", "SIMPLE_CHEMICAL", 119, 127], ["cell membrane", "CELLULAR_COMPONENT", 132, 145], ["some theoretical analysis", "TEST", 10, 35], ["the nearperpendicular penetration", "PROBLEM", 49, 82], ["cell membrane", "OBSERVATION", 132, 145]]], ["Yi and Gao [164] found that graphene sheets in a size-dependent manner would adopt a near-perpendicular configuration or a parallel attachment onto a membrane surface, where the membrane splay and tension energies acted as the main driving force.", [["membrane surface", "ANATOMY", 150, 166], ["membrane", "ANATOMY", 178, 186], ["graphene", "CHEMICAL", 28, 36], ["graphene", "CHEMICAL", 28, 36], ["graphene sheets", "SIMPLE_CHEMICAL", 28, 43], ["membrane surface", "CELLULAR_COMPONENT", 150, 166], ["membrane", "CELLULAR_COMPONENT", 178, 186], ["graphene sheets", "TREATMENT", 28, 43], ["a membrane surface", "TREATMENT", 148, 166], ["tension energies", "PROBLEM", 197, 213], ["perpendicular configuration", "OBSERVATION_MODIFIER", 90, 117], ["tension energies", "OBSERVATION", 197, 213]]], ["They reported that smaller graphene sheets were more freely to pierce through transmembrane, while larger ones lay mainly flat on the surface of bilayers where wreak havoc was created with lipophilic membranes and formed a patch of upturned phospholipids with their tails direct contact with the graphene sheet.Mechanisms of antibacterial activities of graphene-based nanomaterialsHowever, some other findings [166, 167] proposed different antibacterial mechanism that the basal planes of GO may determine its bacterial disinfection.", [["transmembrane", "ANATOMY", 78, 91], ["surface", "ANATOMY", 134, 141], ["membranes", "ANATOMY", 200, 209], ["graphene", "CHEMICAL", 353, 361], ["graphene", "CHEMICAL", 27, 35], ["graphene", "CHEMICAL", 296, 304], ["graphene", "CHEMICAL", 353, 361], ["transmembrane", "CELLULAR_COMPONENT", 78, 91], ["membranes", "CELLULAR_COMPONENT", 200, 209], ["phospholipids", "SIMPLE_CHEMICAL", 241, 254], ["graphene", "SIMPLE_CHEMICAL", 353, 361], ["smaller graphene sheets", "PROBLEM", 19, 42], ["lipophilic membranes", "PROBLEM", 189, 209], ["a patch of upturned phospholipids", "TREATMENT", 221, 254], ["the graphene sheet", "TREATMENT", 292, 310], ["antibacterial activities of graphene", "PROBLEM", 325, 361], ["its bacterial disinfection", "PROBLEM", 506, 532], ["smaller", "OBSERVATION_MODIFIER", 19, 26], ["larger", "OBSERVATION_MODIFIER", 99, 105], ["flat", "OBSERVATION_MODIFIER", 122, 126], ["lipophilic membranes", "OBSERVATION", 189, 209], ["antibacterial activities", "OBSERVATION", 325, 349], ["bacterial disinfection", "OBSERVATION", 510, 532]]], ["Advincula et al. [166] found that GO sheets entirely deposited by Langmuir-Blodgett (LB) film still retained the antibacterial activity, exhibiting positive correlation between the number of LB layers and bacterial inactivation.", [["Langmuir-Blodgett", "CHEMICAL", 66, 83], ["Langmuir-Blodgett", "SIMPLE_CHEMICAL", 66, 83], ["LB layers", "TISSUE", 191, 200], ["Blodgett (LB) film", "TEST", 75, 93], ["the antibacterial activity", "PROBLEM", 109, 135], ["LB layers", "PROBLEM", 191, 200], ["bacterial inactivation", "PROBLEM", 205, 227], ["antibacterial activity", "OBSERVATION", 113, 135], ["bacterial inactivation", "OBSERVATION", 205, 227]]], ["In another study [167] , when bovine serum albumin (BSA) or tryptophan (Trp) molecules were noncovalently adsorbed on GO basal planes, the occupation could cause GO's deactivation against bacteria, suggesting the availability of GO basal planes in the cytotoxicity against bacteria.", [["serum", "ANATOMY", 37, 42], ["tryptophan", "CHEMICAL", 60, 70], ["Trp", "CHEMICAL", 72, 75], ["tryptophan", "CHEMICAL", 60, 70], ["Trp", "CHEMICAL", 72, 75], ["bovine", "ORGANISM", 30, 36], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["albumin", "GENE_OR_GENE_PRODUCT", 43, 50], ["BSA", "SIMPLE_CHEMICAL", 52, 55], ["tryptophan (Trp) molecules", "SIMPLE_CHEMICAL", 60, 86], ["bovine", "SPECIES", 30, 36], ["another study", "TEST", 3, 16], ["bovine serum albumin (BSA", "TEST", 30, 55], ["tryptophan (Trp) molecules", "PROBLEM", 60, 86], ["GO's deactivation", "PROBLEM", 162, 179], ["bacteria", "PROBLEM", 188, 196], ["the cytotoxicity", "TEST", 248, 264], ["bacteria", "PROBLEM", 273, 281]]], ["Recently, Haag et al. [168] confirmed that the antimicrobial property of graphene was very relevant to both its sharp edges, basal planes and tight agglomeration by studying the interactions between functionalized graphene derivatives and bacteria.Mechanisms of antibacterial activities of graphene-based nanomaterialsThe oxidative stress hypothesis.", [["graphene", "CHEMICAL", 73, 81], ["graphene", "CHEMICAL", 214, 222], ["graphene", "CHEMICAL", 290, 298], ["graphene", "CHEMICAL", 73, 81], ["graphene", "CHEMICAL", 214, 222], ["graphene", "CHEMICAL", 290, 298], ["graphene", "SIMPLE_CHEMICAL", 73, 81], ["graphene derivatives", "SIMPLE_CHEMICAL", 214, 234], ["graphene", "SIMPLE_CHEMICAL", 290, 298], ["the antimicrobial property of graphene", "TREATMENT", 43, 81], ["tight agglomeration", "PROBLEM", 142, 161], ["functionalized graphene derivatives", "TREATMENT", 199, 234], ["bacteria", "PROBLEM", 239, 247], ["antibacterial activities of graphene", "PROBLEM", 262, 298], ["The oxidative stress hypothesis", "PROBLEM", 318, 349], ["basal", "ANATOMY_MODIFIER", 125, 130], ["tight", "OBSERVATION_MODIFIER", 142, 147], ["agglomeration", "OBSERVATION", 148, 161], ["antibacterial activities", "OBSERVATION", 262, 286], ["oxidative", "OBSERVATION", 322, 331], ["stress hypothesis", "OBSERVATION", 332, 349]]], ["Graphene-induced oxidative stress has been proposed as another widely recognized mechanism for antimicrobial activities of graphene-based nanomaterials, which is comparable to that of other carbon-based materials, such as CNTs and fullerene with similar structural and physiochemical properties [103, 169, 170] .", [["Graphene", "CHEMICAL", 0, 8], ["graphene", "CHEMICAL", 123, 131], ["CNTs", "CHEMICAL", 222, 226], ["fullerene", "CHEMICAL", 231, 240], ["Graphene", "CHEMICAL", 0, 8], ["graphene", "CHEMICAL", 123, 131], ["carbon", "CHEMICAL", 190, 196], ["fullerene", "CHEMICAL", 231, 240], ["graphene", "SIMPLE_CHEMICAL", 123, 131], ["carbon", "SIMPLE_CHEMICAL", 190, 196], ["CNTs", "SIMPLE_CHEMICAL", 222, 226], ["fullerene", "SIMPLE_CHEMICAL", 231, 240], ["Graphene", "TREATMENT", 0, 8], ["oxidative stress", "PROBLEM", 17, 33], ["antimicrobial activities of graphene-based nanomaterials", "PROBLEM", 95, 151], ["oxidative stress", "OBSERVATION", 17, 33], ["nanomaterials", "OBSERVATION", 138, 151]]], ["Generally, there are two pathways for the production of oxidative stress: ROS-dependent and ROS-independent mechanism.", [["ROS", "CHEMICAL", 74, 77], ["ROS", "CHEMICAL", 92, 95], ["ROS", "SIMPLE_CHEMICAL", 74, 77], ["ROS", "SIMPLE_CHEMICAL", 92, 95], ["oxidative stress", "PROBLEM", 56, 72]]], ["The former arises from the elevated intracellular ROS levels, while the latter brings about damage or oxidation of cellular structure through electron transfer.", [["intracellular", "ANATOMY", 36, 49], ["cellular", "ANATOMY", 115, 123], ["ROS", "CHEMICAL", 50, 53], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 36, 49], ["ROS", "SIMPLE_CHEMICAL", 50, 53], ["cellular", "CELL", 115, 123], ["electron", "SIMPLE_CHEMICAL", 142, 150], ["the elevated intracellular ROS levels", "PROBLEM", 23, 60], ["elevated", "OBSERVATION_MODIFIER", 27, 35], ["intracellular ROS", "OBSERVATION", 36, 53], ["cellular structure", "OBSERVATION", 115, 133]]], ["Oxidative stress can disturb microbial metabolism and destroy cellular functions, resulting in the loss of cell integrity and eventually leading to cell death.Mechanisms of antibacterial activities of graphene-based nanomaterialsROS-dependent pathway occurs via the excess accumulation of ROS, including hydrogen peroxide(H2O2), hydroxyl radicals (OH \u2022 ), superoxide anions (O2 \u2022\u02c9) , or singlet molecular oxygen ( 1 O2).", [["cellular", "ANATOMY", 62, 70], ["cell", "ANATOMY", 107, 111], ["cell", "ANATOMY", 148, 152], ["death", "DISEASE", 153, 158], ["graphene", "CHEMICAL", 201, 209], ["ROS", "CHEMICAL", 229, 232], ["ROS", "CHEMICAL", 289, 292], ["hydrogen peroxide", "CHEMICAL", 304, 321], ["H2O2", "CHEMICAL", 322, 326], ["hydroxyl", "CHEMICAL", 329, 337], ["OH", "CHEMICAL", 348, 350], ["superoxide", "CHEMICAL", 356, 366], ["O2 \u2022\u02c9", "CHEMICAL", 375, 380], ["oxygen", "CHEMICAL", 405, 411], ["1 O2", "CHEMICAL", 414, 418], ["graphene", "CHEMICAL", 201, 209], ["hydrogen peroxide", "CHEMICAL", 304, 321], ["H2O2", "CHEMICAL", 322, 326], ["hydroxyl", "CHEMICAL", 329, 337], ["OH \u2022", "CHEMICAL", 348, 352], ["superoxide", "CHEMICAL", 356, 366], ["O2", "CHEMICAL", 375, 377], ["oxygen", "CHEMICAL", 405, 411], ["O2", "CHEMICAL", 416, 418], ["cellular", "CELL", 62, 70], ["cell", "CELL", 107, 111], ["cell", "CELL", 148, 152], ["graphene", "SIMPLE_CHEMICAL", 201, 209], ["ROS", "SIMPLE_CHEMICAL", 229, 232], ["ROS", "SIMPLE_CHEMICAL", 289, 292], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 304, 321], ["H2O2", "SIMPLE_CHEMICAL", 322, 326], ["hydroxyl radicals", "SIMPLE_CHEMICAL", 329, 346], ["OH \u2022", "SIMPLE_CHEMICAL", 348, 352], ["superoxide anions", "SIMPLE_CHEMICAL", 356, 373], ["O2 \u2022\u02c9", "SIMPLE_CHEMICAL", 375, 380], ["singlet molecular oxygen", "SIMPLE_CHEMICAL", 387, 411], ["1 O2", "SIMPLE_CHEMICAL", 414, 418], ["Oxidative stress", "PROBLEM", 0, 16], ["the loss of cell integrity", "PROBLEM", 95, 121], ["cell death", "PROBLEM", 148, 158], ["antibacterial activities of graphene", "PROBLEM", 173, 209], ["dependent pathway", "PROBLEM", 233, 250], ["the excess accumulation of ROS", "PROBLEM", 262, 292], ["hydrogen peroxide(H2O2)", "TREATMENT", 304, 327], ["hydroxyl radicals (OH \u2022 )", "TREATMENT", 329, 354], ["superoxide anions (O2 \u2022\u02c9)", "TREATMENT", 356, 381], ["singlet molecular oxygen", "TREATMENT", 387, 411], ["cell integrity", "OBSERVATION", 107, 121], ["cell death", "OBSERVATION", 148, 158], ["antibacterial activities", "OBSERVATION", 173, 197]]], ["The elevated ROS level makes cell reach an oxidative state, and further lead to the damage or inactivation to cellular substrates, e.g., proteins, DNA, and lipids, followed by dysfunction of the mitochondria, disintegration of cell membrane, and ultimate cell death by apoptosis or necrosis [171] .", [["cell", "ANATOMY", 29, 33], ["cellular", "ANATOMY", 110, 118], ["mitochondria", "ANATOMY", 195, 207], ["cell membrane", "ANATOMY", 227, 240], ["cell", "ANATOMY", 255, 259], ["ROS", "CHEMICAL", 13, 16], ["death", "DISEASE", 260, 265], ["necrosis", "DISEASE", 282, 290], ["ROS", "SIMPLE_CHEMICAL", 13, 16], ["cell", "CELL", 29, 33], ["cellular", "CELL", 110, 118], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["mitochondria", "CELLULAR_COMPONENT", 195, 207], ["cell membrane", "CELLULAR_COMPONENT", 227, 240], ["cell", "CELL", 255, 259], ["The elevated ROS level", "PROBLEM", 0, 22], ["the damage", "PROBLEM", 80, 90], ["cellular substrates", "TEST", 110, 129], ["DNA", "TEST", 147, 150], ["lipids", "TREATMENT", 156, 162], ["dysfunction of the mitochondria", "PROBLEM", 176, 207], ["cell membrane", "TREATMENT", 227, 240], ["ultimate cell death", "PROBLEM", 246, 265], ["apoptosis", "PROBLEM", 269, 278], ["necrosis", "PROBLEM", 282, 290], ["elevated", "OBSERVATION_MODIFIER", 4, 12], ["ROS", "OBSERVATION", 13, 16], ["oxidative state", "OBSERVATION", 43, 58], ["cell membrane", "OBSERVATION", 227, 240], ["ultimate cell death", "OBSERVATION", 246, 265], ["necrosis", "OBSERVATION", 282, 290]]], ["In the ROS-dependent pathway, antioxidant compounds, like glutathione (GSH), N-acetylcysteine (NAC) [172] , \u03b1-tocopherol [173] , and dichlorodihydrofluorescein diacetate [103, 174] can be oxidized in the presence of ROS and act as intracellular redox state indicator, whose depletion suggests the antibacterial effect of oxidative stress against bacteria.", [["intracellular", "ANATOMY", 231, 244], ["ROS", "CHEMICAL", 7, 10], ["glutathione", "CHEMICAL", 58, 69], ["GSH", "CHEMICAL", 71, 74], ["N-acetylcysteine", "CHEMICAL", 77, 93], ["NAC", "CHEMICAL", 95, 98], ["\u03b1-tocopherol [173] , and dichlorodihydrofluorescein diacetate", "CHEMICAL", 108, 169], ["ROS", "CHEMICAL", 216, 219], ["glutathione", "CHEMICAL", 58, 69], ["GSH", "CHEMICAL", 71, 74], ["N-acetylcysteine", "CHEMICAL", 77, 93], ["NAC", "CHEMICAL", 95, 98], ["\u03b1-tocopherol", "CHEMICAL", 108, 120], ["dichlorodihydrofluorescein diacetate", "CHEMICAL", 133, 169], ["ROS", "SIMPLE_CHEMICAL", 7, 10], ["antioxidant compounds", "SIMPLE_CHEMICAL", 30, 51], ["glutathione", "SIMPLE_CHEMICAL", 58, 69], ["GSH", "SIMPLE_CHEMICAL", 71, 74], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 77, 93], ["NAC", "SIMPLE_CHEMICAL", 95, 98], ["[172]", "SIMPLE_CHEMICAL", 100, 105], ["\u03b1-tocopherol [173]", "SIMPLE_CHEMICAL", 108, 126], ["dichlorodihydrofluorescein diacetate", "SIMPLE_CHEMICAL", 133, 169], ["[103, 174]", "SIMPLE_CHEMICAL", 170, 180], ["ROS", "SIMPLE_CHEMICAL", 216, 219], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 231, 244], ["dependent pathway", "PROBLEM", 11, 28], ["antioxidant compounds", "PROBLEM", 30, 51], ["glutathione (GSH)", "TREATMENT", 58, 75], ["N-acetylcysteine (NAC)", "TREATMENT", 77, 99], ["\u03b1-tocopherol", "TREATMENT", 108, 120], ["dichlorodihydrofluorescein diacetate", "TREATMENT", 133, 169], ["whose depletion", "PROBLEM", 268, 283], ["oxidative stress against bacteria", "PROBLEM", 321, 354], ["antibacterial effect", "OBSERVATION_MODIFIER", 297, 317]]], ["Kim's group [172] measured the levels of ROS in P. aeruginosa cells treated by GO and rGO, which were 3.8-and 2.7-fold higher than that in untreated cells, respectively.", [["cells", "ANATOMY", 62, 67], ["cells", "ANATOMY", 149, 154], ["ROS", "CHEMICAL", 41, 44], ["ROS", "SIMPLE_CHEMICAL", 41, 44], ["P. aeruginosa cells", "CELL", 48, 67], ["rGO", "SIMPLE_CHEMICAL", 86, 89], ["cells", "CELL", 149, 154], ["untreated cells", "CELL_TYPE", 139, 154], ["P. aeruginosa", "SPECIES", 48, 61], ["P. aeruginosa", "SPECIES", 48, 61], ["Kim's group", "TEST", 0, 11], ["P. aeruginosa cells", "PROBLEM", 48, 67], ["rGO", "TEST", 86, 89], ["untreated cells", "OBSERVATION", 139, 154]]], ["It was demonstrated that pretreated cells with the antioxidant GSH or NAC reduced the levels of ROS derived from GO or rGO, implying that cell death is mediated with ROS generation.", [["cells", "ANATOMY", 36, 41], ["cell", "ANATOMY", 138, 142], ["GSH", "CHEMICAL", 63, 66], ["NAC", "CHEMICAL", 70, 73], ["ROS", "CHEMICAL", 96, 99], ["death", "DISEASE", 143, 148], ["ROS", "CHEMICAL", 166, 169], ["GSH", "CHEMICAL", 63, 66], ["NAC", "CHEMICAL", 70, 73], ["cells", "CELL", 36, 41], ["GSH", "SIMPLE_CHEMICAL", 63, 66], ["NAC", "SIMPLE_CHEMICAL", 70, 73], ["ROS", "SIMPLE_CHEMICAL", 96, 99], ["rGO", "SIMPLE_CHEMICAL", 119, 122], ["cell", "CELL", 138, 142], ["ROS", "SIMPLE_CHEMICAL", 166, 169], ["pretreated cells", "CELL_LINE", 25, 41], ["pretreated cells", "PROBLEM", 25, 41], ["the antioxidant GSH", "TREATMENT", 47, 66], ["NAC", "TREATMENT", 70, 73], ["cell death", "PROBLEM", 138, 148], ["cell death", "OBSERVATION", 138, 148]]], ["They further observed a remarkable higher production of O2 \u2022\u02c9 by GO or rGO, directly verifying the toxicity of ROS against E. coli [175] .Mechanisms of antibacterial activities of graphene-based nanomaterialsLipid peroxidation is an important oxidative pathway initiated by ROS-mediated oxidation of lipid molecules, which proceeds by a free radical chain reaction mechanism.", [["O2 \u2022\u02c9", "CHEMICAL", 56, 61], ["rGO", "CHEMICAL", 71, 74], ["toxicity", "DISEASE", 99, 107], ["ROS", "CHEMICAL", 111, 114], ["graphene", "CHEMICAL", 180, 188], ["ROS", "CHEMICAL", 274, 277], ["O2", "CHEMICAL", 56, 58], ["rGO", "CHEMICAL", 71, 74], ["graphene", "CHEMICAL", 180, 188], ["O2 \u2022\u02c9", "SIMPLE_CHEMICAL", 56, 61], ["rGO", "SIMPLE_CHEMICAL", 71, 74], ["ROS", "SIMPLE_CHEMICAL", 111, 114], ["E. coli", "ORGANISM", 123, 130], ["graphene", "SIMPLE_CHEMICAL", 180, 188], ["Lipid", "SIMPLE_CHEMICAL", 208, 213], ["ROS", "SIMPLE_CHEMICAL", 274, 277], ["lipid molecules", "SIMPLE_CHEMICAL", 300, 315], ["E. coli", "SPECIES", 123, 130], ["E. coli", "SPECIES", 123, 130], ["E. coli", "PROBLEM", 123, 130], ["antibacterial activities of graphene", "PROBLEM", 152, 188], ["Lipid peroxidation", "TREATMENT", 208, 226], ["lipid molecules", "PROBLEM", 300, 315], ["a free radical chain reaction mechanism", "TREATMENT", 335, 374], ["antibacterial activities", "OBSERVATION", 152, 176], ["peroxidation", "OBSERVATION", 214, 226], ["lipid molecules", "OBSERVATION", 300, 315]]], ["In lipid peroxidation, lipid peroxide radicals are further formed to propagate the oxidative damage through the membrane.", [["membrane", "ANATOMY", 112, 120], ["peroxide", "CHEMICAL", 29, 37], ["lipid", "SIMPLE_CHEMICAL", 3, 8], ["lipid peroxide radicals", "SIMPLE_CHEMICAL", 23, 46], ["membrane", "CELLULAR_COMPONENT", 112, 120], ["lipid peroxidation", "TREATMENT", 3, 21], ["lipid peroxide radicals", "TREATMENT", 23, 46], ["lipid peroxidation", "OBSERVATION", 3, 21], ["lipid", "OBSERVATION", 23, 28], ["peroxide radicals", "OBSERVATION", 29, 46], ["oxidative damage", "OBSERVATION", 83, 99], ["membrane", "ANATOMY_MODIFIER", 112, 120]]], ["Kim and co-workers [176] found the ultrasound-induced lipid peroxidation was enhanced by 117% and 109% after treatment with 10 and 5 \uf06dg\u00b7mL \u22121 of graphene, respectively.", [["graphene", "CHEMICAL", 145, 153], ["graphene", "CHEMICAL", 145, 153], ["lipid", "SIMPLE_CHEMICAL", 54, 59], ["graphene", "SIMPLE_CHEMICAL", 145, 153], ["the ultrasound", "TEST", 31, 45], ["lipid peroxidation", "PROBLEM", 54, 72], ["treatment", "TREATMENT", 109, 118], ["graphene", "TREATMENT", 145, 153]]], ["Elimelech et al. [142] reported that preincubated bacterial cells with a lipid-soluble antioxidant \u03b1-tocopherol, reduced the antimicrobial effect of GO sheets, indicating that oxidative stress served as a crucial factor in GO-induced cell inactivation.", [["cells", "ANATOMY", 60, 65], ["cell", "ANATOMY", 234, 238], ["\u03b1-tocopherol", "CHEMICAL", 99, 111], ["\u03b1-tocopherol", "CHEMICAL", 99, 111], ["bacterial cells", "CELL", 50, 65], ["lipid", "SIMPLE_CHEMICAL", 73, 78], ["\u03b1-tocopherol", "SIMPLE_CHEMICAL", 99, 111], ["cell", "CELL", 234, 238], ["bacterial cells", "CELL_TYPE", 50, 65], ["preincubated bacterial cells", "PROBLEM", 37, 65], ["a lipid-soluble antioxidant \u03b1-tocopherol", "TREATMENT", 71, 111], ["oxidative stress", "PROBLEM", 176, 192], ["a crucial factor", "PROBLEM", 203, 219], ["bacterial cells", "OBSERVATION", 50, 65], ["cell inactivation", "OBSERVATION", 234, 251]]], ["Moreover, the cytotoxicity of graphene was proven to be effected by mitochondrial membrane depolarization.", [["mitochondrial membrane", "ANATOMY", 68, 90], ["graphene", "CHEMICAL", 30, 38], ["graphene", "CHEMICAL", 30, 38], ["graphene", "SIMPLE_CHEMICAL", 30, 38], ["mitochondrial membrane", "CELLULAR_COMPONENT", 68, 90], ["the cytotoxicity of graphene", "TREATMENT", 10, 38], ["mitochondrial membrane depolarization", "PROBLEM", 68, 105], ["mitochondrial membrane depolarization", "OBSERVATION", 68, 105]]], ["Chen et al. [111] evaluated the cytotoxicity and the related signaling pathways of graphene in murine RAW 264.7 macrophages.", [["RAW 264.7 macrophages", "ANATOMY", 102, 123], ["graphene", "CHEMICAL", 83, 91], ["graphene", "CHEMICAL", 83, 91], ["graphene", "SIMPLE_CHEMICAL", 83, 91], ["murine", "ORGANISM", 95, 101], ["RAW 264.7 macrophages", "CELL", 102, 123], ["murine RAW 264.7 macrophages", "CELL_LINE", 95, 123], ["murine", "SPECIES", 95, 101], ["the cytotoxicity", "TEST", 28, 44], ["264.7 macrophages", "OBSERVATION", 106, 123]]], ["After exposure of cells to graphene, the inactivation of bacteria is generated by the loss of MMP and the accumulation of ROS, followed by triggering apoptosis through activation of the mitochondrial pathway.Mechanisms of antibacterial activities of graphene-based nanomaterialsBesides ROS-mediated damage, the other possible pathway is ROS-independent oxidative stress against bacteria, in which antimicrobial behaviors stem from graphene by disruption or oxidation of cell architecture or component without ROS production.", [["cells", "ANATOMY", 18, 23], ["mitochondrial", "ANATOMY", 186, 199], ["cell", "ANATOMY", 470, 474], ["graphene", "CHEMICAL", 27, 35], ["ROS", "CHEMICAL", 122, 125], ["graphene", "CHEMICAL", 250, 258], ["ROS", "CHEMICAL", 286, 289], ["ROS", "CHEMICAL", 337, 340], ["graphene", "CHEMICAL", 431, 439], ["ROS", "CHEMICAL", 509, 512], ["graphene", "CHEMICAL", 27, 35], ["graphene", "CHEMICAL", 250, 258], ["graphene", "CHEMICAL", 431, 439], ["cells", "CELL", 18, 23], ["graphene", "SIMPLE_CHEMICAL", 27, 35], ["MMP", "GENE_OR_GENE_PRODUCT", 94, 97], ["ROS", "SIMPLE_CHEMICAL", 122, 125], ["mitochondrial", "CELLULAR_COMPONENT", 186, 199], ["graphene", "SIMPLE_CHEMICAL", 250, 258], ["ROS", "SIMPLE_CHEMICAL", 286, 289], ["ROS", "SIMPLE_CHEMICAL", 337, 340], ["graphene", "SIMPLE_CHEMICAL", 431, 439], ["cell", "CELL", 470, 474], ["ROS", "SIMPLE_CHEMICAL", 509, 512], ["MMP", "PROTEIN", 94, 97], ["cells to graphene", "TREATMENT", 18, 35], ["bacteria", "PROBLEM", 57, 65], ["the loss of MMP", "PROBLEM", 82, 97], ["the accumulation of ROS", "PROBLEM", 102, 125], ["the mitochondrial pathway", "TREATMENT", 182, 207], ["antibacterial activities of graphene", "PROBLEM", 222, 258], ["ROS", "PROBLEM", 286, 289], ["mediated damage", "PROBLEM", 290, 305], ["independent oxidative stress", "PROBLEM", 341, 369], ["bacteria", "PROBLEM", 378, 386], ["oxidation of cell architecture", "PROBLEM", 457, 487], ["ROS production", "PROBLEM", 509, 523], ["antibacterial activities", "OBSERVATION", 222, 246], ["damage", "OBSERVATION", 299, 305], ["cell architecture", "OBSERVATION", 470, 487], ["component", "OBSERVATION_MODIFIER", 491, 500], ["without", "UNCERTAINTY", 501, 508], ["ROS production", "OBSERVATION", 509, 523]]], ["This behavior was previously observed in fullerene (C60)-exposed bacteria, where C60 acted as an oxidant and exerted ROS-independent oxidative stress against bacteria [169, 177] .", [["fullerene", "CHEMICAL", 41, 50], ["C60", "CHEMICAL", 52, 55], ["C60", "CHEMICAL", 81, 84], ["ROS", "CHEMICAL", 117, 120], ["fullerene", "CHEMICAL", 41, 50], ["C60", "CHEMICAL", 52, 55], ["C60", "CHEMICAL", 81, 84], ["fullerene (C60)", "SIMPLE_CHEMICAL", 41, 56], ["C60", "SIMPLE_CHEMICAL", 81, 84], ["ROS", "SIMPLE_CHEMICAL", 117, 120], ["exposed bacteria", "PROBLEM", 57, 73], ["bacteria", "PROBLEM", 158, 166]]], ["Liu et al. [138] observed no detectable levels of O2 \u2022\u02c9 in antibacterial activity, indicating that graphene-based nanomaterials mediated little ROS production.", [["O2 \u2022\u02c9", "CHEMICAL", 50, 55], ["graphene", "CHEMICAL", 99, 107], ["ROS", "CHEMICAL", 144, 147], ["O2", "CHEMICAL", 50, 52], ["graphene", "CHEMICAL", 99, 107], ["O2", "SIMPLE_CHEMICAL", 50, 52], ["graphene", "SIMPLE_CHEMICAL", 99, 107], ["ROS", "SIMPLE_CHEMICAL", 144, 147], ["O2", "TREATMENT", 50, 52], ["antibacterial activity", "TEST", 59, 81], ["little ROS production", "PROBLEM", 137, 158], ["antibacterial activity", "OBSERVATION", 59, 81]]], ["They later used Ellman's assay to evaluate the oxidation of GSH and indirectly verified that graphene-based nanomaterials possessed the capacity of mediating ROS-independent oxidative stress against bacteria.Mechanisms of antibacterial activities of graphene-based nanomaterialsLi et al. [178] represented a controversial view that the antibacterial activity of graphene does not arise from ROS-dependent damage but through electron transfer interaction between cell membrane and graphene.", [["cell membrane", "ANATOMY", 462, 475], ["GSH", "CHEMICAL", 60, 63], ["graphene", "CHEMICAL", 93, 101], ["ROS", "CHEMICAL", 158, 161], ["graphene", "CHEMICAL", 250, 258], ["Li", "CHEMICAL", 278, 280], ["graphene", "CHEMICAL", 362, 370], ["ROS", "CHEMICAL", 391, 394], ["GSH", "CHEMICAL", 60, 63], ["graphene", "CHEMICAL", 93, 101], ["graphene", "CHEMICAL", 250, 258], ["graphene", "CHEMICAL", 362, 370], ["graphene", "CHEMICAL", 480, 488], ["GSH", "SIMPLE_CHEMICAL", 60, 63], ["graphene", "SIMPLE_CHEMICAL", 93, 101], ["ROS", "SIMPLE_CHEMICAL", 158, 161], ["graphene", "SIMPLE_CHEMICAL", 250, 258], ["graphene", "SIMPLE_CHEMICAL", 362, 370], ["ROS", "SIMPLE_CHEMICAL", 391, 394], ["electron", "SIMPLE_CHEMICAL", 424, 432], ["cell membrane", "CELLULAR_COMPONENT", 462, 475], ["graphene", "SIMPLE_CHEMICAL", 480, 488], ["Ellman's assay", "TEST", 16, 30], ["mediating ROS", "PROBLEM", 148, 161], ["bacteria", "PROBLEM", 199, 207], ["antibacterial activities of graphene", "PROBLEM", 222, 258], ["the antibacterial activity of graphene", "TREATMENT", 332, 370], ["dependent damage", "PROBLEM", 395, 411], ["cell membrane and graphene", "TREATMENT", 462, 488], ["antibacterial activities", "OBSERVATION", 222, 246]]], ["They found that graphene films deposit on Cu and Ge could inhibit the bacterial growth, whereas no obvious membrane damage was observed by graphene on SiO2.", [["membrane", "ANATOMY", 107, 115], ["graphene", "CHEMICAL", 16, 24], ["Cu", "CHEMICAL", 42, 44], ["Ge", "CHEMICAL", 49, 51], ["graphene", "CHEMICAL", 139, 147], ["SiO2", "CHEMICAL", 151, 155], ["graphene", "CHEMICAL", 16, 24], ["Cu", "CHEMICAL", 42, 44], ["Ge", "CHEMICAL", 49, 51], ["graphene", "CHEMICAL", 139, 147], ["SiO2", "CHEMICAL", 151, 155], ["graphene films", "SIMPLE_CHEMICAL", 16, 30], ["Cu", "SIMPLE_CHEMICAL", 42, 44], ["Ge", "SIMPLE_CHEMICAL", 49, 51], ["membrane", "CELLULAR_COMPONENT", 107, 115], ["graphene", "SIMPLE_CHEMICAL", 139, 147], ["SiO2", "SIMPLE_CHEMICAL", 151, 155], ["graphene films deposit", "PROBLEM", 16, 38], ["the bacterial growth", "PROBLEM", 66, 86], ["obvious membrane damage", "PROBLEM", 99, 122], ["bacterial growth", "OBSERVATION", 70, 86], ["damage", "OBSERVATION", 116, 122]]], ["An electron transfer theory was proposed to explain the phenomena.", [["the phenomena", "PROBLEM", 52, 65], ["phenomena", "OBSERVATION", 56, 65]]], ["A circuit for electron transfer was formed, where the electrons were easily transferred from bacterial membrane to graphene film and then to the conductor Cu or semiconductor Ge substrate, while the electrons could not be transferred to insulator SiO2 substrate.", [["membrane", "ANATOMY", 103, 111], ["graphene", "CHEMICAL", 115, 123], ["Cu", "CHEMICAL", 155, 157], ["graphene", "CHEMICAL", 115, 123], ["Cu", "CHEMICAL", 155, 157], ["Ge", "CHEMICAL", 175, 177], ["SiO2", "CHEMICAL", 247, 251], ["electron", "SIMPLE_CHEMICAL", 14, 22], ["bacterial membrane", "CELLULAR_COMPONENT", 93, 111], ["graphene film", "SIMPLE_CHEMICAL", 115, 128], ["Cu", "SIMPLE_CHEMICAL", 155, 157], ["A circuit", "TREATMENT", 0, 9], ["bacterial membrane to graphene film", "TREATMENT", 93, 128], ["insulator SiO2 substrate", "TREATMENT", 237, 261]]], ["Consequently, the graphene-on-substrate junctions could serve as an electron pump for both Cu and Ge substrates, in which the electrons are quickly and potently extracted away from the bacterial membrane under the negative membrane potential, eventually leading to the destroy of membrane integrity and the loss of cell viability.Mechanisms of antibacterial activities of graphene-based nanomaterialsThe wrapping or trapping hypothesis.", [["membrane", "ANATOMY", 195, 203], ["membrane", "ANATOMY", 223, 231], ["membrane", "ANATOMY", 280, 288], ["cell", "ANATOMY", 315, 319], ["graphene", "CHEMICAL", 18, 26], ["Cu", "CHEMICAL", 91, 93], ["Ge", "CHEMICAL", 98, 100], ["graphene", "CHEMICAL", 372, 380], ["graphene", "CHEMICAL", 18, 26], ["Cu", "CHEMICAL", 91, 93], ["Ge", "CHEMICAL", 98, 100], ["graphene", "CHEMICAL", 372, 380], ["Cu", "SIMPLE_CHEMICAL", 91, 93], ["bacterial membrane", "CELLULAR_COMPONENT", 185, 203], ["membrane", "CELLULAR_COMPONENT", 223, 231], ["membrane", "CELLULAR_COMPONENT", 280, 288], ["cell", "CELL", 315, 319], ["graphene", "SIMPLE_CHEMICAL", 372, 380], ["the graphene-on-substrate junctions", "TREATMENT", 14, 49], ["an electron pump", "TREATMENT", 65, 81], ["the bacterial membrane", "PROBLEM", 181, 203], ["membrane integrity", "PROBLEM", 280, 298], ["the loss of cell viability", "PROBLEM", 303, 329], ["antibacterial activities of graphene", "PROBLEM", 344, 380], ["The wrapping", "TREATMENT", 400, 412], ["trapping hypothesis", "PROBLEM", 416, 435], ["bacterial membrane", "OBSERVATION", 185, 203], ["negative membrane", "OBSERVATION", 214, 231], ["membrane integrity", "OBSERVATION", 280, 298], ["loss of cell viability", "OBSERVATION", 307, 329], ["antibacterial activities", "OBSERVATION", 344, 368], ["wrapping", "OBSERVATION", 404, 412], ["trapping hypothesis", "OBSERVATION", 416, 435]]], ["Owing to its unique flexible 2D lateral nanostructure and the thinnest film, wrapping or trapping bacterial membranes has been regarded as the third mechanism of the antibacterial action.", [["membranes", "ANATOMY", 108, 117], ["membranes", "CELLULAR_COMPONENT", 108, 117], ["its unique flexible 2D lateral nanostructure", "TREATMENT", 9, 53], ["the thinnest film", "TEST", 58, 75], ["trapping bacterial membranes", "PROBLEM", 89, 117], ["the antibacterial action", "TREATMENT", 162, 186], ["trapping", "OBSERVATION", 89, 97], ["bacterial membranes", "OBSERVATION", 98, 117]]], ["Rodrigues's group [179] found PVK-GO nanocomposite displayed excellent antibacterial behaviors through encapsulating the bacterial cells, resulting in reduced metabolic activity and inhibited bacterial growth.", [["cells", "ANATOMY", 131, 136], ["PVK", "CHEMICAL", 30, 33], ["PVK", "SIMPLE_CHEMICAL", 30, 33], ["cells", "CELL", 131, 136], ["bacterial cells", "CELL_TYPE", 121, 136], ["Rodrigues", "TEST", 0, 9], ["PVK", "TEST", 30, 33], ["GO nanocomposite", "PROBLEM", 34, 50], ["the bacterial cells", "PROBLEM", 117, 136], ["reduced metabolic activity", "PROBLEM", 151, 177], ["bacterial growth", "PROBLEM", 192, 208], ["bacterial cells", "OBSERVATION", 121, 136], ["reduced", "OBSERVATION_MODIFIER", 151, 158], ["metabolic activity", "OBSERVATION", 159, 177], ["bacterial growth", "OBSERVATION", 192, 208]]], ["With slight difference, some researchers found that wrapping of bacteria could partly cause bacterial structural damage.", [["slight difference", "PROBLEM", 5, 22], ["bacteria", "PROBLEM", 64, 72], ["bacterial structural damage", "PROBLEM", 92, 119], ["slight", "OBSERVATION_MODIFIER", 5, 11], ["difference", "OBSERVATION_MODIFIER", 12, 22], ["bacteria", "OBSERVATION", 64, 72], ["could partly cause", "UNCERTAINTY", 73, 91], ["bacterial", "OBSERVATION_MODIFIER", 92, 101], ["structural", "OBSERVATION_MODIFIER", 102, 112], ["damage", "OBSERVATION", 113, 119]]], ["Han's group [180] demonstrated that GO interwound or enveloped pathogens using an intact and relatively smooth cell wall or membrane.", [["cell wall", "ANATOMY", 111, 120], ["membrane", "ANATOMY", 124, 132], ["smooth cell wall", "TISSUE", 104, 120], ["membrane", "CELLULAR_COMPONENT", 124, 132], ["enveloped pathogens", "PROBLEM", 53, 72], ["intact", "OBSERVATION", 82, 88], ["smooth cell", "OBSERVATION", 104, 115], ["wall", "ANATOMY_MODIFIER", 116, 120], ["membrane", "OBSERVATION_MODIFIER", 124, 132]]], ["They further observed MMP changes and thus confirmed that GO could induce partly structural damages of pathogens via membrane depolarization, finally causing the bacterial death.", [["membrane", "ANATOMY", 117, 125], ["death", "DISEASE", 172, 177], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["MMP", "PROTEIN", 22, 25], ["MMP changes", "PROBLEM", 22, 33], ["membrane depolarization", "PROBLEM", 117, 140], ["the bacterial death", "PROBLEM", 158, 177], ["membrane depolarization", "OBSERVATION", 117, 140], ["bacterial death", "OBSERVATION", 162, 177]]], ["Similarly, another study [181] found that 3D porous GO membrane could kill S. aureus through mechanical wrapping, disrupting and damaging cell membranes, and ultimate cell lysis.", [["GO membrane", "ANATOMY", 52, 63], ["cell membranes", "ANATOMY", 138, 152], ["cell", "ANATOMY", 167, 171], ["S. aureus", "ORGANISM", 75, 84], ["cell membranes", "CELLULAR_COMPONENT", 138, 152], ["cell", "CELL", 167, 171], ["S. aureus", "SPECIES", 75, 84], ["S. aureus", "SPECIES", 75, 84], ["another study", "TEST", 11, 24], ["3D porous GO membrane", "TREATMENT", 42, 63], ["S. aureus", "PROBLEM", 75, 84], ["mechanical wrapping", "TREATMENT", 93, 112], ["damaging cell membranes", "TREATMENT", 129, 152], ["ultimate cell lysis", "TREATMENT", 158, 177], ["aureus", "OBSERVATION", 78, 84], ["mechanical wrapping", "OBSERVATION", 93, 112], ["damaging cell membranes", "OBSERVATION", 129, 152], ["ultimate cell lysis", "OBSERVATION", 158, 177]]], ["Akhavan et al. [182] proposed E. coli chemically reduced GO sheet could trap within the aggregated sheets, which biologically disconnected the bacteria from suspension and inactivated their proliferation.Mechanisms of antibacterial activities of graphene-based nanomaterialsOther mechanisms.", [["graphene", "CHEMICAL", 246, 254], ["graphene", "CHEMICAL", 246, 254], ["E. coli", "ORGANISM", 30, 37], ["graphene", "SIMPLE_CHEMICAL", 246, 254], ["E. coli", "SPECIES", 30, 37], ["E. coli", "SPECIES", 30, 37], ["E. coli", "PROBLEM", 30, 37], ["the bacteria", "PROBLEM", 139, 151], ["their proliferation", "PROBLEM", 184, 203], ["antibacterial activities of graphene", "PROBLEM", 218, 254], ["proliferation", "OBSERVATION_MODIFIER", 190, 203], ["antibacterial activities", "OBSERVATION", 218, 242]]], ["Besides the mechanisms described above, there are some other viewpoints have been established, including extraction of lipid bilayers, interference of protein-protein interactions, etc. Recent experiments and simulations [141] showed that graphene's sp 2 hybridized 2D carbon architecture has strong interaction with membrane lipids.", [["membrane", "ANATOMY", 317, 325], ["graphene", "CHEMICAL", 239, 247], ["graphene", "CHEMICAL", 239, 247], ["carbon", "CHEMICAL", 269, 275], ["lipid bilayers", "SIMPLE_CHEMICAL", 119, 133], ["graphene", "SIMPLE_CHEMICAL", 239, 247], ["2D carbon", "SIMPLE_CHEMICAL", 266, 275], ["membrane lipids", "CELLULAR_COMPONENT", 317, 332], ["extraction of lipid bilayers", "TREATMENT", 105, 133], ["protein-protein interactions", "PROBLEM", 151, 179], ["graphene's sp 2 hybridized 2D carbon architecture", "TREATMENT", 239, 288], ["membrane lipids", "TREATMENT", 317, 332]]], ["As a consequence, graphene nanosheets could vigorously extract large amounts of phospholipids from the lipid bilayers, causing a deformation of the membrane and thus leading to the loss of membrane integrity.", [["lipid bilayers", "ANATOMY", 103, 117], ["membrane", "ANATOMY", 148, 156], ["membrane", "ANATOMY", 189, 197], ["graphene nanosheets", "CHEMICAL", 18, 37], ["graphene", "CHEMICAL", 18, 26], ["graphene nanosheets", "SIMPLE_CHEMICAL", 18, 37], ["phospholipids", "SIMPLE_CHEMICAL", 80, 93], ["lipid bilayers", "CELLULAR_COMPONENT", 103, 117], ["membrane", "CELLULAR_COMPONENT", 148, 156], ["membrane", "CELLULAR_COMPONENT", 189, 197], ["graphene nanosheets", "TREATMENT", 18, 37], ["phospholipids", "TREATMENT", 80, 93], ["the lipid bilayers", "TREATMENT", 99, 117], ["a deformation of the membrane", "PROBLEM", 127, 156], ["the loss of membrane integrity", "PROBLEM", 177, 207], ["lipid bilayers", "OBSERVATION", 103, 117], ["deformation", "OBSERVATION", 129, 140], ["loss", "OBSERVATION_MODIFIER", 181, 185], ["membrane integrity", "OBSERVATION", 189, 207]]], ["Luan et al. used large-scale all-atom MD simulations [183] to study the potential toxicity of graphene to cell functions.", [["cell", "ANATOMY", 106, 110], ["toxicity", "DISEASE", 82, 90], ["graphene", "CHEMICAL", 94, 102], ["graphene", "CHEMICAL", 94, 102], ["graphene", "SIMPLE_CHEMICAL", 94, 102], ["cell", "CELL", 106, 110], ["large", "OBSERVATION_MODIFIER", 17, 22]]], ["They found the insertion of graphene into the protein-protein interface could destabilize hydrophobic protein-protein interaction.", [["graphene", "CHEMICAL", 28, 36], ["graphene", "CHEMICAL", 28, 36], ["hydrophobic protein", "PROTEIN", 90, 109], ["the insertion of graphene", "TREATMENT", 11, 36], ["hydrophobic protein", "OBSERVATION", 90, 109], ["protein interaction", "OBSERVATION", 110, 129]]], ["The separated protein complexes destroyed cell's function and induced ultimate cell death, which agreed well with previous findings of the genotoxicity of CNTs to DNA [103] .Wound addressingIf skins are damaged, microbes are liable to invade easily and formed severe wound infection.", [["cell", "ANATOMY", 42, 46], ["cell", "ANATOMY", 79, 83], ["Wound", "ANATOMY", 174, 179], ["skins", "ANATOMY", 193, 198], ["wound", "ANATOMY", 267, 272], ["death", "DISEASE", 84, 89], ["CNTs", "CHEMICAL", 155, 159], ["wound infection", "DISEASE", 267, 282], ["cell", "CELL", 42, 46], ["cell", "CELL", 79, 83], ["CNTs", "SIMPLE_CHEMICAL", 155, 159], ["DNA", "CELLULAR_COMPONENT", 163, 166], ["Wound", "PATHOLOGICAL_FORMATION", 174, 179], ["skins", "ORGAN", 193, 198], ["wound", "PATHOLOGICAL_FORMATION", 267, 272], ["protein complexes", "PROTEIN", 14, 31], ["ultimate cell death", "PROBLEM", 70, 89], ["the genotoxicity of CNTs", "TREATMENT", 135, 159], ["severe wound infection", "PROBLEM", 260, 282], ["ultimate cell death", "OBSERVATION", 70, 89], ["skins", "ANATOMY", 193, 198], ["severe", "OBSERVATION_MODIFIER", 260, 266], ["wound", "OBSERVATION_MODIFIER", 267, 272], ["infection", "OBSERVATION", 273, 282]]], ["Commercially available wound dressing, like cotton wool, natural or synthetic bandages and gauzes, is important for an early stage of wound healing; however, they easily adhere onto wound surfaces and cause trauma to the healing wound.", [["wound", "ANATOMY", 23, 28], ["wound", "ANATOMY", 134, 139], ["wound", "ANATOMY", 182, 187], ["wound", "ANATOMY", 229, 234], ["trauma", "DISEASE", 207, 213], ["wound", "PATHOLOGICAL_FORMATION", 23, 28], ["wound", "PATHOLOGICAL_FORMATION", 134, 139], ["wound", "PATHOLOGICAL_FORMATION", 182, 187], ["wound", "PATHOLOGICAL_FORMATION", 229, 234], ["cotton", "SPECIES", 44, 50], ["wound dressing", "TREATMENT", 23, 37], ["cotton wool", "TREATMENT", 44, 55], ["natural or synthetic bandages", "TREATMENT", 57, 86], ["gauzes", "TREATMENT", 91, 97], ["wound healing", "PROBLEM", 134, 147], ["wound surfaces", "TREATMENT", 182, 196], ["trauma", "PROBLEM", 207, 213], ["the healing wound", "PROBLEM", 217, 234], ["wound", "ANATOMY", 23, 28], ["dressing", "OBSERVATION", 29, 37], ["wound", "ANATOMY", 134, 139], ["healing", "OBSERVATION", 140, 147], ["healing", "OBSERVATION_MODIFIER", 221, 228], ["wound", "OBSERVATION", 229, 234]]], ["To overcome this issue, graphene-based nanocomposites in the form of fiber or hydrogel have recently emerged as promising candidates for wound dressing applications.Wound addressingFan's group [184] prepared GO-based antibacterial cotton fabrics via three ways, including direct adsorption, radiation-induced crosslinking, and chemical crosslinking.", [["wound", "ANATOMY", 137, 142], ["Wound", "ANATOMY", 165, 170], ["graphene", "CHEMICAL", 24, 32], ["graphene", "CHEMICAL", 24, 32], ["graphene", "SIMPLE_CHEMICAL", 24, 32], ["fiber", "CELLULAR_COMPONENT", 69, 74], ["wound", "PATHOLOGICAL_FORMATION", 137, 142], ["Wound", "PATHOLOGICAL_FORMATION", 165, 170], ["graphene-based nanocomposites", "TREATMENT", 24, 53], ["fiber or hydrogel", "TREATMENT", 69, 86], ["wound dressing applications", "TREATMENT", 137, 164], ["GO-based antibacterial cotton fabrics", "TREATMENT", 208, 245], ["direct adsorption", "TREATMENT", 272, 289], ["radiation-induced crosslinking", "TREATMENT", 291, 321], ["chemical crosslinking", "TREATMENT", 327, 348], ["chemical crosslinking", "OBSERVATION", 327, 348]]], ["These GO-containing fabrics exhibited strong antibacterial behaviors and could kill 98% of bacteria ( Fig. 8(a) ).", [["fabrics", "PROBLEM", 20, 27], ["strong antibacterial behaviors", "PROBLEM", 38, 68], ["bacteria", "PROBLEM", 91, 99]]], ["Also importantly, these Cotton-GO fabrics could keep a high inactivation efficiency of more than 90% even after being washed 100 times, as well as cause no irritation to wounded skin.", [["skin", "ANATOMY", 178, 182], ["skin", "ORGAN", 178, 182], ["these Cotton-GO fabrics", "TREATMENT", 18, 41], ["a high inactivation efficiency", "PROBLEM", 53, 83], ["irritation to wounded skin", "PROBLEM", 156, 182], ["high inactivation", "OBSERVATION_MODIFIER", 55, 72], ["irritation", "OBSERVATION", 156, 166], ["skin", "ANATOMY", 178, 182]]], ["The flexible, foldable and reusable cotton-GO fabrics provided a good prospect for potential antibacterial applications.", [["The flexible, foldable and reusable cotton", "TREATMENT", 0, 42], ["GO fabrics", "TREATMENT", 43, 53], ["potential antibacterial applications", "TREATMENT", 83, 119]]], ["Karimi et al. [185] developed electroconductive and self-cleaning graphene/TiO2 nanocomposite-coated fabrics.", [["graphene", "CHEMICAL", 66, 74], ["TiO2", "CHEMICAL", 75, 79], ["graphene", "CHEMICAL", 66, 74], ["TiO2", "CHEMICAL", 75, 79], ["graphene", "SIMPLE_CHEMICAL", 66, 74], ["TiO2 nanocomposite", "SIMPLE_CHEMICAL", 75, 93], ["electroconductive", "TREATMENT", 30, 47], ["self-cleaning graphene/TiO2 nanocomposite", "TREATMENT", 52, 93], ["coated fabrics", "PROBLEM", 94, 108]]], ["Those fabrics exhibited excellent antimicrobial action toward S. aureus and E. coli and antifungal activity toward Candida albicans (C. albicans) with no cytotoxicity.", [["S. aureus", "ORGANISM", 62, 71], ["E. coli", "ORGANISM", 76, 83], ["Candida albicans", "ORGANISM", 115, 131], ["C. albicans", "ORGANISM", 133, 144], ["S. aureus", "SPECIES", 62, 71], ["E. coli", "SPECIES", 76, 83], ["Candida albicans", "SPECIES", 115, 131], ["C. albicans", "SPECIES", 133, 144], ["S. aureus", "SPECIES", 62, 71], ["E. coli", "SPECIES", 76, 83], ["Candida albicans", "SPECIES", 115, 131], ["C. albicans", "SPECIES", 133, 144], ["S. aureus", "PROBLEM", 62, 71], ["E. coli", "PROBLEM", 76, 83], ["antifungal activity", "TREATMENT", 88, 107], ["Candida albicans", "PROBLEM", 115, 131], ["cytotoxicity", "PROBLEM", 154, 166], ["aureus", "OBSERVATION", 65, 71], ["E. coli", "OBSERVATION", 76, 83], ["no", "UNCERTAINTY", 151, 153]]], ["Wang and co-workers [186] prepared a series of Ag/graphene composites with acrylic acid and N,N\u0374-methylene bisacrylamide with different mass ratios.", [["Ag", "CHEMICAL", 47, 49], ["acrylic acid", "CHEMICAL", 75, 87], ["N\u0374-methylene bisacrylamide", "CHEMICAL", 94, 120], ["Ag", "CHEMICAL", 47, 49], ["graphene", "CHEMICAL", 50, 58], ["acrylic acid", "CHEMICAL", 75, 87], ["N,N\u0374-methylene bisacrylamide", "CHEMICAL", 92, 120], ["Ag/graphene composites", "SIMPLE_CHEMICAL", 47, 69], ["acrylic acid", "SIMPLE_CHEMICAL", 75, 87], ["N,N\u0374-methylene bisacrylamide", "SIMPLE_CHEMICAL", 92, 120], ["Ag", "PROTEIN", 47, 49], ["Ag/graphene composites", "TREATMENT", 47, 69], ["acrylic acid", "TREATMENT", 75, 87], ["N\u0374-methylene bisacrylamide", "TREATMENT", 94, 120], ["different mass ratios", "PROBLEM", 126, 147], ["mass", "OBSERVATION", 136, 140]]], ["The Ag/graphene composite hydrogel with an optimal mass ratio at 5:1 (Ag5G1) possessed highest swelling ratio.", [["Ag", "CHEMICAL", 4, 6], ["graphene", "CHEMICAL", 7, 15], ["Ag", "CHEMICAL", 4, 6], ["graphene", "CHEMICAL", 7, 15], ["Ag", "GENE_OR_GENE_PRODUCT", 4, 6], ["Ag", "PROTEIN", 4, 6], ["The Ag/graphene composite hydrogel", "TREATMENT", 0, 34], ["an optimal mass ratio", "TEST", 40, 61], ["highest swelling ratio", "PROBLEM", 87, 109], ["mass", "OBSERVATION", 51, 55], ["highest", "OBSERVATION_MODIFIER", 87, 94], ["swelling", "OBSERVATION", 95, 103]]], ["Most significantly, it could accelerate the healing rate of skin wounds of rats and successfully reconstruct complete and thickened epidermis on the wounds after 15-day treatment.", [["skin wounds", "ANATOMY", 60, 71], ["epidermis", "ANATOMY", 132, 141], ["wounds", "ANATOMY", 149, 155], ["skin wounds", "PATHOLOGICAL_FORMATION", 60, 71], ["rats", "ORGANISM", 75, 79], ["epidermis", "TISSUE", 132, 141], ["wounds", "PATHOLOGICAL_FORMATION", 149, 155], ["rats", "SPECIES", 75, 79], ["skin wounds", "PROBLEM", 60, 71], ["thickened epidermis", "PROBLEM", 122, 141], ["the wounds", "PROBLEM", 145, 155], ["healing", "OBSERVATION_MODIFIER", 44, 51], ["skin", "ANATOMY", 60, 64], ["wounds", "OBSERVATION", 65, 71], ["thickened", "OBSERVATION_MODIFIER", 122, 131], ["epidermis", "OBSERVATION", 132, 141], ["wounds", "ANATOMY", 149, 155]]], ["Yang and Lin et al. [187] developed a Ag-based bactericide by anchoring sunlight-driven ultrafine Ag/AgCl NPs on rGO (Ag/AgCl/rGO), which could promote the regeneration of epidermis in burn wound healing.", [["epidermis", "ANATOMY", 172, 181], ["wound", "ANATOMY", 190, 195], ["Ag", "CHEMICAL", 38, 40], ["bactericide", "CHEMICAL", 47, 58], ["Ag", "CHEMICAL", 98, 100], ["AgCl", "CHEMICAL", 101, 105], ["rGO", "CHEMICAL", 113, 116], ["Ag", "CHEMICAL", 118, 120], ["AgCl", "CHEMICAL", 121, 125], ["burn", "DISEASE", 185, 189], ["Ag", "CHEMICAL", 38, 40], ["Ag", "CHEMICAL", 98, 100], ["AgCl", "CHEMICAL", 101, 105], ["rGO", "CHEMICAL", 113, 116], ["Ag", "CHEMICAL", 118, 120], ["AgCl", "CHEMICAL", 121, 125], ["rGO", "CHEMICAL", 126, 129], ["Ag-based bactericide", "SIMPLE_CHEMICAL", 38, 58], ["ultrafine Ag/AgCl NPs", "SIMPLE_CHEMICAL", 88, 109], ["rGO", "SIMPLE_CHEMICAL", 113, 116], ["Ag/AgCl", "SIMPLE_CHEMICAL", 118, 125], ["rGO", "SIMPLE_CHEMICAL", 126, 129], ["epidermis", "TISSUE", 172, 181], ["wound", "PATHOLOGICAL_FORMATION", 190, 195], ["Ag", "PROTEIN", 38, 40], ["rGO", "PROTEIN", 113, 116], ["Ag", "PROTEIN", 118, 120], ["AgCl", "PROTEIN", 121, 125], ["rGO", "PROTEIN", 126, 129], ["a Ag-based bactericide", "TREATMENT", 36, 58], ["ultrafine Ag/AgCl NPs", "TREATMENT", 88, 109], ["rGO (Ag/AgCl/rGO", "TREATMENT", 113, 129], ["epidermis in burn wound healing", "PROBLEM", 172, 203], ["regeneration", "OBSERVATION_MODIFIER", 156, 168], ["epidermis", "OBSERVATION_MODIFIER", 172, 181], ["burn", "OBSERVATION_MODIFIER", 185, 189], ["wound", "OBSERVATION_MODIFIER", 190, 195], ["healing", "OBSERVATION_MODIFIER", 196, 203]]], ["Lu et al. [188] used electrospinning to fabricate chitosan-PVA nanofibers for wound healing.Drug deliveryGraphene is an ideal candidate for drug delivery because of its large surface area, abundant surface chemistry, specific geometry with double side and high-efficiency loading capacity.", [["wound", "ANATOMY", 78, 83], ["surface area", "ANATOMY", 175, 187], ["surface", "ANATOMY", 198, 205], ["chitosan-PVA", "CHEMICAL", 50, 62], ["Graphene", "CHEMICAL", 105, 113], ["PVA", "CHEMICAL", 59, 62], ["Graphene", "CHEMICAL", 105, 113], ["chitosan-PVA nanofibers", "SIMPLE_CHEMICAL", 50, 73], ["wound", "PATHOLOGICAL_FORMATION", 78, 83], ["electrospinning to fabricate chitosan", "TREATMENT", 21, 58], ["PVA nanofibers", "TREATMENT", 59, 73], ["wound healing", "PROBLEM", 78, 91], ["Drug delivery", "TREATMENT", 92, 105], ["drug delivery", "TREATMENT", 140, 153], ["its large surface area", "PROBLEM", 165, 187], ["double side and high-efficiency loading capacity", "TREATMENT", 240, 288], ["wound", "ANATOMY", 78, 83], ["healing", "OBSERVATION", 84, 91], ["large", "OBSERVATION_MODIFIER", 169, 174], ["surface", "OBSERVATION_MODIFIER", 175, 182], ["abundant", "OBSERVATION_MODIFIER", 189, 197], ["surface", "OBSERVATION_MODIFIER", 198, 205], ["high-efficiency", "OBSERVATION_MODIFIER", 256, 271], ["loading capacity", "OBSERVATION", 272, 288]]], ["Dai's group [189] developed pegylated nGO (NGO-PEG) sheets with intrinsic photoluminescence (PL) by conjugating anti-CD20 antibody Rituxan.", [["pegylated nGO", "CHEMICAL", 28, 41], ["NGO-PEG", "CHEMICAL", 43, 50], ["Rituxan", "CHEMICAL", 131, 138], ["pegylated nGO", "CHEMICAL", 28, 41], ["NGO", "CHEMICAL", 43, 46], ["PEG", "CHEMICAL", 47, 50], ["pegylated nGO", "SIMPLE_CHEMICAL", 28, 41], ["NGO-PEG", "SIMPLE_CHEMICAL", 43, 50], ["anti-CD20", "GENE_OR_GENE_PRODUCT", 112, 121], ["anti-CD20 antibody Rituxan", "PROTEIN", 112, 138], ["pegylated nGO (NGO-PEG)", "TREATMENT", 28, 51], ["intrinsic photoluminescence (PL", "TREATMENT", 64, 95], ["conjugating anti-CD20 antibody Rituxan", "TREATMENT", 100, 138]]], ["Chemotherapy drug doxorubicin (DOX) was loaded onto NGO-PEG-Rituxan via \u03c0-stacking interaction for in vitro selective killing of cancer cells.", [["cancer cells", "ANATOMY", 129, 141], ["doxorubicin", "CHEMICAL", 18, 29], ["DOX", "CHEMICAL", 31, 34], ["NGO-PEG-Rituxan", "CHEMICAL", 52, 67], ["cancer", "DISEASE", 129, 135], ["doxorubicin", "CHEMICAL", 18, 29], ["DOX", "CHEMICAL", 31, 34], ["PEG", "CHEMICAL", 56, 59], ["Rituxan", "CHEMICAL", 60, 67], ["doxorubicin", "SIMPLE_CHEMICAL", 18, 29], ["DOX", "SIMPLE_CHEMICAL", 31, 34], ["NGO-PEG-Rituxan", "SIMPLE_CHEMICAL", 52, 67], ["\u03c0-", "SIMPLE_CHEMICAL", 72, 74], ["cancer cells", "CELL", 129, 141], ["cancer cells", "CELL_TYPE", 129, 141], ["Chemotherapy drug doxorubicin (DOX)", "TREATMENT", 0, 35], ["PEG", "TREATMENT", 56, 59], ["Rituxan", "TREATMENT", 60, 67], ["cancer cells", "PROBLEM", 129, 141], ["cancer cells", "OBSERVATION", 129, 141]]], ["Himanshu et al. [190] studied the loading and releasing behavior of bactericidal aminoglycoside antibiotic, gentamicin sulfate from a methanol derived graphene (MDG) sheets.", [["aminoglycoside", "CHEMICAL", 81, 95], ["gentamicin sulfate", "CHEMICAL", 108, 126], ["graphene", "CHEMICAL", 151, 159], ["gentamicin sulfate", "CHEMICAL", 108, 126], ["methanol", "CHEMICAL", 134, 142], ["graphene", "CHEMICAL", 151, 159], ["MDG", "CHEMICAL", 161, 164], ["aminoglycoside", "SIMPLE_CHEMICAL", 81, 95], ["gentamicin sulfate", "SIMPLE_CHEMICAL", 108, 126], ["methanol derived graphene", "SIMPLE_CHEMICAL", 134, 159], ["the loading", "TREATMENT", 30, 41], ["bactericidal aminoglycoside antibiotic", "TREATMENT", 68, 106], ["gentamicin sulfate", "TREATMENT", 108, 126], ["a methanol derived graphene (MDG) sheets", "TREATMENT", 132, 172]]], ["It was found that MDH possessed a high loading capacity of 2.57 mg/mg, and the release of the drug follows the Korsmeyer-Peppas model.", [["MDH", "CHEMICAL", 18, 21], ["MDH", "SIMPLE_CHEMICAL", 18, 21], ["MDH", "PROTEIN", 18, 21], ["a high loading capacity", "TREATMENT", 32, 55], ["the drug", "TREATMENT", 90, 98]]], ["Zhang et al. [191] prepared GO-benzyl penicillin (BP) anion intercalated Mg-Al layered double hydroxide (GO-BP-LDH) hybrid films.", [["GO-benzyl", "CHEMICAL", 28, 37], ["penicillin", "CHEMICAL", 38, 48], ["Mg", "CHEMICAL", 73, 75], ["double hydroxide", "CHEMICAL", 87, 103], ["GO-BP-LDH", "CHEMICAL", 105, 114], ["benzyl penicillin", "CHEMICAL", 31, 48], ["BP", "CHEMICAL", 50, 52], ["Mg", "CHEMICAL", 73, 75], ["Al", "CHEMICAL", 76, 78], ["hydroxide", "CHEMICAL", 94, 103], ["GO-BP-LDH", "CHEMICAL", 105, 114], ["GO-benzyl penicillin", "SIMPLE_CHEMICAL", 28, 48], ["BP", "SIMPLE_CHEMICAL", 50, 52], ["Mg-Al layered double hydroxide", "SIMPLE_CHEMICAL", 73, 103], ["GO-BP-LDH", "SIMPLE_CHEMICAL", 105, 114], ["Mg-Al layered double hydroxide (GO-BP-LDH) hybrid films", "CELL_LINE", 73, 128], ["benzyl penicillin", "TREATMENT", 31, 48], ["BP", "TEST", 50, 52], ["anion intercalated Mg", "TREATMENT", 54, 75], ["Al layered double hydroxide (GO-BP-LDH) hybrid films", "TREATMENT", 76, 128]]], ["The incorporation of BP-LDH and GO could effectively extend the release time for drug delivery, whose kinetics followed the firstorder model.", [["BP-LDH", "CHEMICAL", 21, 27], ["BP-LDH", "CHEMICAL", 21, 27], ["BP-LDH", "SIMPLE_CHEMICAL", 21, 27], ["BP", "PROTEIN", 21, 23], ["LDH", "PROTEIN", 24, 27], ["BP", "TEST", 21, 23], ["LDH", "TEST", 24, 27], ["drug delivery", "TREATMENT", 81, 94]]], ["Nafisi et al. [192] presented a systematic study of the adsorption and release process of tetracycline (TC) on GO surface.", [["GO surface", "ANATOMY", 111, 121], ["tetracycline", "CHEMICAL", 90, 102], ["TC", "CHEMICAL", 104, 106], ["tetracycline", "CHEMICAL", 90, 102], ["tetracycline", "SIMPLE_CHEMICAL", 90, 102], ["TC", "SIMPLE_CHEMICAL", 104, 106], ["a systematic study", "TEST", 30, 48], ["the adsorption", "TREATMENT", 52, 66], ["tetracycline", "TREATMENT", 90, 102]]], ["GO showed a high loading capacity of TC via \u03c0-\u03c0 and cation-\u03c0 interactions, and the adsorption at equilibrium was observed within only 15 min following the pseudo-second-order model.", [["TC", "SIMPLE_CHEMICAL", 37, 39], ["\u03c0-\u03c0", "SIMPLE_CHEMICAL", 44, 47], ["cation-\u03c0", "SIMPLE_CHEMICAL", 52, 60], ["a high loading capacity", "PROBLEM", 10, 33], ["cation-\u03c0 interactions", "TREATMENT", 52, 73]]], ["Recently, Zhang et al. [193] prepared a cross-linking GO-polyethyleneimine hybrid film containing ciprofloxacin and investigated the release behavior of ciprofloxacin under different pH values.", [["GO-polyethyleneimine", "CHEMICAL", 54, 74], ["ciprofloxacin", "CHEMICAL", 98, 111], ["ciprofloxacin", "CHEMICAL", 153, 166], ["polyethyleneimine", "CHEMICAL", 57, 74], ["ciprofloxacin", "CHEMICAL", 98, 111], ["ciprofloxacin", "CHEMICAL", 153, 166], ["ciprofloxacin", "SIMPLE_CHEMICAL", 98, 111], ["ciprofloxacin", "SIMPLE_CHEMICAL", 153, 166], ["a cross-linking GO-polyethyleneimine hybrid film", "TREATMENT", 38, 86], ["ciprofloxacin", "TREATMENT", 98, 111], ["ciprofloxacin", "TREATMENT", 153, 166]]], ["As a result, it showed slow drug release without an initial burst effect, which was consistent with near zero-order kinetics.", [["slow drug release", "PROBLEM", 23, 40], ["burst effect", "OBSERVATION", 60, 72], ["consistent with", "UNCERTAINTY", 84, 99], ["zero-order kinetics", "OBSERVATION", 105, 124]]], ["Tian et al. [194] developed a GQD-based therapeutic agent with DOX loading and Cy dye conjugation via a cathepsin D-responsive peptide (DOX@GQD-P-Cy) for drug delivery, release and response both in vitro and in vivo.", [["GQD", "CHEMICAL", 30, 33], ["DOX", "CHEMICAL", 63, 66], ["Cy dye", "CHEMICAL", 79, 85], ["DOX@GQD-P-Cy", "CHEMICAL", 136, 148], ["DOX", "CHEMICAL", 63, 66], ["Cy", "CHEMICAL", 79, 81], ["DOX@GQD-P-Cy", "CHEMICAL", 136, 148], ["GQD", "SIMPLE_CHEMICAL", 30, 33], ["DOX", "SIMPLE_CHEMICAL", 63, 66], ["Cy dye", "SIMPLE_CHEMICAL", 79, 85], ["cathepsin D", "SIMPLE_CHEMICAL", 104, 115], ["DOX@GQD-P-Cy", "SIMPLE_CHEMICAL", 136, 148], ["a GQD-based therapeutic agent", "TREATMENT", 28, 57], ["DOX loading", "TREATMENT", 63, 74], ["Cy dye conjugation", "TREATMENT", 79, 97], ["a cathepsin D-responsive peptide", "TREATMENT", 102, 134], ["drug delivery", "TREATMENT", 154, 167]]], ["After treatment by DOX@GQD-P-Cy, tumor size was reduced to about 1/3 that that of free DOX.", [["tumor", "ANATOMY", 33, 38], ["DOX@GQD-P-Cy", "CHEMICAL", 19, 31], ["tumor", "DISEASE", 33, 38], ["DOX", "CHEMICAL", 87, 90], ["DOX@GQD-P-Cy", "CHEMICAL", 19, 31], ["DOX", "CHEMICAL", 87, 90], ["DOX@GQD-P-Cy", "SIMPLE_CHEMICAL", 19, 31], ["tumor", "CANCER", 33, 38], ["DOX", "SIMPLE_CHEMICAL", 87, 90], ["treatment", "TREATMENT", 6, 15], ["tumor size", "PROBLEM", 33, 43], ["free DOX", "TREATMENT", 82, 90], ["tumor", "OBSERVATION", 33, 38], ["size", "OBSERVATION_MODIFIER", 39, 43]]], ["In addition, the agents were used as fluorescent probes for tacking of cell apoptosis induction and real-time evaluation (Fig. 8(b) ).", [["cell", "ANATOMY", 71, 75], ["cell", "CELL", 71, 75], ["the agents", "TREATMENT", 13, 23], ["fluorescent probes", "TREATMENT", 37, 55], ["cell apoptosis induction", "TREATMENT", 71, 95], ["real-time evaluation", "TEST", 100, 120], ["cell apoptosis", "OBSERVATION", 71, 85]]], ["Gu et al. developed a cellular protease-mediated graphene-based co-delivery nanosystem incorporating a cell-membrane-targeted anticancer protein and a chemotherapeutic agent for cancer treatment [195] .", [["cellular", "ANATOMY", 22, 30], ["cell", "ANATOMY", 103, 107], ["membrane", "ANATOMY", 108, 116], ["anticancer", "ANATOMY", 126, 136], ["cancer", "ANATOMY", 178, 184], ["graphene", "CHEMICAL", 49, 57], ["cancer", "DISEASE", 178, 184], ["graphene", "CHEMICAL", 49, 57], ["cellular", "CELL", 22, 30], ["graphene", "SIMPLE_CHEMICAL", 49, 57], ["cell", "CELL", 103, 107], ["membrane", "CELLULAR_COMPONENT", 108, 116], ["anticancer", "CANCER", 126, 136], ["cancer", "CANCER", 178, 184], ["anticancer protein", "PROTEIN", 126, 144], ["a cellular protease", "TEST", 20, 39], ["based co-delivery nanosystem", "TREATMENT", 58, 86], ["a cell-membrane", "TREATMENT", 101, 116], ["targeted anticancer protein", "TREATMENT", 117, 144], ["a chemotherapeutic agent", "TREATMENT", 149, 173], ["cancer treatment", "TREATMENT", 178, 194], ["et al", "OBSERVATION", 3, 8]]], ["In further studies, they reported a ATP-responsive anticancer drug delivery system using DNA-graphene nanohybrid aggregates for controlled released of DOX [196] .Water disinfectionNearly 750 million people around the world have little or zero access to safe drinking water, especially, after natural disasters or in poor urban areas where water disinfection infrastructure is in scarcity.", [["anticancer", "ANATOMY", 51, 61], ["ATP", "CHEMICAL", 36, 39], ["DOX", "CHEMICAL", 151, 154], ["ATP", "CHEMICAL", 36, 39], ["graphene", "CHEMICAL", 93, 101], ["DOX", "CHEMICAL", 151, 154], ["ATP", "SIMPLE_CHEMICAL", 36, 39], ["anticancer", "CANCER", 51, 61], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["graphene nanohybrid aggregates", "SIMPLE_CHEMICAL", 93, 123], ["DOX", "SIMPLE_CHEMICAL", 151, 154], ["people", "ORGANISM", 199, 205], ["people", "SPECIES", 199, 205], ["further studies", "TEST", 3, 18], ["a ATP-responsive anticancer drug delivery system", "TREATMENT", 34, 82], ["DNA-graphene nanohybrid aggregates", "TREATMENT", 89, 123], ["Water disinfection", "TREATMENT", 162, 180], ["water disinfection", "OBSERVATION", 339, 357]]], ["Thus, pathogen-contaminated water leads to millions of deaths every year.", [["deaths", "DISEASE", 55, 61], ["pathogen", "PROBLEM", 6, 14]]], ["Therefore, effective and nontoxic water disinfection nanomaterials is in great demand to kill a broad spectrum of pathogenic microbes.", [["nontoxic water disinfection nanomaterials", "TREATMENT", 25, 66], ["pathogenic microbes", "PROBLEM", 114, 133], ["pathogenic microbes", "OBSERVATION", 114, 133]]], ["GO-based nanomaterials provide an effective solution for the development of new technologies of water disinfection.Water disinfectionZhang's group [197] synthesized a 3D Ag/rGO hydrogel through a hydrothermal method, in which the porous rGO network acted as a support for dispersed AgNPs.", [["Ag", "CHEMICAL", 170, 172], ["AgNPs", "CHEMICAL", 282, 287], ["Ag", "CHEMICAL", 170, 172], ["rGO", "CHEMICAL", 173, 176], ["water", "SIMPLE_CHEMICAL", 96, 101], ["AgNPs", "SIMPLE_CHEMICAL", 282, 287], ["an effective solution", "TREATMENT", 31, 52], ["water disinfection", "TREATMENT", 96, 114], ["a 3D Ag/rGO hydrogel", "TREATMENT", 165, 185], ["a hydrothermal method", "TREATMENT", 194, 215], ["the porous rGO network", "TREATMENT", 226, 248], ["a support", "TREATMENT", 258, 267], ["new", "OBSERVATION_MODIFIER", 76, 79], ["water disinfection", "OBSERVATION", 96, 114]]], ["When the water flowed through Ag/rGO hydrogel, more than 97% of viable E. coli cells were killed owing to membrane damage caused by both AgNPs and rGO nanosheets.", [["cells", "ANATOMY", 79, 84], ["membrane", "ANATOMY", 106, 114], ["Ag", "CHEMICAL", 30, 32], ["AgNPs", "CHEMICAL", 137, 142], ["rGO", "CHEMICAL", 147, 150], ["Ag", "CHEMICAL", 30, 32], ["rGO", "CHEMICAL", 33, 36], ["rGO", "CHEMICAL", 147, 150], ["water", "SIMPLE_CHEMICAL", 9, 14], ["Ag", "GENE_OR_GENE_PRODUCT", 30, 32], ["rGO", "SIMPLE_CHEMICAL", 33, 36], ["E. coli cells", "CELL", 71, 84], ["membrane", "CELLULAR_COMPONENT", 106, 114], ["AgNPs", "SIMPLE_CHEMICAL", 137, 142], ["rGO nanosheets", "SIMPLE_CHEMICAL", 147, 161], ["Ag", "PROTEIN", 30, 32], ["E. coli cells", "CELL_LINE", 71, 84], ["E. coli", "SPECIES", 71, 78], ["E. coli", "SPECIES", 71, 78], ["Ag/rGO hydrogel", "TREATMENT", 30, 45], ["viable E. coli cells", "PROBLEM", 64, 84], ["membrane damage", "PROBLEM", 106, 121], ["both AgNPs and rGO nanosheets", "TREATMENT", 132, 161], ["coli cells", "OBSERVATION", 74, 84], ["both AgNPs", "OBSERVATION", 132, 142], ["rGO nanosheets", "OBSERVATION", 147, 161]]], ["For real lake and creek water, the Ag/rGO hydrogel could efficiently inactivate more than 94% E. coli cells as well as around 99% of coliforms (Fig. 8(c) ), which implies its usage for point-of-use water disinfection application.", [["cells", "ANATOMY", 102, 107], ["Ag", "CHEMICAL", 35, 37], ["rGO", "CHEMICAL", 38, 41], ["Ag", "CHEMICAL", 35, 37], ["rGO", "CHEMICAL", 38, 41], ["Ag", "GENE_OR_GENE_PRODUCT", 35, 37], ["E. coli cells", "CELL", 94, 107], ["Ag", "PROTEIN", 35, 37], ["E. coli cells", "CELL_LINE", 94, 107], ["E. coli", "SPECIES", 94, 101], ["E. coli", "SPECIES", 94, 101], ["the Ag/rGO hydrogel", "TREATMENT", 31, 50], ["E. coli cells", "TEST", 94, 107], ["coliforms", "TEST", 133, 142], ["water disinfection application", "TREATMENT", 198, 228], ["coli cells", "OBSERVATION", 97, 107]]], ["Recently, the same group co-decorated highly dispersed TiO2 and carbon dots (C-dots) [198] or WO3 nanorods [199] on rGO, and the two ternary nanocomposites showed enhanced photocatalytic activity for inactivation of E. coli via electron transfer mechanism.", [["TiO2", "CHEMICAL", 55, 59], ["carbon dots", "CHEMICAL", 64, 75], ["C-dots", "CHEMICAL", 77, 83], ["WO3 nanorods", "CHEMICAL", 94, 106], ["TiO2", "CHEMICAL", 55, 59], ["carbon", "CHEMICAL", 64, 70], ["WO3", "CHEMICAL", 94, 97], ["TiO2", "SIMPLE_CHEMICAL", 55, 59], ["carbon dots", "SIMPLE_CHEMICAL", 64, 75], ["C-dots", "SIMPLE_CHEMICAL", 77, 83], ["[198]", "SIMPLE_CHEMICAL", 85, 90], ["WO3 nanorods [199]", "SIMPLE_CHEMICAL", 94, 112], ["rGO", "SIMPLE_CHEMICAL", 116, 119], ["E. coli", "ORGANISM", 216, 223], ["electron", "SIMPLE_CHEMICAL", 228, 236], ["E. coli", "SPECIES", 216, 223], ["E. coli", "SPECIES", 216, 223], ["carbon dots", "TEST", 64, 75], ["WO3 nanorods", "TEST", 94, 106], ["rGO", "TEST", 116, 119], ["the two ternary nanocomposites", "TREATMENT", 125, 155], ["enhanced photocatalytic activity", "TREATMENT", 163, 195], ["E. coli", "PROBLEM", 216, 223], ["photocatalytic activity", "OBSERVATION", 172, 195], ["E. coli", "OBSERVATION", 216, 223]]], ["Ray's group [200] developed a PGLa antimicrobial peptide and glutathione conjugated CNT bridged 3D porous GO membrane, which could capture and inactive E. coli bacteria via synergistic mechanism.", [["GO membrane", "ANATOMY", 106, 117], ["glutathione", "CHEMICAL", 61, 72], ["CNT", "CHEMICAL", 84, 87], ["glutathione", "CHEMICAL", 61, 72], ["PGLa antimicrobial peptide", "SIMPLE_CHEMICAL", 30, 56], ["glutathione", "SIMPLE_CHEMICAL", 61, 72], ["conjugated CNT", "SIMPLE_CHEMICAL", 73, 87], ["E. coli", "ORGANISM", 152, 159], ["E. coli", "SPECIES", 152, 159], ["E. coli", "SPECIES", 152, 159], ["a PGLa antimicrobial peptide", "TREATMENT", 28, 56], ["glutathione conjugated CNT bridged 3D porous GO membrane", "TREATMENT", 61, 117], ["inactive E. coli bacteria via synergistic mechanism", "PROBLEM", 143, 194], ["coli bacteria", "OBSERVATION", 155, 168]]], ["Moreover, such membrane has the capability to simultaneously remove E. coli, As(III), As(V), and Pb(II) from river water sample.", [["membrane", "ANATOMY", 15, 23], ["Pb", "CHEMICAL", 97, 99], ["As(III)", "CHEMICAL", 77, 84], ["As(V)", "CHEMICAL", 86, 91], ["Pb(II)", "CHEMICAL", 97, 103], ["membrane", "CELLULAR_COMPONENT", 15, 23], ["E. coli", "ORGANISM", 68, 75], ["As(V)", "SIMPLE_CHEMICAL", 86, 91], ["Pb(II", "SIMPLE_CHEMICAL", 97, 102], ["E. coli", "SPECIES", 68, 75], ["E. coli", "SPECIES", 68, 75], ["E. coli", "PROBLEM", 68, 75], ["river water sample", "TEST", 109, 127], ["coli", "OBSERVATION", 71, 75]]], ["Srikanth et al. [201] fabricated Ag/Ag2O core/shell and Ag/Ag2O decorated multi-layered graphene (MLG) nanostructures with excellent adsorption capabilities to remove As(III) from water, as well as high antimicrobial ability against E. coli and S. aureus.", [["Ag", "CHEMICAL", 33, 35], ["Ag", "CHEMICAL", 56, 58], ["Ag2O", "CHEMICAL", 59, 63], ["graphene", "CHEMICAL", 88, 96], ["MLG", "CHEMICAL", 98, 101], ["Ag", "CHEMICAL", 33, 35], ["Ag2O", "CHEMICAL", 36, 40], ["Ag", "CHEMICAL", 56, 58], ["Ag2O", "CHEMICAL", 59, 63], ["graphene", "CHEMICAL", 88, 96], ["MLG", "CHEMICAL", 98, 101], ["As(III)", "CHEMICAL", 167, 174], ["Ag/Ag2O core/shell", "SIMPLE_CHEMICAL", 33, 51], ["Ag/Ag2O decorated multi-layered graphene", "SIMPLE_CHEMICAL", 56, 96], ["MLG", "SIMPLE_CHEMICAL", 98, 101], ["water", "SIMPLE_CHEMICAL", 180, 185], ["E. coli", "ORGANISM", 233, 240], ["S. aureus", "ORGANISM", 245, 254], ["Ag", "PROTEIN", 33, 35], ["Ag", "PROTEIN", 56, 58], ["E. coli", "SPECIES", 233, 240], ["S. aureus", "SPECIES", 245, 254], ["E. coli", "SPECIES", 233, 240], ["S. aureus", "SPECIES", 245, 254], ["fabricated Ag/Ag2O core/shell and Ag/Ag2O decorated multi-layered graphene (MLG) nanostructures", "TREATMENT", 22, 117], ["E. coli", "PROBLEM", 233, 240], ["S. aureus", "PROBLEM", 245, 254], ["aureus", "OBSERVATION", 248, 254]]], ["Wang et al. [202] reported an activated carbon (AC) electrode coated with graphene oxide-graft-quaternized chitosan (GO-QC) through capacitive deionization disinfection (CDID).", [["graphene oxide", "CHEMICAL", 74, 88], ["chitosan", "CHEMICAL", 107, 115], ["GO-QC", "CHEMICAL", 117, 122], ["carbon", "CHEMICAL", 40, 46], ["graphene oxide", "CHEMICAL", 74, 88], ["carbon", "SIMPLE_CHEMICAL", 40, 46], ["AC", "SIMPLE_CHEMICAL", 48, 50], ["graphene oxide-graft-quaternized chitosan", "SIMPLE_CHEMICAL", 74, 115], ["GO-QC", "SIMPLE_CHEMICAL", 117, 122], ["an activated carbon (AC) electrode coated with graphene oxide-graft", "TREATMENT", 27, 94], ["quaternized chitosan", "TREATMENT", 95, 115], ["capacitive deionization disinfection", "TREATMENT", 132, 168]]], ["It was found that GO-QC/AC CDID electrode could kill at least 99.9999% of E. coli and be easily regenerated in continuous water through the CDID cell, but showed no observable contamination to the water.", [["CDID cell", "ANATOMY", 140, 149], ["CDID", "CHEMICAL", 27, 31], ["E. coli", "ORGANISM", 74, 81], ["CDID cell", "CELL", 140, 149], ["CDID cell", "CELL_LINE", 140, 149], ["E. coli", "SPECIES", 74, 81], ["E. coli", "SPECIES", 74, 81], ["QC/AC CDID electrode", "TREATMENT", 21, 41], ["E. coli", "PROBLEM", 74, 81], ["E. coli", "OBSERVATION", 74, 81], ["no observable", "UNCERTAINTY", 162, 175], ["contamination", "OBSERVATION", 176, 189]]], ["It highlighted the recent research advances in the preparation and exploration of graphene and its derivatives, the extracellular interactions between graphene and biomacromolecules, the cytotoxicity of graphene, in vivo toxicological effects of graphene, as well as their biological applications in antibacterial activities, wound addressing, water purification and drug delivery.Perspectives and conclusionsDespite the achievements, there still remains some challenges and difficulties in studies on graphene-based nanomaterials in biosystems.", [["extracellular", "ANATOMY", 116, 129], ["wound", "ANATOMY", 326, 331], ["graphene", "CHEMICAL", 82, 90], ["graphene", "CHEMICAL", 151, 159], ["graphene", "CHEMICAL", 203, 211], ["graphene", "CHEMICAL", 246, 254], ["graphene", "CHEMICAL", 502, 510], ["graphene", "CHEMICAL", 82, 90], ["graphene", "CHEMICAL", 151, 159], ["graphene", "CHEMICAL", 203, 211], ["graphene", "CHEMICAL", 246, 254], ["graphene", "CHEMICAL", 502, 510], ["graphene", "SIMPLE_CHEMICAL", 82, 90], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 116, 129], ["graphene", "SIMPLE_CHEMICAL", 151, 159], ["biomacromolecules", "SIMPLE_CHEMICAL", 164, 181], ["graphene", "SIMPLE_CHEMICAL", 203, 211], ["graphene", "SIMPLE_CHEMICAL", 246, 254], ["wound", "PATHOLOGICAL_FORMATION", 326, 331], ["graphene", "SIMPLE_CHEMICAL", 502, 510], ["the preparation", "TREATMENT", 47, 62], ["exploration of graphene", "TREATMENT", 67, 90], ["its derivatives", "TREATMENT", 95, 110], ["graphene and biomacromolecules", "TREATMENT", 151, 181], ["the cytotoxicity of graphene", "TREATMENT", 183, 211], ["graphene", "TREATMENT", 246, 254], ["antibacterial activities", "TREATMENT", 300, 324], ["wound addressing", "TREATMENT", 326, 342], ["water purification", "TREATMENT", 344, 362], ["drug delivery", "TREATMENT", 367, 380], ["some challenges", "PROBLEM", 455, 470], ["difficulties in studies", "PROBLEM", 475, 498]]], ["One of the major challenges is understanding the mechanism about the antibacterial activity of graphene and its derivatives.", [["graphene", "CHEMICAL", 95, 103], ["graphene", "CHEMICAL", 95, 103], ["graphene", "SIMPLE_CHEMICAL", 95, 103], ["the antibacterial activity of graphene", "TREATMENT", 65, 103], ["its derivatives", "TREATMENT", 108, 123]]], ["Several studies claimed that GO had little antimicrobial properties; however, most findings gave a controversial view in supporting antibacterial behavior of graphene and its derivatives.", [["graphene", "CHEMICAL", 158, 166], ["graphene", "CHEMICAL", 158, 166], ["graphene", "SIMPLE_CHEMICAL", 158, 166], ["Several studies", "TEST", 0, 15], ["supporting antibacterial behavior of graphene", "TREATMENT", 121, 166], ["its derivatives", "TREATMENT", 171, 186]]], ["In addition, the mechanism and influencing factor of the antibacterial activities of graphene-based nanomaterials have not been fully understood so far.", [["graphene", "CHEMICAL", 85, 93], ["graphene", "CHEMICAL", 85, 93], ["graphene", "SIMPLE_CHEMICAL", 85, 93], ["the antibacterial activities of graphene", "TREATMENT", 53, 93]]], ["It is still under debate that whether the lateral size, or basal planes, or oxygen content of graphene-based nanomaterials supports its antibacterial activity.", [["oxygen", "CHEMICAL", 76, 82], ["graphene", "CHEMICAL", 94, 102], ["oxygen", "CHEMICAL", 76, 82], ["graphene", "CHEMICAL", 94, 102], ["oxygen", "SIMPLE_CHEMICAL", 76, 82], ["graphene", "SIMPLE_CHEMICAL", 94, 102], ["oxygen content of graphene-based nanomaterials", "TREATMENT", 76, 122], ["lateral", "OBSERVATION_MODIFIER", 42, 49], ["size", "OBSERVATION_MODIFIER", 50, 54], ["basal", "ANATOMY_MODIFIER", 59, 64], ["oxygen content", "OBSERVATION", 76, 90], ["antibacterial activity", "OBSERVATION", 136, 158]]], ["Although many findings claimed that graphene-based nanomaterials produced oxidative damage in the antimicrobial activities, unfortunately, it is still questionable whether graphene-based nanomaterials act as direct oxidants or charge transfer mediators, or generate ROS-mediated oxidative stress.", [["graphene", "CHEMICAL", 36, 44], ["graphene", "CHEMICAL", 172, 180], ["ROS", "CHEMICAL", 266, 269], ["graphene", "CHEMICAL", 36, 44], ["graphene", "CHEMICAL", 172, 180], ["graphene", "SIMPLE_CHEMICAL", 36, 44], ["graphene-based nanomaterials", "SIMPLE_CHEMICAL", 172, 200], ["ROS", "SIMPLE_CHEMICAL", 266, 269], ["oxidative damage in the antimicrobial activities", "PROBLEM", 74, 122], ["oxidative damage", "OBSERVATION", 74, 90], ["antimicrobial activities", "OBSERVATION_MODIFIER", 98, 122]]], ["Thus, it is worthy of a further investigation to obtain a thorough understanding of the related mechanisms and influencing factors of its antimicrobial activities.Perspectives and conclusionsAs graphene-based nanomaterials are applied in a wide range of fields, the directly or indirectly cytotoxicity of graphene has drawn great attention about human health and ecosystem risks.", [["graphene", "CHEMICAL", 194, 202], ["graphene", "CHEMICAL", 305, 313], ["graphene", "CHEMICAL", 194, 202], ["graphene", "CHEMICAL", 305, 313], ["graphene", "SIMPLE_CHEMICAL", 194, 202], ["graphene", "SIMPLE_CHEMICAL", 305, 313], ["human", "ORGANISM", 346, 351], ["human", "SPECIES", 346, 351], ["human", "SPECIES", 346, 351], ["a further investigation", "TEST", 22, 45], ["graphene-based nanomaterials", "TREATMENT", 194, 222], ["indirectly cytotoxicity of graphene", "PROBLEM", 278, 313], ["nanomaterials", "OBSERVATION", 209, 222]]], ["Although a great many studies of graphene toxicity have been reported, it is still unclear whether graphene-based nanomaterials affect normal mammalian cells when they kill microorganisms.", [["cells", "ANATOMY", 152, 157], ["graphene", "CHEMICAL", 33, 41], ["toxicity", "DISEASE", 42, 50], ["graphene", "CHEMICAL", 99, 107], ["graphene", "CHEMICAL", 33, 41], ["graphene", "CHEMICAL", 99, 107], ["graphene", "SIMPLE_CHEMICAL", 33, 41], ["graphene", "SIMPLE_CHEMICAL", 99, 107], ["cells", "CELL", 152, 157], ["normal mammalian cells", "CELL_TYPE", 135, 157], ["graphene toxicity", "PROBLEM", 33, 50], ["mammalian cells", "OBSERVATION", 142, 157]]], ["Due to lack of certain inconsistencies in detailed results and hypotheses of the mechanisms, establishing universal acceptance criteria for toxicity tests is necessary but has not yet been set up.", [["toxicity", "DISEASE", 140, 148], ["toxicity tests", "TEST", 140, 154]]], ["Additionally, a better understanding of the mechanism of graphene toxicology needs further elaboration in future, which might circumvent the problems and find appropriate ways to realize the biocompatibility of graphene.", [["graphene", "CHEMICAL", 57, 65], ["graphene", "CHEMICAL", 211, 219], ["graphene", "CHEMICAL", 57, 65], ["graphene", "CHEMICAL", 211, 219], ["graphene", "SIMPLE_CHEMICAL", 57, 65], ["graphene", "SIMPLE_CHEMICAL", 211, 219], ["the problems", "PROBLEM", 137, 149], ["the biocompatibility of graphene", "TREATMENT", 187, 219]]]], "PMC7172211": [["BackgroundPicornaviruses are ubiquitous and commonly associated with inapparent or mild illness in humans.", [["humans", "ORGANISM", 99, 105], ["humans", "SPECIES", 99, 105], ["humans", "SPECIES", 99, 105], ["inapparent or mild illness in humans", "PROBLEM", 69, 105], ["mild", "OBSERVATION_MODIFIER", 83, 87], ["illness", "OBSERVATION", 88, 95]]], ["However, severe illness is well-recognized, particularly in young children [1].", [["illness", "DISEASE", 16, 23], ["children", "ORGANISM", 66, 74], ["children", "SPECIES", 66, 74], ["severe illness", "PROBLEM", 9, 23], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["illness", "OBSERVATION", 16, 23]]], ["The role of picornaviruses in acute infections in children (e.g., sepsis, meningitis, encephalitis, acute paralysis) is often under-recognized due to lack of appropriate specimens from early in the course of illness and to the lack of testing for certain common picornaviruses, such as parechoviruses (PeV), in most hospitals.", [["specimens", "ANATOMY", 170, 179], ["acute infections", "DISEASE", 30, 46], ["sepsis", "DISEASE", 66, 72], ["meningitis", "DISEASE", 74, 84], ["encephalitis", "DISEASE", 86, 98], ["paralysis", "DISEASE", 106, 115], ["picornaviruses", "ORGANISM", 12, 26], ["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58], ["picornaviruses", "PROBLEM", 12, 26], ["acute infections", "PROBLEM", 30, 46], ["sepsis", "PROBLEM", 66, 72], ["meningitis", "PROBLEM", 74, 84], ["encephalitis", "PROBLEM", 86, 98], ["acute paralysis", "PROBLEM", 100, 115], ["appropriate specimens", "PROBLEM", 158, 179], ["illness", "PROBLEM", 208, 215], ["testing", "TEST", 235, 242], ["certain common picornaviruses", "PROBLEM", 247, 276], ["picornaviruses", "OBSERVATION", 12, 26], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["infections", "OBSERVATION", 36, 46], ["sepsis", "OBSERVATION", 66, 72], ["meningitis", "OBSERVATION", 74, 84], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["paralysis", "OBSERVATION", 106, 115], ["picornaviruses", "OBSERVATION", 262, 276]]], ["Enterovirus (EV) and Parechovirus are genera within the family Picornaviridae that are genetically and biologically distinct but share many epidemiologic and clinical characteristics [2].", [["Enterovirus (EV)", "ORGANISM", 0, 16], ["Parechovirus", "GENE_OR_GENE_PRODUCT", 21, 33], ["Picornaviridae", "GENE_OR_GENE_PRODUCT", 63, 77], ["EV", "SPECIES", 13, 15], ["Enterovirus", "PROBLEM", 0, 11], ["Parechovirus", "TREATMENT", 21, 33], ["Picornaviridae", "TREATMENT", 63, 77]]], ["Morbidity and mortality associated with EVs and PeV may occur at all ages, but generally more severe infections occur in younger age groups [1].", [["EVs", "ANATOMY", 40, 43], ["infections", "DISEASE", 101, 111], ["Morbidity", "PROBLEM", 0, 9], ["mortality", "PROBLEM", 14, 23], ["EVs", "PROBLEM", 40, 43], ["PeV", "PROBLEM", 48, 51], ["severe infections", "PROBLEM", 94, 111], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["infections", "OBSERVATION", 101, 111]]], ["Among pathogens detected in cerebrospinal fluid [CSF] specimens, EV and PeV are common, particularly in young infants.", [["cerebrospinal fluid", "ANATOMY", 28, 47], ["CSF] specimens", "ANATOMY", 49, 63], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 28, 47], ["CSF] specimens", "CELL", 49, 63], ["PeV", "GENE_OR_GENE_PRODUCT", 72, 75], ["infants", "ORGANISM", 110, 117], ["infants", "SPECIES", 110, 117], ["PeV", "SPECIES", 72, 75], ["Among pathogens", "PROBLEM", 0, 15], ["cerebrospinal fluid", "TEST", 28, 47], ["CSF] specimens", "TEST", 49, 63], ["cerebrospinal", "ANATOMY", 28, 41], ["fluid", "OBSERVATION", 42, 47]]], ["Systemic disease associated with EV and PeV can result in seizures, multi-organ involvement, and death, particularly in neonates [2].BackgroundAcquisition of EV and PeV is common among children aged <1 year, accounting for 44% of reports with known age to the National Enterovirus Surveillance System (NESS) during 1970\u20132005 [3].", [["multi-organ", "ANATOMY", 68, 79], ["Systemic disease", "DISEASE", 0, 16], ["seizures", "DISEASE", 58, 66], ["death", "DISEASE", 97, 102], ["Enterovirus", "DISEASE", 269, 280], ["children", "ORGANISM", 185, 193], ["children", "SPECIES", 185, 193], ["Systemic disease", "PROBLEM", 0, 16], ["seizures", "PROBLEM", 58, 66], ["multi-organ involvement", "PROBLEM", 68, 91], ["death", "PROBLEM", 97, 102], ["disease", "OBSERVATION", 9, 16], ["seizures", "OBSERVATION", 58, 66], ["EV", "OBSERVATION", 158, 160]]], ["Historically, detection traditionally relied on slow and labor intensive cell culture methods.", [["cell", "ANATOMY", 73, 77], ["cell", "CELL", 73, 77], ["slow and labor intensive cell culture methods", "TREATMENT", 48, 93]]], ["Advances in laboratory techniques, particularly in molecular methodologies, have allowed for the rapid, sensitive, and specific identification of EV and PeV infections for clinical and public health purposes.", [["infections", "DISEASE", 157, 167], ["EV", "SPECIES", 146, 148], ["PeV", "SPECIES", 153, 156], ["laboratory techniques", "TEST", 12, 33], ["EV", "PROBLEM", 146, 148], ["PeV infections", "PROBLEM", 153, 167]]], ["The 10 EV and PeV types most frequently reported to NESS from all age groups during 2014\u20132016 were enterovirus D68; echoviruses 9, 11, 18, and 30; coxsackieviruses A6, B3, B4, and B5; and parechovirus A3, with predominating virus types varying among years [4].ObjectivesTo better define the role of picornaviruses in acute infections in infants, we characterized EV and PeV infections in previously healthy children aged <1 year who were hospitalized with acute illness at two study sites.", [["NESS", "DISEASE", 52, 56], ["enterovirus D68", "DISEASE", 99, 114], ["acute infections", "DISEASE", 317, 333], ["infections", "DISEASE", 374, 384], ["acute illness", "DISEASE", 456, 469], ["PeV", "GENE_OR_GENE_PRODUCT", 14, 17], ["coxsackieviruses A6", "ORGANISM", 147, 166], ["B3", "GENE_OR_GENE_PRODUCT", 168, 170], ["B4", "GENE_OR_GENE_PRODUCT", 172, 174], ["B5", "GENE_OR_GENE_PRODUCT", 180, 182], ["parechovirus A3", "ORGANISM", 188, 203], ["picornaviruses", "ORGANISM", 299, 313], ["infants", "ORGANISM", 337, 344], ["PeV", "GENE_OR_GENE_PRODUCT", 370, 373], ["children", "ORGANISM", 407, 415], ["B5", "PROTEIN", 180, 182], ["infants", "SPECIES", 337, 344], ["children", "SPECIES", 407, 415], ["EV", "SPECIES", 363, 365], ["PeV", "SPECIES", 370, 373], ["enterovirus", "TEST", 99, 110], ["echoviruses", "TEST", 116, 127], ["coxsackieviruses", "TEST", 147, 163], ["B3", "TEST", 168, 170], ["B4", "TEST", 172, 174], ["B5", "TEST", 180, 182], ["parechovirus A3", "PROBLEM", 188, 203], ["predominating virus types", "PROBLEM", 210, 235], ["picornaviruses", "PROBLEM", 299, 313], ["acute infections", "PROBLEM", 317, 333], ["acute illness", "PROBLEM", 456, 469], ["B4", "ANATOMY", 172, 174], ["B5", "ANATOMY", 180, 182], ["parechovirus A3", "OBSERVATION", 188, 203], ["picornaviruses", "OBSERVATION", 299, 313], ["acute", "OBSERVATION_MODIFIER", 317, 322], ["infections", "OBSERVATION", 323, 333], ["PeV infections", "OBSERVATION", 370, 384]]], ["In addition, all EV- and PeV-negative specimens were tested for other viruses by a broadly reactive pan-viral group polymerase chain reaction (PCR).Population ::: MethodsEligible study participants included all children aged <1 year who were hospitalized at one of 2 study sites, had a lumbar puncture (LP) performed in the course of treatment of acute illness, and had CSF submitted for laboratory testing.Sites ::: MethodsParticipating sites included the Colorado Emerging Infections Program (EIP), which included Children\u2019s Hospital Colorado (CHC), a 444-bed facility that is a pediatric referral hospital for Colorado and surrounding states, and the California EIP, which included the University of California San Francisco (UCSF) Benioff Children\u2019s Hospital Oakland, a 183-bed referral facility, and UCSF Medical Center, a 600-bed referral facility.", [["specimens", "ANATOMY", 38, 47], ["lumbar", "ANATOMY", 286, 292], ["acute illness", "DISEASE", 347, 360], ["Infections", "DISEASE", 475, 485], ["CHC", "DISEASE", 546, 549], ["PeV", "GENE_OR_GENE_PRODUCT", 25, 28], ["children", "ORGANISM", 211, 219], ["CSF", "ORGANISM_SUBSTANCE", 370, 373], ["participants", "SPECIES", 185, 197], ["children", "SPECIES", 211, 219], ["Children", "SPECIES", 516, 524], ["Children", "SPECIES", 743, 751], ["all EV", "TEST", 13, 19], ["other viruses", "PROBLEM", 64, 77], ["a broadly reactive pan-viral group polymerase chain reaction", "PROBLEM", 81, 141], ["PCR", "TEST", 143, 146], ["a lumbar puncture", "TEST", 284, 301], ["LP", "TEST", 303, 305], ["treatment", "TREATMENT", 334, 343], ["acute illness", "PROBLEM", 347, 360], ["CSF", "TEST", 370, 373], ["laboratory testing", "TEST", 388, 406], ["reactive", "OBSERVATION_MODIFIER", 91, 99], ["lumbar", "ANATOMY", 286, 292], ["acute", "OBSERVATION_MODIFIER", 347, 352], ["illness", "OBSERVATION", 353, 360]]], ["Eligible participants were enrolled at the Colorado site from January 1 to December 31, 2016 and at the California site from June 1 to December 31, 2016.Medical chart abstraction ::: MethodsFor each enrolled participant, data on demographics, symptoms, and hospital course were abstracted from the medical charts following patient discharge.", [["participants", "ORGANISM", 9, 21], ["patient", "ORGANISM", 323, 330], ["participants", "SPECIES", 9, 21], ["participant", "SPECIES", 208, 219], ["patient", "SPECIES", 323, 330], ["symptoms", "PROBLEM", 243, 251]]], ["These data were entered into a web-based database and de-identified.Specimens and molecular-based testing ::: MethodsAvailable residual CSF and serum specimens collected during hospitalization were shipped to CDC for laboratory testing.", [["Specimens", "ANATOMY", 68, 77], ["serum specimens", "ANATOMY", 144, 159], ["CSF", "ORGANISM_SUBSTANCE", 136, 139], ["serum specimens", "ORGANISM_SUBSTANCE", 144, 159], ["Specimens", "TEST", 68, 77], ["MethodsAvailable residual CSF", "TEST", 110, 139], ["serum specimens", "TEST", 144, 159], ["laboratory testing", "TEST", 217, 235]]], ["All specimens were screened using pan-EV and pan-PeV real-time RT-PCR tests [5,6].", [["specimens", "ANATOMY", 4, 13], ["All specimens", "TEST", 0, 13], ["pan-EV", "TEST", 34, 40], ["RT-PCR tests", "TEST", 63, 75]]], ["Additionally, all CSF specimens were tested using EV and PeV VP1 RT-PCR assays, followed by Sanger sequencing of amplicons to determine type [7,8].Specimens and molecular-based testing ::: MethodsSamples that were negative for EV and PeV were tested for other viruses using pan-viral family and genus PCR assays for the following viruses: alphaviruses, astroviruses, bornaviruses, bunyaviruses, coronaviruses, flaviruses, influenza viruses, paramyxoviruses, rhabdoviruses, adenoviruses, anelloviruses, and herpesviruses [[9], [10], [11], [12]].", [["CSF specimens", "ANATOMY", 18, 31], ["Specimens", "ANATOMY", 147, 156], ["influenza viruses", "DISEASE", 422, 439], ["CSF specimens", "CANCER", 18, 31], ["PeV", "GENE_OR_GENE_PRODUCT", 234, 237], ["astroviruses", "GENE_OR_GENE_PRODUCT", 353, 365], ["bornaviruses", "GENE_OR_GENE_PRODUCT", 367, 379], ["bunyaviruses", "GENE_OR_GENE_PRODUCT", 381, 393], ["coronaviruses", "ORGANISM", 395, 408], ["flaviruses", "GENE_OR_GENE_PRODUCT", 410, 420], ["influenza viruses", "ORGANISM", 422, 439], ["rhabdoviruses", "GENE_OR_GENE_PRODUCT", 458, 471], ["adenoviruses", "ORGANISM", 473, 485], ["anelloviruses", "GENE_OR_GENE_PRODUCT", 487, 500], ["[10], [11], [12]]", "SIMPLE_CHEMICAL", 526, 543], ["PeV", "SPECIES", 57, 60], ["PeV", "SPECIES", 234, 237], ["all CSF specimens", "TEST", 14, 31], ["EV", "TEST", 50, 52], ["PeV VP1 RT-PCR assays", "TEST", 57, 78], ["Specimens", "TEST", 147, 156], ["MethodsSamples", "TEST", 189, 203], ["EV", "TEST", 227, 229], ["PeV", "TEST", 234, 237], ["other viruses", "PROBLEM", 254, 267], ["genus PCR assays", "TEST", 295, 311], ["alphaviruses", "PROBLEM", 339, 351], ["astroviruses", "PROBLEM", 353, 365], ["bornaviruses", "TEST", 367, 379], ["bunyaviruses", "PROBLEM", 381, 393], ["coronaviruses", "PROBLEM", 395, 408], ["flaviruses", "PROBLEM", 410, 420], ["influenza viruses", "PROBLEM", 422, 439], ["paramyxoviruses", "PROBLEM", 441, 456], ["rhabdoviruses", "PROBLEM", 458, 471], ["adenoviruses", "PROBLEM", 473, 485], ["anelloviruses", "PROBLEM", 487, 500], ["herpesviruses", "PROBLEM", 506, 519], ["influenza viruses", "OBSERVATION", 422, 439]]], ["Positive bands of the expected size were Sanger sequenced with the PCR primers to determine virus species.Data ::: MethodsData analysis was performed using Microsoft Excel and SAS 9.3.Ethics ::: MethodsFunding for this study was provided by the CDC\u2019s National Center for Immunizations and Respiratory Diseases through cooperative agreements with the two EIP sites.", [["PCR primers", "DNA", 67, 78], ["Positive bands", "PROBLEM", 0, 14], ["the PCR primers", "TEST", 63, 78], ["virus species", "PROBLEM", 92, 105], ["MethodsData analysis", "TEST", 115, 135], ["Microsoft Excel", "TEST", 156, 171], ["SAS", "TEST", 176, 179], ["this study", "TEST", 214, 224], ["Immunizations", "TREATMENT", 271, 284], ["Respiratory Diseases", "PROBLEM", 289, 309], ["bands", "OBSERVATION_MODIFIER", 9, 14], ["size", "OBSERVATION_MODIFIER", 31, 35], ["Respiratory Diseases", "OBSERVATION", 289, 309]]], ["This study protocol was reviewed by the human subjects research committees at the participating sites and approved as research (CHC, where Institutional Review Board approval was obtained) or determined to be public health practice (both UCSF hospitals, where IRB approval was not required).", [["human", "ORGANISM", 40, 45], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["This study protocol", "TEST", 0, 19]]], ["Although the CDC determined that this study was human subjects research, CDC IRB approval was not required because CDC was considered not engaged in the research.ResultsDuring 2016, 472 case-patients met the eligibility criteria (Fig. 1).", [["human", "ORGANISM", 48, 53], ["patients", "ORGANISM", 191, 199], ["human", "SPECIES", 48, 53], ["patients", "SPECIES", 191, 199], ["human", "SPECIES", 48, 53], ["this study", "TEST", 33, 43], ["CDC", "TEST", 115, 118]]], ["Residual CSF for testing was received at CDC for 319 case-patients (67.6%).", [["CSF", "GENE_OR_GENE_PRODUCT", 9, 12], ["patients", "ORGANISM", 58, 66], ["CSF", "PROTEIN", 9, 12], ["patients", "SPECIES", 58, 66], ["Residual CSF for testing", "TEST", 0, 24]]], ["There was no difference (\u03c7\u00b2 test, \u03b1 = 0.05) in age (p = 0.2718), underlying medical conditions (p = 0.7633), or ICU admission (p = 0.7598) between these case-patients and those with no residual CSF.", [["patients", "ORGANISM", 158, 166], ["CSF", "ORGANISM_SUBSTANCE", 194, 197], ["patients", "SPECIES", 158, 166], ["difference (\u03c7\u00b2 test", "PROBLEM", 13, 32], ["underlying medical conditions", "PROBLEM", 65, 94], ["residual CSF", "PROBLEM", 185, 197], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["Serum specimen was received for 80 case-patients with residual CSF (25% of n = 319).", [["Serum specimen", "ANATOMY", 0, 14], ["Serum specimen", "ORGANISM_SUBSTANCE", 0, 14], ["patients", "ORGANISM", 40, 48], ["CSF", "ORGANISM_SUBSTANCE", 63, 66], ["patients", "SPECIES", 40, 48], ["Serum specimen", "TEST", 0, 14], ["residual CSF", "TEST", 54, 66]]], ["Among the 319 case-patients, CSF specimens from 24 (7.5%) tested positive for either EV (n = 13, 54.2%) or PeV (n = 11, 45.8%) (Table 1).", [["CSF specimens", "ANATOMY", 29, 42], ["patients", "ORGANISM", 19, 27], ["CSF specimens", "CANCER", 29, 42], ["patients", "SPECIES", 19, 27], ["CSF specimens", "TEST", 29, 42], ["EV", "TEST", 85, 87], ["PeV", "TEST", 107, 110]]], ["All serum specimens tested negative for EV and PeV.ResultsA majority (86.8%, n = 277) of enrolled cases were aged less than 2 months, as were all EV- and PeV-positive cases.", [["serum specimens", "ANATOMY", 4, 19], ["serum specimens", "ORGANISM_SUBSTANCE", 4, 19], ["PeV", "GENE_OR_GENE_PRODUCT", 154, 157], ["All serum specimens", "TEST", 0, 19], ["EV", "TEST", 40, 42], ["PeV.", "TEST", 47, 51], ["ResultsA", "TEST", 51, 59], ["all EV", "TEST", 142, 148], ["PeV", "TEST", 154, 157]]], ["Males comprised 58% (n = 186) of all enrolled cases, including 62% (n = 8) of EV-positive cases and 64% (n = 7) of PeV-positive cases.", [["PeV", "GENE_OR_GENE_PRODUCT", 115, 118], ["all enrolled cases", "TEST", 33, 51], ["EV", "TEST", 78, 80], ["PeV", "TEST", 115, 118]]], ["EV-positive cases were admitted during May \u2013 December, and PeV-positive cases were admitted during March \u2013 December (Fig. 2).ResultsNone of the 24 EV- or PeV-positive case-patients had underlying conditions; 3 EV-positive case-patients were delivered preterm (33\u201336 weeks gestational age).", [["EV", "ORGANISM", 0, 2], ["PeV", "GENE_OR_GENE_PRODUCT", 59, 62], ["PeV", "GENE_OR_GENE_PRODUCT", 154, 157], ["patients", "ORGANISM", 172, 180], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 227, 235], ["EV", "TEST", 0, 2], ["EV", "TEST", 147, 149], ["PeV", "TEST", 154, 157], ["underlying conditions", "PROBLEM", 185, 206]]], ["The chief complaint was reported as fever for 22 (91.7%) of the EV- or PeV-positive cases, rash for 1 (4.2%) EV-positive case, and cheek swelling for 1 (4.2%) PeV-positive case.", [["cheek", "ANATOMY", 131, 136], ["fever", "DISEASE", 36, 41], ["rash", "DISEASE", 91, 95], ["cheek swelling", "DISEASE", 131, 145], ["cheek", "ORGAN", 131, 136], ["PeV", "GENE_OR_GENE_PRODUCT", 159, 162], ["fever", "PROBLEM", 36, 41], ["the EV", "TEST", 60, 66], ["PeV-positive cases", "PROBLEM", 71, 89], ["rash", "PROBLEM", 91, 95], ["EV", "TEST", 109, 111], ["cheek swelling", "PROBLEM", 131, 145], ["cheek", "ANATOMY", 131, 136], ["swelling", "OBSERVATION", 137, 145]]], ["Length of hospital stay ranged from 1 to 5 days (median 2 days) for EV-positive cases and from 1 to 9 days (median 2 days) for PeV-positive cases.", [["EV", "TEST", 68, 70], ["PeV", "TEST", 127, 130]]], ["None of the EV- or PeV-positive cases required mechanical ventilation, and all were discharged to home in improved condition.ResultsAll 24 EV- or PeV-positive case-patients received antimicrobials empirically during hospitalization, and blood culture, CSF culture, and CSF gram stain revealed no bacterial etiologies.", [["blood", "ANATOMY", 237, 242], ["PeV", "GENE_OR_GENE_PRODUCT", 19, 22], ["PeV", "GENE_OR_GENE_PRODUCT", 146, 149], ["patients", "ORGANISM", 164, 172], ["blood", "ORGANISM_SUBSTANCE", 237, 242], ["CSF", "ORGANISM_SUBSTANCE", 252, 255], ["patients", "SPECIES", 164, 172], ["the EV", "TEST", 8, 14], ["PeV", "TEST", 19, 22], ["mechanical ventilation", "TREATMENT", 47, 69], ["EV", "TEST", 139, 141], ["PeV", "TEST", 146, 149], ["antimicrobials", "TREATMENT", 182, 196], ["blood culture", "TEST", 237, 250], ["CSF culture", "TEST", 252, 263], ["CSF gram stain", "TEST", 269, 283], ["bacterial etiologies", "PROBLEM", 296, 316], ["mechanical ventilation", "OBSERVATION", 47, 69], ["no", "UNCERTAINTY", 293, 295], ["bacterial etiologies", "OBSERVATION", 296, 316]]], ["Urine culture for one EV-positive case-patient was positive for Escherichia coli.", [["Urine", "ANATOMY", 0, 5], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["patient", "ORGANISM", 39, 46], ["Escherichia coli", "ORGANISM", 64, 80], ["patient", "SPECIES", 39, 46], ["Escherichia coli", "SPECIES", 64, 80], ["Escherichia coli", "SPECIES", 64, 80], ["Urine culture", "TEST", 0, 13], ["one EV", "TEST", 18, 24], ["Escherichia coli", "PROBLEM", 64, 80], ["Escherichia coli", "OBSERVATION", 64, 80]]], ["Acyclovir was empirically administered to 6 (46.2%) EV-positive case-patients and 3 (27.3%) PeV-positive case-patients.", [["Acyclovir", "CHEMICAL", 0, 9], ["Acyclovir", "CHEMICAL", 0, 9], ["Acyclovir", "SIMPLE_CHEMICAL", 0, 9], ["patients", "ORGANISM", 69, 77], ["PeV", "GENE_OR_GENE_PRODUCT", 92, 95], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 110, 118], ["Acyclovir", "TREATMENT", 0, 9], ["PeV", "TEST", 92, 95]]], ["Among case-patients with non-traumatic LP (defined as CSF red blood cell count < 500 /\u03bcL), the median CSF white blood cell count was 2 cells/\u03bcL (range 0\u2013720) for neonates aged < 30 days (n = 10) and 5.5 cells/\u03bcL (range 1\u201395) for infants aged \u2265 30 days (n = 8) (Table 2).", [["red blood cell", "ANATOMY", 58, 72], ["CSF white blood cell", "ANATOMY", 102, 122], ["cells", "ANATOMY", 135, 140], ["cells", "ANATOMY", 203, 208], ["patients", "ORGANISM", 11, 19], ["CSF red blood cell", "CELL", 54, 72], ["blood cell", "CELL", 112, 122], ["cells", "CELL", 135, 140], ["neonates", "ORGANISM", 162, 170], ["cells", "CELL", 203, 208], ["infants", "ORGANISM", 229, 236], ["patients", "SPECIES", 11, 19], ["infants", "SPECIES", 229, 236], ["non-traumatic LP", "TEST", 25, 41], ["CSF red blood cell count", "TEST", 54, 78], ["the median CSF white blood cell count", "TEST", 91, 128], ["cells", "TEST", 135, 140], ["\u03bcL", "TEST", 141, 143], ["neonates", "TEST", 162, 170], ["cells/\u03bcL", "TEST", 203, 211]]], ["Typing was successfully performed for 11 (84.6%) of the EV-positive cases and revealed a diversity of types (Table 2).", [["Typing", "TEST", 0, 6], ["the EV", "TEST", 52, 58], ["diversity", "OBSERVATION", 89, 98]]], ["Each of the following 9 types was identified in a unique case: coxsackieviruses (CV) A6, A10, A16, and B4 and echoviruses 3, 7, 11, 17, and 25.", [["B4", "GENE_OR_GENE_PRODUCT", 103, 105], ["echoviruses 3", "GENE_OR_GENE_PRODUCT", 110, 123], ["echoviruses 3, 7, 11, 17, and 25", "DNA", 110, 142], ["A16", "SPECIES", 94, 97], ["coxsackieviruses", "PROBLEM", 63, 79], ["A10", "TEST", 89, 92], ["A16", "TEST", 94, 97], ["B4", "TEST", 103, 105], ["echoviruses", "TEST", 110, 121], ["coxsackieviruses", "OBSERVATION", 63, 79], ["B4", "ANATOMY", 103, 105]]], ["CV-B5 was identified in 2 separate cases.", [["CV-B5", "CELL", 0, 5], ["B5", "ANATOMY", 3, 5]]], ["In comparison, the PeV-positive cases were dominated by a single type, PeV-A3, which was identified in 10 (90.9%) cases.", [["PeV", "GENE_OR_GENE_PRODUCT", 19, 22], ["PeV-A3", "GENE_OR_GENE_PRODUCT", 71, 77], ["PeV", "PROTEIN", 19, 22], ["PeV-A3", "SPECIES", 71, 77]]], ["PeV-A4 was identified in 1 case.ResultsSpecimens with negative results for EV or PeV were tested for other viruses.", [["PeV-A4", "GENE_OR_GENE_PRODUCT", 0, 6], ["PeV", "PROTEIN", 0, 3], ["A4", "DNA", 4, 6], ["PeV-A4", "SPECIES", 0, 6], ["PeV", "SPECIES", 81, 84], ["ResultsSpecimens", "TEST", 32, 48], ["EV", "TEST", 75, 77], ["PeV", "PROBLEM", 81, 84], ["other viruses", "PROBLEM", 101, 114]]], ["Human herpesvirus 6B was detected in the CSF specimen of one 20-day old male who presented with fever, lower limb cellulitis, and myositis, was admitted to neonatal ICU, and was discharged after 13 days.", [["CSF specimen", "ANATOMY", 41, 53], ["lower limb", "ANATOMY", 103, 113], ["fever", "DISEASE", 96, 101], ["lower limb cellulitis", "DISEASE", 103, 124], ["myositis", "DISEASE", 130, 138], ["Human herpesvirus 6B", "ORGANISM", 0, 20], ["CSF specimen", "ORGANISM_SUBSTANCE", 41, 53], ["lower limb", "ORGANISM_SUBDIVISION", 103, 113], ["Human", "SPECIES", 0, 5], ["Human herpesvirus 6B", "SPECIES", 0, 20], ["Human herpesvirus 6B", "TEST", 0, 20], ["fever", "PROBLEM", 96, 101], ["lower limb cellulitis", "PROBLEM", 103, 124], ["myositis", "PROBLEM", 130, 138], ["fever", "OBSERVATION", 96, 101], ["lower limb", "ANATOMY", 103, 113], ["cellulitis", "OBSERVATION", 114, 124], ["myositis", "OBSERVATION", 130, 138]]], ["The serum specimens of 3 case-patients were positive using a pan-anellovirus PCR assay.", [["serum specimens", "ANATOMY", 4, 19], ["serum specimens", "ORGANISM_SUBSTANCE", 4, 19], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["The serum specimens", "TEST", 0, 19], ["a pan-anellovirus PCR assay", "TEST", 59, 86]]], ["All other specimens were negative for all viruses tested.ConclusionsAmong children aged <1 year hospitalized with acute illness at our study sites in 2016, 4.1% had EV and 3.4% had PeV detected in CSF.", [["specimens", "ANATOMY", 10, 19], ["acute illness", "DISEASE", 114, 127], ["specimens", "CANCER", 10, 19], ["children", "ORGANISM", 74, 82], ["CSF", "ORGANISM_SUBSTANCE", 197, 200], ["children", "SPECIES", 74, 82], ["All other specimens", "TEST", 0, 19], ["all viruses", "PROBLEM", 38, 49], ["acute illness", "PROBLEM", 114, 127], ["EV", "TEST", 165, 167], ["PeV", "PROBLEM", 181, 184], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["illness", "OBSERVATION", 120, 127], ["CSF", "ANATOMY", 197, 200]]], ["Half of the positive case-patients were initially admitted to ICU, but hospital length of stay was brief and illnesses were generally self-limiting.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["illnesses", "PROBLEM", 109, 118]]], ["The picornaviruses detected in CSF represent a range of common circulating types, with most children presenting with acute febrile illness [3,4].", [["acute febrile illness", "DISEASE", 117, 138], ["picornaviruses", "ORGANISM", 4, 18], ["CSF", "GENE_OR_GENE_PRODUCT", 31, 34], ["children", "ORGANISM", 92, 100], ["children", "SPECIES", 92, 100], ["The picornaviruses", "PROBLEM", 0, 18], ["acute febrile illness", "PROBLEM", 117, 138], ["picornaviruses", "OBSERVATION", 4, 18]]], ["In previous retrospective studies using comparable populations, EV positivity ranged from 3% to 14% and PeV-positivity ranged from 5% to 17%, possibly reflecting differences in study methods and timing of enrollment relative to the seasonal and annual variations in picornavirus circulation [[13], [14], [15]].", [["PeV", "GENE_OR_GENE_PRODUCT", 104, 107], ["previous retrospective studies", "TEST", 3, 33], ["EV positivity", "TEST", 64, 77], ["PeV-positivity", "TEST", 104, 118], ["study methods", "TEST", 177, 190], ["the seasonal and annual variations in picornavirus circulation", "PROBLEM", 228, 290]]], ["A prospective study spanning 4 years found EV in 37% and PeV in 15%; however, EV typing was only successful on 6.5% and PeV-typing on 3.4% [16].", [["A prospective study", "TEST", 0, 19], ["EV", "TEST", 43, 45], ["PeV", "TEST", 57, 60], ["EV typing", "TEST", 78, 87], ["PeV", "TEST", 120, 123]]], ["The availability of specimens earlier in the course of illness and the inclusion of multiple years may have contributed to the higher proportions of EV and PeV detected in comparison with this study.", [["specimens", "ANATOMY", 20, 29], ["illness", "DISEASE", 55, 62], ["illness", "PROBLEM", 55, 62], ["this study", "TEST", 188, 198]]], ["As noted in previous studies, EV and PeV detections were concentrated among children aged <2 months [14,16,17].ConclusionsA wide diversity of EV types and the predominance of PeV-A3 among PeV-positive case-patients are characteristic of those with severe picornavirus infections [14,15,17].", [["picornavirus infections", "DISEASE", 255, 278], ["PeV", "GENE_OR_GENE_PRODUCT", 37, 40], ["children", "ORGANISM", 76, 84], ["PeV-A3", "GENE_OR_GENE_PRODUCT", 175, 181], ["PeV", "GENE_OR_GENE_PRODUCT", 188, 191], ["patients", "ORGANISM", 206, 214], ["children", "SPECIES", 76, 84], ["patients", "SPECIES", 206, 214], ["PeV-A3", "SPECIES", 175, 181], ["previous studies", "TEST", 12, 28], ["wide diversity of EV types", "PROBLEM", 124, 150], ["PeV", "PROBLEM", 175, 178], ["severe picornavirus infections", "PROBLEM", 248, 278], ["EV types", "OBSERVATION_MODIFIER", 142, 150], ["severe", "OBSERVATION_MODIFIER", 248, 254], ["picornavirus", "OBSERVATION", 255, 267]]], ["All EV and PeV types detected in this study were represented among NESS reports during 2016; CV-A6, CV-A10, CVA-16, CV-B4, E11, and PeV-A3 were among the top 15 most frequently reported types that year.ConclusionsChildren aged <2 months constituted more than 85% of enrolled case-patients.", [["PeV", "GENE_OR_GENE_PRODUCT", 11, 14], ["CV-A6", "CELL", 93, 98], ["CV-A10", "CELL", 100, 106], ["CVA-16", "ORGANISM", 108, 114], ["CV-B4", "CELL", 116, 121], ["E11", "CELL", 123, 126], ["PeV-A3", "CELL", 132, 138], ["Children", "ORGANISM", 213, 221], ["patients", "ORGANISM", 280, 288], ["Children", "SPECIES", 213, 221], ["patients", "SPECIES", 280, 288], ["CV-A6", "SPECIES", 93, 98], ["CV-A10", "SPECIES", 100, 106], ["CV-B4", "SPECIES", 116, 121], ["PeV-A3", "SPECIES", 132, 138], ["this study", "TEST", 33, 43], ["CV", "TEST", 93, 95], ["CV", "TEST", 100, 102], ["CVA", "TEST", 108, 111], ["PeV types", "OBSERVATION_MODIFIER", 11, 20]]], ["Young infants presenting with fever typically have an LP performed, are admitted with empiric antibiotic treatment while undergoing diagnostic evaluation for bacterial sepsis, and, in some cases, placed on acyclovir for suspicion of disseminated herpes simplex virus (HSV) infection.", [["fever", "DISEASE", 30, 35], ["bacterial sepsis", "DISEASE", 158, 174], ["acyclovir", "CHEMICAL", 206, 215], ["herpes simplex virus (HSV) infection", "DISEASE", 246, 282], ["acyclovir", "CHEMICAL", 206, 215], ["infants", "ORGANISM", 6, 13], ["acyclovir", "SIMPLE_CHEMICAL", 206, 215], ["disseminated", "ORGANISM", 233, 245], ["herpes simplex virus", "ORGANISM", 246, 266], ["HSV", "ORGANISM", 268, 271], ["infants", "SPECIES", 6, 13], ["herpes simplex virus", "SPECIES", 246, 266], ["herpes simplex virus", "SPECIES", 246, 266], ["HSV", "SPECIES", 268, 271], ["fever", "PROBLEM", 30, 35], ["an LP", "TEST", 51, 56], ["empiric antibiotic treatment", "TREATMENT", 86, 114], ["diagnostic evaluation", "TEST", 132, 153], ["bacterial sepsis", "PROBLEM", 158, 174], ["acyclovir", "TREATMENT", 206, 215], ["disseminated herpes simplex virus (HSV) infection", "PROBLEM", 233, 282], ["bacterial", "OBSERVATION_MODIFIER", 158, 167], ["sepsis", "OBSERVATION", 168, 174], ["disseminated", "OBSERVATION_MODIFIER", 233, 245], ["herpes simplex virus", "OBSERVATION", 246, 266], ["infection", "OBSERVATION", 273, 282]]], ["Children aged \u22652 months are less likely to have an LP performed, which may have decreased the likelihood of EV or PeV detections in CSF from this group.ConclusionsThis study was subject to limitations.", [["Children", "ORGANISM", 0, 8], ["PeV", "GENE_OR_GENE_PRODUCT", 114, 117], ["CSF", "ORGANISM_SUBSTANCE", 132, 135], ["Children", "SPECIES", 0, 8], ["an LP", "TEST", 48, 53], ["EV", "PROBLEM", 108, 110], ["PeV detections in CSF", "PROBLEM", 114, 135], ["This study", "TEST", 163, 173]]], ["Multiple years of enrollment would more comprehensively describe EV and PeV circulation among acutely ill infants.", [["acutely ill", "DISEASE", 94, 105], ["infants", "ORGANISM", 106, 113], ["infants", "SPECIES", 106, 113]]], ["Second, a substantial proportion (32.4% of 472 eligible case-patients) had no residual CSF specimens available for testing at CDC and were not able to be included in the study although they did not significantly differ from those with residual CSF on key parameters.", [["CSF specimens", "ANATOMY", 87, 100], ["patients", "ORGANISM", 61, 69], ["CSF specimens", "CANCER", 87, 100], ["CSF", "GENE_OR_GENE_PRODUCT", 244, 247], ["patients", "SPECIES", 61, 69], ["residual CSF specimens", "PROBLEM", 78, 100], ["testing at CDC", "TEST", 115, 129], ["the study", "TEST", 166, 175], ["residual CSF on key parameters", "PROBLEM", 235, 265]]], ["Third, the specimens were initially collected for clinical diagnostic testing, with residual specimen stored and later transported for further characterization at CDC.", [["specimens", "ANATOMY", 11, 20], ["specimen", "ANATOMY", 93, 101], ["specimens", "CANCER", 11, 20], ["the specimens", "TEST", 7, 20], ["clinical diagnostic testing", "TEST", 50, 77], ["residual specimen", "TEST", 84, 101], ["further characterization", "TEST", 135, 159]]], ["Repeated freeze-thaw cycles might have adversely affected specimen quality, potentially contributing to false negative results.ConclusionsPicornaviruses are associated with a range of symptoms and severity in children.", [["specimen", "ANATOMY", 58, 66], ["children", "ORGANISM", 209, 217], ["children", "SPECIES", 209, 217], ["Repeated freeze-thaw cycles", "TREATMENT", 0, 27], ["adversely affected specimen quality", "PROBLEM", 39, 74], ["false negative results", "PROBLEM", 104, 126], ["Picornaviruses", "PROBLEM", 138, 152], ["symptoms", "PROBLEM", 184, 192], ["Picornaviruses", "OBSERVATION", 138, 152]]], ["The clinical manifestations associated with specific EV and PeV types remain poorly characterized, owing in part to changing laboratory testing practices and decreasing clinical requests for viral typing [18].", [["The clinical manifestations", "PROBLEM", 0, 27], ["viral typing", "TEST", 191, 203], ["PeV types", "OBSERVATION_MODIFIER", 60, 69], ["poorly characterized", "OBSERVATION_MODIFIER", 77, 97]]], ["While qualitative testing for EV is common among clinical laboratories, these tests do not detect PeV.", [["EV", "SPECIES", 30, 32], ["qualitative testing", "TEST", 6, 25], ["these tests", "TEST", 72, 83], ["PeV.", "PROBLEM", 98, 102]]], ["Most clinical laboratories do not perform qualitative testing to detect PeV even though pan-PeV assays are available [6].", [["PeV", "PROTEIN", 72, 75], ["qualitative testing", "TEST", 42, 61], ["PeV", "PROBLEM", 72, 75], ["pan-PeV assays", "TEST", 88, 102]]], ["Specific laboratory diagnostics are needed to distinguish EV and PeV illness from that due to HSV, which may exhibit a similar clinical syndrome early in the course of illness and requires empiric antiviral treatment while undergoing diagnostic evaluation.ConclusionsLarge studies of infants within the first months of life, with enrollment occurring during peak enterovirus season and spanning multiple seasons, are needed in order to better understand illness severity and management of hospitalized children associated with individual EV and PeV types.", [["PeV illness", "DISEASE", 65, 76], ["illness", "DISEASE", 168, 175], ["illness", "DISEASE", 454, 461], ["HSV", "ORGANISM", 94, 97], ["infants", "ORGANISM", 284, 291], ["children", "ORGANISM", 502, 510], ["infants", "SPECIES", 284, 291], ["children", "SPECIES", 502, 510], ["EV", "SPECIES", 58, 60], ["PeV", "SPECIES", 65, 68], ["HSV", "SPECIES", 94, 97], ["Specific laboratory diagnostics", "TEST", 0, 31], ["EV", "PROBLEM", 58, 60], ["PeV illness", "PROBLEM", 65, 76], ["HSV", "PROBLEM", 94, 97], ["a similar clinical syndrome", "PROBLEM", 117, 144], ["illness", "PROBLEM", 168, 175], ["empiric antiviral treatment", "TREATMENT", 189, 216], ["diagnostic evaluation", "TEST", 234, 255], ["Large studies", "TEST", 267, 280], ["Large", "OBSERVATION_MODIFIER", 267, 272]]], ["Furthermore, increased surveillance and testing for EV and PeV are needed to understand severe illness in infants.", [["illness", "DISEASE", 95, 102], ["infants", "ORGANISM", 106, 113], ["infants", "SPECIES", 106, 113], ["EV", "SPECIES", 52, 54], ["increased surveillance", "TEST", 13, 35], ["testing", "TEST", 40, 47], ["severe illness in infants", "PROBLEM", 88, 113]]], ["Clinicians should consider EV and PeV infections in infants presenting with acute febrile illness.FundingFunding for this study was provided by the CDC\u2019s National Center for Immunizations and Respiratory Diseases through cooperative agreements with the Colorado and California Emerging Infections Program sites.Competing interestsNone declared.Ethical approvalThe study protocol was reviewed by the human subjects research committees at the participating sites and approved as research (Colorado Children\u2019s Hospital, where Institutional Review Board approval was obtained) or determined to be public health practice (both University of California San Francisco hospitals, where IRB approval not required).", [["infections", "DISEASE", 38, 48], ["acute febrile illness", "DISEASE", 76, 97], ["Respiratory Diseases", "DISEASE", 192, 212], ["Infections", "DISEASE", 286, 296], ["infants", "ORGANISM", 52, 59], ["human", "ORGANISM", 399, 404], ["infants", "SPECIES", 52, 59], ["human", "SPECIES", 399, 404], ["Children", "SPECIES", 496, 504], ["human", "SPECIES", 399, 404], ["PeV infections", "PROBLEM", 34, 48], ["acute febrile illness", "PROBLEM", 76, 97], ["this study", "TEST", 117, 127], ["Immunizations", "TREATMENT", 174, 187], ["Respiratory Diseases", "PROBLEM", 192, 212], ["Ethical approval", "TREATMENT", 344, 360], ["The study protocol", "TEST", 360, 378], ["infections", "OBSERVATION", 38, 48], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["febrile", "OBSERVATION", 82, 89]]], ["Although the CDC determined that this study was human subjects research, CDC IRB approval was not required because CDC was considered not engaged in the research.CRediT authorship contribution statement", [["human", "ORGANISM", 48, 53], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["this study", "TEST", 33, 43], ["CDC", "TEST", 115, 118]]]], "52f17730ade55e1781cb9ac31bc5ea892d28af6a": [["BackgroundNumerous gene families, including glutathione S-transferases (GSTs) superfamily, are involved in cellular detoxification process and neutralizing oxidative stress.", [["cellular", "ANATOMY", 107, 115], ["glutathione", "CHEMICAL", 44, 55], ["glutathione", "CHEMICAL", 44, 55], ["S", "CHEMICAL", 56, 57], ["glutathione S-transferases", "GENE_OR_GENE_PRODUCT", 44, 70], ["GSTs", "GENE_OR_GENE_PRODUCT", 72, 76], ["cellular", "CELL", 107, 115], ["BackgroundNumerous gene families", "DNA", 0, 32], ["glutathione S-transferases (GSTs) superfamily", "PROTEIN", 44, 89], ["neutralizing oxidative stress", "PROBLEM", 143, 172]]], ["The GSTP1 (MIM: 134660, belong to class pi) has many genetic variations in human.", [["GSTP1", "GENE_OR_GENE_PRODUCT", 4, 9], ["class pi", "GENE_OR_GENE_PRODUCT", 34, 42], ["human", "ORGANISM", 75, 80], ["GSTP1", "DNA", 4, 9], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["many genetic variations in human", "PROBLEM", 48, 80], ["genetic variations", "OBSERVATION", 53, 71]]], ["A missense variant A/G (rs1695) in exon 5 of the GSTP1 result in amino acid substitution Ile105Val.", [["amino acid", "CHEMICAL", 65, 75], ["amino acid", "CHEMICAL", 65, 75], ["Ile", "CHEMICAL", 89, 92], ["A/G (rs1695)", "GENE_OR_GENE_PRODUCT", 19, 31], ["GSTP1", "GENE_OR_GENE_PRODUCT", 49, 54], ["amino acid", "AMINO_ACID", 65, 75], ["Ile105Val", "AMINO_ACID", 89, 98], ["exon 5", "DNA", 35, 41], ["GSTP1", "DNA", 49, 54], ["the GSTP1", "TEST", 45, 54], ["amino acid substitution", "TREATMENT", 65, 88], ["missense", "OBSERVATION", 2, 10]]], ["The stability of the Val105 form is less than the other form [1] .", [["Val105", "GENE_OR_GENE_PRODUCT", 21, 27], ["Val105 form", "PROTEIN", 21, 32], ["stability", "OBSERVATION_MODIFIER", 4, 13]]], ["This alteration decreased the GSTP1 enzyme activity [2] [3] [4] .BackgroundThe GSTP1 is expressed in all tissues and cells, including lung epithelial cells and lung-resident macrophages [5] [6] [7] .", [["tissues", "ANATOMY", 105, 112], ["cells", "ANATOMY", 117, 122], ["lung epithelial cells", "ANATOMY", 134, 155], ["lung", "ANATOMY", 160, 164], ["macrophages", "ANATOMY", 174, 185], ["GSTP1", "GENE_OR_GENE_PRODUCT", 30, 35], ["GSTP1", "GENE_OR_GENE_PRODUCT", 79, 84], ["tissues", "TISSUE", 105, 112], ["cells", "CELL", 117, 122], ["lung epithelial cells", "CELL", 134, 155], ["lung", "ORGAN", 160, 164], ["macrophages", "CELL", 174, 185], ["GSTP1 enzyme", "PROTEIN", 30, 42], ["GSTP1", "PROTEIN", 79, 84], ["lung epithelial cells", "CELL_TYPE", 134, 155], ["lung-resident macrophages", "CELL_TYPE", 160, 185], ["This alteration", "PROBLEM", 0, 15], ["the GSTP1 enzyme activity", "TEST", 26, 51], ["The GSTP1", "TEST", 75, 84], ["lung epithelial cells", "TEST", 134, 155], ["GSTP1", "OBSERVATION", 79, 84], ["all tissues", "ANATOMY", 101, 112], ["lung", "ANATOMY", 134, 138], ["epithelial cells", "OBSERVATION", 139, 155], ["lung", "ANATOMY", 160, 164]]], ["In occupationally di-isocyanate-induced asthma, the Val105 allele is positively associated with the bronchial hyperreactivity [8] .", [["bronchial", "ANATOMY", 100, 109], ["di-isocyanate", "CHEMICAL", 18, 31], ["asthma", "DISEASE", 40, 46], ["di-isocyanate", "CHEMICAL", 18, 31], ["di-isocyanate", "SIMPLE_CHEMICAL", 18, 31], ["Val105", "GENE_OR_GENE_PRODUCT", 52, 58], ["Val105 allele", "DNA", 52, 65], ["asthma", "PROBLEM", 40, 46], ["the Val105 allele", "PROBLEM", 48, 65], ["the bronchial hyperreactivity", "PROBLEM", 96, 125], ["asthma", "OBSERVATION", 40, 46], ["bronchial", "ANATOMY", 100, 109], ["hyperreactivity", "OBSERVATION", 110, 125]]], ["Exposure to high \"diesel exhaust particle\" increased the risk of wheezing phenotypes only among the carriers of the Val105 allele (Ile/Val and Val/ Val genotypes) [9] .", [["wheezing", "DISEASE", 65, 73], ["Ile", "CHEMICAL", 131, 134], ["Val", "CHEMICAL", 135, 138], ["Val", "CHEMICAL", 143, 146], ["Val", "CHEMICAL", 148, 151], ["Val105", "GENE_OR_GENE_PRODUCT", 116, 122], ["Val105 allele", "DNA", 116, 129], ["high \"diesel exhaust particle", "PROBLEM", 12, 41], ["wheezing phenotypes", "PROBLEM", 65, 84], ["the Val105 allele (Ile/Val and Val/ Val genotypes)", "TREATMENT", 112, 162], ["high", "OBSERVATION_MODIFIER", 12, 16], ["diesel exhaust", "OBSERVATION", 18, 32]]], ["Children with the Val/Val genotype had slower lung function growth than the other genotypes [10] .", [["lung", "ANATOMY", 46, 50], ["Val", "CHEMICAL", 18, 21], ["Children", "ORGANISM", 0, 8], ["lung", "ORGAN", 46, 50], ["Children", "SPECIES", 0, 8], ["the Val/Val genotype", "TREATMENT", 14, 34], ["slower lung function growth", "PROBLEM", 39, 66], ["lung", "ANATOMY", 46, 50]]], ["Downregulation of the GSTP1 mRNA level and lower total GST activity were reported in a mouse model of asthma following allergen challenge [11] .", [["asthma", "DISEASE", 102, 108], ["GSTP1", "GENE_OR_GENE_PRODUCT", 22, 27], ["GST", "GENE_OR_GENE_PRODUCT", 55, 58], ["mouse", "ORGANISM", 87, 92], ["GSTP1 mRNA", "RNA", 22, 32], ["GST", "PROTEIN", 55, 58], ["mouse", "SPECIES", 87, 92], ["mouse", "SPECIES", 87, 92], ["the GSTP1 mRNA level", "PROBLEM", 18, 38], ["lower total GST activity", "PROBLEM", 43, 67], ["asthma", "PROBLEM", 102, 108], ["allergen challenge", "TREATMENT", 119, 137], ["GSTP1 mRNA", "OBSERVATION", 22, 32], ["lower", "OBSERVATION_MODIFIER", 43, 48], ["asthma", "OBSERVATION", 102, 108]]], ["Taken together, it is concluded that the GSTP1 has a central role in lung function.BackgroundCoronavirus disease 2019 (COVID-19) is a contagious disease; therefore, its prevalence (per 10 6 people), casefatality (per 100 infected cases), and mortality (per 10 6 people) may be affected by various social factors, such as the life expectancy at birth, country income, etc. Very recently some investigators suggested that some genetic polymorphisms might be involved in susceptibility to genetic polymorphisms or outcome of the disease [12] [13] [14] [15] [16] .BackgroundOxidative stress is an important issue in COVID-19 [17] [18] [19] .", [["lung", "ANATOMY", 69, 73], ["BackgroundCoronavirus disease", "DISEASE", 83, 112], ["COVID-19", "CHEMICAL", 119, 127], ["contagious disease", "DISEASE", 134, 152], ["casefatality", "DISEASE", 199, 211], ["COVID-19 [17] [18]", "CHEMICAL", 612, 630], ["COVID-19", "CHEMICAL", 612, 620], ["GSTP1", "GENE_OR_GENE_PRODUCT", 41, 46], ["lung", "ORGAN", 69, 73], ["[12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 534, 558], ["COVID-19 [17] [18] [19]", "SIMPLE_CHEMICAL", 612, 635], ["GSTP1", "PROTEIN", 41, 46], ["people", "SPECIES", 190, 196], ["people", "SPECIES", 262, 268], ["BackgroundCoronavirus disease 2019 (COVID-19", "SPECIES", 83, 127], ["the GSTP1", "PROBLEM", 37, 46], ["BackgroundCoronavirus disease", "PROBLEM", 83, 112], ["COVID", "TEST", 119, 124], ["a contagious disease", "PROBLEM", 132, 152], ["some genetic polymorphisms", "PROBLEM", 420, 446], ["the disease", "PROBLEM", 522, 533], ["BackgroundOxidative stress", "PROBLEM", 560, 586], ["central", "OBSERVATION_MODIFIER", 53, 60], ["lung", "ANATOMY", 69, 73], ["contagious", "OBSERVATION_MODIFIER", 134, 144], ["disease", "OBSERVATION", 145, 152], ["Oxidative stress", "OBSERVATION", 570, 586]]], ["Considering that GSTP1 is involved in cellular detoxification and it has important role in lung function, it is suggested that GSTP1 plays an important role in susceptibility to SARS-CoV-2 infection and/or its outcome.", [["cellular", "ANATOMY", 38, 46], ["lung", "ANATOMY", 91, 95], ["SARS", "DISEASE", 178, 182], ["infection", "DISEASE", 189, 198], ["GSTP1", "GENE_OR_GENE_PRODUCT", 17, 22], ["cellular", "CELL", 38, 46], ["lung", "ORGAN", 91, 95], ["GSTP1", "GENE_OR_GENE_PRODUCT", 127, 132], ["SARS-CoV-2", "ORGANISM", 178, 188], ["GSTP1", "PROTEIN", 17, 22], ["GSTP1", "PROTEIN", 127, 132], ["SARS-CoV", "SPECIES", 178, 186], ["GSTP1", "PROBLEM", 17, 22], ["cellular detoxification", "TREATMENT", 38, 61], ["GSTP1", "PROBLEM", 127, 132], ["SARS", "PROBLEM", 178, 182], ["CoV-2 infection", "PROBLEM", 183, 198], ["lung", "ANATOMY", 91, 95]]], ["Very recently, association between some genetic polymorphisms and morbidity/mortality of COVID-19 were reported [12] [13] [14] [15] [16] .", [["COVID-19", "CHEMICAL", 89, 97], ["[12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 112, 136], ["some genetic polymorphisms", "PROBLEM", 35, 61], ["morbidity", "PROBLEM", 66, 75], ["COVID", "TEST", 89, 94]]], ["A study showed that the COVID-19 mortality and case-fatality are associated with the GSTT1 polymorphism [12] .", [["GSTT1", "DNA", 85, 90], ["A study", "TEST", 0, 7], ["the COVID", "TEST", 20, 29], ["the GSTT1 polymorphism", "PROBLEM", 81, 103]]], ["There are no data on the association between COVID-19 epidemiologic parameters and the rs1695.", [["rs1695", "GENE_OR_GENE_PRODUCT", 87, 93], ["COVID", "PROTEIN", 45, 50], ["COVID", "TEST", 45, 50], ["epidemiologic parameters", "TEST", 54, 78], ["no", "UNCERTAINTY", 10, 12]]], ["These facts sufficiently provide us with a theoretical hypothesis to carry out the present study.MethodsIn this study, the life expectancy at birth (LE), density of medical doctors, density of nursing and midwifery personnel, and the gross national income (GNI) per capita (PPP international $) as the indices for economic situation and health services in different countries were considered as the potential risk factors for susceptibility to COVID-19 or the disease outcome.", [["COVID-19", "CHEMICAL", 444, 452], ["a theoretical hypothesis", "PROBLEM", 41, 65], ["the present study", "TEST", 79, 96], ["this study", "TEST", 107, 117], ["COVID", "TEST", 444, 449], ["the disease outcome", "PROBLEM", 456, 475]]], ["The latest data available for countries were achieved from the World Health Organization website www.who.int/countries/en/.", [["The latest data", "TEST", 0, 15]]], ["The latest data for GNI per capita for countries were obtained from the World Bank data (https://data.worldbank.org/indicator/NY.GNP.PCAP.PP.CD).MethodsThe number of COVID-19 diagnostic tests performed per one million population in each country was also used as another risk variable.", [["COVID", "PROTEIN", 166, 171], ["Methods", "TREATMENT", 145, 152], ["COVID", "TEST", 166, 171], ["diagnostic tests", "TEST", 175, 191]]], ["Data for the prevalence, fatality, mortality, and level of performed diagnostic test of COVID-19 on July 7, 2020, were achieved from the website www.worldo meters. info/coronavirus/countries.", [["coronavirus", "ORGANISM", 169, 180], ["info/coronavirus", "SPECIES", 164, 180], ["diagnostic test", "TEST", 69, 84], ["COVID", "TEST", 88, 93]]], ["The Val105 allelic frequency in different countries was obtained from previous reports (Table S1 in supplement file).", [["Val105", "GENE_OR_GENE_PRODUCT", 4, 10]]], ["Data from 45 countries were included in the analysis.", [["the analysis", "TEST", 40, 52]]], ["Data from Argentina, Australia, Brazil, Bulgaria, Canada, China, Colombia, Czech, Denmark, Egypt, Finland, France, Germany, Hungary, Iceland, India, Iran, Iraq, Italy, Jamaica, Japan, Jordan, Kazakhstan, Lebanon, Mexico, Moldova, Morocco, Netherland, Norway, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovenia, South Africa, South Korea, Spain, Sweden, Thailand, Turkey, the UK, and the USA were included in the analysis.MethodsVariables were checked for their normality by onesample Kolmogorov-Smirnov test.", [["the USA", "TEST", 409, 416], ["the analysis", "TEST", 434, 446], ["MethodsVariables", "TEST", 447, 463]]], ["Non-normally distributed variables (prevalence, mortality, case-fatality rates, and number diagnostic test performed per 10 6 people) were log-transformed.", [["people", "ORGANISM", 126, 132], ["people", "SPECIES", 126, 132], ["diagnostic test", "TEST", 91, 106]]], ["Variables with p \u2264 0.1 in the univariable analysis were introduced into the multivariable models.", [["the univariable analysis", "TEST", 26, 50]]], ["Only two different models were fitted for combination of the epidemiologic parameters with the rs1695 polymorphism.", [["rs1695", "GENE_OR_GENE_PRODUCT", 95, 101], ["the epidemiologic parameters", "TEST", 57, 85]]], ["The log-transformed variables were considered as outcome variables, and the allelic frequency and the risk factors were introduced into the model as explanatory variables.", [["the allelic frequency", "PROBLEM", 72, 93], ["the risk factors", "PROBLEM", 98, 114]]], ["A backward removal method was used for each model construction.", [["A backward removal method", "TREATMENT", 0, 25], ["each model construction", "TREATMENT", 39, 62]]], ["Analyses were performed using the SPSS statistical soft-ware (Chicago, IL, USA, version 24).", [["Analyses", "TEST", 0, 8]]], ["A p < 0.05 was considered statistically significant differenceResultsIn univariate analysis, the frequency of the Val105 allele showed no significant correlations with the logprevalence (r = 0.331, df = 44, p = 0.025), log-mortality (r = 0.363, df = 44, p = 0.013), and log-fatality (r = 0.175, df = 44, p = 0.244) of the COVID-19.", [["Val105", "GENE_OR_GENE_PRODUCT", 114, 120], ["Val105 allele", "DNA", 114, 127], ["univariate analysis", "TEST", 72, 91], ["the Val105 allele", "TEST", 110, 127], ["df", "TEST", 198, 200], ["p", "TEST", 207, 208], ["log-mortality", "TEST", 219, 232], ["df", "TEST", 245, 247], ["p", "TEST", 254, 255], ["df", "TEST", 295, 297], ["p", "TEST", 304, 305], ["the COVID", "TEST", 318, 327]]], ["Table 1 shows the association between potential risk factors and the log-transformed of prevalence, mortality, and case-fatality of COVID-19.", [["potential risk factors", "PROBLEM", 38, 60], ["COVID", "TEST", 132, 137]]], ["Variables with p \u2264 0.1 in the univariable analysis were used in multivariable linear regression analyses (Table 1) .ResultsTwo different models were fitted for combination of prevalence and mortality with the rs1695 polymorphism.", [["rs1695", "GENE_OR_GENE_PRODUCT", 209, 215], ["the univariable analysis", "TEST", 26, 50], ["multivariable linear regression analyses", "TEST", 64, 104]]], ["The log-prevalence and log-mortality were considered as outcome variables, and the Val105 allelic frequency and the risk factors were introduced into the model as explanatory variables.ResultsResults of multivariate analysis are summarized in Table 2 .", [["Val105", "GENE_OR_GENE_PRODUCT", 83, 89], ["the Val105 allelic frequency", "PROBLEM", 79, 107], ["the risk factors", "PROBLEM", 112, 128], ["multivariate analysis", "TEST", 203, 224]]], ["Based on multivariate analyses, the frequency of Val105 was positively associated with the log-mortality (partial r = 0.316, p = 0.037) and log-prevalence of COVID-19 (partial r = 0.308, p = 0.042).ResultsIn next step, only countries with the gross national income (GNI) per capita (PPP international $) more than $15,000 were included in the analysis.", [["Val105", "GENE_OR_GENE_PRODUCT", 49, 55], ["COVID", "PROTEIN", 158, 163], ["multivariate analyses", "TEST", 9, 30], ["p", "TEST", 125, 126], ["COVID", "TEST", 158, 163], ["the analysis", "TEST", 339, 351]]], ["Table 3 summarizes the associations between the risk factors and the log-transformed of epidemiologic parameters of COVID-19 in the selected countries.", [["epidemiologic parameters", "TEST", 88, 112], ["COVID", "TEST", 116, 121]]], ["The results of multivariate analysis are summarized in Table 4 .", [["multivariate analysis", "TEST", 15, 36]]], ["In the selected countries, the frequency of Val105 was positively associated with the log-prevalence (partial r = 0.456, p = 0.009) and log-mortality of COVID-19 (partial r = 0.544, p = 0.001).DiscussionThe main findings of the present study are that the frequency of Val105 was positively associated with the logprevalence and log-mortality of COVID-19.", [["Val105", "GENE_OR_GENE_PRODUCT", 44, 50], ["Val105", "GENE_OR_GENE_PRODUCT", 268, 274], ["COVID", "TEST", 153, 158], ["p", "TEST", 182, 183], ["the present study", "TEST", 224, 241], ["COVID", "TEST", 345, 350]]], ["It means that countries with higher Val105 allelic frequency showed higher prevalence of COVID-19 and mortality due to COVID-19.", [["Val105", "GENE_OR_GENE_PRODUCT", 36, 42], ["Val105", "DNA", 36, 42], ["COVID-19", "DNA", 119, 127], ["higher Val105 allelic frequency", "PROBLEM", 29, 60], ["COVID", "TEST", 89, 94], ["COVID", "TEST", 119, 124]]], ["The present findings may explain, at least in part, some differences in COVID-19 mortality between East Asian and European populations by the Val105 allelic frequency.", [["Val105", "GENE_OR_GENE_PRODUCT", 142, 148], ["COVID", "TEST", 72, 77], ["may explain", "UNCERTAINTY", 21, 32]]], ["Numerous facts are indicated that GSTP1 plays an important role in lung function [5, [8] [9] [10] [11] 20] .", [["lung", "ANATOMY", 67, 71], ["GSTP1", "GENE_OR_GENE_PRODUCT", 34, 39], ["lung", "ORGAN", 67, 71], ["[8] [9] [10] [11] 20", "SIMPLE_CHEMICAL", 85, 105], ["GSTP1", "PROTEIN", 34, 39], ["lung function", "TEST", 67, 80], ["lung", "ANATOMY", 67, 71]]], ["GSTP1 has pleiotropic properties; it binds directly to c-Jun Nterminal kinases and acts as a negative regulator.", [["GSTP1", "GENE_OR_GENE_PRODUCT", 0, 5], ["c-Jun Nterminal kinases", "GENE_OR_GENE_PRODUCT", 55, 78], ["GSTP1", "PROTEIN", 0, 5], ["c-Jun Nterminal kinases", "PROTEIN", 55, 78], ["GSTP1", "PROBLEM", 0, 5], ["pleiotropic properties", "TREATMENT", 10, 32], ["pleiotropic properties", "OBSERVATION_MODIFIER", 10, 32]]], ["It also has a negative regulatory role in regulating tumor necrosis factor-alpha (TNF\u03b1)-induced MAPK signaling.", [["tumor", "DISEASE", 53, 58], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 53, 80], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 82, 86], ["MAPK", "GENE_OR_GENE_PRODUCT", 96, 100], ["tumor necrosis factor-alpha", "PROTEIN", 53, 80], ["TNF\u03b1", "PROTEIN", 82, 86], ["MAPK", "PROTEIN", 96, 100], ["regulating tumor necrosis factor", "PROBLEM", 42, 74], ["alpha (TNF\u03b1", "TEST", 75, 86], ["induced MAPK signaling", "PROBLEM", 88, 110], ["negative", "OBSERVATION", 14, 22], ["tumor", "OBSERVATION_MODIFIER", 53, 58], ["necrosis", "OBSERVATION", 59, 67]]], ["These functions are independent from its enzyme activity [21] .DiscussionIt is widely acknowledged that the mortality due to severe respiratory problems in patients infected by SARS-CoV-2 is high [22] .", [["respiratory", "ANATOMY", 132, 143], ["respiratory problems", "DISEASE", 132, 152], ["SARS", "DISEASE", 177, 181], ["patients", "ORGANISM", 156, 164], ["SARS-CoV-2", "ORGANISM", 177, 187], ["patients", "SPECIES", 156, 164], ["SARS-CoV", "SPECIES", 177, 185], ["its enzyme activity", "TEST", 37, 56], ["severe respiratory problems", "PROBLEM", 125, 152], ["CoV", "TEST", 182, 185], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["respiratory", "ANATOMY", 132, 143], ["problems", "OBSERVATION", 144, 152]]], ["On the other hand, COVID-19 is associated with oxidative stress [17, 18] .", [["COVID-19", "CHEMICAL", 19, 27], ["COVID-19", "DNA", 19, 27], ["COVID", "TEST", 19, 24], ["oxidative stress", "PROBLEM", 47, 63]]], ["It is suggested that COVID-19 mortality might be associated with oxidative stress and/or SARS-CoV-2-activated cytokine storm syndrome.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 89, 99], ["cytokine", "PROTEIN", 110, 118], ["COVID", "TEST", 21, 26], ["oxidative stress", "PROBLEM", 65, 81], ["SARS", "PROBLEM", 89, 93], ["CoV", "TEST", 94, 97], ["activated cytokine storm syndrome", "PROBLEM", 100, 133], ["cytokine storm syndrome", "OBSERVATION", 110, 133]]], ["Both of these phenomena might be interpreted with the pleiotropy properties of GSTP1.DiscussionIt is worth mentioning that the Val105 form compared to the other form has lower detoxification activity; therefore, COVID-19 patients, who are carriers of Val105, often experience severe oxidative stress compared to the Ile/Ile genotype.", [["Ile", "CHEMICAL", 316, 319], ["Ile", "CHEMICAL", 320, 323], ["GSTP1", "GENE_OR_GENE_PRODUCT", 79, 84], ["Val105", "GENE_OR_GENE_PRODUCT", 127, 133], ["COVID-19", "ORGANISM", 212, 220], ["patients", "ORGANISM", 221, 229], ["Val105", "GENE_OR_GENE_PRODUCT", 251, 257], ["GSTP1", "PROTEIN", 79, 84], ["Val105 form", "PROTEIN", 127, 138], ["patients", "SPECIES", 221, 229], ["severe oxidative stress", "PROBLEM", 276, 299], ["the Ile/Ile genotype", "TREATMENT", 312, 332], ["phenomena", "OBSERVATION", 14, 23]]], ["This may lead to severity of the disease and subsequently death due to COVID-19 in the carriers of Val105.DiscussionA literature review indicated that COVID-19 has affected more males than females, and also male gender significantly increases the case fatality [23, 24] .", [["death", "DISEASE", 58, 63], ["COVID-19", "CHEMICAL", 71, 79], ["COVID-19", "CHEMICAL", 151, 159], ["COVID-19", "CHEMICAL", 71, 79], ["Val105", "GENE_OR_GENE_PRODUCT", 99, 105], ["the disease", "PROBLEM", 29, 40], ["COVID", "TEST", 71, 76], ["COVID", "TEST", 151, 156], ["disease", "OBSERVATION", 33, 40]]], ["This difference, at least in part, may be explained by the sexual dimorphisms of GSTP1 enzyme activity.", [["GSTP1", "GENE_OR_GENE_PRODUCT", 81, 86], ["GSTP1 enzyme", "PROTEIN", 81, 93], ["GSTP1 enzyme activity", "PROBLEM", 81, 102], ["may be explained", "UNCERTAINTY", 35, 51]]], ["The enzyme activity is higher in females than males [25] .", [["The enzyme activity", "TEST", 0, 19], ["activity", "OBSERVATION_MODIFIER", 11, 19], ["higher", "OBSERVATION_MODIFIER", 23, 29]]], ["Several observational and experimental studies should be carried out to approve the present findings and the abovementioned hypotheses.ConclusionsThe present findings indicate that countries with Val105 higher allelic frequency of the rs1695 polymorphism showed higher prevalence and mortality of COVID-19.", [["Val105", "GENE_OR_GENE_PRODUCT", 196, 202], ["rs1695", "GENE_OR_GENE_PRODUCT", 235, 241], ["rs1695", "DNA", 235, 241], ["experimental studies", "TEST", 26, 46], ["Val105 higher allelic frequency", "PROBLEM", 196, 227], ["the rs1695 polymorphism", "TEST", 231, 254], ["COVID", "TEST", 297, 302]]]], "PMC2797517": [["BackgroundMany infectious diseases of public health importance exhibit predictable periodicity, with major increases in incidence during a specific season of the year [1].", [["infectious diseases", "DISEASE", 15, 34], ["predictable periodicity", "PROBLEM", 71, 94], ["Many", "OBSERVATION_MODIFIER", 10, 14], ["infectious", "OBSERVATION", 15, 25], ["major", "OBSERVATION_MODIFIER", 101, 106], ["increases", "OBSERVATION_MODIFIER", 107, 116]]], ["Despite this wealth of experiential evidence, the mechanisms underlying seasonality are poorly understood, especially diseases characterized by person-to-person transmission [1].BackgroundInvasive bacterial disease due to Streptococcus pneumoniae and other respiratory pathogens exhibits striking seasonality in its occurrence [3-7].", [["Invasive bacterial disease", "DISEASE", 188, 214], ["Streptococcus pneumoniae", "DISEASE", 222, 246], ["respiratory pathogens", "DISEASE", 257, 278], ["Streptococcus pneumoniae", "ORGANISM", 222, 246], ["person", "SPECIES", 144, 150], ["person", "SPECIES", 154, 160], ["Streptococcus pneumoniae", "SPECIES", 222, 246], ["Streptococcus pneumoniae", "SPECIES", 222, 246], ["diseases", "PROBLEM", 118, 126], ["BackgroundInvasive bacterial disease", "PROBLEM", 178, 214], ["Streptococcus pneumoniae", "PROBLEM", 222, 246], ["other respiratory pathogens", "PROBLEM", 251, 278], ["Invasive", "OBSERVATION_MODIFIER", 188, 196], ["bacterial disease", "OBSERVATION", 197, 214], ["Streptococcus pneumoniae", "OBSERVATION", 222, 246], ["respiratory pathogens", "OBSERVATION", 257, 278], ["striking", "OBSERVATION_MODIFIER", 288, 296], ["seasonality", "OBSERVATION_MODIFIER", 297, 308]]], ["Pneumococcal infections are a common cause of severe, community-acquired illnesses, including community-acquired pneumonia requiring hospitalization, bacteremia, and meningitis [8].", [["Pneumococcal infections", "DISEASE", 0, 23], ["pneumonia", "DISEASE", 113, 122], ["bacteremia", "DISEASE", 150, 160], ["meningitis", "DISEASE", 166, 176], ["Pneumococcal infections", "PROBLEM", 0, 23], ["acquired illnesses", "PROBLEM", 64, 82], ["community-acquired pneumonia", "PROBLEM", 94, 122], ["bacteremia", "PROBLEM", 150, 160], ["meningitis", "PROBLEM", 166, 176], ["infections", "OBSERVATION", 13, 23], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["pneumonia", "OBSERVATION", 113, 122], ["bacteremia", "OBSERVATION", 150, 160], ["meningitis", "OBSERVATION", 166, 176]]], ["While the introduction of antibiotics dramatically reduced the case fatality rate (CFR) for pneumococcal disease, the current CFR for bacteremic pneumococcal disease is still estimated at 5-10% in the United States, and may be twice as high among the elderly and in cases of meningitis [9,10].", [["pneumococcal disease", "DISEASE", 92, 112], ["bacteremic pneumococcal disease", "DISEASE", 134, 165], ["meningitis", "DISEASE", 275, 285], ["pneumococcal", "SPECIES", 92, 104], ["pneumococcal", "SPECIES", 145, 157], ["antibiotics", "TREATMENT", 26, 37], ["pneumococcal disease", "PROBLEM", 92, 112], ["bacteremic pneumococcal disease", "PROBLEM", 134, 165], ["meningitis", "PROBLEM", 275, 285], ["pneumococcal disease", "OBSERVATION", 92, 112], ["bacteremic", "OBSERVATION_MODIFIER", 134, 144], ["pneumococcal disease", "OBSERVATION", 145, 165], ["meningitis", "OBSERVATION", 275, 285]]], ["The emergence of antimicrobial resistance to beta-lactam agents, macrolides, and other antibiotic classes is an important clinical concern [11].", [["beta-lactam agents", "CHEMICAL", 45, 63], ["macrolides", "CHEMICAL", 65, 75], ["beta-lactam", "CHEMICAL", 45, 56], ["macrolides", "CHEMICAL", 65, 75], ["beta-lactam agents", "SIMPLE_CHEMICAL", 45, 63], ["macrolides", "SIMPLE_CHEMICAL", 65, 75], ["antimicrobial resistance", "TREATMENT", 17, 41], ["beta-lactam agents", "TREATMENT", 45, 63], ["macrolides", "TREATMENT", 65, 75], ["other antibiotic classes", "TREATMENT", 81, 105], ["antimicrobial resistance", "OBSERVATION", 17, 41]]], ["Although the introduction of conjugate pneumococcal vaccines has been associated with a reduction in disease incidence [12], the recent increase in invasive infection by non-vaccine serotypes [13], which may be highly resistant to commonly-used antimicrobials [14], suggests that this microorganism will persist in challenging both the medical and public health communities.BackgroundThe incidence of IPD peaks in the winter months, with annual periodicity [4,5], but the forces that drive this characteristic seasonality are unknown.", [["infection", "DISEASE", 157, 166], ["IPD", "DISEASE", 401, 404], ["pneumococcal", "ORGANISM", 39, 51], ["pneumococcal", "SPECIES", 39, 51], ["conjugate pneumococcal vaccines", "TREATMENT", 29, 60], ["a reduction in disease incidence", "PROBLEM", 86, 118], ["invasive infection", "PROBLEM", 148, 166], ["non-vaccine serotypes", "PROBLEM", 170, 191], ["antimicrobials", "TREATMENT", 245, 259], ["this microorganism", "PROBLEM", 280, 298], ["IPD peaks", "PROBLEM", 401, 410], ["annual periodicity", "PROBLEM", 438, 456], ["reduction", "OBSERVATION_MODIFIER", 88, 97], ["increase", "OBSERVATION_MODIFIER", 136, 144], ["invasive", "OBSERVATION_MODIFIER", 148, 156], ["infection", "OBSERVATION", 157, 166], ["IPD peaks", "OBSERVATION", 401, 410]]], ["Wintertime seasonality of communicable respiratory diseases are often assumed to be driven by seasonal changes in environmental conditions (e.g., diminished ultraviolet radiation (UV) exposure, decreased temperature) but such associations may be confounded by other seasonally varying factors, including population behaviours (e.g., clustering indoors), co-occurrence of other infections (e.g., influenza) [4], and frequency of laboratory testing [15].BackgroundA more thorough understanding of the effect of environmental factors on seasonal IPD incidence could offer significant insight into pathogenesis, improve disease forecasting, and help determine the likely direction of pneumococcal disease incidence in the face of global climate change [16].", [["respiratory", "ANATOMY", 39, 50], ["respiratory diseases", "DISEASE", 39, 59], ["infections", "DISEASE", 377, 387], ["influenza", "DISEASE", 395, 404], ["IPD", "DISEASE", 543, 546], ["pneumococcal disease", "DISEASE", 680, 700], ["pneumococcal", "SPECIES", 680, 692], ["communicable respiratory diseases", "PROBLEM", 26, 59], ["seasonal changes in environmental conditions", "PROBLEM", 94, 138], ["diminished ultraviolet radiation", "TREATMENT", 146, 178], ["decreased temperature", "PROBLEM", 194, 215], ["population behaviours", "PROBLEM", 304, 325], ["other infections (e.g., influenza)", "PROBLEM", 371, 405], ["laboratory testing", "TEST", 428, 446], ["environmental factors", "PROBLEM", 509, 530], ["seasonal IPD incidence", "TREATMENT", 534, 556], ["pneumococcal disease incidence", "PROBLEM", 680, 710], ["global climate change", "PROBLEM", 726, 747], ["respiratory diseases", "OBSERVATION", 39, 59], ["infections", "OBSERVATION", 377, 387], ["pneumococcal", "OBSERVATION_MODIFIER", 680, 692], ["disease", "OBSERVATION", 693, 700]]], ["Our objective was to investigate how environmental factors influence IPD occurrence in Philadelphia County.", [["IPD", "DISEASE", 69, 72]]], ["We used both traditional analytic methods (i.e., Poisson regression with seasonal smoothers) and a novel case-crossover method to examine the effects of acute weather fluctuations on IPD occurrence.", [["IPD", "DISEASE", 183, 186], ["acute weather fluctuations", "PROBLEM", 153, 179], ["IPD occurrence", "PROBLEM", 183, 197]]], ["Both methods reduce confounding by environmental, behavioural, and infectious influences that might otherwise distort the observed magnitude of environmental effects on disease risk.Environmental Exposure Data ::: MethodsMeteorological data including temperature, relative humidity, wind speed, atmospheric pressure, and precipitation for the period from 2002 to 2006 was obtained from the weather station at Philadelphia International Airport, located eight kilometres southwest of Philadelphia's city center [19].", [["infectious influences", "PROBLEM", 67, 88], ["disease risk", "PROBLEM", 169, 181], ["temperature", "TEST", 251, 262], ["atmospheric pressure", "TREATMENT", 295, 315], ["infectious", "OBSERVATION", 67, 77]]], ["Information pertaining to air quality in Philadelphia County during the years of interest-including concentrations of lead, ozone, sulphur oxides and particulate matter-was obtained from the Environmental Protection Agency [20].", [["ozone", "CHEMICAL", 124, 129], ["sulphur oxides", "CHEMICAL", 131, 145], ["ozone", "CHEMICAL", 124, 129], ["sulphur oxides", "CHEMICAL", 131, 145], ["lead", "SIMPLE_CHEMICAL", 118, 122], ["ozone", "SIMPLE_CHEMICAL", 124, 129], ["sulphur oxides", "SIMPLE_CHEMICAL", 131, 145], ["lead, ozone", "TREATMENT", 118, 129], ["sulphur oxides", "TREATMENT", 131, 145]]], ["Because daily readings were taken at various locations throughout the region, the arithmetic means of the air quality values were used as exposure variables.", [["the air quality values", "TEST", 102, 124], ["air quality", "OBSERVATION", 106, 117]]], ["UV index forecast estimates for Philadelphia during the same period were retrieved from the National Weather Service Climate Prediction Center [21].", [["Philadelphia", "PROBLEM", 32, 44]]], ["Clear-sky UV indices represent an integral of measured UV radiation levels weighted by the ability of the different UV wavelengths to cause skin erythema.", [["skin", "ANATOMY", 140, 144], ["skin erythema", "DISEASE", 140, 153], ["skin erythema", "PATHOLOGICAL_FORMATION", 140, 153], ["sky UV indices", "TEST", 6, 20], ["UV radiation levels", "TREATMENT", 55, 74], ["the different UV wavelengths", "TREATMENT", 102, 130], ["skin erythema", "PROBLEM", 140, 153], ["UV wavelengths", "OBSERVATION", 116, 130], ["skin", "ANATOMY", 140, 144], ["erythema", "OBSERVATION", 145, 153]]], ["The issued UV index is a similar measure, which accounts for the effect of clouds on radiation transmission; because of inconsistencies in cloud measurement during the study period, we used the clear-sky UV index as our exposure variable.Statistical Methods ::: MethodsRates of invasive pneumococcal disease were calculated using demographic data for Philadelphia County from the year 2000 US Census, as well as 2006 population estimates from the Bureau of the Census, with linear interpolation and extrapolation used to generate estimates for population by age and sex in other years [17].", [["pneumococcal disease", "DISEASE", 287, 307], ["pneumococcal", "SPECIES", 287, 299], ["The issued UV index", "TEST", 0, 19], ["radiation transmission", "TREATMENT", 85, 107], ["cloud measurement", "TEST", 139, 156], ["the study", "TEST", 164, 173], ["sky UV index", "TREATMENT", 200, 212], ["invasive pneumococcal disease", "PROBLEM", 278, 307], ["demographic data", "TEST", 330, 346], ["linear interpolation", "TREATMENT", 474, 494], ["UV index", "OBSERVATION", 11, 19], ["invasive", "OBSERVATION_MODIFIER", 278, 286], ["pneumococcal disease", "OBSERVATION", 287, 307]]], ["We evaluated the seasonality of disease occurrence through construction of periodograms and autocorrelograms [15,22] for weekly case counts.", [["disease occurrence", "PROBLEM", 32, 50], ["periodograms", "TEST", 75, 87], ["autocorrelograms", "TEST", 92, 108], ["weekly case counts", "TEST", 121, 139]]], ["As yearly periodicity was observed, we estimated seasonal and year-on-year trends in IPD occurrence using Poisson regression models that incorporated sine and cosine oscillators, with 52 week (annual) frequencies (i.e., incorporated fast Fourier transforms) [7,22].Statistical Methods ::: MethodsUsing these parameters, the expression for the expected number of case counts for a given week, E (Y) is given by:Statistical Methods ::: Methodswhere cases is an autoregressive model term reflecting the cumulative case count in the month prior to case occurrence, (i.e., cases = ).Statistical Methods ::: MethodsThe phase-shift of the composite waveform generated by combining sine and cosine components of the above equation can be approximated as the arctangent of \u03b22/\u03b23, and can be used to estimate the timing of peak disease incidence [22].", [["IPD", "DISEASE", 85, 88], ["\u03b22", "GENE_OR_GENE_PRODUCT", 764, 766], ["\u03b23", "GENE_OR_GENE_PRODUCT", 767, 769], ["\u03b22", "PROTEIN", 764, 766], ["\u03b23", "PROTEIN", 767, 769], ["IPD occurrence", "PROBLEM", 85, 99], ["Poisson regression models", "TREATMENT", 106, 131], ["Methods", "TREATMENT", 602, 609], ["the composite waveform", "TEST", 628, 650], ["peak disease incidence", "PROBLEM", 813, 835]]], ["We also included model terms that controlled for longer term trends in incidence of invasive pneumococcal disease, which may have reflected the initiation of surveillance, the introduction of public funding for conjugate pneumococcal vaccination [12], changes in medical diagnostic practices, or other long-term changes in real or apparent pneumococcal epidemiology.", [["pneumococcal disease", "DISEASE", 93, 113], ["pneumococcal", "SPECIES", 93, 105], ["pneumococcal", "SPECIES", 221, 233], ["pneumococcal", "SPECIES", 340, 352], ["invasive pneumococcal disease", "PROBLEM", 84, 113], ["surveillance", "TEST", 158, 170], ["public funding", "TREATMENT", 192, 206], ["conjugate pneumococcal vaccination", "TREATMENT", 211, 245], ["other long-term changes", "PROBLEM", 296, 319], ["invasive", "OBSERVATION_MODIFIER", 84, 92], ["pneumococcal disease", "OBSERVATION", 93, 113]]], ["As year-on-year trends in disease occurrence reflected a non-linear increase in disease risk, we used models that incorporated both linear and quadratic yearly terms.Statistical Methods ::: MethodsThe quadratic model term was statistically significant, but is difficult to interpret, thus we present our final Poisson model with separate linear yearly terms for the period from 2002 to 2003, and the period from 2004 to 2007 [23].", [["disease occurrence", "PROBLEM", 26, 44], ["a non-linear increase in disease risk", "PROBLEM", 55, 92], ["Methods", "TREATMENT", 190, 197], ["non-linear", "OBSERVATION_MODIFIER", 57, 67], ["increase", "OBSERVATION_MODIFIER", 68, 76], ["disease", "OBSERVATION", 80, 87], ["linear", "OBSERVATION_MODIFIER", 132, 138], ["significant", "OBSERVATION_MODIFIER", 240, 251]]], ["We evaluated the impact of environmental exposures on weekly IPD incidence by incorporating exposure variables into Poisson models both individually, and using a backwards elimination algorithm (with variables retained for P < 0.2 [24]).Statistical Methods ::: MethodsTo explore the possibility of effect modification by subject characteristics, we evaluated stratum-specific estimates of effect for age categories and genders.", [["IPD", "DISEASE", 61, 64], ["a backwards elimination algorithm", "TEST", 160, 193], ["Methods", "TREATMENT", 261, 268]]], ["Heterogeneity of effects across strata was assessed using meta-analytic techniques, including both graphical inspection and calculation of meta-analytic Q-statistics [25].", [["meta-analytic techniques", "TEST", 58, 82], ["both graphical inspection", "TEST", 94, 119], ["meta-analytic Q-statistics", "TEST", 139, 165]]], ["We further explored the sources of between-stratum heterogeneity through construction of meta-regression models that estimate the contribution of group-level covariates to between-stratum variation in effects [25].Statistical Methods ::: MethodsWe used a case-crossover approach to evaluate acute (i.e., daily) associations between environmental exposures and IPD occurrence.", [["IPD", "DISEASE", 360, 363], ["meta-regression models", "TREATMENT", 89, 111], ["group-level covariates", "TREATMENT", 146, 168], ["a case-crossover approach", "TREATMENT", 253, 278], ["IPD occurrence", "PROBLEM", 360, 374]]], ["We used a time-stratified 2:1 matched case-crossover design in which hazard periods were defined as the reported date of IPD onset from Philadelphia County public health.", [["IPD", "DISEASE", 121, 124], ["IPD onset", "PROBLEM", 121, 130]]], ["Beginning on January 1, 2002 the person-time at risk was divided into three-week time strata.", [["person", "SPECIES", 33, 39]]], ["Random directionality of control selection was used in order to avoid biases that can occur with unidirectional or uniform bidirectional control selection [26].", [["control selection", "TREATMENT", 25, 42]]], ["The 1-3 day incubation period of S. pneumoniae was used to estimate the lag days between acute environmental occurrence and case onset, or plausible effect period [28].", [["S. pneumoniae", "ORGANISM", 33, 46], ["S. pneumoniae", "SPECIES", 33, 46], ["S. pneumoniae", "SPECIES", 33, 46], ["S. pneumoniae", "PROBLEM", 33, 46], ["pneumoniae", "OBSERVATION", 36, 46]]], ["We also evaluated effects during the period immediately preceding incubation (i.e., 4-6 day lags) to evaluate the possibility that environmental conditions might affect risk via enhanced transmission of S. pneumoniae.", [["S. pneumoniae", "ORGANISM", 203, 216], ["S. pneumoniae", "SPECIES", 203, 216], ["S. pneumoniae", "SPECIES", 203, 216], ["environmental conditions", "PROBLEM", 131, 155], ["S. pneumoniae", "PROBLEM", 203, 216], ["pneumoniae", "OBSERVATION", 206, 216]]], ["Analyses were performed using SAS version 8.01 (SAS Institute, Cary, NC) and Stata version 9.1 (Stata Corporation, College Station, TX).Descriptive Epidemiology ::: ResultsBetween January 1, 2002 and April 30, 2007 there were 602 reported cases of IPD in Philadelphia County, for a crude annual incidence of 6.84 cases per 100,000 [95% CI 6.32 to 7.42].", [["IPD", "DISEASE", 248, 251], ["Analyses", "TEST", 0, 8], ["SAS version", "TEST", 30, 41], ["NC", "TREATMENT", 69, 71], ["Stata version", "TEST", 77, 90], ["TX", "TREATMENT", 132, 134], ["IPD", "PROBLEM", 248, 251], ["CI", "TEST", 336, 338]]], ["Incidence of IPD was highest at the age extremes, with a slight male:female predominance (incidence rate ratio (IRR) 1.16, 95% CI 0.99 to 1.36); the case fatality rate was approximately 10% (Table 1).Descriptive Epidemiology ::: ResultsBoth spectral decomposition and construction of autocorrelograms identified annual periodicity of infection, with peak incidence in mid-February (phase = 6 weeks) (Figures 1 and 2).", [["IPD", "DISEASE", 13, 16], ["infection", "DISEASE", 334, 343], ["IPD", "PROBLEM", 13, 16], ["incidence rate ratio", "TEST", 90, 110], ["IRR", "TEST", 112, 115], ["CI", "TEST", 127, 129], ["the case fatality rate", "TEST", 145, 167], ["Both spectral decomposition", "TEST", 236, 263], ["construction of autocorrelograms", "TEST", 268, 300], ["infection", "PROBLEM", 334, 343], ["Figures", "TEST", 400, 407], ["slight", "OBSERVATION_MODIFIER", 57, 63], ["infection", "OBSERVATION", 334, 343]]], ["Strong statistical evidence for seasonal oscillation was obtained from Poisson regression models (P for seasonal oscillation < 0.001).", [["seasonal oscillation", "PROBLEM", 32, 52], ["seasonal oscillation", "TEST", 104, 124], ["evidence for", "UNCERTAINTY", 19, 31], ["seasonal oscillation", "OBSERVATION", 32, 52]]], ["A significant annual increase in incidence was seen throughout the study period, though this was more marked prior to 2004 (IRR per year 1.34, 95% CI 1.08 to 1.66) than subsequently (IRR 1.22, per year 95% 1.16 to 1.34) (Figure 3).", [["A significant annual increase", "PROBLEM", 0, 29], ["the study", "TEST", 63, 72], ["CI", "TEST", 147, 149], ["IRR", "TEST", 183, 186], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["annual", "OBSERVATION_MODIFIER", 14, 20], ["increase", "OBSERVATION_MODIFIER", 21, 29]]], ["We found no clear trends in the incidence of IPD or case-fatality in individual age groups, and no significant heterogeneity was detected between age groups with respect to year-on-year trends in incidence or case-fatality (see Additional File 1 and Additional File 2).Weekly Environmental Effects ::: ResultsIn univariable models the risk of IPD increased with several seasonally oscillating environmental exposures, including temperature, humidity, pressure, air pollution, and UV radiation, as shown in Table 2.", [["IPD", "DISEASE", 45, 48], ["IPD", "DISEASE", 343, 346], ["UV", "CHEMICAL", 480, 482], ["IPD", "PROBLEM", 45, 48], ["significant heterogeneity", "PROBLEM", 99, 124], ["IPD", "PROBLEM", 343, 346], ["temperature, humidity", "TREATMENT", 428, 449], ["pressure, air pollution", "TREATMENT", 451, 474], ["UV radiation", "TREATMENT", 480, 492], ["no", "UNCERTAINTY", 9, 11], ["clear", "OBSERVATION_MODIFIER", 12, 17], ["trends", "OBSERVATION", 18, 24], ["no", "UNCERTAINTY", 96, 98], ["significant", "OBSERVATION_MODIFIER", 99, 110], ["heterogeneity", "OBSERVATION", 111, 124], ["IPD", "OBSERVATION_MODIFIER", 343, 346], ["increased", "OBSERVATION_MODIFIER", 347, 356], ["pressure", "OBSERVATION_MODIFIER", 451, 459], ["air pollution", "OBSERVATION", 461, 474]]], ["Risk of IPD increased with average weekly barometric pressure, sulphur and nitrous oxides, and decreased with average weekly temperature, relative humidity, and UV index.", [["IPD", "DISEASE", 8, 11], ["sulphur", "CHEMICAL", 63, 70], ["nitrous oxides", "CHEMICAL", 75, 89], ["sulphur", "CHEMICAL", 63, 70], ["nitrous oxides", "CHEMICAL", 75, 89], ["sulphur", "SIMPLE_CHEMICAL", 63, 70], ["nitrous oxides", "SIMPLE_CHEMICAL", 75, 89], ["IPD", "PROBLEM", 8, 11], ["average weekly barometric pressure", "TREATMENT", 27, 61], ["sulphur", "TREATMENT", 63, 70], ["nitrous oxides", "TREATMENT", 75, 89], ["UV index", "TEST", 161, 169], ["IPD", "OBSERVATION_MODIFIER", 8, 11], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["UV index", "OBSERVATION", 161, 169]]], ["However, after controlling for seasonal oscillation and longer term temporal trends, only cooling-degree days (i.e., average number of degrees above 18\u00b0C), maximum temperature, and clear-sky UV index were independently associated with case occurrencein a final multivariable model (Table 2).", [["seasonal oscillation", "PROBLEM", 31, 51], ["longer term temporal trends", "PROBLEM", 56, 83], ["maximum temperature", "TEST", 156, 175], ["sky UV index", "TEST", 187, 199]]], ["Risk increased with increasing maximal temperature, but decreased with cooling degree days, indicating a threshold of 18\u00b0C above which the qualitative effect of temperature changed.Weekly Environmental Effects ::: ResultsThere was significant heterogeneity in the effect of clear-sky UV index in individuals aged less than 15 years (IRR 0.26, 95% CI 0.11 to 0.61) as compared to older individuals (IRR 0.81, 95% CI 0.64 to 1.03), (Q-statistic 6.31 on 1 d.f., P = 0.012).", [["C", "GENE_OR_GENE_PRODUCT", 121, 122], ["increasing maximal temperature", "PROBLEM", 20, 50], ["significant heterogeneity", "PROBLEM", 231, 256], ["sky UV index", "TEST", 280, 292], ["IRR", "TEST", 333, 336], ["CI", "TEST", 347, 349], ["IRR", "TEST", 398, 401], ["CI", "TEST", 412, 414], ["Q-statistic", "TEST", 431, 442], ["P", "TEST", 459, 460], ["increased", "OBSERVATION_MODIFIER", 5, 14], ["increasing", "OBSERVATION_MODIFIER", 20, 30], ["maximal temperature", "OBSERVATION_MODIFIER", 31, 50], ["significant", "OBSERVATION_MODIFIER", 231, 242], ["heterogeneity", "OBSERVATION", 243, 256], ["clear", "OBSERVATION", 274, 279], ["sky UV index", "OBSERVATION", 280, 292]]], ["No heterogeneity in UV effects was found when evaluated in individuals aged over 64 as compared to younger individuals (Q-statistic 0.48 on 1 d.f., P = 0.523), or when evaluated in males as compared to females (Q-statistic 1.68 on 1 d.f., P for heterogeneity = 0.194).", [["heterogeneity in UV effects", "PROBLEM", 3, 30], ["P", "TEST", 148, 149], ["heterogeneity", "TEST", 245, 258], ["heterogeneity", "OBSERVATION", 3, 16], ["UV effects", "OBSERVATION", 20, 30]]], ["Meta-regression models constructed using stratum-specific estimates of effect for age groups, by 10-year age increments, identified a log-linear trend in the effect of UV radiation on disease risk by age stratum, with strongest effects in youngest strata, and effects diminishing with increasing age (change in natural logarithm of IRR = 0.13 per decade, 95% CI 0.04 to 0.23, P = 0.007) (Figure 4).Acute Environmental Effects ::: ResultsEvaluating associations between environmental and meteorological exposures and IPD risk using a case-crossover approach, we identified an inverse association between ambient levels of sulphur oxides and disease risk during the likely incubation period (Table 3).", [["UV", "CHEMICAL", 168, 170], ["IPD", "DISEASE", 516, 519], ["sulphur oxides", "CHEMICAL", 621, 635], ["sulphur oxides", "CHEMICAL", 621, 635], ["sulphur oxides", "SIMPLE_CHEMICAL", 621, 635], ["Meta-regression models", "TEST", 0, 22], ["UV radiation", "TREATMENT", 168, 180], ["IRR", "TEST", 332, 335], ["CI", "TEST", 359, 361], ["IPD risk", "PROBLEM", 516, 524], ["a case-crossover approach", "TREATMENT", 531, 556], ["sulphur oxides", "TREATMENT", 621, 635], ["disease risk", "PROBLEM", 640, 652], ["UV radiation", "OBSERVATION", 168, 180], ["diminishing", "OBSERVATION_MODIFIER", 268, 279], ["Environmental Effects", "OBSERVATION", 404, 425], ["sulphur oxides", "OBSERVATION", 621, 635]]], ["No other significant associations between environmental exposures and risk were identified either during the incubation period, or in the period immediately prior to incubation.", [["significant", "OBSERVATION_MODIFIER", 9, 20]]], ["In particular, occurrence of IPD was not affected by daily changes in clear-sky UV index, temperature or cooling-degree days, in contrast to associations on longer time scales described above.DiscussionNotwithstanding the existence of vaccination and effective antibiotic therapy, invasive pneumococcal disease remains an important source of population morbidity and mortality.", [["IPD", "DISEASE", 29, 32], ["pneumococcal disease", "DISEASE", 290, 310], ["pneumococcal", "SPECIES", 290, 302], ["IPD", "PROBLEM", 29, 32], ["sky UV index", "TEST", 76, 88], ["vaccination", "TREATMENT", 235, 246], ["effective antibiotic therapy", "TREATMENT", 251, 279], ["invasive pneumococcal disease", "PROBLEM", 281, 310], ["population morbidity", "PROBLEM", 342, 362], ["IPD", "OBSERVATION", 29, 32]]], ["The seasonality of IPD is well recognized, but poorly understood.", [["IPD", "DISEASE", 19, 22], ["IPD", "PROBLEM", 19, 22]]], ["Epidemiological mechanisms invoked to explain this pattern have included co-occurrence of other infectious diseases [4], wintertime social gatherings [5], and seasonal oscillation in immune function [29].", [["infectious diseases", "DISEASE", 96, 115], ["Epidemiological mechanisms", "PROBLEM", 0, 26], ["other infectious diseases", "PROBLEM", 90, 115]]], ["However, concurrent seasonal changes in a variety of environmental, behavioural, and epidemiogical exposures make identification of causal associations particularly challenging [30].", [["concurrent seasonal changes", "PROBLEM", 9, 36], ["seasonal changes", "OBSERVATION", 20, 36]]], ["We attempted to address this challenge by using analytic approaches that should control for seasonal confounders, known and unknown, at different time scales.", [["this challenge", "TREATMENT", 24, 38], ["analytic approaches", "TREATMENT", 48, 67], ["seasonal confounders", "PROBLEM", 92, 112]]], ["At a weekly time scale we found increases in UV radiation to be most strongly associated with decreased numbers of invasive pneumococcal disease cases, though average temperatures also appeared to influence disease risk.", [["UV", "CHEMICAL", 45, 47], ["pneumococcal disease", "DISEASE", 124, 144], ["pneumococcal", "SPECIES", 124, 136], ["UV radiation", "TREATMENT", 45, 57], ["invasive pneumococcal disease cases", "PROBLEM", 115, 150], ["average temperatures", "PROBLEM", 159, 179], ["influence disease risk", "PROBLEM", 197, 219], ["increases", "OBSERVATION_MODIFIER", 32, 41], ["UV radiation", "OBSERVATION", 45, 57], ["invasive", "OBSERVATION_MODIFIER", 115, 123], ["pneumococcal disease", "OBSERVATION", 124, 144]]], ["At short time scales, fluctuations in ambient air quality, as manifested by differences in concentrations of sulphur oxides, were associated with changes in risk.", [["sulphur oxides", "CHEMICAL", 109, 123], ["sulphur oxides", "CHEMICAL", 109, 123], ["sulphur oxides", "SIMPLE_CHEMICAL", 109, 123], ["fluctuations in ambient air quality", "PROBLEM", 22, 57], ["sulphur oxides", "TREATMENT", 109, 123], ["fluctuations", "OBSERVATION_MODIFIER", 22, 34], ["ambient", "OBSERVATION_MODIFIER", 38, 45], ["air quality", "OBSERVATION", 46, 57], ["sulphur oxides", "OBSERVATION", 109, 123]]], ["The direction of this association was at variance with existing models relating air pollution to pneumonia occurrence [3,31,32].DiscussionThe casual (as opposed to causal) association between low UV radiation in the winter and surges in respiratory disease has been noted previously [33], and has been proposed as an important driver of influenza seasonality, but has not to our knowledge been evaluated in a way that accounts for coincident seasonal changes in other seasonally oscillatory factors.", [["respiratory", "ANATOMY", 237, 248], ["pneumonia", "DISEASE", 97, 106], ["UV", "CHEMICAL", 196, 198], ["respiratory disease", "DISEASE", 237, 256], ["seasonally oscillatory factors", "PROTEIN", 468, 498], ["pneumonia occurrence", "PROBLEM", 97, 117], ["low UV radiation", "TREATMENT", 192, 208], ["respiratory disease", "PROBLEM", 237, 256], ["influenza seasonality", "PROBLEM", 337, 358], ["seasonal changes in other seasonally oscillatory factors", "PROBLEM", 442, 498], ["air pollution", "OBSERVATION", 80, 93], ["pneumonia", "OBSERVATION", 97, 106], ["respiratory disease", "OBSERVATION", 237, 256], ["influenza", "OBSERVATION", 337, 346]]], ["The degree to which such seasonal oscillation can result in \"just so\" stories that lead to misattribution of causation to non-specific seasonal exposures is highlighted in the univariable analyses we conducted without including seasonal oscillators.", [["seasonal oscillation", "PROBLEM", 25, 45], ["non-specific seasonal exposures", "PROBLEM", 122, 153], ["the univariable analyses", "TEST", 172, 196], ["seasonal oscillators", "TREATMENT", 228, 248], ["degree", "OBSERVATION_MODIFIER", 4, 10]]], ["In these models, a variety of environmental conditions, including weather variables and air quality indices, were strongly associated with IPD risk.", [["IPD", "DISEASE", 139, 142], ["air quality indices", "TEST", 88, 107], ["IPD risk", "PROBLEM", 139, 147]]], ["However, after controlling for non-specific seasonality, only UV radiation (and, more weakly, temperature) were associated with disease risk; indeed, the apparent protective effect of UV radiation was actually strengthened after controlling for seasonal oscillation.", [["UV", "CHEMICAL", 62, 64], ["UV", "CHEMICAL", 184, 186], ["non-specific seasonality", "PROBLEM", 31, 55], ["UV radiation", "TREATMENT", 62, 74], ["disease risk", "PROBLEM", 128, 140], ["UV radiation", "TREATMENT", 184, 196], ["seasonal oscillation", "PROBLEM", 245, 265]]], ["The interpretation of such a model is that increases in UV radiation reduce IPD risk, even after accounting for the fact that IPD risk is maximal during low-UV periods of the year.DiscussionAn important consideration is whether changes in UV radiation, operating at a weekly time scale, constitute a biologically plausible mechanism that explains seasonal oscillation in pneumococcal disease risk.", [["UV", "CHEMICAL", 56, 58], ["IPD", "DISEASE", 76, 79], ["IPD", "DISEASE", 126, 129], ["pneumococcal disease", "DISEASE", 371, 391], ["pneumococcal", "SPECIES", 371, 383], ["UV radiation", "TREATMENT", 56, 68], ["IPD risk", "PROBLEM", 76, 84], ["IPD risk", "PROBLEM", 126, 134], ["UV radiation", "TREATMENT", 239, 251], ["a biologically plausible mechanism", "PROBLEM", 298, 332], ["seasonal oscillation", "PROBLEM", 347, 367], ["pneumococcal disease risk", "PROBLEM", 371, 396], ["increases", "OBSERVATION_MODIFIER", 43, 52], ["UV radiation", "OBSERVATION", 56, 68], ["pneumococcal disease", "OBSERVATION", 371, 391]]], ["Modulation of risk may occur through direct effects of UV radiation on host immune function: Dowell reviewed a variety of immunological changes associated with diminished UV radiation exposure in experimental settings, and noted that in granulocyte and monocyte function were reduced during periods of short light exposure [33].", [["granulocyte", "ANATOMY", 237, 248], ["monocyte", "ANATOMY", 253, 261], ["UV", "CHEMICAL", 55, 57], ["UV", "CHEMICAL", 171, 173], ["granulocyte", "CELL", 237, 248], ["monocyte", "CELL", 253, 261], ["UV radiation", "TREATMENT", 55, 67], ["immunological changes", "PROBLEM", 122, 143], ["diminished UV radiation exposure", "TREATMENT", 160, 192], ["granulocyte", "TEST", 237, 248], ["monocyte function", "TEST", 253, 270], ["short light exposure", "PROBLEM", 302, 322], ["diminished", "OBSERVATION_MODIFIER", 160, 170], ["UV radiation exposure", "OBSERVATION", 171, 192], ["granulocyte", "ANATOMY", 237, 248], ["monocyte function", "OBSERVATION", 253, 270], ["short light", "OBSERVATION_MODIFIER", 302, 313]]], ["UV radiation also influences the production of 1,25-(OH)2-vitamin D, which has important immunomodulatory functions [34].", [["UV", "CHEMICAL", 0, 2], ["1,25-(OH)2-vitamin D", "CHEMICAL", 47, 67], ["1,25-(OH)2-vitamin D", "CHEMICAL", 47, 67], ["1,25-(OH)2-vitamin D", "SIMPLE_CHEMICAL", 47, 67], ["UV radiation", "TREATMENT", 0, 12], ["1,25-(OH)", "TREATMENT", 47, 56], ["vitamin D", "TREATMENT", 58, 67]]], ["Namely, enhanced maturation of macrophages, macrophage secretion of bactericidal substances such as lysozomal enzyme phosphatase and hydrogen peroxide [33,35], and secretion of antimicrobial peptides (including cathelicidins and defensins) by both immune cells, and respiratory tract epithelium [36].", [["macrophages", "ANATOMY", 31, 42], ["macrophage", "ANATOMY", 44, 54], ["immune cells", "ANATOMY", 248, 260], ["respiratory tract epithelium", "ANATOMY", 266, 294], ["hydrogen peroxide", "CHEMICAL", 133, 150], ["hydrogen peroxide", "CHEMICAL", 133, 150], ["macrophages", "CELL", 31, 42], ["macrophage", "CELL", 44, 54], ["lysozomal enzyme phosphatase", "GENE_OR_GENE_PRODUCT", 100, 128], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 133, 150], ["33,35", "SIMPLE_CHEMICAL", 152, 157], ["cathelicidins", "GENE_OR_GENE_PRODUCT", 211, 224], ["defensins", "GENE_OR_GENE_PRODUCT", 229, 238], ["immune cells", "CELL", 248, 260], ["tract epithelium", "TISSUE", 278, 294], ["macrophages", "CELL_TYPE", 31, 42], ["lysozomal enzyme phosphatase", "PROTEIN", 100, 128], ["cathelicidins", "PROTEIN", 211, 224], ["defensins", "PROTEIN", 229, 238], ["immune cells", "CELL_TYPE", 248, 260], ["macrophages", "PROBLEM", 31, 42], ["bactericidal substances", "TREATMENT", 68, 91], ["lysozomal enzyme phosphatase", "TEST", 100, 128], ["hydrogen peroxide", "TEST", 133, 150], ["antimicrobial peptides", "TREATMENT", 177, 199], ["cathelicidins and defensins", "TREATMENT", 211, 238], ["respiratory tract epithelium", "PROBLEM", 266, 294], ["macrophages", "OBSERVATION", 31, 42], ["antimicrobial peptides", "OBSERVATION", 177, 199], ["immune cells", "OBSERVATION", 248, 260], ["respiratory tract", "ANATOMY", 266, 283]]], ["Vitamin D deficiency is associated with a marked increase in the risk of pneumonia [37], and most human vitamin D is acquired via sun exposure.", [["Vitamin D", "CHEMICAL", 0, 9], ["pneumonia", "DISEASE", 73, 82], ["vitamin D", "CHEMICAL", 104, 113], ["Vitamin D", "CHEMICAL", 0, 9], ["vitamin D", "CHEMICAL", 104, 113], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["human", "ORGANISM", 98, 103], ["vitamin D", "SIMPLE_CHEMICAL", 104, 113], ["sun", "ORGANISM_SUBDIVISION", 130, 133], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["Vitamin D deficiency", "PROBLEM", 0, 20], ["a marked increase", "PROBLEM", 40, 57], ["pneumonia", "PROBLEM", 73, 82], ["most human vitamin D", "TREATMENT", 93, 113], ["deficiency", "OBSERVATION", 10, 20], ["marked", "OBSERVATION_MODIFIER", 42, 48], ["increase", "OBSERVATION_MODIFIER", 49, 57], ["pneumonia", "OBSERVATION", 73, 82]]], ["Thus, extended periods of low UV light could result in an increased susceptibility to S. pneumoniae infection resulting from a lack of vitamin D production, though the week-to-week fluctuations in risk described in this paper may be too rapid to represent a vitamin D effect.DiscussionAn alternative mechanism of action of UV radiation in reducing IPD risk could be direct effects of radiation on pathogen survival.", [["S. pneumoniae infection", "DISEASE", 86, 109], ["vitamin D", "CHEMICAL", 135, 144], ["vitamin D", "CHEMICAL", 258, 267], ["UV", "CHEMICAL", 323, 325], ["IPD", "DISEASE", 348, 351], ["vitamin D", "CHEMICAL", 135, 144], ["vitamin D", "CHEMICAL", 258, 267], ["S. pneumoniae", "ORGANISM", 86, 99], ["vitamin D", "SIMPLE_CHEMICAL", 135, 144], ["vitamin D", "SIMPLE_CHEMICAL", 258, 267], ["S. pneumoniae", "SPECIES", 86, 99], ["S. pneumoniae", "SPECIES", 86, 99], ["low UV light", "PROBLEM", 26, 38], ["an increased susceptibility", "PROBLEM", 55, 82], ["S. pneumoniae infection", "PROBLEM", 86, 109], ["vitamin D production", "PROBLEM", 135, 155], ["a vitamin D effect", "TREATMENT", 256, 274], ["UV radiation", "TREATMENT", 323, 335], ["reducing IPD risk", "TREATMENT", 339, 356], ["pathogen survival", "TREATMENT", 397, 414], ["low UV", "OBSERVATION_MODIFIER", 26, 32], ["increased", "OBSERVATION_MODIFIER", 58, 67], ["pneumoniae", "OBSERVATION_MODIFIER", 89, 99], ["infection", "OBSERVATION", 100, 109]]], ["Many bacterial respiratory pathogens, including pneumococcus, are transmitted in respiratory secretions over short distances (i.e., via \"large droplet transmission\"), and thus encounter the physical environment directly during transmission events.", [["respiratory secretions", "ANATOMY", 81, 103], ["respiratory pathogens", "DISEASE", 15, 36], ["Many bacterial respiratory pathogens", "PROBLEM", 0, 36], ["pneumococcus", "PROBLEM", 48, 60], ["transmitted in respiratory secretions", "PROBLEM", 66, 103], ["bacterial", "OBSERVATION_MODIFIER", 5, 14], ["respiratory pathogens", "OBSERVATION", 15, 36], ["pneumococcus", "OBSERVATION", 48, 60], ["respiratory secretions", "OBSERVATION", 81, 103], ["large", "OBSERVATION_MODIFIER", 137, 142], ["droplet", "OBSERVATION", 143, 150]]], ["The bactericidal effects of UV-B radiation have been well known for decades; such radiation inactivates bacteria by causing harmful genetic mutations through creation of pyrimidine dimers [38].", [["UV-B", "CHEMICAL", 28, 32], ["pyrimidine", "CHEMICAL", 170, 180], ["pyrimidine", "CHEMICAL", 170, 180], ["pyrimidine dimers", "SIMPLE_CHEMICAL", 170, 187], ["UV-B radiation", "TREATMENT", 28, 42], ["such radiation inactivates bacteria", "PROBLEM", 77, 112], ["harmful genetic mutations", "PROBLEM", 124, 149], ["creation of pyrimidine dimers", "TREATMENT", 158, 187], ["bactericidal", "OBSERVATION_MODIFIER", 4, 16]]], ["A model of UV effect via diminished transmissibility, rather than decreased host susceptibility, is supported by our finding that UV effect is strongest in the youngest individuals in the population (i.e., toddlers), where disease risk is likely to be driven by mobility, contact with peers, prolonged carriage and carelessness with respiratory secretions.", [["respiratory secretions", "ANATOMY", 333, 355], ["carelessness", "DISEASE", 315, 327], ["UV effect", "PROBLEM", 11, 20], ["diminished transmissibility", "PROBLEM", 25, 52], ["decreased host susceptibility", "PROBLEM", 66, 95], ["respiratory secretions", "PROBLEM", 333, 355], ["UV effect", "OBSERVATION", 11, 20], ["diminished", "OBSERVATION_MODIFIER", 25, 35], ["transmissibility", "OBSERVATION", 36, 52], ["host susceptibility", "OBSERVATION", 76, 95], ["likely to be", "UNCERTAINTY", 239, 251]]], ["We found very little protective effect against IPD in oldest individuals, whose risk may be more strongly linked to immune senescence than to high rates of contact with infectious contemporaries [39,40].DiscussionAn unexpected finding in our case-crossover analysis was the identification of increased levels of ambient sulphur oxides with diminished risk of IPD.", [["IPD", "DISEASE", 47, 50], ["sulphur oxides", "CHEMICAL", 320, 334], ["IPD", "DISEASE", 359, 362], ["sulphur oxides", "CHEMICAL", 320, 334], ["sulphur oxides", "SIMPLE_CHEMICAL", 320, 334], ["IPD", "PROBLEM", 47, 50], ["immune senescence", "PROBLEM", 116, 133], ["ambient sulphur oxides", "TREATMENT", 312, 334], ["IPD", "PROBLEM", 359, 362], ["very", "OBSERVATION_MODIFIER", 9, 13], ["little protective", "OBSERVATION_MODIFIER", 14, 31], ["sulphur oxides", "OBSERVATION", 320, 334]]], ["This may represent a chance association, due to the established association between sulphur dioxide and adverse respiratory outcomes [32], as well as the previously described correlation between ambient sulphur dioxide and pneumonia risk [3].", [["respiratory", "ANATOMY", 112, 123], ["sulphur dioxide", "CHEMICAL", 84, 99], ["sulphur dioxide", "CHEMICAL", 203, 218], ["pneumonia", "DISEASE", 223, 232], ["sulphur dioxide", "CHEMICAL", 84, 99], ["sulphur dioxide", "CHEMICAL", 203, 218], ["sulphur dioxide", "SIMPLE_CHEMICAL", 84, 99], ["sulphur dioxide", "SIMPLE_CHEMICAL", 203, 218], ["sulphur dioxide", "TREATMENT", 84, 99], ["adverse respiratory outcomes", "PROBLEM", 104, 132], ["ambient sulphur dioxide", "TREATMENT", 195, 218], ["pneumonia risk", "PROBLEM", 223, 237], ["may represent", "UNCERTAINTY", 5, 18], ["sulphur dioxide", "OBSERVATION", 203, 218], ["pneumonia", "OBSERVATION", 223, 232]]], ["Nonetheless, this association may warrant further exploration; for example, ambient air pollutants might have adverse effects on respiratory tract pathogens as well as hosts.DiscussionOther findings in this study are also worthy of comment; in Philadelphia, the wintertime peak in pneumococcal incidence occurred about six weeks later than previously been described in U.S. adults [5].", [["respiratory tract", "ANATOMY", 129, 146], ["respiratory tract pathogens", "DISEASE", 129, 156], ["tract", "ORGANISM_SUBDIVISION", 141, 146], ["pneumococcal", "ORGANISM", 281, 293], ["pneumococcal", "SPECIES", 281, 293], ["further exploration", "TEST", 42, 61], ["ambient air pollutants", "PROBLEM", 76, 98], ["respiratory tract pathogens", "PROBLEM", 129, 156], ["this study", "TEST", 202, 212], ["pneumococcal incidence", "PROBLEM", 281, 303], ["respiratory tract", "ANATOMY", 129, 146], ["pneumococcal", "OBSERVATION_MODIFIER", 281, 293]]], ["In addition, a gradual increase in cases was observed during the 5-year study period.", [["a gradual increase in cases", "PROBLEM", 13, 40], ["gradual", "OBSERVATION_MODIFIER", 15, 22], ["increase", "OBSERVATION_MODIFIER", 23, 31]]], ["We suspect that this increase is less likely to represent a true surge in disease rates, which have actually been falling in the U.S. with the introduction of 7-valent conjugate pneumococcal vaccine [41]; rather, we suspect that this increase, which is more attenuated after 2003, represents the gradual increase in reporting that commonly follows implementation of new infectious disease reporting requirements [42].DiscussionLike any observational study, ours has several limitations.", [["7-valent conjugate", "SIMPLE_CHEMICAL", 159, 177], ["pneumococcal", "ORGANISM", 178, 190], ["pneumococcal", "SPECIES", 178, 190], ["a true surge in disease rates", "PROBLEM", 58, 87], ["7-valent conjugate pneumococcal vaccine", "TREATMENT", 159, 198], ["any observational study", "TEST", 432, 455], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["less likely to represent", "UNCERTAINTY", 33, 57], ["true", "OBSERVATION_MODIFIER", 60, 64], ["surge", "OBSERVATION", 65, 70], ["gradual", "OBSERVATION_MODIFIER", 296, 303], ["increase", "OBSERVATION_MODIFIER", 304, 312], ["new", "OBSERVATION_MODIFIER", 366, 369], ["infectious", "OBSERVATION", 370, 380]]], ["First among these is our heavy reliance on public health surveillance data which is known to suffer from under-reporting of notifiable infectious diseases [43].", [["infectious diseases", "DISEASE", 135, 154], ["surveillance data", "TEST", 57, 74], ["notifiable infectious diseases", "PROBLEM", 124, 154]]], ["Thus our data set may be incomplete, consisting of only a subset of the cases of IPD in Philadelphia during the study period.", [["IPD", "DISEASE", 81, 84], ["IPD", "PROBLEM", 81, 84], ["the study", "TEST", 108, 117], ["Philadelphia", "OBSERVATION", 88, 100]]], ["However, selection bias will only be introduced if the notification of infectious diseases to public health was correlated with meteorological patterns (e.g., cases which occur during days with higher UV index have a greater likelihood of being diagnosed and reported), which seems unlikely [44].", [["infectious diseases", "DISEASE", 71, 90], ["higher UV index", "PROBLEM", 194, 209]]], ["Second, we obtained weather data from a single site at Philadelphia International Airport, and air pollution and UV data were averaged over several locations throughout the county, which may not represent the true exposure status of individual cases.", [["air pollution and UV data", "TEST", 95, 120], ["air pollution", "OBSERVATION", 95, 108], ["may not represent", "UNCERTAINTY", 187, 204]]], ["This is probable non-differential misclassification, and will bias the results towards the null hypothesis.", [["non-differential misclassification", "PROBLEM", 17, 51], ["the null hypothesis", "PROBLEM", 87, 106], ["probable", "UNCERTAINTY", 8, 16], ["non-differential misclassification", "OBSERVATION", 17, 51]]], ["The effects seen here are most likely conservative, weakening the strength of observed associations and suggesting our estimates tend towards the lower bound [44].ConclusionIn summary, we described the occurrence of IPD in a major U.S. urban center and found that incidence was associated with marked wintertime seasonality that may be partly explained by diminished exposure to UV-B radiation in winter months.", [["IPD", "DISEASE", 216, 219], ["UV-B", "CHEMICAL", 379, 383], ["IPD", "PROBLEM", 216, 219], ["UV-B radiation", "TREATMENT", 379, 393], ["most likely", "UNCERTAINTY", 26, 37], ["marked", "OBSERVATION_MODIFIER", 294, 300], ["wintertime seasonality", "OBSERVATION", 301, 323], ["may be partly explained", "UNCERTAINTY", 329, 352], ["diminished", "OBSERVATION", 356, 366]]], ["Further study is needed, but this result is consistent with observed patterns of respiratory infectious disease, and would be consistent with several biologically plausible models of effect.", [["respiratory infectious disease", "DISEASE", 81, 111], ["Further study", "TEST", 0, 13], ["respiratory infectious disease", "PROBLEM", 81, 111], ["consistent with", "UNCERTAINTY", 44, 59], ["respiratory", "ANATOMY", 81, 92], ["infectious", "OBSERVATION", 93, 103], ["consistent with", "UNCERTAINTY", 126, 141]]], ["As the nature of future changes in UV radiation related to climate change are more difficult to predict than general changes in temperatures or precipitation patterns, the implications of these findings for future pneumococcal disease epidemiology are unclear [45].", [["UV", "CHEMICAL", 35, 37], ["pneumococcal", "SPECIES", 214, 226], ["UV radiation", "TREATMENT", 35, 47], ["general changes in temperatures", "PROBLEM", 109, 140], ["future pneumococcal disease epidemiology", "PROBLEM", 207, 247]]], ["Nonetheless, we believe this observation goes some way towards explaining the notable seasonality of IPD, and could conceivably lead to novel disease control strategies through improved understanding of this common and virulent infectious disease.Competing interestsThe authors declare that they have no competing interests.Authors' contributionsAW performed the majority of the analysis and interpretation of the data, and drafted the manuscript.", [["IPD", "DISEASE", 101, 104], ["infectious disease", "DISEASE", 228, 246], ["IPD", "PROBLEM", 101, 104], ["novel disease control strategies", "PROBLEM", 136, 168], ["this common and virulent infectious disease", "PROBLEM", 203, 246], ["the analysis", "TEST", 375, 387], ["the data", "TEST", 410, 418], ["virulent", "OBSERVATION_MODIFIER", 219, 227], ["infectious", "OBSERVATION", 228, 238]]], ["CJ and CS acquired the case and exposure data, and each performed revisions of the manuscript.", [["exposure data", "TEST", 32, 45]]], ["LK analysed and interpreted data, and was involved in drafting and revising the manuscript.", [["LK analysed", "TEST", 0, 11]]], ["VN adapted the analysis tools for the data, assisted in its interpretation and was involved in critically reviewing the manuscript.", [["VN", "PROTEIN", 0, 2]]], ["DF performed data analysis, interpretation, and was involved in both the drafting and critical review process of the manuscript.", [["data analysis", "TEST", 13, 26]]], ["All authors have given approval for the final version to be published.Pre-publication historyThe pre-publication history for this paper can be accessed here:Pre-publication historyhttp://www.biomedcentral.com/1471-2334/9/196/prepub", [["Pre-publication", "DISEASE", 70, 85], ["pre-publication", "DISEASE", 97, 112], ["Pre-publication", "DISEASE", 157, 172]]]], "75bf710f6122644a9cbb713cf9b68f0dce00d832": [["IntroductionHuman adenoviruses (HAdVs) are responsible for a broad spectrum of clinical diseases, including febrile respiratory illnesses (FRI), gastroenteritis, pneumonia, and kidney infections [1] [2] [3] [4] .", [["respiratory", "ANATOMY", 116, 127], ["kidney", "ANATOMY", 177, 183], ["febrile respiratory illnesses", "DISEASE", 108, 137], ["FRI", "DISEASE", 139, 142], ["gastroenteritis", "DISEASE", 145, 160], ["pneumonia", "DISEASE", 162, 171], ["kidney infections", "DISEASE", 177, 194], ["adenoviruses", "ORGANISM", 18, 30], ["HAdVs", "GENE_OR_GENE_PRODUCT", 32, 37], ["kidney", "ORGAN", 177, 183], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 195, 210], ["IntroductionHuman adenoviruses", "TREATMENT", 0, 30], ["clinical diseases", "PROBLEM", 79, 96], ["febrile respiratory illnesses", "PROBLEM", 108, 137], ["gastroenteritis", "PROBLEM", 145, 160], ["pneumonia", "PROBLEM", 162, 171], ["kidney infections", "PROBLEM", 177, 194], ["gastroenteritis", "OBSERVATION", 145, 160], ["pneumonia", "OBSERVATION", 162, 171], ["kidney", "ANATOMY", 177, 183], ["infections", "OBSERVATION", 184, 194]]], ["These ubiquitous viruses belong to the genus Mastadenovirus in the family Adenoviridae.", [["These ubiquitous viruses", "PROBLEM", 0, 24], ["viruses", "OBSERVATION", 17, 24], ["genus Mastadenovirus", "OBSERVATION", 39, 59]]], ["So far, 68 genotypes of HAdV have been recognized and classified into seven species (A-G) based on their biological and genetic characteristics (http://HAdVwg.gmu.edu/).", [["HAdV", "ORGANISM", 24, 28], ["A-G", "CELL", 85, 88], ["HAdV", "PROBLEM", 24, 28]]], ["Among these genotypes, a re-emerged HAdV-B [P14H11F14] virus has attracted increasing attention in China.", [["HAdV-B", "CHEMICAL", 36, 42], ["HAdV-B [P14H11F14] virus", "ORGANISM", 36, 60], ["HAdV-B [P14H11F14] virus", "SPECIES", 36, 60], ["virus", "PROBLEM", 55, 60], ["increasing", "OBSERVATION_MODIFIER", 75, 85]]], ["This HAdV-B [P14H11F14] virus is an intertypic recombinant of HAdV-B11 and HAdV-B14.", [["HAdV-B", "CHEMICAL", 5, 11], ["HAdV-B [P14H11F14] virus", "ORGANISM", 5, 29], ["HAdV-B11", "ORGANISM", 62, 70], ["HAdV-B14", "ORGANISM", 75, 83], ["HAdV-B [P14H11F14] virus", "SPECIES", 5, 29], ["HAdV-B11", "SPECIES", 62, 70], ["HAdV-B14", "SPECIES", 75, 83], ["This HAdV", "TEST", 0, 9], ["HAdV", "TEST", 62, 66], ["HAdV", "PROBLEM", 75, 79], ["B14", "TREATMENT", 80, 83]]], ["It has a HAdV-14 genome chassis, including the HAdV-14 penton gene and fiber gene, but a partial HAdV-11 hexon gene, which encodes the antigenic epitopes of the virus [5] .", [["HAdV-14", "ORGANISM", 9, 16], ["fiber", "CELLULAR_COMPONENT", 71, 76], ["HAdV-14 genome chassis", "DNA", 9, 31], ["HAdV-14 penton gene", "DNA", 47, 66], ["fiber gene", "DNA", 71, 81], ["partial HAdV-11 hexon gene", "DNA", 89, 115], ["antigenic epitopes", "PROTEIN", 135, 153], ["a HAdV-14 genome chassis", "PROBLEM", 7, 31], ["the HAdV", "PROBLEM", 43, 51], ["a partial HAdV", "PROBLEM", 87, 101], ["hexon gene", "TREATMENT", 105, 115], ["the virus", "PROBLEM", 157, 166]]], ["This virus not only could possess the virulence of HAdV-14 but also could avoid the neutralizing antibody against HAdV-14, which exists much more widely in the population than that against this HAdV-B [P14H11F14] virus [6] .IntroductionAn HAdV-B [P14H11F14] virus was first identified as an atypical HAdV-11 strain in Spain in 1969 [7] .", [["HAdV-B", "CHEMICAL", 239, 245], ["HAdV-14", "ORGANISM", 51, 58], ["HAdV-14", "ORGANISM", 114, 121], ["HAdV-B [P14H11F14] virus", "ORGANISM", 194, 218], ["HAdV-B [P14H11F14] virus", "ORGANISM", 239, 263], ["HAdV-14", "SPECIES", 51, 58], ["HAdV-14", "SPECIES", 114, 121], ["HAdV-B [P14H11F14] virus", "SPECIES", 194, 218], ["HAdV-B [P14H11F14] virus", "SPECIES", 239, 263], ["This virus", "PROBLEM", 0, 10], ["HAdV", "TEST", 51, 55], ["the neutralizing antibody", "TEST", 80, 105], ["HAdV", "PROBLEM", 114, 118], ["this HAdV", "TEST", 189, 198], ["virus", "PROBLEM", 258, 263], ["an atypical HAdV", "PROBLEM", 288, 304], ["more widely", "OBSERVATION_MODIFIER", 141, 152], ["atypical", "OBSERVATION_MODIFIER", 291, 299], ["HAdV", "OBSERVATION", 300, 304]]], ["It then appeared in a Turkish military camp in 2004, where hundreds of military trainees fell ill and one man died in this Y. Dongliu, Y. Guoliang, X. Haocheng and Q. Shuaijia contributed equally to this paper. outbreak.", [["man", "ORGANISM", 106, 109], ["man", "SPECIES", 106, 109], ["outbreak", "PROBLEM", 211, 219]]], ["In recent years, this acute FRI pathogen has reemerged several times, once in Singapore in 2005 [8] , and twice in China, in Shannxi Province in 2006 [6] and in Beijing in 2011 [9] .", [["this acute FRI pathogen", "PROBLEM", 17, 40]]], ["In some outbreaks, it has caused severe respiratory disease and death in immunocompetent adults, including military recruits and high school students [5, 10] .IntroductionIn a serological study, this respiratory tract pathogen was classified as ''HAdV 14-11 intermediate'' [11] .", [["respiratory", "ANATOMY", 40, 51], ["respiratory tract", "ANATOMY", 200, 217], ["respiratory disease", "DISEASE", 40, 59], ["death", "DISEASE", 64, 69], ["respiratory tract pathogen", "DISEASE", 200, 226], ["severe respiratory disease", "PROBLEM", 33, 59], ["death", "PROBLEM", 64, 69], ["a serological study", "TEST", 174, 193], ["this respiratory tract pathogen", "PROBLEM", 195, 226], ["some", "OBSERVATION_MODIFIER", 3, 7], ["outbreaks", "OBSERVATION", 8, 17], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["respiratory disease", "OBSERVATION", 40, 59]]], ["Based on genome typing by restriction enzyme analysis, this virus was designated as HAdV-B11a [12, 13] .", [["HAdV", "ORGANISM", 84, 88], ["restriction enzyme", "PROTEIN", 26, 44], ["HAdV-B11a", "SPECIES", 84, 93], ["genome typing", "TEST", 9, 22], ["enzyme analysis", "TEST", 38, 53], ["this virus", "PROBLEM", 55, 65]]], ["When the computational genomic analysis method was used in 2010 by Walsh et al. , the results showed that within the context of the molecular evolution of HAdV, this pathogen is a novel adenoviral type and should be designated HAdV-B55 [P14H11F14] [14] .", [["P14H11F14", "CHEMICAL", 237, 246], ["HAdV", "ORGANISM", 155, 159], ["adenoviral", "ORGANISM", 186, 196], ["HAdV-B55", "ORGANISM", 227, 235], ["HAdV", "PROBLEM", 155, 159], ["this pathogen", "PROBLEM", 161, 174], ["a novel adenoviral type", "PROBLEM", 178, 201]]], ["According to a previous study, HAdV-55 has become a major causative agent of acute severe pneumonia in the Chinese population [15] .IntroductionHere, we report an outbreak of acute FRI in a Chinese military training center in 2014.", [["HAdV-55", "CHEMICAL", 31, 38], ["pneumonia", "DISEASE", 90, 99], ["HAdV-55", "ORGANISM", 31, 38], ["HAdV-55", "SPECIES", 31, 38], ["a previous study", "TEST", 13, 29], ["HAdV", "PROBLEM", 31, 35], ["acute severe pneumonia", "PROBLEM", 77, 99], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["pneumonia", "OBSERVATION", 90, 99]]], ["Over 36 days, from 7 May to 11 June, 164 individuals were affected.", [["individuals", "ORGANISM", 41, 52]]], ["Molecular characterization, phylogenetic analysis, and serological assays revealed that HAdV-B [P14H11F14] virus was the etiological agent of this outbreak, and the complete E1A gene, penton base gene, hexon gene, fiber gene of this virus all belonged to the HAdV-55 type.", [["HAdV-B [P14H11F14] virus", "ORGANISM", 88, 112], ["E1A", "GENE_OR_GENE_PRODUCT", 174, 177], ["penton base gene", "GENE_OR_GENE_PRODUCT", 184, 200], ["fiber", "CELLULAR_COMPONENT", 214, 219], ["HAdV-55", "ORGANISM", 259, 266], ["E1A gene", "DNA", 174, 182], ["penton base gene", "DNA", 184, 200], ["hexon gene", "DNA", 202, 212], ["fiber gene", "DNA", 214, 224], ["HAdV-B [P14H11F14] virus", "SPECIES", 88, 112], ["Molecular characterization", "TEST", 0, 26], ["phylogenetic analysis", "TEST", 28, 49], ["serological assays", "TEST", 55, 73], ["HAdV", "PROBLEM", 88, 92], ["virus", "PROBLEM", 107, 112], ["this outbreak", "PROBLEM", 142, 155], ["the complete E1A gene", "TREATMENT", 161, 182], ["penton base gene", "TREATMENT", 184, 200], ["hexon gene", "TREATMENT", 202, 212], ["this virus", "PROBLEM", 228, 238]]], ["This is the first epidemiological and etiological report of a type-55-like HAdV-B [P14H11F14] virus associated with an FRI outbreak in a Chinese military camp.", [["-55-like", "ORGANISM", 66, 74], ["HAdV-B [P14H11F14] virus", "ORGANISM", 75, 99], ["type-55-like HAdV-B [P14H11F14] virus", "SPECIES", 62, 99], ["a type-55-like HAdV", "PROBLEM", 60, 79], ["virus", "PROBLEM", 94, 99]]], ["The clinical characteristics of this outbreak differ from those of previous HAdV-55 outbreaks reported in Chinese civilians and foreign armies.", [["HAdV-55", "ORGANISM", 76, 83], ["HAdV-55", "SPECIES", 76, 83], ["previous HAdV", "PROBLEM", 67, 80], ["foreign armies", "PROBLEM", 128, 142], ["foreign armies", "OBSERVATION", 128, 142]]], ["Unlike other HAdV-55 outbreaks, no case of pneumonia developed in any patient.Materials and methodsResponses to the outbreak According to the training plan, the training schedule included daytime mid-range marches (twice a week) and night fire training (twice a week) between 21 April and 17 May.Materials and methodsIn May 2014, clustered cases of acute FRI (febrile respiratory illnesses) appeared in this MTC, which was defined as an individual with a body temperature[37.5\u00b0C and with at least one sign or symptom of acute respiratory tract infection, such as a cough or sore throat.", [["respiratory", "ANATOMY", 368, 379], ["body", "ANATOMY", 455, 459], ["respiratory tract", "ANATOMY", 526, 543], ["pneumonia", "DISEASE", 43, 52], ["FRI", "DISEASE", 355, 358], ["febrile respiratory illnesses", "DISEASE", 360, 389], ["MTC", "DISEASE", 408, 411], ["respiratory tract infection", "DISEASE", 526, 553], ["cough", "DISEASE", 565, 570], ["sore throat", "DISEASE", 574, 585], ["HAdV-55", "ORGANISM", 13, 20], ["patient", "ORGANISM", 70, 77], ["MTC", "CANCER", 408, 411], ["body", "ORGANISM_SUBDIVISION", 455, 459], ["tract", "ORGANISM_SUBDIVISION", 538, 543], ["patient", "SPECIES", 70, 77], ["other HAdV", "PROBLEM", 7, 17], ["pneumonia", "PROBLEM", 43, 52], ["the training schedule", "TREATMENT", 157, 178], ["daytime mid-range marches", "TREATMENT", 188, 213], ["methodsIn", "TREATMENT", 310, 319], ["acute FRI", "PROBLEM", 349, 358], ["febrile respiratory illnesses", "PROBLEM", 360, 389], ["a body temperature", "TEST", 453, 471], ["acute respiratory tract infection", "PROBLEM", 520, 553], ["a cough", "PROBLEM", 563, 570], ["sore throat", "PROBLEM", 574, 585], ["pneumonia", "OBSERVATION", 43, 52], ["acute", "OBSERVATION_MODIFIER", 349, 354], ["acute", "OBSERVATION_MODIFIER", 520, 525], ["respiratory tract", "ANATOMY", 526, 543], ["infection", "OBSERVATION", 544, 553]]], ["In the early stage of the outbreak, 1-2 cases of FRI were admitted to the MTC hospital every day.", [["FRI", "DISEASE", 49, 52], ["MTC", "DISEASE", 74, 77]]], ["This situation did not draw the attention of the MTC managers, and the outbreak was mistaken for severe seasonal influenza by the doctors of the MTC hospital.", [["MTC", "DISEASE", 49, 52], ["influenza", "DISEASE", 113, 122], ["MTC", "DISEASE", 145, 148], ["the MTC managers", "TREATMENT", 45, 61], ["severe seasonal influenza", "PROBLEM", 97, 122]]], ["However, after 22 May, the incidence of disease suddenly increased to more than 10 cases per day, and all patients showed similar symptoms.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["disease", "PROBLEM", 40, 47], ["similar symptoms", "PROBLEM", 122, 138], ["disease", "OBSERVATION", 40, 47]]], ["The MTC managers also appealed to the regional Center for Disease Control and Prevention (CDC) for help.", [["Disease Control", "TREATMENT", 58, 73]]], ["On 30 May, an epidemic survey was conducted by the regional CDC.", [["an epidemic survey", "TEST", 11, 29], ["regional CDC", "OBSERVATION", 51, 63]]], ["At the same time, disease control and prevention measures were adopted to control the outbreak, including the cessation of training, isolation of affected individuals, environmental disinfection, and morning temperature screening.", [["disease control", "TREATMENT", 18, 33], ["prevention measures", "TREATMENT", 38, 57], ["training", "TREATMENT", 123, 131], ["affected individuals", "PROBLEM", 146, 166], ["environmental disinfection", "TREATMENT", 168, 194], ["morning temperature screening", "TEST", 200, 229], ["disease", "OBSERVATION", 18, 25]]], ["No new cases were reported after 11 June.Specimen collectionTo investigate the etiological agent of this outbreak, throat swab specimens (n = 49, from the date of onset on 27 May to 11 June) were collected.", [["throat swab specimens", "ANATOMY", 115, 136], ["Specimen collectionTo", "TEST", 41, 62], ["this outbreak", "PROBLEM", 100, 113], ["throat swab specimens", "TEST", 115, 136], ["new", "OBSERVATION_MODIFIER", 3, 6], ["cases", "OBSERVATION", 7, 12]]], ["Sixty serum samples from FRI patients affected after 7 May were collected on 30 May.", [["serum samples", "ANATOMY", 6, 19], ["serum samples", "ORGANISM_SUBSTANCE", 6, 19], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["Sixty serum samples", "TEST", 0, 19]]], ["On 15 June, 43 paired serum samples from patients in the convalescent phase were also collected.", [["serum samples", "ANATOMY", 22, 35], ["serum samples", "ORGANISM_SUBSTANCE", 22, 35], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["paired serum samples", "TEST", 15, 35]]], ["At the same time, another 51 healthy soldiers were randomly selected from all of the training camps as the control group.", [["the training camps", "TREATMENT", 81, 99]]], ["Their paired sera were collected on 31 May (as the outbreak-phase samples) and 20 June (as the after-outbreak-phase samples).", [["sera", "ANATOMY", 13, 17], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["Their paired sera", "TEST", 0, 17]]], ["The sera and swab specimens were transferred to the regional CDC laboratory at 4\u00b0C within 24 h and stored at -20\u00b0C and -80\u00b0C, respectively, until further analysis.Specimen collectionExtraction and analysis of viral nucleic acids from throat swabs Viral nucleic acids were extracted directly from the throat swab specimens using a MiniBEST Viral RNA/DNA Extraction Kit (TaKaRa, Dalian, China).", [["sera", "ANATOMY", 4, 8], ["swab specimens", "ANATOMY", 13, 27], ["throat swab specimens", "ANATOMY", 300, 321], ["nucleic acids", "CHEMICAL", 215, 228], ["nucleic acids", "CHEMICAL", 253, 266], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["swab specimens", "ORGANISM_SUBSTANCE", 13, 27], ["throat swab specimens", "ORGANISM_SUBSTANCE", 300, 321], ["DNA", "CELLULAR_COMPONENT", 349, 352], ["The sera and swab specimens", "TEST", 0, 27], ["further analysis", "TEST", 146, 162], ["Specimen collectionExtraction", "TEST", 163, 192], ["analysis", "TEST", 197, 205], ["viral nucleic acids", "TEST", 209, 228], ["throat swabs", "TEST", 234, 246], ["Viral nucleic acids", "TEST", 247, 266], ["the throat swab specimens", "TEST", 296, 321], ["a MiniBEST Viral RNA/DNA Extraction", "TREATMENT", 328, 363], ["viral nucleic acids", "OBSERVATION", 209, 228], ["throat", "ANATOMY", 300, 306]]], ["A one-step reverse transcription (RT)-PCR was then performed using an RV13 PCR Detection Kit (Neuro Hemin, Hangzhou, China).", [["RV13", "SPECIES", 70, 74], ["PCR", "TEST", 38, 41], ["an RV13 PCR", "TEST", 67, 78]]], ["This PCR kit can detect 11 types of RNA virus (including influenza type A viruses, influenza type B viruses, human respiratory syncytial viruses A and B, human metapneumovirus, human parainfluenza viruses 1, 2, and 3, human rhinovirus, human coronaviruses 229E and OC43, and human enteroviruses) and two types of DNA virus (human bocavirus 1, 2, 3, 4 and human adenovirus).Specimen collectionThe primary identification of HAdV in the positive specimen was performed by PCR using the adenovirusspecific primers described by Allard et al. [16] .", [["specimen", "ANATOMY", 443, 451], ["influenza type A viruses", "DISEASE", 57, 81], ["influenza type B", "DISEASE", 83, 99], ["respiratory syncytial viruses", "DISEASE", 115, 144], ["human metapneumovirus", "DISEASE", 154, 175], ["parainfluenza viruses", "DISEASE", 183, 204], ["influenza type A viruses", "ORGANISM", 57, 81], ["influenza type B viruses", "ORGANISM", 83, 107], ["human respiratory syncytial viruses A", "ORGANISM", 109, 146], ["human metapneumovirus", "ORGANISM", 154, 175], ["human", "ORGANISM", 177, 182], ["parainfluenza viruses 1", "ORGANISM", 183, 206], ["2", "GENE_OR_GENE_PRODUCT", 208, 209], ["3", "GENE_OR_GENE_PRODUCT", 215, 216], ["human", "ORGANISM", 218, 223], ["rhinovirus", "ORGANISM", 224, 234], ["human", "ORGANISM", 236, 241], ["coronaviruses 229E", "ORGANISM", 242, 260], ["OC43", "GENE_OR_GENE_PRODUCT", 265, 269], ["human", "ORGANISM", 275, 280], ["enteroviruses", "CANCER", 281, 294], ["DNA", "CELLULAR_COMPONENT", 313, 316], ["human bocavirus 1", "ORGANISM", 324, 341], ["3", "GENE_OR_GENE_PRODUCT", 346, 347], ["human", "ORGANISM", 355, 360], ["adenovirus", "ORGANISM", 361, 371], ["HAdV", "ORGANISM", 422, 426], ["adenovirusspecific primers", "DNA", 483, 509], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 154, 159], ["metapneumovirus", "SPECIES", 160, 175], ["human", "SPECIES", 177, 182], ["parainfluenza viruses", "SPECIES", 183, 204], ["human", "SPECIES", 218, 223], ["rhinovirus", "SPECIES", 224, 234], ["human", "SPECIES", 236, 241], ["human", "SPECIES", 275, 280], ["human", "SPECIES", 324, 329], ["human", "SPECIES", 355, 360], ["influenza type A viruses", "SPECIES", 57, 81], ["influenza type B viruses", "SPECIES", 83, 107], ["human respiratory syncytial viruses A", "SPECIES", 109, 146], ["human metapneumovirus", "SPECIES", 154, 175], ["human parainfluenza viruses 1", "SPECIES", 177, 206], ["human rhinovirus", "SPECIES", 218, 234], ["human coronaviruses 229E", "SPECIES", 236, 260], ["human", "SPECIES", 275, 280], ["human bocavirus 1", "SPECIES", 324, 341], ["human", "SPECIES", 355, 360], ["HAdV", "SPECIES", 422, 426], ["This PCR kit", "TEST", 0, 12], ["RNA virus", "PROBLEM", 36, 45], ["influenza type A viruses", "PROBLEM", 57, 81], ["influenza type B viruses", "PROBLEM", 83, 107], ["human respiratory syncytial viruses", "PROBLEM", 109, 144], ["human metapneumovirus", "PROBLEM", 154, 175], ["human parainfluenza viruses", "TEST", 177, 204], ["human rhinovirus", "PROBLEM", 218, 234], ["human coronaviruses", "TEST", 236, 255], ["OC43", "TEST", 265, 269], ["human enteroviruses", "PROBLEM", 275, 294], ["DNA virus", "PROBLEM", 313, 322], ["human bocavirus", "TEST", 324, 339], ["Specimen collection", "TEST", 373, 392], ["HAdV in the positive specimen", "PROBLEM", 422, 451], ["PCR", "TEST", 469, 472], ["the adenovirusspecific primers", "TREATMENT", 479, 509], ["RNA virus", "OBSERVATION", 36, 45], ["respiratory syncytial viruses", "OBSERVATION", 115, 144], ["collection", "OBSERVATION", 382, 392]]], ["The amplified target of this specific PCR was the partial hexon gene sequence (467 bp) in the HAdV genome.", [["HAdV", "ORGANISM", 94, 98], ["hexon gene sequence", "DNA", 58, 77], ["HAdV genome", "DNA", 94, 105], ["this specific PCR", "TEST", 24, 41], ["bp", "TEST", 83, 85], ["HAdV genome", "OBSERVATION", 94, 105]]], ["The amplicon was sequenced and analyzed using the BLAST program (National Center for Biotechnology Information).Cell culture and viral isolationRhabdomyosarcoma (RD) cells (ATCC CCL-136) were cultured in Dulbecco's modified Eagle's medium (DMEM, containing 10 % fetal bovine serum, 100 U/ml penicillin G, 100 lg/ml streptomycin; Gibco, Carlsbad, California, USA) at 37\u00b0C in an closed system with 5 % CO 2 incubation.Cell culture and viral isolationTo isolate the virus, RD cells were inoculated with the patients' throat swab specimens (300 ll of each specimen) and cultured in DMEM containing 2 % fetal bovine serum, 100 U/ml penicillin G, 100 lg/ml streptomycin (Gibco, Carlsbad, California, USA) at 37\u00b0C in an closed system with 5 % CO 2 incubation.", [["Cell", "ANATOMY", 112, 116], ["Rhabdomyosarcoma (RD) cells", "ANATOMY", 144, 171], ["ATCC CCL-136", "ANATOMY", 173, 185], ["fetal bovine serum", "ANATOMY", 262, 280], ["Cell", "ANATOMY", 416, 420], ["RD cells", "ANATOMY", 470, 478], ["throat swab specimens", "ANATOMY", 514, 535], ["ll", "ANATOMY", 541, 543], ["specimen", "ANATOMY", 552, 560], ["fetal bovine serum", "ANATOMY", 598, 616], ["Rhabdomyosarcoma", "DISEASE", 144, 160], ["CCL-136", "CHEMICAL", 178, 185], ["penicillin", "CHEMICAL", 291, 301], ["streptomycin", "CHEMICAL", 315, 327], ["penicillin", "CHEMICAL", 627, 637], ["streptomycin", "CHEMICAL", 651, 663], ["penicillin G", "CHEMICAL", 291, 303], ["streptomycin", "CHEMICAL", 315, 327], ["CO 2", "CHEMICAL", 400, 404], ["penicillin G", "CHEMICAL", 627, 639], ["streptomycin", "CHEMICAL", 651, 663], ["CO 2", "CHEMICAL", 736, 740], ["Cell", "CELL", 112, 116], ["Rhabdomyosarcoma (RD) cells", "CELL", 144, 171], ["ATCC CCL-136", "CELL", 173, 185], ["bovine", "ORGANISM", 268, 274], ["serum", "ORGANISM_SUBSTANCE", 275, 280], ["penicillin G", "SIMPLE_CHEMICAL", 291, 303], ["streptomycin", "SIMPLE_CHEMICAL", 315, 327], ["Cell", "CELL", 416, 420], ["RD cells", "CELL", 470, 478], ["patients", "ORGANISM", 504, 512], ["throat swab specimens", "ORGANISM_SUBSTANCE", 514, 535], ["bovine", "ORGANISM", 604, 610], ["serum", "ORGANISM_SUBSTANCE", 611, 616], ["penicillin G", "SIMPLE_CHEMICAL", 627, 639], ["streptomycin", "SIMPLE_CHEMICAL", 651, 663], ["Rhabdomyosarcoma (RD) cells", "CELL_LINE", 144, 171], ["ATCC CCL-136", "CELL_LINE", 173, 185], ["RD cells", "CELL_TYPE", 470, 478], ["bovine", "SPECIES", 268, 274], ["patients", "SPECIES", 504, 512], ["bovine", "SPECIES", 604, 610], ["ATCC CCL-136", "SPECIES", 173, 185], ["bovine", "SPECIES", 268, 274], ["bovine", "SPECIES", 604, 610], ["The amplicon", "TREATMENT", 0, 12], ["Cell culture", "TEST", 112, 124], ["viral isolationRhabdomyosarcoma", "PROBLEM", 129, 160], ["ATCC CCL", "TEST", 173, 181], ["Dulbecco", "TEST", 204, 212], ["DMEM", "TEST", 240, 244], ["fetal bovine serum", "TEST", 262, 280], ["penicillin G", "TREATMENT", 291, 303], ["streptomycin", "TREATMENT", 315, 327], ["Gibco", "PROBLEM", 329, 334], ["Cell culture", "TEST", 416, 428], ["viral isolationTo isolate the virus", "PROBLEM", 433, 468], ["RD cells", "PROBLEM", 470, 478], ["the patients' throat swab specimens", "TEST", 500, 535], ["each specimen", "TEST", 547, 560], ["DMEM", "TEST", 578, 582], ["fetal bovine serum", "TEST", 598, 616], ["penicillin G", "TREATMENT", 627, 639], ["streptomycin", "TREATMENT", 651, 663], ["viral isolationRhabdomyosarcoma", "OBSERVATION", 129, 160]]], ["The cultures were observed daily for a cytopathic effect (CPE).", [["cultures", "ANATOMY", 4, 12], ["The cultures", "TEST", 0, 12], ["a cytopathic effect (CPE", "PROBLEM", 37, 61]]], ["In 2-7 days, the cultures displaying an adenovirus-like CPE were passaged again to confirm the presence of the virus.", [["cultures", "ANATOMY", 17, 25], ["adenovirus", "ORGANISM", 40, 50], ["the cultures", "TEST", 13, 25], ["an adenovirus", "PROBLEM", 37, 50], ["CPE", "PROBLEM", 56, 59], ["the virus", "PROBLEM", 107, 116], ["virus", "OBSERVATION", 111, 116]]], ["The positive isolates were identified by adenovirus-specific PCR as described by Allard et al. [16] .Extraction of viral DNA and gene amplificationViral DNA was extracted from the HAdV-positive cell cultures using a TaKaRa MiniBEST Viral RNA/DNA Extraction Kit.", [["cell cultures", "ANATOMY", 194, 207], ["adenovirus", "ORGANISM", 41, 51], ["DNA", "CELLULAR_COMPONENT", 121, 124], ["Viral", "ORGANISM", 147, 152], ["DNA", "CELLULAR_COMPONENT", 153, 156], ["HAdV", "ORGANISM", 180, 184], ["cell cultures", "CELL", 194, 207], ["DNA", "CELLULAR_COMPONENT", 242, 245], ["viral DNA", "DNA", 115, 124], ["HAdV-positive cell cultures", "CELL_LINE", 180, 207], ["adenovirus", "SPECIES", 41, 51], ["The positive isolates", "PROBLEM", 0, 21], ["adenovirus", "PROBLEM", 41, 51], ["specific PCR", "TEST", 52, 64], ["Extraction", "TREATMENT", 101, 111], ["viral DNA", "PROBLEM", 115, 124], ["gene amplificationViral DNA", "PROBLEM", 129, 156], ["the HAdV", "TEST", 176, 184], ["positive cell cultures", "PROBLEM", 185, 207], ["a TaKaRa", "TREATMENT", 214, 222], ["positive isolates", "OBSERVATION", 4, 21], ["viral DNA", "OBSERVATION", 115, 124], ["positive cell", "OBSERVATION", 185, 198]]], ["The complete E1A, penton base, hexon, and fiber genes were amplified and sequenced using specific primer sets designed at the Jinan Junqu CDC (listed in Table 1 ).", [["E1A", "GENE_OR_GENE_PRODUCT", 13, 16], ["penton", "GENE_OR_GENE_PRODUCT", 18, 24], ["hexon", "GENE_OR_GENE_PRODUCT", 31, 36], ["fiber", "CELLULAR_COMPONENT", 42, 47], ["E1A, penton base, hexon, and fiber genes", "DNA", 13, 53], ["The complete E1A", "TREATMENT", 0, 16], ["penton base", "TREATMENT", 18, 29], ["hexon, and fiber genes", "TREATMENT", 31, 53], ["E1A", "OBSERVATION", 13, 16]]], ["The PCR was performed using a Ready-To-Use PCR Kit (Pfu B532073; Sangon, Shanghai, China).", [["The PCR", "TEST", 0, 7], ["PCR Kit", "TEST", 43, 50], ["Sangon", "TEST", 65, 71]]], ["The 50-ll PCR reaction mixture contained 25 ll of 2 9 HiFi PCR Master, 21 ll of sterile ddH 2 O, 2 ll of DNA template, and 0.2 lM each primer.", [["DNA", "CELLULAR_COMPONENT", 105, 108], ["sterile ddH 2 O, 2 ll of DNA template", "DNA", 80, 117], ["ll PCR reaction mixture", "TEST", 7, 30], ["HiFi PCR", "TEST", 54, 62], ["DNA template", "TREATMENT", 105, 117], ["25 ll", "OBSERVATION_MODIFIER", 41, 46]]], ["The PCR cycling parameters were initial denaturation at 94\u00b0C for 4 min, followed by 35 cycles of denaturation at 94\u00b0C for 30 s, annealing at 51\u00b0C for 50 s, and extension at 72\u00b0C for 80 s, with a final extension step at 72\u00b0C for 10 min.", [["The PCR cycling parameters", "TEST", 0, 26], ["initial denaturation", "PROBLEM", 32, 52], ["denaturation", "TREATMENT", 97, 109], ["extension", "TEST", 160, 169]]], ["The amplification products were analyzed by 1.5 % agarose gel electrophoresis.Sequence determination and phylogenetic analysisThe amplified products were sequenced in both directions by the dye terminator method (BigDye Terminator v3.1 Cycle Sequencing Kit; Applied Biosystems) using an ABI Prism 3100 Genetic Analyzer (Applied Biosystems).", [["agarose", "SIMPLE_CHEMICAL", 50, 57], ["The amplification products", "TREATMENT", 0, 26], ["1.5 % agarose gel electrophoresis", "TREATMENT", 44, 77], ["Sequence determination", "TEST", 78, 100], ["phylogenetic analysis", "TEST", 105, 126], ["The amplified products", "TREATMENT", 126, 148], ["an ABI Prism", "TEST", 284, 296], ["Genetic Analyzer (Applied Biosystems", "TREATMENT", 302, 338]]], ["The nucleotide and predicted amino acid sequences were analyzed using the BioEdit program (http://www.mbio.ncsu. edu/BioEdit/bioedit.html).", [["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 29, 39], ["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 29, 39], ["amino acid", "AMINO_ACID", 29, 39], ["bioedit.html", "DNA", 125, 137], ["The nucleotide and predicted amino acid sequences", "TEST", 0, 49], ["the BioEdit program", "TREATMENT", 70, 89]]], ["Nucleotide sequence homologies were inferred from the identity scores determined using the BLASTn program (National Center for Biotechnology Information, Bethesda, MD, USA).", [["Nucleotide sequence homologies", "TEST", 0, 30]]], ["Sequence alignments were constructed with ClustalX version 2.1 [17] , and phylogenetic analyses were performed with the MEGA 5 program [18] .", [["Sequence alignments", "TEST", 0, 19], ["ClustalX version", "TEST", 42, 58], ["phylogenetic analyses", "TEST", 74, 95]]], ["The reference sequences were retrieved from GenBank (www.ncbi.nlm.nih.gov/GenBank).", [["The reference sequences", "TEST", 0, 23]]], ["The reliability of the phylogenetic trees was examined with 1000 bootstrap pseudoreplicates.Sequence determination and phylogenetic analysisHAdV-specific antibody detection using enzymelinked immunosorbent assays (ELISAs) All serum specimens from patients (including 43 specimens collected in the acute phase and 60 specimens collected in the convalescent phase) in this outbreak and from healthy controls (including the paired specimens collected during the outbreak phase and after the outbreak phase from 51 healthy soldiers) were examined using an ELISAClinical characteristics of the patientsThe clinical characteristics of the patients are summarized in Table 2 .", [["serum specimens", "ANATOMY", 226, 241], ["specimens", "ANATOMY", 270, 279], ["specimens", "ANATOMY", 316, 325], ["specimens", "ANATOMY", 428, 437], ["serum specimens", "ORGANISM_SUBSTANCE", 226, 241], ["patients", "ORGANISM", 247, 255], ["patients", "ORGANISM", 589, 597], ["patients", "ORGANISM", 633, 641], ["patients", "SPECIES", 247, 255], ["patients", "SPECIES", 589, 597], ["patients", "SPECIES", 633, 641], ["Sequence determination", "TEST", 92, 114], ["phylogenetic analysisHAdV", "TEST", 119, 144], ["specific antibody detection", "TEST", 145, 172], ["enzymelinked immunosorbent assays", "TEST", 179, 212], ["All serum specimens", "TEST", 222, 241], ["specimens", "TEST", 270, 279], ["the acute phase", "TEST", 293, 308], ["specimens", "TEST", 316, 325], ["the paired specimens", "TEST", 417, 437], ["convalescent phase", "OBSERVATION_MODIFIER", 343, 361]]], ["Among the 164 hospitalized patients, all presented with fever, and most had a sore throat or tonsillitis.", [["fever", "DISEASE", 56, 61], ["sore throat", "DISEASE", 78, 89], ["tonsillitis", "DISEASE", 93, 104], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["fever", "PROBLEM", 56, 61], ["a sore throat", "PROBLEM", 76, 89], ["tonsillitis", "PROBLEM", 93, 104], ["fever", "OBSERVATION", 56, 61], ["sore throat", "ANATOMY", 78, 89], ["tonsillitis", "OBSERVATION", 93, 104]]], ["Other symptoms reported by the patients were headache, fatigue, cough, sputum, nasal discharge, and diarrhea.", [["sputum", "ANATOMY", 71, 77], ["nasal", "ANATOMY", 79, 84], ["headache", "DISEASE", 45, 53], ["fatigue", "DISEASE", 55, 62], ["cough", "DISEASE", 64, 69], ["diarrhea", "DISEASE", 100, 108], ["patients", "ORGANISM", 31, 39], ["nasal", "ORGANISM_SUBDIVISION", 79, 84], ["patients", "SPECIES", 31, 39], ["Other symptoms", "PROBLEM", 0, 14], ["headache", "PROBLEM", 45, 53], ["fatigue", "PROBLEM", 55, 62], ["cough", "PROBLEM", 64, 69], ["sputum", "PROBLEM", 71, 77], ["nasal discharge", "PROBLEM", 79, 94], ["diarrhea", "PROBLEM", 100, 108], ["nasal", "ANATOMY", 79, 84], ["discharge", "OBSERVATION", 85, 94], ["diarrhea", "OBSERVATION", 100, 108]]], ["Two patients were admitted to the intensive care unit (ICU) of the military regional central hospital because of the prolonged fever (fever more than 5 days, peak temperature over than 39\u00b0C. Patient 1 was diagnosed with acute suppurative tonsillitis, with a peak temperature of 40.0\u00b0C, elevated neutrophilic granulocytes (NE %, 73.4 %, reference value range, 50-70 %), and decreased lympholeukocytes (LYM %, 17.9 %,) reference value range, 20-40 %).", [["neutrophilic granulocytes", "ANATOMY", 295, 320], ["lympholeukocytes", "ANATOMY", 383, 399], ["fever", "DISEASE", 127, 132], ["fever", "DISEASE", 134, 139], ["tonsillitis", "DISEASE", 238, 249], ["patients", "ORGANISM", 4, 12], ["neutrophilic granulocytes", "CELL", 295, 320], ["neutrophilic granulocytes", "CELL_TYPE", 295, 320], ["patients", "SPECIES", 4, 12], ["Patient", "SPECIES", 191, 198], ["the prolonged fever", "PROBLEM", 113, 132], ["fever", "PROBLEM", 134, 139], ["peak temperature", "TEST", 158, 174], ["acute suppurative tonsillitis", "PROBLEM", 220, 249], ["a peak temperature", "TEST", 256, 274], ["elevated neutrophilic granulocytes", "PROBLEM", 286, 320], ["NE", "TEST", 322, 324], ["decreased lympholeukocytes", "PROBLEM", 373, 399], ["LYM", "TEST", 401, 404], ["prolonged", "OBSERVATION_MODIFIER", 117, 126], ["fever", "OBSERVATION", 127, 132], ["acute", "OBSERVATION_MODIFIER", 220, 225], ["suppurative", "OBSERVATION_MODIFIER", 226, 237], ["tonsillitis", "OBSERVATION", 238, 249], ["elevated", "OBSERVATION_MODIFIER", 286, 294], ["neutrophilic granulocytes", "OBSERVATION", 295, 320], ["decreased", "OBSERVATION_MODIFIER", 373, 382], ["lympholeukocytes", "OBSERVATION", 383, 399]]], ["Patient 2 was diagnosed with upper respiratory tract infection, with a peak temperature of 39.5\u00b0C, decreased leukocyte counts (WBC, 1.7 9 10 9 /L, reference value range 4.0-10.0 9 10 9 /L)).", [["upper respiratory tract", "ANATOMY", 29, 52], ["leukocyte", "ANATOMY", 109, 118], ["respiratory tract infection", "DISEASE", 35, 62], ["upper", "ORGANISM_SUBDIVISION", 29, 34], ["respiratory tract", "ORGANISM_SUBDIVISION", 35, 52], ["leukocyte", "CELL", 109, 118], ["Patient", "SPECIES", 0, 7], ["upper respiratory tract infection", "PROBLEM", 29, 62], ["a peak temperature", "TEST", 69, 87], ["decreased leukocyte counts", "PROBLEM", 99, 125], ["WBC", "TEST", 127, 130], ["upper", "ANATOMY_MODIFIER", 29, 34], ["respiratory tract", "ANATOMY", 35, 52], ["infection", "OBSERVATION", 53, 62]]], ["Other patients were observed and treated at the MTC hospital.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["On average, the FRI lasted for 4-7 days and all of the patients recovered well.", [["patients", "ORGANISM", 55, 63], ["FRI", "DNA", 16, 19], ["patients", "SPECIES", 55, 63]]], ["X-ray examinations were conducted of 31 patients (including the two patients admitted to the ICU and 29 patients in the MTC hospital), but no radiological evidence of pneumonia was confirmed.", [["MTC", "DISEASE", 120, 123], ["pneumonia", "DISEASE", 167, 176], ["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 104, 112], ["X-ray examinations", "TEST", 0, 18], ["pneumonia", "PROBLEM", 167, 176], ["no radiological evidence of", "UNCERTAINTY", 139, 166], ["pneumonia", "OBSERVATION", 167, 176]]], ["Therefore, no case of pneumonia developed in this FRI outbreak.Detection and identification of the pathogenic agentA series of serological tests and routine blood cultures were performed to detect Streptococcus, Coxiella, Rickettsia, Mycoplasma, Chlamydia, Legionella, Brucella, and typhoid fever, but all were negative.", [["blood cultures", "ANATOMY", 157, 171], ["pneumonia", "DISEASE", 22, 31], ["Mycoplasma, Chlamydia, Legionella, Brucella", "DISEASE", 234, 277], ["typhoid fever", "DISEASE", 283, 296], ["blood", "ORGANISM_SUBSTANCE", 157, 162], ["Mycoplasma", "ORGANISM", 234, 244], ["Chlamydia", "ORGANISM", 246, 255], ["pneumonia", "PROBLEM", 22, 31], ["serological tests", "TEST", 127, 144], ["routine blood cultures", "TEST", 149, 171], ["Streptococcus", "PROBLEM", 197, 210], ["Coxiella", "PROBLEM", 212, 220], ["Rickettsia", "PROBLEM", 222, 232], ["Mycoplasma", "PROBLEM", 234, 244], ["Chlamydia", "PROBLEM", 246, 255], ["Legionella", "PROBLEM", 257, 267], ["Brucella", "PROBLEM", 269, 277], ["typhoid fever", "PROBLEM", 283, 296], ["no case of", "UNCERTAINTY", 11, 21], ["pneumonia", "OBSERVATION", 22, 31]]], ["A diagnostic one-step RT-PCR was performed on all throat swab samples using an RV13 PCR Detection Kit (Neuro Hemin, Hangzhou, China).", [["throat swab samples", "ANATOMY", 50, 69], ["RV13", "SPECIES", 79, 83], ["step RT-PCR", "TEST", 17, 28], ["all throat swab samples", "TEST", 46, 69], ["an RV13 PCR", "TEST", 76, 87]]], ["Of the 49 patient swab specimens, 45 specimens were positive for HAdV DNA, and all 49 specimens were negative for 11other viruses.", [["swab specimens", "ANATOMY", 18, 32], ["specimens", "ANATOMY", 37, 46], ["specimens", "ANATOMY", 86, 95], ["patient", "ORGANISM", 10, 17], ["swab specimens", "CANCER", 18, 32], ["specimens", "CANCER", 37, 46], ["HAdV", "ORGANISM", 65, 69], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["specimens", "CANCER", 86, 95], ["HAdV DNA", "DNA", 65, 73], ["patient", "SPECIES", 10, 17], ["HAdV", "SPECIES", 65, 69], ["patient swab specimens", "TEST", 10, 32], ["45 specimens", "TEST", 34, 46], ["HAdV DNA", "PROBLEM", 65, 73], ["all 49 specimens", "TEST", 79, 95], ["11other viruses", "PROBLEM", 114, 129]]], ["Then, all 49 specimens were re-tested by HAdV-specific PCR with primers specific for aVirus isolation and amplification of the major structural protein genesTo isolate the virus, RD cells were inoculated with patient throat swab specimens (n = 20).", [["specimens", "ANATOMY", 13, 22], ["RD cells", "ANATOMY", 179, 187], ["throat swab specimens", "ANATOMY", 217, 238], ["specimens", "CANCER", 13, 22], ["HAdV", "ORGANISM", 41, 45], ["RD cells", "CELL", 179, 187], ["patient", "ORGANISM", 209, 216], ["major structural protein genes", "DNA", 127, 157], ["RD cells", "CELL_LINE", 179, 187], ["patient", "SPECIES", 209, 216], ["specific PCR", "TEST", 46, 58], ["primers", "TEST", 64, 71], ["aVirus isolation", "TREATMENT", 85, 101], ["the major structural protein genes", "PROBLEM", 123, 157], ["the virus", "PROBLEM", 168, 177], ["RD cells", "PROBLEM", 179, 187], ["patient throat swab specimens", "TEST", 209, 238], ["protein genes", "OBSERVATION", 144, 157], ["virus", "OBSERVATION", 172, 177]]], ["The characteristic adenovirus-like CPE was observed in six cultures from six throat swab specimens, and all these cultures were confirmed to be HAdV positive by HAdV-specific PCR.", [["cultures", "ANATOMY", 59, 67], ["throat swab specimens", "ANATOMY", 77, 98], ["adenovirus", "ORGANISM", 19, 29], ["HAdV", "ORGANISM", 144, 148], ["HAdV", "ORGANISM", 161, 165], ["The characteristic adenovirus-like CPE", "PROBLEM", 0, 38], ["six cultures", "TEST", 55, 67], ["six throat swab specimens", "TEST", 73, 98], ["all these cultures", "TEST", 104, 122], ["HAdV positive", "PROBLEM", 144, 157], ["specific PCR", "TEST", 166, 178], ["adenovirus", "OBSERVATION", 19, 29]]], ["According to the BLAST analysis, the amplicon sequences (partial hexon gene fragment, 467 bp) of the six HAdV isolates were 100 % identical to each other and to their sequencing results before virus isolation.", [["HAdV", "ORGANISM", 105, 109], ["amplicon sequences", "DNA", 37, 55], ["partial hexon gene fragment", "DNA", 57, 84], ["the BLAST analysis", "TEST", 13, 31], ["the amplicon sequences (partial hexon gene fragment", "TREATMENT", 33, 84], ["bp", "TEST", 90, 92], ["the six HAdV isolates", "TEST", 97, 118], ["virus isolation", "TREATMENT", 193, 208]]], ["One of the six HAdV isolates (strain SD77001) was selected for further genetic study.", [["HAdV", "ORGANISM", 15, 19], ["further genetic study", "TEST", 63, 84]]], ["The complete penton base, hexon, fiber, and E1A genes were amplified and sequenced using the specific primer sets listed in Table 1 .", [["fiber", "CELLULAR_COMPONENT", 33, 38], ["E1A", "GENE_OR_GENE_PRODUCT", 44, 47], ["penton base, hexon, fiber, and E1A genes", "DNA", 13, 53], ["The complete penton base", "TREATMENT", 0, 24], ["hexon, fiber", "TREATMENT", 26, 38], ["E1A genes", "TREATMENT", 44, 53]]], ["The sequence data were deposited in GenBank.", [["The sequence data", "TEST", 0, 17]]], ["(GenBank accession numbers: SD77001 strain complete hexon gene sequence: KR912178; penton base gene sequence: KT253552; fiber gene sequence: KT253553; E1A gene sequence: KT253554).Molecular and phylogenetic analysis of the HAdV strainTo investigate the genetic relationships between isolate SD77001 and other HAdV strains, phylogenetic trees were constructed by the maximum-likelihood method with 1000 bootstrap pseudoreplicates using the MEGA 5 program [18] .", [["E1A", "GENE_OR_GENE_PRODUCT", 151, 154], ["HAdV", "ORGANISM", 223, 227], ["HAdV", "ORGANISM", 309, 313], ["hexon gene sequence", "DNA", 52, 71], ["penton base gene sequence", "DNA", 83, 108], ["KT253552; fiber gene sequence", "DNA", 110, 139], ["E1A gene sequence", "DNA", 151, 168], ["phylogenetic analysis", "TEST", 194, 215], ["other HAdV strains", "PROBLEM", 303, 321], ["the MEGA 5 program", "TREATMENT", 435, 453]]], ["The phylogenetic analyses were based on the complete hexon, penton base, fiber, and E1A gene sequences of strain SD77001 and their counterparts in 23 other HAdV strains representing HAdV species A-G.", [["fiber", "CELLULAR_COMPONENT", 73, 78], ["E1A", "GENE_OR_GENE_PRODUCT", 84, 87], ["HAdV", "ORGANISM", 156, 160], ["HAdV", "ORGANISM", 182, 186], ["hexon", "DNA", 53, 58], ["penton base, fiber, and E1A gene sequences", "DNA", 60, 102], ["The phylogenetic analyses", "TEST", 0, 25], ["penton base, fiber", "TREATMENT", 60, 78], ["E1A gene sequences", "TREATMENT", 84, 102], ["HAdV species", "PROBLEM", 182, 194], ["HAdV species", "OBSERVATION", 182, 194]]], ["In these analyses, HAdV isolate SD77001 clustered with the HAdV-55 strains (Fig. 2) .", [["HAdV", "ORGANISM", 19, 23], ["HAdV-55 strains", "ORGANISM", 59, 74], ["HAdV-55", "SPECIES", 59, 66], ["these analyses", "TEST", 3, 17], ["the HAdV", "TEST", 55, 63]]], ["In the phylogenetic analysis based on the complete HAdV hexon gene sequence (Fig. 2a) , the hexon gene sequence of SD77001 clustered with those of the HAdV-55 strains and HAdV-11 strains.", [["HAdV", "ORGANISM", 51, 55], ["HAdV-55 strains", "ORGANISM", 151, 166], ["HAdV-11 strains", "ORGANISM", 171, 186], ["HAdV hexon gene sequence", "DNA", 51, 75], ["hexon gene sequence", "DNA", 92, 111], ["HAdV-55", "SPECIES", 151, 158], ["HAdV-11", "SPECIES", 171, 178], ["the phylogenetic analysis", "TEST", 3, 28], ["the complete HAdV hexon gene sequence", "TEST", 38, 75], ["the hexon gene sequence", "TEST", 88, 111], ["the HAdV", "TEST", 147, 155], ["HAdV", "TEST", 171, 175]]], ["The strains most similar to SD77001 were HAdV-55 strain QS_DLL_China and ak36_Argentina (BLAST score, 5241; identity, 99 %), followed by Singapore HAdV-11a strain SGN1222 and Taiwanese HAdV-11a strain 760 (BLAST score, 5236; identity, 99 %).", [["SD77001", "CHEMICAL", 28, 35], ["HAdV-55", "ORGANISM", 41, 48], ["ak36_", "GENE_OR_GENE_PRODUCT", 73, 78], ["HAdV-55", "SPECIES", 41, 48], ["Singapore HAdV-11a strain SGN1222", "SPECIES", 137, 170], ["Taiwanese HAdV-11a strain 760", "SPECIES", 175, 204], ["The strains", "PROBLEM", 0, 11], ["HAdV", "TEST", 41, 45], ["Argentina (BLAST score", "TEST", 78, 100], ["identity", "TEST", 108, 116], ["Taiwanese HAdV", "TEST", 175, 189], ["BLAST score", "TEST", 206, 217], ["identity", "TEST", 225, 233]]], ["On the phylogenetic tree based on the entire penton base gene sequence (Fig. 2b) , isolate SD77001 clustered with all the HAdV-55 strains and two HAdV-14 strains: de-Wit and GZ01.", [["HAdV-55 strains", "ORGANISM", 122, 137], ["HAdV-14 strains", "ORGANISM", 146, 161], ["GZ01", "ORGANISM", 174, 178], ["penton base gene sequence", "DNA", 45, 70], ["HAdV-55", "SPECIES", 122, 129], ["the HAdV", "TEST", 118, 126], ["GZ01", "TREATMENT", 174, 178], ["tree", "ANATOMY_MODIFIER", 20, 24]]], ["The penton base sequence of almost every HAdV-55 strain was 100 % identical to that of SD77001, including that of Singapore strain SGN1222, Chinese strains QS-DLL and CQ-814, Egyptian strain AK37, and Argentinian strain ak36 (BLAST score, 3092; identity, 100 %).", [["CQ-814", "CHEMICAL", 167, 173], ["HAdV-55", "ORGANISM", 41, 48], ["Singapore strain SGN1222", "ORGANISM", 114, 138], ["QS-DLL", "CELL", 156, 162], ["CQ-814", "CELL", 167, 173], ["Egyptian strain AK37", "ORGANISM", 175, 195], ["penton base sequence", "DNA", 4, 24], ["HAdV-55", "SPECIES", 41, 48], ["Singapore strain SGN1222", "SPECIES", 114, 138], ["Chinese strains QS-DLL", "SPECIES", 140, 162], ["CQ-814", "SPECIES", 167, 173], ["Egyptian strain AK37", "SPECIES", 175, 195], ["The penton base sequence", "TEST", 0, 24], ["Chinese strains QS", "TEST", 140, 158], ["DLL", "TEST", 159, 162], ["CQ", "TEST", 167, 169], ["Egyptian strain AK37", "PROBLEM", 175, 195], ["Argentinian strain", "TEST", 201, 219], ["BLAST score", "TEST", 226, 237], ["identity", "TEST", 245, 253]]], ["On the fiber sequence phylogenetic tree (Fig. 2c ), SD77001 clustered with the HAdV-55 strains and HAdV-14 strains.", [["HAdV-55 strains", "ORGANISM", 79, 94], ["HAdV-14 strains", "ORGANISM", 99, 114], ["HAdV-55", "SPECIES", 79, 86], ["HAdV-14", "SPECIES", 99, 106], ["the HAdV", "TEST", 75, 83], ["HAdV", "TEST", 99, 103]]], ["According to the BLASTn analysis, the fiber gene sequence of SD77001 was 100 % identical to those of HAdV-B55 strain 760_Taiwan, strain QS-DLL_China, and strain South-Dakota_USA (BLAST score, 1807; identity, 100 %), and 99 % identical to HAdV-B55 strains 273_Spain, ak36_Argentina, SGN1222_Singapore, and ak37_Egypt (BLAST score, 1801; identity, 99 %).", [["fiber", "CELLULAR_COMPONENT", 38, 43], ["HAdV-B55 strain 760_Taiwan", "ORGANISM", 101, 127], ["HAdV-B55", "ORGANISM", 238, 246], ["ak37_", "GENE_OR_GENE_PRODUCT", 305, 310], ["fiber gene sequence", "DNA", 38, 57], ["HAdV-B55", "SPECIES", 101, 109], ["HAdV-B55", "SPECIES", 238, 246], ["the BLASTn analysis", "TEST", 13, 32], ["HAdV", "TEST", 101, 105], ["BLAST score", "TEST", 317, 328], ["identity", "TEST", 336, 344]]], ["In the phylogenetic tree based on E1A (Fig. 2d) , the E1A sequence of isolate SD77001 clustered with those of the HAdV-55 and HAdV-14 strains.", [["E1A", "GENE_OR_GENE_PRODUCT", 34, 37], ["E1A", "GENE_OR_GENE_PRODUCT", 54, 57], ["HAdV-55", "ORGANISM", 114, 121], ["HAdV-14 strains", "ORGANISM", 126, 141], ["E1A", "DNA", 34, 37], ["E1A sequence", "DNA", 54, 66], ["HAdV-55", "SPECIES", 114, 121], ["HAdV-14", "SPECIES", 126, 133], ["the E1A sequence", "TEST", 50, 66], ["the HAdV", "TEST", 110, 118], ["HAdV", "TEST", 126, 130], ["phylogenetic", "ANATOMY_MODIFIER", 7, 19], ["tree", "ANATOMY_MODIFIER", 20, 24]]], ["Most of the HAdV-55 strains were 100 % identical to SD77001 in the E1A gene sequence.", [["SD77001", "CHEMICAL", 52, 59], ["HAdV-55", "ORGANISM", 12, 19], ["strains", "ORGANISM", 20, 27], ["E1A", "GENE_OR_GENE_PRODUCT", 67, 70], ["SD77001", "DNA", 52, 59], ["E1A gene sequence", "DNA", 67, 84], ["HAdV-55", "SPECIES", 12, 19], ["the HAdV", "TEST", 8, 16]]], ["To determine the genetic relationships between SD77001 and the other HAdV-B2 strains, a phylogenetic tree was constructed based on the complete hexon gene sequences of isolate SD77001 and reference strains of HAdV subspecies B2 (Fig. 2e) .", [["HAdV-B2", "ORGANISM", 69, 76], ["HAdV", "ORGANISM", 209, 213], ["hexon gene sequences", "DNA", 144, 164], ["HAdV-B2", "SPECIES", 69, 76], ["HAdV subspecies B2", "SPECIES", 209, 227], ["the other HAdV-B2 strains", "PROBLEM", 59, 84]]], ["On this tree, isolate SD77001 clustered with the HAdV-55 strains and HAdV-11 strains.", [["HAdV-55 strains", "ORGANISM", 49, 64], ["HAdV-11 strains", "ORGANISM", 69, 84], ["HAdV-55", "SPECIES", 49, 56], ["HAdV-11", "SPECIES", 69, 76], ["the HAdV", "TEST", 45, 53], ["HAdV", "PROBLEM", 69, 73]]], ["Four main clades were formed in the HAdV-55 (11a) cluster.", [["HAdV-55 (11a) cluster", "DNA", 36, 57], ["the HAdV", "TEST", 32, 40], ["main", "OBSERVATION_MODIFIER", 5, 9], ["clades", "OBSERVATION_MODIFIER", 10, 16]]], ["The first clade was composed of Argentinian strain ak36, some Chinese HAdV-55 strains, and SD77001.", [["SD77001", "CHEMICAL", 91, 98], ["HAdV-55", "ORGANISM", 70, 77], ["SD77001", "SIMPLE_CHEMICAL", 91, 98], ["Chinese HAdV-55", "SPECIES", 62, 77], ["Argentinian strain ak36", "PROBLEM", 32, 55], ["some Chinese HAdV", "PROBLEM", 57, 74]]], ["The second clade contained Taiwanese strains.", [["Taiwanese strains", "PROBLEM", 27, 44], ["Taiwanese strains", "OBSERVATION", 27, 44]]], ["The third clade included the HAdV-11a strains from Egypt,HAdV-specific serological assayTo confirm the etiological agent of this outbreak, HAdVspecific serological assays were performed.", [["HAdV-11a strains", "ORGANISM", 29, 45], ["HAdV", "ORGANISM", 57, 61], ["HAdV-11a", "SPECIES", 29, 37], ["The third clade", "PROBLEM", 0, 15], ["the HAdV", "PROBLEM", 25, 33], ["specific serological assay", "TEST", 62, 88], ["HAdVspecific serological assays", "TEST", 139, 170]]], ["All serum specimens from patients and healthy controls were examined using a classic ELISA HAdV IgA kit and IgG kit (Institute Virion/Serion GmbH).", [["serum specimens", "ANATOMY", 4, 19], ["serum specimens", "ORGANISM_SUBSTANCE", 4, 19], ["patients", "ORGANISM", 25, 33], ["HAdV", "ORGANISM", 91, 95], ["IgA", "GENE_OR_GENE_PRODUCT", 96, 99], ["classic ELISA HAdV IgA kit", "PROTEIN", 77, 103], ["IgG kit", "PROTEIN", 108, 115], ["patients", "SPECIES", 25, 33], ["All serum specimens", "TEST", 0, 19], ["IgG kit", "TEST", 108, 115]]], ["The detection results are summarized in Table 3 .", [["The detection", "TEST", 0, 13]]], ["The statistical analysis revealed that in the acute phase (within 4 days of onset), the proportion of IgA-positive samples was significantly higher in the patient group than in the control group, but the proportion of IgG-positive samples did not differ significantly between the patient and control groups (Table 3 ).", [["samples", "ANATOMY", 115, 122], ["samples", "ANATOMY", 231, 238], ["IgA", "GENE_OR_GENE_PRODUCT", 102, 105], ["patient", "ORGANISM", 155, 162], ["IgG", "GENE_OR_GENE_PRODUCT", 218, 221], ["patient", "ORGANISM", 280, 287], ["IgA", "PROTEIN", 102, 105], ["IgG", "PROTEIN", 218, 221], ["patient", "SPECIES", 155, 162], ["patient", "SPECIES", 280, 287], ["The statistical analysis", "TEST", 0, 24], ["IgA-positive samples", "TEST", 102, 122], ["IgG", "TEST", 218, 221], ["positive samples", "PROBLEM", 222, 238], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["higher", "OBSERVATION_MODIFIER", 141, 147]]], ["In the convalescent phase ([12 days after onset), the proportion of IgA-positive samples was significantly higher in the patient group than in the control group, and the proportion of IgG-positive samples was also significantly higher in the patient group than in the control group.", [["samples", "ANATOMY", 81, 88], ["samples", "ANATOMY", 197, 204], ["IgA", "GENE_OR_GENE_PRODUCT", 68, 71], ["patient", "ORGANISM", 121, 128], ["IgG", "GENE_OR_GENE_PRODUCT", 184, 187], ["patient", "ORGANISM", 242, 249], ["IgA", "PROTEIN", 68, 71], ["IgG", "PROTEIN", 184, 187], ["patient", "SPECIES", 121, 128], ["patient", "SPECIES", 242, 249], ["IgA-positive samples", "TEST", 68, 88], ["IgG", "TEST", 184, 187], ["positive samples", "PROBLEM", 188, 204], ["convalescent phase", "OBSERVATION_MODIFIER", 7, 25], ["higher", "OBSERVATION_MODIFIER", 107, 113], ["higher", "OBSERVATION_MODIFIER", 228, 234]]], ["These results confirm that HAdV was associated with this outbreak.", [["HAdV", "ORGANISM", 27, 31], ["HAdV", "PROBLEM", 27, 31], ["this outbreak", "PROBLEM", 52, 65], ["HAdV", "OBSERVATION", 27, 31]]], ["On the other, in hand, the healthy group, there were significant differences in the proportions of IgA-positive samples (11.8 % vs 52.9 %, P-IgA \u00a00.01, v 2 = 19.76) and in the proportions of IgG-positive samples (13.7 % vs 58.8 %, P IgG \u00a00.01, v 2 = 22.44) between the outbreak phase and the after-outbreak phase (same period of acute phase and convalescent phase).", [["samples", "ANATOMY", 112, 119], ["samples", "ANATOMY", 204, 211], ["hand", "ORGANISM_SUBDIVISION", 17, 21], ["IgA", "GENE_OR_GENE_PRODUCT", 99, 102], ["IgG", "GENE_OR_GENE_PRODUCT", 191, 194], ["IgA", "PROTEIN", 99, 102], ["IgG", "PROTEIN", 191, 194], ["IgA", "TEST", 99, 102], ["vs", "TEST", 128, 130], ["P", "TEST", 139, 140], ["IgA", "TEST", 141, 144], ["v", "TEST", 152, 153], ["IgG", "TEST", 191, 194], ["vs", "TEST", 220, 222], ["P", "TEST", 231, 232], ["IgG", "TEST", 233, 236], ["v", "TEST", 244, 245], ["the outbreak phase", "TEST", 265, 283], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["acute phase", "OBSERVATION_MODIFIER", 329, 340]]], ["This implies the presence of undetected infections in this military camp, which may have played an important role in the transmission of HAdV.HAdV-specific serological assayIn conclusion, the regional CDC officials concluded that a type-55-like human adenovirus B human/CHN/SD77001/ 2014/[P14H11F14] virus was the etiological pathogen responsible for this acute FRI outbreak based on the clinical manifestations in the patients, the epidemiological characteristics of the outbreak, the HAdV-DNA-specific PCR results, isolation of the virus, sequencing and alignment of the PCR amplicons, homology and phylogenetic analyses based on the complete E1A, penton base, hexon, and fiber gene sequences, and serological assays specific for HAdV IgA/IgG.DiscussionThis report describes an acute FRI outbreak caused by a type-55-like HAdV-B [P14H11F14] virus.", [["infections", "DISEASE", 40, 50], ["HAdV", "ORGANISM", 137, 141], ["type-55", "ORGANISM", 232, 239], ["human", "ORGANISM", 245, 250], ["adenovirus B human", "ORGANISM", 251, 269], ["CHN/SD77001/ 2014/[P14H11F14] virus", "ORGANISM", 270, 305], ["patients", "ORGANISM", 419, 427], ["DNA", "CELLULAR_COMPONENT", 491, 494], ["E1A", "GENE_OR_GENE_PRODUCT", 645, 648], ["fiber", "CELLULAR_COMPONENT", 674, 679], ["HAdV", "ORGANISM", 732, 736], ["IgA", "GENE_OR_GENE_PRODUCT", 737, 740], ["IgG", "GENE_OR_GENE_PRODUCT", 741, 744], ["HAdV-B [P14H11F14] virus", "ORGANISM", 824, 848], ["PCR amplicons", "DNA", 573, 586], ["E1A, penton base, hexon, and fiber gene sequences", "DNA", 645, 694], ["HAdV IgA", "PROTEIN", 732, 740], ["IgG", "PROTEIN", 741, 744], ["human", "SPECIES", 245, 250], ["human", "SPECIES", 264, 269], ["patients", "SPECIES", 419, 427], ["human", "SPECIES", 245, 250], ["B human/CHN/SD77001/ 2014/[P14H11F14] virus", "SPECIES", 262, 305], ["HAdV", "SPECIES", 732, 736], ["HAdV-B [P14H11F14] virus", "SPECIES", 824, 848], ["undetected infections", "PROBLEM", 29, 50], ["a type", "TEST", 230, 236], ["P14H11F14", "TREATMENT", 289, 298], ["virus", "TREATMENT", 300, 305], ["the etiological pathogen", "PROBLEM", 310, 334], ["this acute FRI outbreak", "PROBLEM", 351, 374], ["the outbreak", "PROBLEM", 468, 480], ["the HAdV", "TEST", 482, 490], ["specific PCR", "TEST", 495, 507], ["the virus", "PROBLEM", 530, 539], ["the PCR amplicons", "TEST", 569, 586], ["phylogenetic analyses", "TEST", 601, 622], ["penton base", "TREATMENT", 650, 661], ["hexon", "TREATMENT", 663, 668], ["fiber gene sequences", "TEST", 674, 694], ["serological assays", "TEST", 700, 718], ["HAdV IgA", "TEST", 732, 740], ["an acute FRI outbreak", "PROBLEM", 777, 798], ["a type-55-like HAdV", "PROBLEM", 809, 828], ["virus", "PROBLEM", 843, 848], ["undetected", "OBSERVATION_MODIFIER", 29, 39], ["infections", "OBSERVATION", 40, 50], ["acute", "OBSERVATION_MODIFIER", 780, 785]]], ["This virus shared the most sequence similarity with the HAdV-55 in the complete E1A gene, penton base gene, hexon gene, and fiber gene.", [["HAdV-55", "ORGANISM", 56, 63], ["E1A", "GENE_OR_GENE_PRODUCT", 80, 83], ["penton base gene", "GENE_OR_GENE_PRODUCT", 90, 106], ["fiber", "CELLULAR_COMPONENT", 124, 129], ["HAdV-55", "DNA", 56, 63], ["E1A gene", "DNA", 80, 88], ["penton base gene", "DNA", 90, 106], ["hexon gene", "DNA", 108, 118], ["fiber gene", "DNA", 124, 134], ["HAdV-55", "SPECIES", 56, 63], ["This virus", "PROBLEM", 0, 10], ["the HAdV", "TEST", 52, 60], ["penton base gene", "TREATMENT", 90, 106], ["hexon gene, and fiber gene", "TREATMENT", 108, 134], ["fiber gene", "OBSERVATION", 124, 134]]], ["HAdV-55 infections are often associated with severe respiratory tract diseases and pneumonia, including Recombination is an important feature of the genetic evolution of HAdV.", [["respiratory tract", "ANATOMY", 52, 69], ["infections", "DISEASE", 8, 18], ["respiratory tract diseases", "DISEASE", 52, 78], ["pneumonia", "DISEASE", 83, 92], ["HAdV", "DISEASE", 170, 174], ["HAdV-55", "ORGANISM", 0, 7], ["tract", "ORGANISM_SUBDIVISION", 64, 69], ["HAdV", "ORGANISM", 170, 174], ["HAdV-55", "SPECIES", 0, 7], ["HAdV", "PROBLEM", 0, 4], ["55 infections", "PROBLEM", 5, 18], ["severe respiratory tract diseases", "PROBLEM", 45, 78], ["pneumonia", "PROBLEM", 83, 92], ["HAdV", "PROBLEM", 170, 174], ["infections", "OBSERVATION", 8, 18], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["respiratory tract diseases", "OBSERVATION", 52, 78], ["pneumonia", "OBSERVATION", 83, 92]]], ["According to our analysis, the E1A, penton base, and hexon genes of isolate SD77001 are most closely related to those of Chinese mainland strain QS-DLL_2006 and Argentinean strain ak36_2005.", [["E1A", "GENE_OR_GENE_PRODUCT", 31, 34], ["penton", "GENE_OR_GENE_PRODUCT", 36, 42], ["SD77001", "GENE_OR_GENE_PRODUCT", 76, 83], ["QS-DLL_2006", "CELL", 145, 156], ["E1A, penton base", "DNA", 31, 47], ["hexon genes", "DNA", 53, 64], ["Chinese mainland strain QS-DLL_2006", "SPECIES", 121, 156], ["our analysis", "TEST", 13, 25], ["the E1A", "TREATMENT", 27, 34], ["penton base", "TREATMENT", 36, 47], ["hexon genes of isolate SD77001", "TREATMENT", 53, 83]]], ["However, its fiber gene is 100 % identical to those of USA strain South Dakota/6380_1997, Taiwanese strain 760_2002, and Chinese strain QS-DLL_2006 but differs slightly from that of the Argentinean strain.", [["fiber", "CELLULAR_COMPONENT", 13, 18], ["Taiwanese strain 760_2002", "ORGANISM", 90, 115], ["QS-DLL_2006", "CELL", 136, 147], ["fiber gene", "DNA", 13, 23], ["South Dakota/6380_1997", "SPECIES", 66, 88], ["Chinese strain QS-DLL_2006", "SPECIES", 121, 147], ["Taiwanese strain", "TEST", 90, 106], ["Chinese strain QS", "TEST", 121, 138]]], ["These characteristics may be the features of regional variants of the same genotype but these variations may have affected the infectivity or virulence of the new recombinant.", [["regional variants", "PROBLEM", 45, 62], ["the same genotype", "PROBLEM", 66, 83], ["the infectivity", "PROBLEM", 123, 138], ["regional variants", "OBSERVATION", 45, 62], ["new", "OBSERVATION_MODIFIER", 159, 162], ["recombinant", "OBSERVATION_MODIFIER", 163, 174]]], ["Further research, including complete genome sequencing and analysis, is required to identify any other relevant genetic variations that are responsible for the milder clinical manifestations of this HAdV-B [P14H11F14] strain.DiscussionMany seroprevalence studies among military recruits have shown that lack of pre-existing immunity to some particular serotypes of pathogen is a critical factor determining susceptibility to infection.", [["infection", "DISEASE", 425, 434], ["HAdV-B", "ORGANISM", 199, 205], ["complete genome sequencing", "TEST", 28, 54], ["analysis", "TEST", 59, 67], ["the milder clinical manifestations", "PROBLEM", 156, 190], ["this HAdV", "PROBLEM", 194, 203], ["strain", "PROBLEM", 218, 224], ["seroprevalence studies", "TEST", 240, 262], ["pathogen", "PROBLEM", 365, 373], ["susceptibility to infection", "PROBLEM", 407, 434], ["infection", "OBSERVATION", 425, 434]]], ["From an epidemiological perspective, outbreaks of respiratory illness in a military camp usually show higher infection rate among new recruits than among regular soldiers.", [["respiratory", "ANATOMY", 50, 61], ["respiratory illness", "DISEASE", 50, 69], ["infection", "DISEASE", 109, 118], ["respiratory illness", "PROBLEM", 50, 69], ["higher infection rate", "PROBLEM", 102, 123], ["respiratory illness", "OBSERVATION", 50, 69], ["higher", "OBSERVATION_MODIFIER", 102, 108], ["infection", "OBSERVATION", 109, 118]]], ["However, in the present outbreak, there was no significant difference in the incidence rates of the new recruits and regular soldiers.", [["no", "UNCERTAINTY", 44, 46], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["difference", "OBSERVATION_MODIFIER", 59, 69], ["new", "OBSERVATION_MODIFIER", 100, 103]]], ["This phenomenon suggests that the main pathogen of this outbreak is an unfamiliar pathogen to these troops, or even in this whole area.", [["main", "OBSERVATION_MODIFIER", 34, 38]]], ["Therefore, both the recruits and regular soldiers lacked pre-existing immunity to this pathogen.", [["this pathogen", "PROBLEM", 82, 95]]], ["Some earlier statistical analyses have shown that marching training and firing training are significantly associated with the onset of pneumonia and FRI, especially in HAdV outbreaks [19] .", [["pneumonia", "DISEASE", 135, 144], ["FRI", "DISEASE", 149, 152], ["HAdV", "ORGANISM", 168, 172], ["Some earlier statistical analyses", "PROBLEM", 0, 33], ["marching training", "TREATMENT", 50, 67], ["firing training", "TREATMENT", 72, 87], ["pneumonia", "PROBLEM", 135, 144], ["FRI", "PROBLEM", 149, 152], ["pneumonia", "OBSERVATION", 135, 144]]], ["During a respiratory illness outbreak in an MTC in the USA, HAdV was detected on rifle surfaces [20] .", [["respiratory illness", "DISEASE", 9, 28], ["MTC", "DISEASE", 44, 47], ["HAdV", "ORGANISM", 60, 64], ["a respiratory illness outbreak", "PROBLEM", 7, 37], ["HAdV", "PROBLEM", 60, 64]]], ["During the early period of the present outbreak, the main components of the training schedule were mid-range marches and night firing training, which may have contributed to the increased patient numbers or exacerbated their symptoms.", [["patient", "ORGANISM", 188, 195], ["patient", "SPECIES", 188, 195], ["the training schedule", "TREATMENT", 72, 93], ["the increased patient numbers", "PROBLEM", 174, 203], ["their symptoms", "PROBLEM", 219, 233], ["main", "OBSERVATION_MODIFIER", 53, 57], ["components", "OBSERVATION_MODIFIER", 58, 68], ["increased", "OBSERVATION_MODIFIER", 178, 187]]], ["Based on this experience, appropriate measures must be identified and implemented to prevent outbreaks of respiratory illnesses in military training units, such as postponing firing training until after the peak stage of the epidemic and disinfecting the training rifles when they are transferred from one trainee to another.", [["respiratory", "ANATOMY", 106, 117], ["respiratory illnesses", "DISEASE", 106, 127], ["appropriate measures", "TREATMENT", 26, 46], ["respiratory illnesses", "PROBLEM", 106, 127], ["military training units", "TREATMENT", 131, 154], ["postponing firing training", "TREATMENT", 164, 190]]], ["In the acute FRI outbreak reported here, about 25 new cases appeared with the same symptoms in the 15 days after 7 May.", [["the acute FRI outbreak", "PROBLEM", 3, 25], ["the same symptoms", "PROBLEM", 74, 91], ["acute", "OBSERVATION_MODIFIER", 7, 12]]], ["No correct diagnostic procedures were implemented, no epidemiological investigation was commenced, and the supervisory CDC received no information about the new cases.", [["epidemiological investigation", "TEST", 54, 83]]], ["When a large wave of new cases (n = 79) appeared between 22 May and 30 May, in an effort to control the outbreak, the MTC healthy managers gathered about 798 soldiers into several crowded classrooms for health education, which may have contributed greatly to the transmission of the disease, and 7 days later, the highest incidence peak of the entire outbreak was observed (Fig. 1) .", [["MTC", "DISEASE", 118, 121], ["health education", "TREATMENT", 203, 219], ["the disease", "PROBLEM", 279, 290], ["the entire outbreak", "PROBLEM", 340, 359], ["large", "OBSERVATION_MODIFIER", 7, 12], ["wave", "OBSERVATION_MODIFIER", 13, 17], ["disease", "OBSERVATION", 283, 290]]], ["Had the health officials dealt with the outbreak correctly from the very beginning, the spread of this FRI may have been restricted to a much smaller scale.DiscussionBecause outbreaks of HAdV-55 infections have been frequent in recent years, HAdV-55-associated FRI pose a serious threat to the Chinese army.", [["HAdV-55 infections", "DISEASE", 187, 205], ["HAdV-55", "CHEMICAL", 242, 249], ["FRI", "DISEASE", 261, 264], ["HAdV-55", "ORGANISM", 187, 194], ["HAdV-55", "ORGANISM", 242, 249], ["FRI", "DNA", 103, 106], ["HAdV-55", "SPECIES", 187, 194], ["HAdV-55", "SPECIES", 242, 249], ["this FRI", "TREATMENT", 98, 106], ["a much smaller scale", "TREATMENT", 135, 155], ["HAdV", "PROBLEM", 187, 191], ["HAdV", "PROBLEM", 242, 246]]], ["Therefore, improved epidemiological and virological surveillance of HAdV and many other dangerous pathogens by the Chinese military health system is urgently required.", [["HAdV", "DISEASE", 68, 72], ["HAdV", "ORGANISM", 68, 72], ["HAdV", "SPECIES", 68, 72], ["virological surveillance", "TEST", 40, 64], ["HAdV", "PROBLEM", 68, 72], ["many other dangerous pathogens", "PROBLEM", 77, 107], ["improved", "OBSERVATION_MODIFIER", 11, 19]]], ["Some simple and accurate diagnostic methods that distinguish HAdV-55 infections from other similar diseases must be established.", [["infections", "DISEASE", 69, 79], ["HAdV-55", "ORGANISM", 61, 68], ["HAdV-55", "SPECIES", 61, 68], ["HAdV", "PROBLEM", 61, 65], ["55 infections", "PROBLEM", 66, 79], ["other similar diseases", "PROBLEM", 85, 107], ["diseases", "OBSERVATION", 99, 107]]], ["Moreover, in view of the U.S. army's experience with an HAdV vaccination program, the development and application of HAdV vaccines may be an excellent way to protect the health of Chinese soldiers.DiscussionThe present study has several limitations.", [["HAdV", "ORGANISM", 117, 121], ["HAdV", "SPECIES", 117, 121], ["an HAdV vaccination program", "TREATMENT", 53, 80], ["HAdV vaccines", "TREATMENT", 117, 130], ["The present study", "TEST", 207, 224]]], ["First, although 91.84 % (45 of 49) of throat swab specimens were positive when using an RV13 kit and HAdV-specific PCR and the amplicons from the 45 PCR-positive samples were found to have high sequence similarities to the HAdV-B55 strains, the remaining 115 FRI cases were still not detected by the specific PCR and sequencing analysis.", [["throat swab specimens", "ANATOMY", 38, 59], ["samples", "ANATOMY", 162, 169], ["throat swab specimens", "CANCER", 38, 59], ["HAdV", "ORGANISM", 101, 105], ["HAdV-B55 strains", "ORGANISM", 223, 239], ["HAdV-specific PCR", "DNA", 101, 118], ["RV13", "SPECIES", 88, 92], ["HAdV-B55", "SPECIES", 223, 231], ["throat swab specimens", "TEST", 38, 59], ["an RV13 kit", "TEST", 85, 96], ["HAdV", "PROBLEM", 101, 105], ["specific PCR", "TEST", 106, 118], ["the amplicons", "TEST", 123, 136], ["the 45 PCR", "TEST", 142, 152], ["high sequence similarities", "PROBLEM", 189, 215], ["the HAdV", "TEST", 219, 227], ["B55 strains", "PROBLEM", 228, 239], ["FRI cases", "TEST", 259, 268], ["the specific PCR", "TEST", 296, 312], ["sequencing analysis", "TEST", 317, 336], ["throat", "ANATOMY", 38, 44]]], ["Therefore, it was still difficult to ensure this HAdV-B55-like virus was the only pathogenic agent responsible for this outbreak.", [["HAdV-B55-like virus", "ORGANISM", 49, 68], ["HAdV-B55", "SPECIES", 49, 57], ["this HAdV", "PROBLEM", 44, 53], ["B55-like virus", "PROBLEM", 54, 68], ["this outbreak", "PROBLEM", 115, 128]]], ["It is possible that some other pathogens were involved in this outbreak.", [["some other pathogens", "PROBLEM", 20, 40], ["pathogens", "OBSERVATION", 31, 40]]], ["In some previously published descriptions of outbreaks of HAdV infection among military trainees, the co-circulation of two or more types of HAdV had already been reported.", [["HAdV infection", "DISEASE", 58, 72], ["HAdV", "DISEASE", 141, 145], ["HAdV", "ORGANISM", 58, 62], ["HAdV", "ORGANISM", 141, 145], ["HAdV", "SPECIES", 58, 62], ["HAdV infection", "PROBLEM", 58, 72], ["HAdV", "PROBLEM", 141, 145], ["HAdV", "OBSERVATION_MODIFIER", 58, 62], ["infection", "OBSERVATION", 63, 72]]], ["Second, the members of the healthy control group were randomly selected from the asymptomatic soldiers in the same MTC on 30 May.", [["MTC", "DISEASE", 115, 118]]], ["At the same time, the disease prevention and control measures had been implemented.", [["the disease prevention", "TREATMENT", 18, 40], ["control measures", "TREATMENT", 45, 61], ["disease", "OBSERVATION", 22, 29]]], ["None of the healthy controls showed any respiratory tract disease symptoms during the outbreak period.", [["respiratory tract", "ANATOMY", 40, 57], ["respiratory tract disease", "DISEASE", 40, 65], ["controls", "ORGANISM", 20, 28], ["respiratory tract", "ORGANISM_SUBDIVISION", 40, 57], ["any respiratory tract disease symptoms", "PROBLEM", 36, 74], ["respiratory tract", "ANATOMY", 40, 57]]], ["However, these healthy controls had not been screened by laboratory detection methods such as viral nucleic acid detection.", [["nucleic acid", "CHEMICAL", 100, 112], ["laboratory detection methods", "TEST", 57, 85], ["viral nucleic acid detection", "TEST", 94, 122]]], ["Considering the results of the IgA and IgG detection in the healthy control group, there may have been asymptomatic infection cases hiding in the healthy control group.", [["infection", "DISEASE", 116, 125], ["IgA", "GENE_OR_GENE_PRODUCT", 31, 34], ["IgG", "GENE_OR_GENE_PRODUCT", 39, 42], ["IgA", "PROTEIN", 31, 34], ["IgG", "PROTEIN", 39, 42], ["the IgA", "TEST", 27, 34], ["IgG detection", "TEST", 39, 52], ["asymptomatic infection cases", "PROBLEM", 103, 131], ["asymptomatic", "OBSERVATION_MODIFIER", 103, 115], ["infection", "OBSERVATION", 116, 125]]], ["Many ''healthy control group'' members had already been infected by this HAdV virus.", [["HAdV virus", "ORGANISM", 73, 83], ["HAdV virus", "SPECIES", 73, 83], ["this HAdV virus", "PROBLEM", 68, 83]]], ["In a future outbreak study, the healthy controls should be selected from a camp where the virus was not present and be screened using laboratory detection methods to differentiate the asymptomatic infection cases.", [["infection", "DISEASE", 197, 206], ["a future outbreak study", "TEST", 3, 26], ["a camp where the virus", "PROBLEM", 73, 95], ["laboratory detection methods", "TEST", 134, 162], ["the asymptomatic infection cases", "PROBLEM", 180, 212], ["asymptomatic", "OBSERVATION_MODIFIER", 184, 196], ["infection", "OBSERVATION", 197, 206]]]], "PMC7316066": [["IntroductionThe 2020 novel coronavirus SARS-CoV-2 and subsequent coronavirus disease-19 (COVID-19) pandemic has caused unprecedented societal disruption worldwide.", [["SARS", "DISEASE", 39, 43], ["coronavirus disease", "DISEASE", 65, 84], ["COVID-19", "CHEMICAL", 89, 97], ["coronavirus SARS-CoV-2", "ORGANISM", 27, 49], ["coronavirus disease-19", "ORGANISM", 65, 87], ["COVID-19", "ORGANISM", 89, 97], ["coronavirus SARS-CoV", "SPECIES", 27, 47], ["coronavirus disease-19 (COVID-19", "SPECIES", 65, 97], ["novel coronavirus SARS", "TEST", 21, 43], ["CoV", "TEST", 44, 47], ["subsequent coronavirus disease", "PROBLEM", 54, 84], ["COVID", "TEST", 89, 94], ["pandemic", "PROBLEM", 99, 107], ["coronavirus disease", "OBSERVATION", 65, 84], ["unprecedented", "OBSERVATION_MODIFIER", 119, 132], ["societal disruption", "OBSERVATION", 133, 152]]], ["While most Americans' daily lives and routines have markedly changed during the pandemic, Americans with chronic disease, including epilepsy, are at unique risk for health-related disruptions.", [["chronic disease", "DISEASE", 105, 120], ["epilepsy", "DISEASE", 132, 140], ["chronic disease", "PROBLEM", 105, 120], ["epilepsy", "PROBLEM", 132, 140], ["health-related disruptions", "PROBLEM", 165, 191], ["chronic", "OBSERVATION_MODIFIER", 105, 112], ["disease", "OBSERVATION", 113, 120], ["epilepsy", "OBSERVATION", 132, 140]]], ["Both Federal and state mandates put in place to quell the spread of COVID-19, and the risk of contracting the virus, have potentially created unique barriers for those with epilepsy.IntroductionFirst reported in China, COVID-19 is caused by a novel virus that leads to respiratory illness in varying degrees of severity, from asymptomatic to respiratory failure and death.", [["respiratory", "ANATOMY", 269, 280], ["respiratory", "ANATOMY", 342, 353], ["epilepsy", "DISEASE", 173, 181], ["respiratory illness", "DISEASE", 269, 288], ["respiratory failure", "DISEASE", 342, 361], ["death", "DISEASE", 366, 371], ["COVID-19", "SPECIES", 219, 227], ["COVID", "TEST", 68, 73], ["contracting the virus", "PROBLEM", 94, 115], ["epilepsy", "PROBLEM", 173, 181], ["a novel virus", "PROBLEM", 241, 254], ["respiratory illness", "PROBLEM", 269, 288], ["severity", "PROBLEM", 311, 319], ["respiratory failure", "PROBLEM", 342, 361], ["death", "PROBLEM", 366, 371], ["varying degrees", "OBSERVATION_MODIFIER", 292, 307], ["respiratory failure", "OBSERVATION", 342, 361]]], ["Nearly 3 million cases of COVID-19 have been confirmed globally, with the US currently having the most at nearly 1 million confirmed cases; nearly 200,000 people [1], including more than 50,000 Americans [2], have died from COVID-19.", [["people", "ORGANISM", 155, 161], ["people", "SPECIES", 155, 161], ["COVID", "TEST", 26, 31], ["the US", "TEST", 70, 76], ["COVID", "TEST", 224, 229]]], ["Given its novelty, COVID-19 has been especially difficult to contain, with public health experts scrambling to determine details about the virus' spread and ability to live on surfaces.", [["COVID", "TEST", 19, 24], ["the virus' spread", "PROBLEM", 135, 152]]], ["The unknown aspects of the highly contagious virus' spread and effective treatment have caused Federal- and state-level government action on a scale not seen since some states enacted social distancing during the 1918 Spanish Flu pandemic [3].IntroductionPresident Trump has ordered the nation to follow drastic social distancing guidelines, which include staying at least six feet apart from others outside of family, only leaving the house for essential purposes, and working from home whenever possible.", [["the highly contagious virus' spread", "PROBLEM", 23, 58], ["effective treatment", "TREATMENT", 63, 82]]], ["Even in states beginning to open, daily environments are far from normal.IntroductionIn the midst of a personal protective equipment and ventilator shortage, governors have halted nonemergent surgeries and procedures, and many health clinics are closed or only seeing patients in the event of an emergency [5].", [["patients", "ORGANISM", 268, 276], ["patients", "SPECIES", 268, 276], ["a personal protective equipment", "TREATMENT", 101, 132], ["ventilator shortage", "TREATMENT", 137, 156], ["nonemergent surgeries", "TREATMENT", 180, 201], ["procedures", "TREATMENT", 206, 216], ["normal", "OBSERVATION", 66, 72]]], ["These necessary precautions have resulted in not only economic collapse but also extreme alterations in a healthcare system on which 3 million Americans rely for treatment and management of their epilepsy, a condition which the Centers for Disease Control and Prevention (CDC) has indicated increases the risk for serious COVID-19 infection [6].", [["epilepsy", "DISEASE", 196, 204], ["infection", "DISEASE", 331, 340], ["COVID-19", "CHEMICAL", 322, 330], ["These necessary precautions", "TREATMENT", 0, 27], ["economic collapse", "PROBLEM", 54, 71], ["extreme alterations", "PROBLEM", 81, 100], ["treatment", "TREATMENT", 162, 171], ["management", "TREATMENT", 176, 186], ["their epilepsy", "PROBLEM", 190, 204], ["Disease Control", "TREATMENT", 240, 255], ["serious COVID-19 infection", "PROBLEM", 314, 340], ["collapse", "OBSERVATION", 63, 71], ["extreme", "OBSERVATION_MODIFIER", 81, 88], ["alterations", "OBSERVATION", 89, 100], ["epilepsy", "OBSERVATION", 196, 204]]], ["In the midst of a healthcare crisis focused on preventing and treating COVID-19, another question arises\u2014how does the pandemic affect the health of patients not affected by COVID-19, and especially those managing chronic diseases like epilepsy?", [["chronic diseases", "DISEASE", 213, 229], ["epilepsy", "DISEASE", 235, 243], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["COVID", "TEST", 71, 76], ["COVID", "TEST", 173, 178], ["chronic diseases", "PROBLEM", 213, 229], ["epilepsy", "PROBLEM", 235, 243], ["chronic", "OBSERVATION_MODIFIER", 213, 220], ["diseases", "OBSERVATION", 221, 229], ["epilepsy", "OBSERVATION", 235, 243]]], ["This question is especially important to consider given that the nation will likely have to engage in additional rounds of social distancing until a vaccine for COVID-19 is available [7].IntroductionEpilepsy self-management is key to achievement of epilepsy-related outcomes [8] and refers to a patient managing the treatments and day-to-day lifestyle changes associated with epilepsy.", [["epilepsy", "DISEASE", 249, 257], ["epilepsy", "DISEASE", 376, 384], ["patient", "ORGANISM", 295, 302], ["patient", "SPECIES", 295, 302], ["a vaccine", "TREATMENT", 147, 156], ["COVID", "TEST", 161, 166], ["epilepsy", "PROBLEM", 249, 257], ["the treatments", "TREATMENT", 312, 326], ["epilepsy", "PROBLEM", 376, 384], ["epilepsy", "OBSERVATION", 376, 384]]], ["Specifically, epilepsy self-management is the process during which patients incorporate multidimensional strategies that meet their self-identified needs to manage and cope with epilepsy within the context of their daily living; successful management of both functioning in day-to-day life along with management of chronic illness requires the individual to continually monitor health and functional status and take appropriate actions during acute phases, and this management often involves a familial caregiver [9].", [["epilepsy", "DISEASE", 14, 22], ["epilepsy", "DISEASE", 178, 186], ["chronic illness", "DISEASE", 315, 330], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["epilepsy", "PROBLEM", 14, 22], ["multidimensional strategies", "TREATMENT", 88, 115], ["epilepsy", "PROBLEM", 178, 186], ["successful management", "TREATMENT", 229, 250], ["management", "TREATMENT", 301, 311], ["chronic illness", "PROBLEM", 315, 330], ["chronic", "OBSERVATION_MODIFIER", 315, 322], ["illness", "OBSERVATION", 323, 330]]], ["The COVID-19 pandemic creates a rare opportunity to explore how epilepsy self-management is altered when societal, economic, and healthcare structures do not exist in their usual forms in the US.", [["epilepsy", "DISEASE", 64, 72]]], ["The purpose of this descriptive study was to, from the perspective of adult people with epilepsy (PWE) and caregivers of PWE, explore the effects of the current pandemic and resulting societal changes on epilepsy self-management.", [["epilepsy", "DISEASE", 88, 96], ["PWE", "DISEASE", 98, 101], ["epilepsy", "DISEASE", 204, 212], ["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82], ["this descriptive study", "TEST", 15, 37], ["epilepsy", "PROBLEM", 88, 96], ["resulting societal changes", "PROBLEM", 174, 200], ["epilepsy self-management", "TREATMENT", 204, 228]]], ["Specifically, we sought to explore how mandated isolation, social distancing orders, closure of many businesses, and COVID-19 infections have affected PWE and their caregivers' ability to self-manage (control seizures, access medications, manage triggers, and communicate with providers).", [["infections", "DISEASE", 126, 136], ["seizures", "DISEASE", 209, 217], ["closure", "TREATMENT", 85, 92], ["seizures", "PROBLEM", 209, 217], ["access medications", "TREATMENT", 219, 237]]], ["Further, we explored the frequency and severity of affective symptoms, as well as other PWE- and caregiver-identified difficulties that have arisen during the pandemic.Materials and methodsThe study was submitted to the Indiana University IRB and deemed exempt.", [["affective symptoms", "DISEASE", 51, 69], ["affective symptoms", "PROBLEM", 51, 69], ["The study", "TEST", 189, 198]]], ["Using social media, an advertisement for the survey was shared via various epilepsy-related Facebook pages and via Twitter with the appropriate hashtags to render it searchable (#COVID-19, #epilepsy, #pandemic, and #research).", [["epilepsy", "DISEASE", 75, 83], ["epilepsy", "DISEASE", 190, 198], ["epilepsy", "PROBLEM", 190, 198], ["pandemic", "PROBLEM", 201, 209]]], ["All participants self-referred to the study via the link embedded in the online advertisement.Materials and methodsInclusion criteria were the following: age 18 years or older, a person diagnosed with epilepsy taking antiseizure medication OR the caregiver of a child/loved one with epilepsy currently taking antiseizure medication for epilepsy, fluent in English, reliable access to the Internet, and currently living in the US.", [["epilepsy", "DISEASE", 201, 209], ["epilepsy", "DISEASE", 283, 291], ["epilepsy", "DISEASE", 336, 344], ["participants", "SPECIES", 4, 16], ["person", "SPECIES", 179, 185], ["the study", "TEST", 34, 43], ["epilepsy", "PROBLEM", 201, 209], ["antiseizure medication", "TREATMENT", 217, 239], ["epilepsy", "PROBLEM", 283, 291], ["antiseizure medication", "TREATMENT", 309, 331], ["epilepsy", "PROBLEM", 336, 344]]], ["Participants lacking these criteria were excluded and automatically directed to the end of the survey.", [["Participants", "SPECIES", 0, 12]]], ["The survey included a total of 65 questions, 50 of which were relevant to this manuscript, and included questions related to demographics, perceived changes in epilepsy self-management, social distancing, and affective symptoms since the pandemic began.", [["epilepsy", "DISEASE", 160, 168], ["affective symptoms", "DISEASE", 209, 227], ["epilepsy self-management", "TREATMENT", 160, 184], ["affective symptoms", "PROBLEM", 209, 227]]], ["During this three day period, 31 states were under some version of stay-at-home orders.Materials and methodsUsing SPSS version 26, descriptive statistics were run on all quantitative variables.", [["SPSS version", "TEST", 114, 126], ["descriptive statistics", "TEST", 131, 153]]], ["Paired t-tests were used to detect statistically significant differences on items that involved respondents providing a pre- and postpandemic score.", [["Paired t-tests", "TEST", 0, 14]]], ["Qualitative comments were analyzed using traditional content analysis.Demographics ::: ResultsThe survey was accessed by 112 people.", [["people", "ORGANISM", 125, 131], ["people", "SPECIES", 125, 131], ["traditional content analysis", "TEST", 41, 69]]], ["Five surveys were discarded because of high recaptcha scores on Qualtrics, indicating high likelihood of bot completion.", [["Five surveys", "TEST", 0, 12], ["high recaptcha scores", "PROBLEM", 39, 60], ["high", "OBSERVATION_MODIFIER", 86, 90]]], ["Thus, 107 completed the survey, and 94 participants completed every single survey item.", [["participants", "SPECIES", 39, 51]]], ["The final sample size was thus 94.", [["The final sample size", "TEST", 0, 21], ["size", "OBSERVATION_MODIFIER", 17, 21]]], ["The gender of the sample was equally split, with 47 men and 47 women.", [["men", "ORGANISM", 52, 55], ["women", "ORGANISM", 63, 68], ["men", "SPECIES", 52, 55], ["women", "SPECIES", 63, 68]]], ["Participants were White (80%), African American (9%), American Indian/Alaskan Native (4%), Native Hawaiian or Pacific Islander (4%), Asian (2%), or Other (1%).", [["Participants", "SPECIES", 0, 12]]], ["Participants resided in the Midwest (30%), Northeast (19%), Mid-Atlantic (18%), West (17%), Northwest (7%), Southeast (6%), and Southwest (3%) regions of the US.", [["Participants", "SPECIES", 0, 12], ["the US", "TEST", 154, 160]]], ["Sixty respondents indicated that they or their loved ones with epilepsy had not been tested for COVID-19, 16 of whom reported that they had current symptoms (fever, cough, or shortness of breath) that they believed could have been contributed to COVID-19.", [["epilepsy", "DISEASE", 63, 71], ["fever", "DISEASE", 158, 163], ["cough", "DISEASE", 165, 170], ["shortness of breath", "DISEASE", 175, 194], ["COVID-19", "CHEMICAL", 246, 254], ["epilepsy", "PROBLEM", 63, 71], ["current symptoms", "PROBLEM", 140, 156], ["fever", "PROBLEM", 158, 163], ["cough", "PROBLEM", 165, 170], ["shortness of breath", "PROBLEM", 175, 194], ["COVID", "TEST", 246, 251]]], ["Thirty-one participants reported that they or their loved ones with epilepsy had been tested for COVID-19; of these, 7 reported that they (or their loved one with epilepsy) were COVID-19 positive, while 24 reported negative COVID-19 testing results.", [["epilepsy", "DISEASE", 68, 76], ["epilepsy", "DISEASE", 163, 171], ["participants", "ORGANISM", 11, 23], ["participants", "SPECIES", 11, 23], ["epilepsy", "PROBLEM", 68, 76], ["COVID", "TEST", 97, 102], ["epilepsy", "PROBLEM", 163, 171], ["COVID", "TEST", 178, 183], ["COVID", "TEST", 224, 229]]], ["Sixty-nine percent of the sample (n = 65) indicated that they were aware that the CDC has named PWE as high risk for serious COVID-19 infections, and the majority (82%) learned this from the Epilepsy Foundation social media accounts.", [["COVID", "DISEASE", 125, 130], ["infections", "DISEASE", 134, 144], ["Epilepsy", "DISEASE", 191, 199], ["the sample", "TEST", 22, 32], ["serious COVID-19 infections", "PROBLEM", 117, 144], ["infections", "OBSERVATION", 134, 144]]], ["No demographic variables were statistically significantly correlated with other measures.Social distancing ::: ResultsRespondents were asked to describe the degree to which they have been practicing social distancing.", [["demographic variables", "PROBLEM", 3, 24]]], ["Seventy-seven respondents indicated that they were struggling to practice social distancing; 40 participants reported that having to report to work for an essential job interfered with their ability to practice social distancing.", [["participants", "SPECIES", 96, 108]]], ["Table 2includes additional results related to respondents' experiences with social distancing.Epilepsy- and self-management-related changes ::: ResultsWe asked various questions aimed at determining how respondents' epilepsy and epilepsy self-management have been affected by the pandemic.", [["Epilepsy", "DISEASE", 94, 102], ["epilepsy", "DISEASE", 216, 224], ["epilepsy", "DISEASE", 229, 237], ["Epilepsy", "PROBLEM", 94, 102], ["epilepsy", "PROBLEM", 216, 224], ["epilepsy", "PROBLEM", 229, 237]]], ["More than one-third (35%, n = 33) of respondents indicated that they or their loved ones have experienced increased seizure frequency since pandemic onset.", [["seizure", "DISEASE", 116, 123], ["pandemic", "DISEASE", 140, 148], ["increased seizure frequency", "PROBLEM", 106, 133], ["pandemic onset", "PROBLEM", 140, 154]]], ["Of those who indicated worsening seizures during the pandemic, on a scale of 0\u201310 with 0 being seizure frequency has not increased at all and 10 being seizure frequency has increased very much, the mean score was 6.88 (SD: 0.98, range: 3\u20138).", [["seizures", "DISEASE", 33, 41], ["seizure", "DISEASE", 95, 102], ["seizure", "DISEASE", 151, 158], ["worsening seizures", "PROBLEM", 23, 41], ["seizure frequency", "PROBLEM", 95, 112], ["seizure frequency", "PROBLEM", 151, 168], ["the mean score", "TEST", 194, 208], ["worsening", "OBSERVATION_MODIFIER", 23, 32], ["seizures", "OBSERVATION", 33, 41], ["increased", "OBSERVATION_MODIFIER", 121, 130]]], ["Respondents were asked to rank the degree to which several epilepsy self-management-related activities (ability to control seizures, ability to get seizure medication from pharmacy when needed, ability to reach healthcare provider, ability to take/give seizure medication at the correct time, ability to manage stress, ability to stay in a normal sleeping routine, and ability to track seizures and medication) were affected by the pandemic.", [["epilepsy", "DISEASE", 59, 67], ["seizures", "DISEASE", 123, 131], ["seizure", "DISEASE", 148, 155], ["seizure", "DISEASE", 253, 260], ["seizures", "DISEASE", 386, 394], ["seizures", "PROBLEM", 123, 131], ["seizure medication", "TREATMENT", 148, 166], ["seizure medication", "TREATMENT", 253, 271], ["stress", "PROBLEM", 311, 317], ["seizures", "PROBLEM", 386, 394], ["medication", "TREATMENT", 399, 409]]], ["Ability to get medications from the pharmacy was most affected by the pandemic, with 73% of the sample indicating that this area of epilepsy self-management was made \u201cmuch more difficult\u201d by the pandemic.", [["epilepsy", "DISEASE", 132, 140], ["medications", "TREATMENT", 15, 26], ["the sample", "TEST", 92, 102], ["epilepsy", "PROBLEM", 132, 140], ["epilepsy", "OBSERVATION", 132, 140]]], ["More than 40% of the sample indicated that managing seizures, managing stress, and reaching their epilepsy healthcare provider were made \u201cmuch more difficult\u201d by the pandemic.", [["seizures", "DISEASE", 52, 60], ["epilepsy", "DISEASE", 98, 106], ["managing seizures", "PROBLEM", 43, 60]]], ["Fig. 1displays more detailed results of respondents' rankings in response to this question.Epilepsy- and self-management-related changes ::: ResultsRespondents were asked to rate the degree to which they feel confident that they could get timely help from their/their loved one's epilepsy provider, hospital, and pharmacy using a 0\u201310 scale, with 0 being not at all confident and 10 being very confident.", [["Epilepsy", "DISEASE", 91, 99], ["epilepsy", "DISEASE", 280, 288], ["Epilepsy", "PROBLEM", 91, 99], ["self-management", "TREATMENT", 105, 120]]], ["Respondents were least confident in their ability to get timely help for epilepsy at a hospital (mean = 5.19, SD: 2.69), followed by their confidence in receiving help from pharmacies (mean = 5.89, SD: 2.65).", [["epilepsy", "DISEASE", 73, 81], ["epilepsy", "PROBLEM", 73, 81]]], ["Respondents had the highest level of confidence in receiving help from epilepsy providers (mean = 5.91, SD: 2.44), resulting in the highest level of confidence being just above \u201csomewhat confident.\u201dAffective symptoms ::: ResultsParticipants were asked to describe the degree to which their support networks, feelings of isolation, and anxiety had changed as compared with before the pandemic.", [["epilepsy", "DISEASE", 71, 79], ["anxiety", "DISEASE", 335, 342], ["mean", "TEST", 91, 95], ["Affective symptoms", "PROBLEM", 198, 216], ["anxiety", "PROBLEM", 335, 342]]], ["Respondents rated the strength of their social support networks using a 10-point Likert scale (0 = not at all strong, 10 = very strong) before and after the pandemic, and there was a statistically significant difference in pre- and postpandemic social support network strength (mean score pre = 7.52; mean score post = 7.41; t = 3.02, p < .003).", [["mean score", "TEST", 301, 311], ["t", "TEST", 325, 326]]], ["The same was true for perceived isolation pre- and postpandemic (mean score pre = 6.27; mean score post = 7.18; t = 4.12, p = .000).", [["perceived isolation", "TEST", 22, 41], ["mean score", "TEST", 88, 98], ["t", "TEST", 112, 113], ["p", "TEST", 122, 123]]], ["Using the PROMIS anxiety scale [10], respondents reported statistically significant higher levels of anxiety postpandemic than prepandemic (mean score pre = 22.2; mean score post = 26.7; t = \u2212 6.86; p = .000).", [["anxiety", "DISEASE", 17, 24], ["anxiety", "DISEASE", 101, 108], ["the PROMIS anxiety scale", "TREATMENT", 6, 30], ["anxiety postpandemic", "PROBLEM", 101, 121], ["mean score", "TEST", 140, 150], ["mean score", "TEST", 163, 173], ["t", "TEST", 187, 188], ["p", "TEST", 199, 200]]], ["Asked to rate how they were coping with the current pandemic on a scale of 0\u201310, with 0 being not at all and 10 being very well, the mean score was 7.08 (SD: 1.89; range: 0\u201310).Difficulties with social distancing ::: Qualitative comments ::: ResultsMany (n = 23) respondents described how current responsibilities interfered with social distancing.", [["the mean score", "TEST", 129, 143]]], ["One participant stated, \u201cI live alone, so grocery shopping and pharmacy are all on me.\u201d", [["participant", "SPECIES", 4, 15]]], ["I also do not drive due to my seizures so I need to rely on others for transportation, which has limited my ability to social distance.\u201d", [["seizures", "DISEASE", 30, 38], ["my seizures", "PROBLEM", 27, 38]]], ["Another participant remarked, \u201cI have to report to work where 50 people are daily.\u201d", [["people", "ORGANISM", 65, 71], ["participant", "SPECIES", 8, 19], ["people", "SPECIES", 65, 71]]], ["Others noted that the ability to work from home has been very helpful in social distancing, \u201cWith the ability to telework 100%\u2026 we were able to prepare early by stocking food supplies to limit trips out of the house and obtain 90 day supplies of antiseizure meds, and critical vitamins and minerals for health stability.", [["vitamins", "SIMPLE_CHEMICAL", 277, 285], ["minerals", "SIMPLE_CHEMICAL", 290, 298], ["antiseizure meds", "TREATMENT", 246, 262], ["critical vitamins and minerals", "TREATMENT", 268, 298]]], ["If we were not able to telework we would suffer with caring for our daughter and providing a safe situation for seizure monitoring.\u201dImpact on seizure frequency and severity ::: Qualitative comments ::: ResultsNine of 33 respondents who indicated a worsening of seizure frequency and/or severity left comments about how the pandemic has directly affected their seizure frequency and severity.", [["seizure", "DISEASE", 112, 119], ["seizure", "DISEASE", 142, 149], ["seizure", "DISEASE", 261, 268], ["seizure", "DISEASE", 360, 367], ["seizure monitoring", "TEST", 112, 130], ["a worsening of seizure frequency", "PROBLEM", 246, 278], ["severity", "PROBLEM", 382, 390], ["worsening", "OBSERVATION_MODIFIER", 248, 257]]], ["According to one respondent, \u201cI'm having a lot more complex partial seizures.", [["seizures", "DISEASE", 68, 76], ["a lot more complex partial seizures", "PROBLEM", 41, 76], ["partial", "OBSERVATION_MODIFIER", 60, 67], ["seizures", "OBSERVATION", 68, 76]]], ["And I had a tonic clonic that was almost 8 minutes & the vns didn't seem to help like it usually does.\u201d", [["clonic", "DISEASE", 18, 24], ["a tonic clonic", "PROBLEM", 10, 24]]], ["Caregivers reported similar seizure increases, with one stating, \u201cHe has had more seizures in the past week\u2026since all this started.\u201d", [["seizure", "DISEASE", 28, 35], ["seizures", "DISEASE", 82, 90], ["similar seizure increases", "PROBLEM", 20, 45], ["seizures", "PROBLEM", 82, 90]]], ["Others responded with the exact numbers of seizures they have experienced since the onset of the pandemic, with respondents reporting an increase by 3 (two respondents), 4 (two respondents), 5, and 10 (three respondents), seizures beyond their normal seizure frequency since pandemic onset.Changes in routine affecting self-management ::: Qualitative comments ::: ResultsSome respondents reported changes that directly affected their ability to self-manage their epilepsy or that of their loved ones.", [["seizures", "DISEASE", 43, 51], ["pandemic", "DISEASE", 97, 105], ["seizures", "DISEASE", 222, 230], ["seizure", "DISEASE", 251, 258], ["pandemic", "DISEASE", 275, 283], ["epilepsy", "DISEASE", 463, 471], ["seizures", "PROBLEM", 43, 51], ["seizures", "PROBLEM", 222, 230], ["their normal seizure frequency", "PROBLEM", 238, 268], ["pandemic onset", "PROBLEM", 275, 289], ["their epilepsy", "PROBLEM", 457, 471], ["increase", "OBSERVATION_MODIFIER", 137, 145]]], ["As one respondent explained, \u201cIt is more difficult to obtain medications from the pharmacy due to reduced hours, living alone and not having adequate transportation without ride sharing (which has been greatly reduced in this area currently).", [["medications", "TREATMENT", 61, 72], ["reduced", "OBSERVATION_MODIFIER", 210, 217]]], ["Doctors are not accepting appointments except for sick patients, so follow ups are nonexistent currently.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63]]], ["There is added stress from work, which also makes a normal sleep routine more difficult.", [["stress", "OBSERVATION", 15, 21]]], ["All of these things ultimately lead to poor seizure control over time.\u201d", [["seizure", "DISEASE", 44, 51], ["poor seizure control", "PROBLEM", 39, 59]]], ["Another respondent noted, \u201cWith social distancing it has been more difficult to get the medications when needed.", [["the medications", "TREATMENT", 84, 99]]], ["Stress has also been a factor just worrying about if you were to have a seizure that we would need to go to the hospital and being exposed there.\u201d", [["seizure", "DISEASE", 72, 79], ["a seizure", "PROBLEM", 70, 79]]], ["\u201cIt's changed my daily routine & that of the people I live with (for instance my brother being out of school) so my sleep has changed.", [["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51]]], ["One respondent explained the inability to get epilepsy-related questions answered during this time, stating \u201cYou cannot get help for things that are not life or death right now, including small seizures or questions about medications\u2026it's not clear when or if I am allowed to call them with a question if it's not an emergency.\u201d", [["epilepsy", "DISEASE", 46, 54], ["death", "DISEASE", 161, 166], ["seizures", "DISEASE", 194, 202], ["epilepsy", "PROBLEM", 46, 54], ["small seizures", "PROBLEM", 188, 202], ["medications", "TREATMENT", 222, 233]]], ["Similarly, a caregiver shared, \u201cI feel guilty calling to ask anything\u2026we have only been dealing with this about 7 months and I still have tons of questions but am afraid to ask right now because I know everyone else has it far worse.\u201dFear ::: Qualitative comments ::: ResultsSeveral respondents spoke of being fearful of contracting COVID-19 or having care rationed in the event they or their loved ones needed hospitalization related to seizures.", [["seizures", "DISEASE", 438, 446], ["seizures", "PROBLEM", 438, 446]]], ["As one respondent explained, \u201cI dare not go to the hospital for regular testing because I am worried that the hospital will take in many patients infected with the virus.", [["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["regular testing", "TEST", 64, 79], ["the virus", "PROBLEM", 160, 169]]], ["I also dare not go to the pharmacy, which makes me feel panic.\u201d", [["panic", "DISEASE", 56, 61], ["panic", "PROBLEM", 56, 61]]], ["One respondent with epilepsy explained fear regarding COVID-19's effect on epilepsy, stating, \u201c[I have] fear of getting the virus.", [["epilepsy", "DISEASE", 20, 28], ["epilepsy", "DISEASE", 75, 83], ["epilepsy", "PROBLEM", 20, 28], ["epilepsy", "PROBLEM", 75, 83], ["the virus", "PROBLEM", 120, 129]]], ["I have seizure clusters with fevers so I'm worried what will happen if I get it.", [["seizure", "DISEASE", 7, 14], ["fevers", "DISEASE", 29, 35], ["seizure clusters", "PROBLEM", 7, 23], ["fevers", "PROBLEM", 29, 35]]], ["A caregiver of a child with epilepsy noted being concerned about rationing of ventilators, stating, \u201cWorried that if she needs any kind of hospital care she will be less likely to receive a ventilator \u2014 not likely if she get Co-Vid to get a vent\u2026her cognitive function is greatly delayed and if care is rationed she is in a group that will be at the bottom of the list.", [["epilepsy", "DISEASE", 28, 36], ["child", "ORGANISM", 17, 22], ["child", "SPECIES", 17, 22], ["epilepsy", "PROBLEM", 28, 36], ["ventilators", "TREATMENT", 78, 89], ["a ventilator", "TREATMENT", 188, 200]]], ["That worries me greatly.\u201dLimitations ::: DiscussionThis study is not without limitations.", [["This study", "TEST", 51, 61]]], ["First, we were not able to collect data on important variables (affective symptoms, for example) prior to the pandemic.", [["important variables (affective symptoms", "PROBLEM", 43, 82], ["the pandemic", "PROBLEM", 106, 118]]], ["Second, our sample represents mostly White, middle-class people with college degrees.", [["people", "ORGANISM", 57, 63], ["people", "SPECIES", 57, 63], ["our sample", "TEST", 8, 18], ["mostly", "OBSERVATION_MODIFIER", 30, 36], ["White", "OBSERVATION_MODIFIER", 37, 42], ["middle", "ANATOMY_MODIFIER", 44, 50]]], ["Finally, our sample of 94 is somewhat small; if possible, similar research should be repeated with a larger, more diverse sample in the event of a similar situation.ConclusionsThe COVID-19 pandemic has upended normal life, and current findings demonstrate that it has also disrupted epilepsy self-management for PWE and their caregivers.", [["epilepsy", "DISEASE", 283, 291], ["our sample", "TEST", 9, 19], ["The COVID", "TEST", 176, 185], ["somewhat small", "OBSERVATION_MODIFIER", 29, 43]]], ["While there has been and will be a future need to put off \u201cnonurgent\u201d healthcare during subsequent local and state shut downs, those citizens with chronic diseases, including epilepsy, have daily management needs that do not go away during a pandemic or other life-altering change; conversely, these needs are heightened.", [["chronic diseases", "DISEASE", 147, 163], ["epilepsy", "DISEASE", 175, 183], ["chronic diseases", "PROBLEM", 147, 163], ["epilepsy", "PROBLEM", 175, 183], ["daily management", "TREATMENT", 190, 206], ["chronic", "OBSERVATION_MODIFIER", 147, 154], ["diseases", "OBSERVATION", 155, 163]]], ["Physicians and nurses who provide care to PWE should prioritize making plans with PWE and caregivers in the event of significant disruptions.", [["significant disruptions", "PROBLEM", 117, 140], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["disruptions", "OBSERVATION", 129, 140]]], ["Members of our sample would have benefitted greatly from clear-cut guidance from epilepsy providers regarding how to communicate with them and that they were allowed to do so.", [["epilepsy", "DISEASE", 81, 89]]], ["In light of current results, the professional epilepsy community should consider treatment and management guidelines for pandemic-like societal and health system disruptions.", [["epilepsy", "DISEASE", 46, 54], ["treatment", "TREATMENT", 81, 90], ["management guidelines", "TREATMENT", 95, 116], ["pandemic", "PROBLEM", 121, 129]]], ["In addition, prioritization of robust self-management skills upon epilepsy diagnosis and continuing throughout the disease course remains necessary for PWE and the caregivers who assist them.Declaration of competing interestThe authors declare that they have no known competing interest.", [["epilepsy", "DISEASE", 66, 74], ["epilepsy diagnosis", "PROBLEM", 66, 84]]]], "ed8be13266b1bf10596832ff4101729f8fa05935": [["IntroductionImmunoglobulins (Igs) are glycoprotein molecules that function as antibodies and are only expressed in jawed vertebrates (Flajnik and Kasahara, 2010) .", [["IntroductionImmunoglobulins", "GENE_OR_GENE_PRODUCT", 0, 27], ["Igs", "GENE_OR_GENE_PRODUCT", 29, 32], ["IntroductionImmunoglobulins", "PROTEIN", 0, 27], ["Igs", "PROTEIN", 29, 32], ["glycoprotein molecules", "PROTEIN", 38, 60], ["antibodies", "PROTEIN", 78, 88], ["IntroductionImmunoglobulins (Igs", "TREATMENT", 0, 32], ["glycoprotein molecules", "TEST", 38, 60]]], ["Typically, Igs compose two identical heavy (IgH) and two identical light chains (IgL).", [["Igs", "GENE_OR_GENE_PRODUCT", 11, 14], ["IgH", "GENE_OR_GENE_PRODUCT", 44, 47], ["IgL", "GENE_OR_GENE_PRODUCT", 81, 84], ["Igs", "PROTEIN", 11, 14], ["IgH", "PROTEIN", 44, 47], ["light chains", "PROTEIN", 67, 79], ["IgL", "PROTEIN", 81, 84], ["light chains", "OBSERVATION_MODIFIER", 67, 79]]], ["Both heavy and light chains can be divided into two regions, i.e., the constant region and the variable region, based on the variability of amino acid sequences.", [["amino acid", "CHEMICAL", 140, 150], ["amino acid", "CHEMICAL", 140, 150], ["amino acid", "AMINO_ACID", 140, 150], ["heavy and light chains", "PROTEIN", 5, 27], ["amino acid sequences", "PROTEIN", 140, 160], ["Both heavy and light chains", "TREATMENT", 0, 27], ["amino acid sequences", "TEST", 140, 160], ["heavy", "OBSERVATION_MODIFIER", 5, 10], ["light chains", "OBSERVATION_MODIFIER", 15, 27], ["variable", "OBSERVATION_MODIFIER", 95, 103]]], ["In general, the variable region recognizes antigens, whereas the constant region specifies critical effector or signaling functions, such as phagocytosis, binding Fc (fragment crystallizable) receptors and activation of complement (Schroeder and Cavacini et al., 2010) .", [["fragment crystallizable) receptors", "GENE_OR_GENE_PRODUCT", 167, 201], ["antigens", "PROTEIN", 43, 51], ["binding Fc (fragment crystallizable) receptors", "PROTEIN", 155, 201], ["signaling functions", "PROBLEM", 112, 131], ["phagocytosis", "PROBLEM", 141, 153], ["binding Fc (fragment crystallizable", "TREATMENT", 155, 190]]], ["The classification of Igs is based on their heavy chain constant (IGHC) genes (Bengt\u00e9n et al., 2000) .", [["Igs", "GENE_OR_GENE_PRODUCT", 22, 25], ["Igs", "PROTEIN", 22, 25], ["heavy chain constant (IGHC) genes", "DNA", 44, 77], ["Igs", "OBSERVATION", 22, 25]]], ["To date, several IgH isotypes, including IgM, IgD, IgG, IgE, and IgA, have been identified in multiple vertebrates, and they are encoded by the IGHM, IGHD, IGHG, IGHE and IGHA genes respectively (Schroeder and Cavacini et al., 2010) .", [["IgH", "GENE_OR_GENE_PRODUCT", 17, 20], ["IgM", "GENE_OR_GENE_PRODUCT", 41, 44], ["IgD", "GENE_OR_GENE_PRODUCT", 46, 49], ["IgG", "GENE_OR_GENE_PRODUCT", 51, 54], ["IgE", "GENE_OR_GENE_PRODUCT", 56, 59], ["IgA", "GENE_OR_GENE_PRODUCT", 65, 68], ["IGHM", "GENE_OR_GENE_PRODUCT", 144, 148], ["IGHD", "GENE_OR_GENE_PRODUCT", 150, 154], ["IGHG", "GENE_OR_GENE_PRODUCT", 156, 160], ["IGHE", "GENE_OR_GENE_PRODUCT", 162, 166], ["IGHA", "GENE_OR_GENE_PRODUCT", 171, 175], ["IgH isotypes", "PROTEIN", 17, 29], ["IgM", "PROTEIN", 41, 44], ["IgD", "PROTEIN", 46, 49], ["IgG", "PROTEIN", 51, 54], ["IgE", "PROTEIN", 56, 59], ["IgA", "PROTEIN", 65, 68], ["IGHM, IGHD, IGHG, IGHE and IGHA genes", "DNA", 144, 181], ["several IgH isotypes", "PROBLEM", 9, 29], ["IgM", "TEST", 41, 44], ["IgD", "TEST", 46, 49], ["IgG", "TEST", 51, 54], ["IgE", "TEST", 56, 59], ["IgA", "TEST", 65, 68], ["IgH isotypes", "OBSERVATION", 17, 29]]], ["Both IgM and IgD have been reported to be the most ancient IgH isotypes among jawed vertebrates, with IgM very conserved but IgD showing a high degree of structural and (presumably) functional diversity and even being lost in some species over evolutionary time (Sun et al., 2011; Ohta and Flajnik, 2006) .", [["IgM", "GENE_OR_GENE_PRODUCT", 5, 8], ["IgD", "GENE_OR_GENE_PRODUCT", 13, 16], ["IgH", "GENE_OR_GENE_PRODUCT", 59, 62], ["IgM", "GENE_OR_GENE_PRODUCT", 102, 105], ["IgD", "GENE_OR_GENE_PRODUCT", 125, 128], ["IgM", "PROTEIN", 5, 8], ["IgD", "PROTEIN", 13, 16], ["IgH isotypes", "PROTEIN", 59, 71], ["IgM", "PROTEIN", 102, 105], ["IgD", "PROTEIN", 125, 128], ["IgM", "TEST", 102, 105], ["IgD", "PROBLEM", 125, 128], ["a high degree of structural and (presumably) functional diversity", "PROBLEM", 137, 202], ["IgM", "OBSERVATION", 5, 8], ["high degree", "OBSERVATION_MODIFIER", 139, 150]]], ["IgG and IgE are both exclusively present in mammals (Bengt\u00e9n et al., 2000; Flajnik and Kasahara, 2010) , the former being the predominant serum antibody and binding receptors on phagocytic cells and the latter predominantly functioning in immunity against parasites (Maizels, 2005) .", [["serum", "ANATOMY", 138, 143], ["phagocytic cells", "ANATOMY", 178, 194], ["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgE", "GENE_OR_GENE_PRODUCT", 8, 11], ["serum", "ORGANISM_SUBSTANCE", 138, 143], ["phagocytic cells", "CELL", 178, 194], ["IgG", "PROTEIN", 0, 3], ["IgE", "PROTEIN", 8, 11], ["serum antibody", "PROTEIN", 138, 152], ["binding receptors", "PROTEIN", 157, 174], ["phagocytic cells", "CELL_TYPE", 178, 194], ["IgG", "TEST", 0, 3], ["Flajnik", "TEST", 75, 82], ["Kasahara", "TEST", 87, 95], ["serum antibody", "TEST", 138, 152], ["phagocytic cells", "TEST", 178, 194], ["phagocytic cells", "OBSERVATION", 178, 194]]], ["Additionally, IgA was found in reptiles first, with similar functions in all animals (Flajnik and Kasahara, 2010) .", [["IgA", "GENE_OR_GENE_PRODUCT", 14, 17], ["IgA", "PROTEIN", 14, 17], ["IgA", "TEST", 14, 17]]], ["Participating in mucosal immunity, IgA coats pathogens to prevent proliferation and defend against local infection (Macpherson et al., 2008) .IntroductionExtant marine mammals descended from terrestrial ancestors that re-entered in the aquatic environment at different times (Uhen, 2010) .", [["mucosal", "ANATOMY", 17, 24], ["infection", "DISEASE", 105, 114], ["mucosal", "MULTI-TISSUE_STRUCTURE", 17, 24], ["IgA", "GENE_OR_GENE_PRODUCT", 35, 38], ["IgA", "PROTEIN", 35, 38], ["IgA coats pathogens", "PROBLEM", 35, 54], ["proliferation", "PROBLEM", 66, 79], ["local infection", "PROBLEM", 99, 114], ["mucosal", "ANATOMY", 17, 24], ["infection", "OBSERVATION", 105, 114]]], ["There are five main groups of extant marine mammals: Cetacea (dolphins, porpoises and whales), Sirenia (manatees, dugongs), Pinnipedia (walruses, sea lions and seals), polar bear (Ursus maritimus) and sea otter (Enhydra lutris) (Uhen, 2007) .", [["dolphins", "ORGANISM_SUBDIVISION", 62, 70], ["whales", "ORGANISM_SUBDIVISION", 86, 92], ["seals", "ORGANISM_SUBDIVISION", 160, 165], ["Ursus maritimus", "ORGANISM", 180, 195], ["sea otter", "ORGANISM", 201, 210], ["Enhydra lutris", "ORGANISM", 212, 226], ["Ursus maritimus", "SPECIES", 180, 195], ["sea otter", "SPECIES", 201, 210], ["Enhydra lutris", "SPECIES", 212, 226], ["Ursus maritimus", "SPECIES", 180, 195], ["Enhydra lutris", "SPECIES", 212, 226], ["Cetacea (dolphins", "PROBLEM", 53, 70], ["Sirenia (manatees", "TREATMENT", 95, 112], ["Pinnipedia", "TREATMENT", 124, 134], ["five", "OBSERVATION_MODIFIER", 10, 14], ["main", "OBSERVATION_MODIFIER", 15, 19], ["extant", "OBSERVATION_MODIFIER", 30, 36], ["marine mammals", "OBSERVATION", 37, 51], ["polar", "ANATOMY_MODIFIER", 168, 173]]], ["Cetacea and Sirenia are the only known completely aquatic mammals, and they appeared to return to the aquatic environment at approximately the same time, i.e. \u223c50 Mya (million years ago) (Uhen, 2010; Thewissen et al., 2007) .", [["Cetacea", "CHEMICAL", 0, 7], ["Cetacea", "TREATMENT", 0, 7], ["Sirenia", "TREATMENT", 12, 19], ["completely", "OBSERVATION_MODIFIER", 39, 49], ["aquatic mammals", "OBSERVATION", 50, 65]]], ["Despite the independent evolutionary origins of these marine mammals groups, they have developed a series of specializations for aquatic lifestyles, such as loss of hair, thickened blubber, derivation of echolocation, and so on (Uhen, 2007) .IntroductionDuring their transition from terrestrial environment to the sea, marine mammals must have faced dramatic changes in pathogens.", [["hair", "ANATOMY", 165, 169], ["blubber", "ANATOMY", 181, 188], ["hair", "TISSUE", 165, 169], ["blubber", "ORGANISM_SUBDIVISION", 181, 188], ["sea", "ORGANISM_SUBDIVISION", 314, 317], ["loss of hair", "PROBLEM", 157, 169], ["thickened blubber", "PROBLEM", 171, 188], ["faced dramatic changes in pathogens", "PROBLEM", 344, 379], ["thickened", "OBSERVATION_MODIFIER", 171, 180], ["blubber", "OBSERVATION_MODIFIER", 181, 188], ["echolocation", "OBSERVATION_MODIFIER", 204, 216]]], ["Recent studies have shown that cetacean TLR4 and MHC were subjected to adaptive evolution, particularly in the lineages with dramatic habitat transition (e.g. the lineage leading to hippo + whale representing the early stage of aquatic adaptation) or rapid radiation lineages such as extant dolphins (Shen et al., 2012; Zhang et al., 2016) .", [["TLR4", "GENE_OR_GENE_PRODUCT", 40, 44], ["MHC", "GENE_OR_GENE_PRODUCT", 49, 52], ["TLR4", "PROTEIN", 40, 44], ["MHC", "PROTEIN", 49, 52], ["Recent studies", "TEST", 0, 14], ["cetacean TLR4 and MHC", "TREATMENT", 31, 52], ["dramatic habitat transition", "PROBLEM", 125, 152], ["rapid radiation lineages", "PROBLEM", 251, 275], ["cetacean TLR4", "OBSERVATION", 31, 44], ["dramatic", "OBSERVATION_MODIFIER", 125, 133], ["habitat transition", "OBSERVATION", 134, 152]]], ["However, the evolution of Ig in the aquatic adaptation of marine mammals remains poorly explored, except for a few reports about the cloning and sequencing of IGHC genes in bottlenose dolphin (Tursiops truncatus) (Mancia et al., 2006 (Mancia et al., , 2007 Lundqvist et al., 2002) and the Florida manatee (Trichechus manatus latirostris) (Breaux et al., 2017) and the identification of IgM, IgG and IgA and lineage-specific IGHG gene duplication in some cetaceans (Mancia et al., 2006) , and so on.", [["Ig", "GENE_OR_GENE_PRODUCT", 26, 28], ["IGHC", "GENE_OR_GENE_PRODUCT", 159, 163], ["bottlenose dolphin", "ORGANISM", 173, 191], ["Tursiops truncatus", "ORGANISM", 193, 211], ["Trichechus manatus latirostris", "ORGANISM", 306, 336], ["IgM", "GENE_OR_GENE_PRODUCT", 386, 389], ["IgG", "GENE_OR_GENE_PRODUCT", 391, 394], ["IgA", "GENE_OR_GENE_PRODUCT", 399, 402], ["IGHG", "GENE_OR_GENE_PRODUCT", 424, 428], ["Ig", "PROTEIN", 26, 28], ["IGHC genes", "DNA", 159, 169], ["IgM", "PROTEIN", 386, 389], ["IgG", "PROTEIN", 391, 394], ["IgA", "PROTEIN", 399, 402], ["IGHG gene duplication", "DNA", 424, 445], ["bottlenose dolphin", "SPECIES", 173, 191], ["Tursiops truncatus", "SPECIES", 193, 211], ["Trichechus manatus latirostris", "SPECIES", 306, 336], ["bottlenose dolphin", "SPECIES", 173, 191], ["Tursiops truncatus", "SPECIES", 193, 211], ["Trichechus manatus latirostris", "SPECIES", 306, 336], ["Ig", "TREATMENT", 26, 28], ["IGHC genes", "PROBLEM", 159, 169], ["IgM", "TEST", 386, 389], ["IgG", "TEST", 391, 394], ["IgA", "TEST", 399, 402], ["bottlenose dolphin", "OBSERVATION", 173, 191]]], ["Therefore, in the present study, we first retrieved IGHC genes from the genomes of ten representative marine mammals.", [["IGHC", "GENE_OR_GENE_PRODUCT", 52, 56], ["IGHC genes", "DNA", 52, 62], ["the present study", "TEST", 14, 31]]], ["The genomic organization of IGHC cluster was identified and positive selection on the marine mammals was detected to address whether they experienced adaptive evolution in response to aquatic environments.Genomic identification of IGHC genesWe first downloaded the IGHC genes of 13 terrestrial mammals, including cow (Bos taurus), pig (Sus scrofa), horse (Equus caballus), dog (Canis lupus familiaris), giant panda (Ailuropoda melanoleuca), black flying fox (Pteropus alecto), little brown bat (Myotis lucifugus), human (Homo sapiens), rhesus monkey (Macaca mulatta), rat (Rattus norvegicus), rabbit (Oryctolagus cuniculus), opossum (Monodelphis domestica) and platypus (Ornithorhynchus anatinus) from the National Center for Biotechnology Information (NCBI), Ensemble databases and the International ImMunoGeneTics information system (IMGT).", [["IGHC", "GENE_OR_GENE_PRODUCT", 28, 32], ["IGHC", "GENE_OR_GENE_PRODUCT", 231, 235], ["IGHC", "GENE_OR_GENE_PRODUCT", 265, 269], ["cow", "ORGANISM_SUBDIVISION", 313, 316], ["Bos taurus", "ORGANISM", 318, 328], ["pig", "ORGANISM", 331, 334], ["Sus scrofa", "ORGANISM", 336, 346], ["horse", "ORGANISM", 349, 354], ["Equus caballus", "ORGANISM", 356, 370], ["dog", "ORGANISM", 373, 376], ["Canis lupus familiaris", "ORGANISM", 378, 400], ["giant panda", "ORGANISM", 403, 414], ["Ailuropoda melanoleuca", "ORGANISM", 416, 438], ["black flying fox", "ORGANISM", 441, 457], ["Pteropus alecto", "ORGANISM", 459, 474], ["brown bat", "ORGANISM", 484, 493], ["Myotis lucifugus", "ORGANISM", 495, 511], ["human", "ORGANISM", 514, 519], ["Homo sapiens", "ORGANISM", 521, 533], ["rhesus monkey", "ORGANISM", 536, 549], ["Macaca mulatta", "ORGANISM", 551, 565], ["rat", "ORGANISM", 568, 571], ["Rattus norvegicus", "ORGANISM", 573, 590], ["rabbit", "ORGANISM", 593, 599], ["Oryctolagus cuniculus", "ORGANISM", 601, 622], ["opossum", "ORGANISM", 625, 632], ["Monodelphis domestica", "ORGANISM", 634, 655], ["platypus", "ORGANISM", 661, 669], ["Ornithorhynchus anatinus", "ORGANISM", 671, 695], ["IGHC cluster", "DNA", 28, 40], ["IGHC genesWe", "DNA", 231, 243], ["IGHC genes", "DNA", 265, 275], ["cow", "SPECIES", 313, 316], ["Bos taurus", "SPECIES", 318, 328], ["pig", "SPECIES", 331, 334], ["Sus scrofa", "SPECIES", 336, 346], ["horse", "SPECIES", 349, 354], ["Equus caballus", "SPECIES", 356, 370], ["dog", "SPECIES", 373, 376], ["Canis", "SPECIES", 378, 383], ["lupus familiaris", "SPECIES", 384, 400], ["giant panda", "SPECIES", 403, 414], ["Ailuropoda melanoleuca", "SPECIES", 416, 438], ["black flying fox", "SPECIES", 441, 457], ["Pteropus alecto", "SPECIES", 459, 474], ["brown bat", "SPECIES", 484, 493], ["Myotis lucifugus", "SPECIES", 495, 511], ["human", "SPECIES", 514, 519], ["Homo sapiens", "SPECIES", 521, 533], ["rhesus monkey", "SPECIES", 536, 549], ["Macaca mulatta", "SPECIES", 551, 565], ["rat", "SPECIES", 568, 571], ["Rattus norvegicus", "SPECIES", 573, 590], ["rabbit", "SPECIES", 593, 599], ["Oryctolagus cuniculus", "SPECIES", 601, 622], ["opossum", "SPECIES", 625, 632], ["Monodelphis domestica", "SPECIES", 634, 655], ["Ornithorhynchus anatinus", "SPECIES", 671, 695], ["cow", "SPECIES", 313, 316], ["Bos taurus", "SPECIES", 318, 328], ["pig", "SPECIES", 331, 334], ["Sus scrofa", "SPECIES", 336, 346], ["horse", "SPECIES", 349, 354], ["Equus caballus", "SPECIES", 356, 370], ["Canis lupus familiaris", "SPECIES", 378, 400], ["giant panda", "SPECIES", 403, 414], ["Ailuropoda melanoleuca", "SPECIES", 416, 438], ["black flying fox", "SPECIES", 441, 457], ["Pteropus alecto", "SPECIES", 459, 474], ["brown bat", "SPECIES", 484, 493], ["Myotis lucifugus", "SPECIES", 495, 511], ["human", "SPECIES", 514, 519], ["Homo sapiens", "SPECIES", 521, 533], ["rhesus monkey", "SPECIES", 536, 549], ["Macaca mulatta", "SPECIES", 551, 565], ["rat", "SPECIES", 568, 571], ["Rattus norvegicus", "SPECIES", 573, 590], ["rabbit", "SPECIES", 593, 599], ["Oryctolagus cuniculus", "SPECIES", 601, 622], ["Monodelphis domestica", "SPECIES", 634, 655], ["Ornithorhynchus anatinus", "SPECIES", 671, 695], ["IGHC cluster", "PROBLEM", 28, 40], ["cow (Bos taurus)", "PROBLEM", 313, 329], ["pig (Sus scrofa)", "PROBLEM", 331, 347], ["dog (Canis lupus familiaris", "PROBLEM", 373, 400], ["giant panda", "PROBLEM", 403, 414], ["little brown bat (Myotis lucifugus", "PROBLEM", 477, 511], ["human (Homo sapiens)", "TREATMENT", 514, 534], ["rabbit (Oryctolagus cuniculus", "TREATMENT", 593, 622], ["opossum (Monodelphis domestica", "TREATMENT", 625, 655], ["genomic", "OBSERVATION_MODIFIER", 4, 11], ["organization", "OBSERVATION_MODIFIER", 12, 24], ["IGHC cluster", "OBSERVATION", 28, 40], ["positive", "OBSERVATION_MODIFIER", 60, 68], ["selection", "OBSERVATION_MODIFIER", 69, 78], ["terrestrial mammals", "OBSERVATION", 282, 301], ["brown bat", "ANATOMY", 484, 493]]], ["The accession numbers of these sequences are compiled in Supplemental Table 1 .", [["these sequences", "TEST", 25, 40]]], ["Then we used IGHC sequences of these terrestrial relatives as a query to search for the orthologous genes from 10 marine mammal genomes with TBLASTN and BLASTN approaches, including bottlenose dolphin (Tursiops truncatus), killer whale (Orcinus orca), Yangtze finless porpoise (Neophocuena asiaeorientalis), baiji (Lipotes vexillifer), sperm whale (Physeter catodon), minke whale (Balaena acutorostrata), bowhead whale (Balaena mysticetus), Weddell seal (Leptonychotes weddellii), Pacific walrus (Odobenus rosmarus), and Florida manatee (Trichechus manatus latirostris).", [["sperm", "ANATOMY", 336, 341], ["bottlenose dolphin", "ORGANISM", 182, 200], ["Tursiops truncatus", "ORGANISM", 202, 220], ["killer whale", "ORGANISM", 223, 235], ["Orcinus orca", "ORGANISM", 237, 249], ["Yangtze finless porpoise", "ORGANISM", 252, 276], ["Neophocuena asiaeorientalis", "ORGANISM", 278, 305], ["baiji", "ORGANISM", 308, 313], ["Lipotes vexillifer", "ORGANISM", 315, 333], ["sperm whale", "ORGANISM", 336, 347], ["Physeter catodon", "ORGANISM", 349, 365], ["minke whale", "ORGANISM", 368, 379], ["Balaena acutorostrata", "ORGANISM", 381, 402], ["bowhead whale", "ORGANISM", 405, 418], ["Balaena mysticetus", "ORGANISM", 420, 438], ["Weddell seal", "ORGANISM", 441, 453], ["Leptonychotes weddellii", "ORGANISM", 455, 478], ["Pacific walrus", "ORGANISM", 481, 495], ["Odobenus rosmarus", "ORGANISM", 497, 514], ["Florida manatee", "ORGANISM", 521, 536], ["Trichechus manatus latirostris", "ORGANISM", 538, 568], ["IGHC sequences", "DNA", 13, 27], ["orthologous genes", "DNA", 88, 105], ["marine mammal genomes", "DNA", 114, 135], ["bottlenose dolphin", "SPECIES", 182, 200], ["Tursiops truncatus", "SPECIES", 202, 220], ["killer whale", "SPECIES", 223, 235], ["Orcinus orca", "SPECIES", 237, 249], ["Yangtze finless", "SPECIES", 252, 267], ["Neophocuena asiaeorientalis", "SPECIES", 278, 305], ["baiji", "SPECIES", 308, 313], ["Lipotes vexillifer", "SPECIES", 315, 333], ["Physeter catodon", "SPECIES", 349, 365], ["minke", "SPECIES", 368, 373], ["Balaena acutorostrata", "SPECIES", 381, 402], ["bowhead whale", "SPECIES", 405, 418], ["Balaena mysticetus", "SPECIES", 420, 438], ["Leptonychotes weddellii", "SPECIES", 455, 478], ["Pacific walrus", "SPECIES", 481, 495], ["Odobenus rosmarus", "SPECIES", 497, 514], ["manatee", "SPECIES", 529, 536], ["Trichechus manatus", "SPECIES", 538, 556], ["latirostris", "SPECIES", 557, 568], ["bottlenose dolphin", "SPECIES", 182, 200], ["killer whale", "SPECIES", 223, 235], ["Orcinus orca", "SPECIES", 237, 249], ["Yangtze finless porpoise", "SPECIES", 252, 276], ["Neophocuena asiaeorientalis", "SPECIES", 278, 305], ["Physeter catodon", "SPECIES", 349, 365], ["minke whale", "SPECIES", 368, 379], ["Balaena acutorostrata", "SPECIES", 381, 402], ["bowhead whale", "SPECIES", 405, 418], ["Balaena mysticetus", "SPECIES", 420, 438], ["Leptonychotes weddellii", "SPECIES", 455, 478], ["Pacific walrus", "SPECIES", 481, 495], ["Odobenus rosmarus", "SPECIES", 497, 514], ["Florida manatee", "SPECIES", 521, 536], ["Trichechus manatus latirostris", "SPECIES", 538, 568], ["IGHC sequences", "TREATMENT", 13, 27], ["the orthologous genes", "PROBLEM", 84, 105], ["TBLASTN", "TREATMENT", 141, 148], ["BLASTN approaches", "TREATMENT", 153, 170], ["killer whale (Orcinus orca)", "TREATMENT", 223, 250], ["Neophocuena asiaeorientalis)", "TREATMENT", 278, 306], ["baiji (Lipotes vexillifer)", "TREATMENT", 308, 334], ["sperm whale (Physeter catodon", "TREATMENT", 336, 365], ["Weddell seal (Leptonychotes weddellii", "TREATMENT", 441, 478]]], ["In addition, IGHC genes were also scanned from the genomes of three additional terrestrial mammals, i.e., hedgehog (Erinaceus europaeus), European shrew (Sorex araneus), and elephant (Loxodonta africana).", [["IGHC", "GENE_OR_GENE_PRODUCT", 13, 17], ["hedgehog", "GENE_OR_GENE_PRODUCT", 106, 114], ["Erinaceus europaeus", "ORGANISM", 116, 135], ["European shrew", "ORGANISM", 138, 152], ["Sorex araneus", "ORGANISM", 154, 167], ["elephant", "ORGANISM", 174, 182], ["Loxodonta africana", "ORGANISM", 184, 202], ["IGHC genes", "DNA", 13, 23], ["Erinaceus europaeus", "SPECIES", 116, 135], ["shrew", "SPECIES", 147, 152], ["Sorex araneus", "SPECIES", 154, 167], ["elephant", "SPECIES", 174, 182], ["Loxodonta africana", "SPECIES", 184, 202], ["Erinaceus europaeus", "SPECIES", 116, 135], ["European shrew", "SPECIES", 138, 152], ["Sorex araneus", "SPECIES", 154, 167], ["Loxodonta africana", "SPECIES", 184, 202], ["IGHC genes", "PROBLEM", 13, 23], ["hedgehog (Erinaceus europaeus", "TREATMENT", 106, 135], ["European shrew (Sorex araneus", "TREATMENT", 138, 167], ["elephant (Loxodonta africana", "TREATMENT", 174, 202], ["terrestrial mammals", "OBSERVATION", 79, 98]]], ["The detailed information about the genome assemblies used in this study is given in Table 1 .", [["this study", "TEST", 61, 71]]], ["Finally, we checked whether the newly identified putative IGHC genes were their best hit by a blast search against the non-redundant database from GenBank.", [["IGHC", "GENE_OR_GENE_PRODUCT", 58, 62], ["IGHC genes", "DNA", 58, 68]]], ["The newly identified IGHC genes were further separated into intact genes, partial genes and pseudogenes based on the amino acid alignment and blast results.", [["amino acid", "CHEMICAL", 117, 127], ["amino acid", "CHEMICAL", 117, 127], ["IGHC", "GENE_OR_GENE_PRODUCT", 21, 25], ["amino acid", "AMINO_ACID", 117, 127], ["IGHC genes", "DNA", 21, 31], ["intact genes", "DNA", 60, 72], ["partial genes", "DNA", 74, 87], ["The newly identified IGHC genes", "PROBLEM", 0, 31], ["partial genes and pseudogenes", "PROBLEM", 74, 103], ["the amino acid alignment", "TEST", 113, 137], ["IGHC genes", "OBSERVATION", 21, 31], ["intact genes", "OBSERVATION", 60, 72]]], ["The genomic coordinates of the newly identified IGHC genes are listed in Supplemental Table 2 .Sequence alignment and phylogenetic analysisTo confirm that the regions of alignment had sufficient confidence to test for positive selection and determine phylogenetic relationships, the unaligned multiple sequence alignment (MSA) of IGHC genes translated to amino-acid sequences and further back-translated into the corresponding codon were submitted to GUIDANCE (Penn et al., 2010a, b) to obtain alignment confidence scores.", [["amino-acid", "CHEMICAL", 355, 365], ["amino-acid", "CHEMICAL", 355, 365], ["IGHC", "GENE_OR_GENE_PRODUCT", 48, 52], ["IGHC", "GENE_OR_GENE_PRODUCT", 330, 334], ["amino", "AMINO_ACID", 355, 360], ["IGHC genes", "DNA", 48, 58], ["IGHC genes", "DNA", 330, 340], ["Sequence alignment", "TEST", 95, 113], ["phylogenetic analysis", "TEST", 118, 139], ["positive selection", "PROBLEM", 218, 236], ["the unaligned multiple sequence alignment", "TEST", 279, 320], ["IGHC genes", "PROBLEM", 330, 340], ["amino-acid sequences", "TEST", 355, 375]]], ["GUIDANCE used a PRANK alignment program (version 140,110) and returned a colored MSA that allowed to delimit aligned regions ambiguously.", [["a colored MSA", "PROBLEM", 71, 84]]], ["Then the columns with confidence scores lower than the threshold were excluded from further analyses.Sequence alignment and phylogenetic analysisPhylogenetic trees were reconstructed using Bayesian inference (BI) in MrBayes 3.2.2 (Huelsenbeck and Ronquist, 2001) and Maximum likelihood (ML) in RAxML 8.0.26 (Stamatakis, 2006) .", [["confidence scores", "TEST", 22, 39], ["further analyses", "TEST", 84, 100], ["Sequence alignment", "TEST", 101, 119], ["phylogenetic analysis", "TEST", 124, 145], ["MrBayes", "TEST", 216, 223], ["RAxML", "TEST", 294, 299], ["columns", "OBSERVATION_MODIFIER", 9, 16]]], ["Bayesian inference analysis was run for 10 6 generations with one cold and three heated Markov chains to ensure the analysis remaining in global rather than local optima and trees were sampled every 100 generations.", [["Bayesian inference analysis", "TEST", 0, 27], ["three heated Markov chains", "TREATMENT", 75, 101], ["the analysis", "TEST", 112, 124]]], ["Because the samples from the beginning of the chain are unreliable.", [["samples", "ANATOMY", 12, 19], ["the samples", "TEST", 8, 19]]], ["For ML analysis, the maximum likelihood tree was reconstructed with 1000 bootstrap replications.Detection of positive selectionThe rate of nonsynonymous (d N ) and synonymous (d S ) substitution (d N /d S or omega, \u03c9) measures the direction and intensity of natural selection, with \u03c9 = 1, \u03c9 > 1 and \u03c9 < 1 indicating neutral evolution, positive and purifying selection, respectively.", [["ML analysis", "TEST", 4, 15], ["1000 bootstrap replications", "TREATMENT", 68, 95], ["nonsynonymous (d N", "TREATMENT", 139, 157], ["synonymous (d S ) substitution (d N /d S", "TREATMENT", 164, 204], ["natural selection", "TEST", 258, 275], ["\u03c9", "TEST", 282, 283], ["positive selection", "OBSERVATION", 109, 127], ["natural selection", "OBSERVATION", 258, 275], ["neutral evolution", "OBSERVATION", 316, 333], ["positive", "OBSERVATION", 335, 343]]], ["To detect the impact of natural selection on IGHC genes, we performed a number of statistical tests based on calculating the \u03c9 values using the CODEML program implemented in PAML 4.7 package (Yang, 2007) .", [["IGHC", "GENE_OR_GENE_PRODUCT", 45, 49], ["IGHC genes", "DNA", 45, 55], ["statistical tests", "TEST", 82, 99], ["the CODEML program", "TREATMENT", 140, 158]]], ["The selection analyses using the gene tree reconstructed by BI and ML methods generated nearly the same results as those from the well-supported species phylogeny (Perelman et al., 2011; Zhou et al., 2011a) ; thus, only the latter analysis is shown here.Detection of positive selectionTo detect positively selected sites on IGHC genes, we first performed the site specific models, i.e., M8a (nearly neutral, beta distribution: 0 < \u03c9 0 < 1 and \u03c9 1 = 1) versus M8 (positive selection, beta distribution: 0 < \u03c9 0 < 1 and \u03c9 1 > 1), as implemented in CODEML program.", [["IGHC", "GENE_OR_GENE_PRODUCT", 324, 328], ["IGHC genes", "DNA", 324, 334], ["The selection analyses", "TEST", 0, 22], ["the gene tree", "TREATMENT", 29, 42], ["the latter analysis", "TEST", 220, 239], ["positive selection", "PROBLEM", 267, 285], ["positively selected sites on IGHC genes", "PROBLEM", 295, 334], ["M8", "TEST", 459, 461], ["beta distribution", "TEST", 483, 500]]], ["In addition, positively selected sites were identified using Datamonkey, which incorporated the rate of synonymous substitution, whereas the d S was fixed in PAML.", [["d S", "DNA", 141, 144], ["synonymous substitution", "TREATMENT", 104, 127], ["synonymous substitution", "OBSERVATION", 104, 127]]], ["Three ML methods, i.e. the single likelihood ancestor counting (SLAC), fixed-effect likelihood (FEL), and random-effect likelihood (REL) implemented in the Datamonkey website (Pond and Frost, 2005a) , were used to infer the positively selected sites with default settings and significance levels of 0.1, 0.1, and 50, respectively.", [["Three ML methods", "TREATMENT", 0, 16], ["default settings", "TEST", 255, 271], ["significance levels", "TEST", 276, 295]]], ["Although SLAC, a conservative method, is suitable for large data sets, it usually underestimates the substitution rate.", [["SLAC", "PROTEIN", 9, 13], ["a conservative method", "TREATMENT", 15, 36], ["the substitution rate", "TEST", 97, 118], ["SLAC", "OBSERVATION", 9, 13]]], ["FEL method seems to capture the pattern of rate variation better than SLAC and REL, but it tends to be less conservative than SLAC to detect selection in data sets of intermediate size.", [["intermediate", "OBSERVATION_MODIFIER", 167, 179], ["size", "OBSERVATION_MODIFIER", 180, 184]]], ["REL approach is more powerful than SLAC and FEL, but it has the higher rates of false positives for small data sets (Pond and Frost, 2005a,b) .", [["more powerful", "OBSERVATION_MODIFIER", 16, 29], ["false positives", "OBSERVATION", 80, 95]]], ["These three predictions were conducted to estimating \u03c9 value of each site.Detection of positive selectionTo further detect whether the possibility of positive selection was limited on specific lineages, we compared the free-ratio model, which estimated a separate \u03c9 ratio for each lineage, with the one-ratio model that estimated a same \u03c9 ratio for all lineages in the tree (Yang, 1998) .", [["positive selection", "PROBLEM", 87, 105], ["positive selection", "PROBLEM", 150, 168], ["tree", "ANATOMY_MODIFIER", 369, 373]]], ["In addition, the branch-site model were conducted to detect evidence of positive selection on individual codon along a specific lineage (Zhang et al., 2005) .", [["positive selection on individual codon", "PROBLEM", 72, 110], ["branch", "ANATOMY_MODIFIER", 17, 23], ["positive", "OBSERVATION_MODIFIER", 72, 80], ["selection", "OBSERVATION", 81, 90]]], ["In branch-site model, we compared Ma (positive selection, 0 < \u03c9 0 < 1, \u03c9 1 = 1 and \u03c9 2 \u2265 1) with Ma0 (neutral selection, 0 < \u03c9 0 < 1, \u03c9 1 = 1 and \u03c9 2 = 1) to detect positive selection.", [["Ma", "TEST", 34, 36], ["selection", "TEST", 47, 56], ["\u03c9", "TEST", 71, 72], ["Ma0", "TEST", 97, 100], ["neutral selection", "TEST", 102, 119], ["\u03c9", "TEST", 134, 135], ["positive selection", "PROBLEM", 165, 183], ["branch", "ANATOMY_MODIFIER", 3, 9], ["site model", "OBSERVATION", 10, 20], ["positive selection", "OBSERVATION", 165, 183]]], ["The significance of the differences between two nested models was tested using likelihood ratio tests (LRT) statistic (-2[LogLikelihood1-LogLike-lihood2]) with a chi-square distribution.", [["two nested models", "TEST", 44, 61], ["likelihood ratio tests", "TEST", 79, 101], ["statistic", "TEST", 108, 117], ["LogLikelihood1", "TEST", 122, 136]]], ["Bayes Empirical Bayes (BEB) approach implemented in the CODEML was used to test the posterior probabilities (PPs) of positively selected sites, where sites with PPs > 0.90 were considered as candidates undergoing positive selection.", [["sites", "ANATOMY", 150, 155], ["CODEML", "DNA", 56, 62], ["Empirical Bayes (BEB) approach", "TREATMENT", 6, 36], ["PPs", "TEST", 161, 164], ["posterior", "ANATOMY_MODIFIER", 84, 93]]], ["Finally, to support the PAML results, we employed a complementary protein-level approach implemented in TreeSAAP (Woolley et al., 2003) that detected the significant changes in amino acid physicochemical properties.Genomic organization of IGHC genes in marine mammalsIn the present study, we retrieved IGHC genes from the genomes of ten marine mammals (including seven cetaceans, one manatee and two pinnipeds) and compared them with those of terrestrial relatives to provide insights into the evolution of IGHC genes in marine mammals.", [["amino acid", "CHEMICAL", 177, 187], ["amino acid", "CHEMICAL", 177, 187], ["amino acid", "AMINO_ACID", 177, 187], ["IGHC", "GENE_OR_GENE_PRODUCT", 239, 243], ["IGHC", "GENE_OR_GENE_PRODUCT", 302, 306], ["IGHC", "GENE_OR_GENE_PRODUCT", 507, 511], ["IGHC genes", "DNA", 239, 249], ["IGHC genes", "DNA", 302, 312], ["IGHC genes", "DNA", 507, 517], ["a complementary protein-level approach", "TREATMENT", 50, 88], ["the significant changes in amino acid physicochemical properties", "PROBLEM", 150, 214], ["IGHC genes", "PROBLEM", 239, 249], ["the present study", "TEST", 270, 287], ["significant", "OBSERVATION_MODIFIER", 154, 165], ["amino acid", "OBSERVATION", 177, 187], ["IGHC genes", "OBSERVATION", 239, 249]]], ["We found that the genomic regions containing an IGHC cluster are conservative with special flanking sequences, i.e., the TMEM121 and IGH diversity gene cluster (Eguchi-Ogawa et al., 2012) , which helped us obtain the complete IGHC genes in mammalian genomes.", [["IGHC", "GENE_OR_GENE_PRODUCT", 48, 52], ["TMEM121", "GENE_OR_GENE_PRODUCT", 121, 128], ["IGH", "GENE_OR_GENE_PRODUCT", 133, 136], ["IGHC", "GENE_OR_GENE_PRODUCT", 226, 230], ["genomic regions", "DNA", 18, 33], ["IGHC cluster", "DNA", 48, 60], ["special flanking sequences", "DNA", 83, 109], ["TMEM121 and IGH diversity gene cluster", "DNA", 121, 159], ["IGHC genes", "DNA", 226, 236], ["mammalian genomes", "DNA", 240, 257], ["special flanking sequences", "TEST", 83, 109], ["IGHC", "OBSERVATION_MODIFIER", 48, 52], ["cluster", "OBSERVATION_MODIFIER", 53, 60], ["mammalian genomes", "OBSERVATION", 240, 257]]], ["A total of 182 IGHC genes were identified in the 26 mammals in our study (Fig. 1) , including 79 sequences that were newly identified in 13 species.", [["IGHC", "CANCER", 15, 19], ["IGHC genes", "DNA", 15, 25], ["our study", "TEST", 63, 72], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["For the 10 marine mammals, a total of 59 sequences were identified in this study.Genomic organization of IGHC genes in marine mammalsTo define the orthologous relationships among IGHC genes, we reconstructed phylogenetic trees for each gene, as well as a phylogenetic tree incorporating all members of IGHC genes from 26 mammals using two different methods (BI and ML).", [["IGHC", "GENE_OR_GENE_PRODUCT", 105, 109], ["IGHC", "GENE_OR_GENE_PRODUCT", 179, 183], ["IGHC", "GENE_OR_GENE_PRODUCT", 302, 306], ["IGHC genes", "DNA", 105, 115], ["IGHC genes", "DNA", 179, 189], ["IGHC genes", "DNA", 302, 312], ["this study", "TEST", 70, 80], ["IGHC genes", "PROBLEM", 105, 115], ["IGHC genes", "TREATMENT", 302, 312], ["IGHC genes", "OBSERVATION", 105, 115]]], ["Similar tree topologies were inferred (Fig. 2, Supplemental Figs.", [["Similar tree topologies", "PROBLEM", 0, 23], ["tree topologies", "OBSERVATION", 8, 23]]], ["The phylogenetic relationship showed that the IGHC genes of marine mammals could be clustered well with those of their terrestrial relatives, suggesting that marine mammals possess the typical isotype repertoire as other eutherian mammals.", [["IGHC", "GENE_OR_GENE_PRODUCT", 46, 50], ["marine mammals", "ORGANISM", 60, 74], ["marine mammals", "ORGANISM", 158, 172], ["IGHC genes", "DNA", 46, 56]]], ["Similar to other mammals, marine mammals were found to contain a single IGHM, IGHD, IGHE, and IGHA genes, and several IGHG genes based on the phylogenetic reconstruction.", [["marine mammals", "ORGANISM", 26, 40], ["IGHM", "GENE_OR_GENE_PRODUCT", 72, 76], ["IGHD", "GENE_OR_GENE_PRODUCT", 78, 82], ["IGHE", "GENE_OR_GENE_PRODUCT", 84, 88], ["IGHA", "GENE_OR_GENE_PRODUCT", 94, 98], ["IGHG", "GENE_OR_GENE_PRODUCT", 118, 122], ["IGHM, IGHD, IGHE, and IGHA genes", "DNA", 72, 104], ["IGHG genes", "DNA", 118, 128], ["a single IGHM, IGHD, IGHE, and IGHA genes", "PROBLEM", 63, 104], ["several IGHG genes", "PROBLEM", 110, 128], ["the phylogenetic reconstruction", "TREATMENT", 138, 169]]], ["The order of IGHC genes in the IgH locus of marine mammals was determined to be 5\u2032-IGHM-IGHD-IGHG-IGHE-IGHA-3\u2032, which is in agreement with their terrestrial relatives (Supplemental Fig. 12) .", [["IGHC", "GENE_OR_GENE_PRODUCT", 13, 17], ["IgH", "GENE_OR_GENE_PRODUCT", 31, 34], ["IGHC genes", "DNA", 13, 23], ["IgH locus", "DNA", 31, 40], ["IGHC genes", "TREATMENT", 13, 23]]], ["Furthermore, we found that the first domain (CH1) of IGHM and the CH1 of IGHD of cetaceans shared nearly identical sequences, as shown in artiodactylas (Zhao et al., 2002) (Supplemental Fig. 13 ).", [["IGHM", "GENE_OR_GENE_PRODUCT", 53, 57], ["CH1", "PROTEIN", 45, 48], ["IGHM", "PROTEIN", 53, 57], ["CH1", "PROTEIN", 66, 69], ["the first domain (CH1) of IGHM", "PROBLEM", 27, 57], ["IGHD of cetaceans", "PROBLEM", 73, 90]]], ["The genomic organization of marine mammal IGHC genes is similar to that of other species examined, which suggested a constraint acting on their genomic arrangement and the conserved genomic organization of the IGHC genes.Genomic organization of IGHC genes in marine mammalsThe expansion of the IgG subclass is primarily a feature of mammals (Hsu et al., 2006) .", [["IGHC", "GENE_OR_GENE_PRODUCT", 42, 46], ["IGHC", "GENE_OR_GENE_PRODUCT", 210, 214], ["IGHC", "GENE_OR_GENE_PRODUCT", 245, 249], ["IgG", "GENE_OR_GENE_PRODUCT", 294, 297], ["marine mammal IGHC genes", "DNA", 28, 52], ["IGHC genes", "DNA", 210, 220], ["IGHC genes", "DNA", 245, 255], ["IgG subclass", "PROTEIN", 294, 306], ["marine mammal IGHC genes", "PROBLEM", 28, 52], ["IGHC genes", "PROBLEM", 245, 255], ["marine", "OBSERVATION_MODIFIER", 28, 34], ["mammal", "OBSERVATION_MODIFIER", 35, 41], ["IGHC genes", "OBSERVATION", 42, 52], ["IGHC genes", "OBSERVATION", 245, 255], ["expansion", "OBSERVATION_MODIFIER", 277, 286], ["IgG subclass", "OBSERVATION_MODIFIER", 294, 306]]], ["The IgG-like Igs of chicken and lizard showed no subclass diversification (Butler et al., 2011) .", [["IgG", "GENE_OR_GENE_PRODUCT", 4, 7], ["Igs", "GENE_OR_GENE_PRODUCT", 13, 16], ["chicken", "ORGANISM", 20, 27], ["IgG", "PROTEIN", 4, 7], ["Igs", "PROTEIN", 13, 16], ["chicken", "SPECIES", 20, 27], ["chicken", "SPECIES", 20, 27], ["The IgG", "TEST", 0, 7], ["subclass diversification", "PROBLEM", 49, 73], ["no", "UNCERTAINTY", 46, 48], ["subclass diversification", "OBSERVATION", 49, 73]]], ["The gene duplication of IGHG genes is believed to have occurred most recently, and it belongs to a lineage-specific event (Wagner et al., 2002) .", [["IGHG", "GENE_OR_GENE_PRODUCT", 24, 28], ["IGHG genes", "DNA", 24, 34], ["The gene duplication of IGHG genes", "PROBLEM", 0, 34], ["duplication", "OBSERVATION_MODIFIER", 9, 20], ["IGHG genes", "OBSERVATION", 24, 34]]], ["In the present study, we found that there are usually two or four IGHG genes in marine mammals (Fig. 1) .", [["IGHG", "GENE_OR_GENE_PRODUCT", 66, 70], ["IGHG genes", "DNA", 66, 76], ["the present study", "TEST", 3, 20], ["marine mammals", "OBSERVATION", 80, 94]]], ["Like other mammals, the IGHG gene in marine mammals comprises three CH domains and a hinge segment.", [["IGHG", "GENE_OR_GENE_PRODUCT", 24, 28], ["IGHG gene", "DNA", 24, 33], ["CH domains", "PROTEIN", 68, 78], ["hinge segment", "PROTEIN", 85, 98], ["hinge segment", "ANATOMY_MODIFIER", 85, 98]]], ["Furthermore, they have close sequence similarities to the IGHG genes in their terrestrial relatives.", [["IGHG", "GENE_OR_GENE_PRODUCT", 58, 62], ["IGHG genes", "DNA", 58, 68]]], ["Based on the phylogenetic tree, it was found that IGHG genes within one species clustered together rather than with those of other species (Fig. 2) .", [["IGHG", "GENE_OR_GENE_PRODUCT", 50, 54], ["IGHG genes", "DNA", 50, 60], ["IGHG genes", "PROBLEM", 50, 60], ["other species (Fig", "PROBLEM", 125, 143]]], ["However, the IGHG genes of five species grouped together with their true orthologues in closely related species, including bottlenose dolphin, killer whale, Yangtze finless porpoise, Weddell seal and Pacific walrus, likely due to the species of Delphinidae (e.g., dolphin, killer whale) rapidly diverging during a very narrow time frame of \u223c3 million years (Zhou et al., 2011b) from the last common ancestral IGHG genes.", [["IGHG", "GENE_OR_GENE_PRODUCT", 13, 17], ["bottlenose dolphin", "ORGANISM", 123, 141], ["killer whale", "ORGANISM", 143, 155], ["killer whale", "ORGANISM", 273, 285], ["IGHG", "GENE_OR_GENE_PRODUCT", 409, 413], ["IGHG genes", "DNA", 13, 23], ["IGHG genes", "DNA", 409, 419], ["bottlenose dolphin", "SPECIES", 123, 141], ["bottlenose dolphin", "SPECIES", 123, 141], ["killer whale", "SPECIES", 143, 155], ["Yangtze finless porpoise", "SPECIES", 157, 181], ["killer whale", "SPECIES", 273, 285], ["the IGHG genes of five species", "PROBLEM", 9, 39], ["Weddell seal", "TREATMENT", 183, 195], ["IGHG genes", "OBSERVATION", 409, 419]]], ["These observations provided evidence to support the view that species-specific duplication of IGHG genes occurred during the evolution of mammalian species (Wagner et al., 2002) .", [["IGHG", "GENE_OR_GENE_PRODUCT", 94, 98], ["IGHG genes", "DNA", 94, 104], ["the view", "TEST", 48, 56], ["specific duplication of IGHG genes", "PROBLEM", 70, 104], ["IGHG genes", "OBSERVATION", 94, 104]]], ["Overall, the presence of IgG subclasses and species-specific duplication of IGHG genes in marine mammals further confirmed the finding that IGHC genes of marine mammals fit the canonical pattern of their terrestrial relatives.Genomic organization of IGHC genes in marine mammalsThe number of IGHC genes has been noted to vary among different mammals.", [["IgG", "GENE_OR_GENE_PRODUCT", 25, 28], ["IGHG", "GENE_OR_GENE_PRODUCT", 76, 80], ["IGHC", "GENE_OR_GENE_PRODUCT", 140, 144], ["marine mammals", "ORGANISM", 154, 168], ["IGHC", "GENE_OR_GENE_PRODUCT", 250, 254], ["IGHC", "GENE_OR_GENE_PRODUCT", 292, 296], ["IgG subclasses", "PROTEIN", 25, 39], ["IGHG genes", "DNA", 76, 86], ["IGHC genes", "DNA", 140, 150], ["IGHC genes", "DNA", 250, 260], ["IGHC genes", "DNA", 292, 302], ["IgG subclasses", "PROBLEM", 25, 39], ["specific duplication of IGHG genes", "PROBLEM", 52, 86], ["IGHC genes", "PROBLEM", 250, 260], ["IgG subclasses", "OBSERVATION", 25, 39], ["IGHC genes", "OBSERVATION", 250, 260], ["IGHC genes", "OBSERVATION", 292, 302]]], ["For example, 2 IGHA genes were present in humans and platypuses (Mage et al., 2006) , whereas 13 IGHA genes were found in rabbits (Mccallum et al., 2004) .", [["IGHA", "GENE_OR_GENE_PRODUCT", 15, 19], ["humans", "ORGANISM", 42, 48], ["IGHA", "GENE_OR_GENE_PRODUCT", 97, 101], ["rabbits", "ORGANISM", 122, 129], ["IGHA genes", "DNA", 15, 25], ["IGHA genes", "DNA", 97, 107], ["humans", "SPECIES", 42, 48], ["rabbits", "SPECIES", 122, 129], ["humans", "SPECIES", 42, 48], ["rabbits", "SPECIES", 122, 129], ["2 IGHA genes", "PROBLEM", 13, 25]]], ["For IGHG genes, seven copies were found in horses (Wagner et al., 2004) , five in humans (Takahashi et al., 1982) , and only one in rabbits (Mage et al., 2006) and opossum .", [["IGHG", "GENE_OR_GENE_PRODUCT", 4, 8], ["humans", "ORGANISM", 82, 88], ["rabbits", "ORGANISM", 132, 139], ["opossum", "ORGANISM", 164, 171], ["IGHG genes", "DNA", 4, 14], ["humans", "SPECIES", 82, 88], ["rabbits", "SPECIES", 132, 139], ["humans", "SPECIES", 82, 88], ["rabbits", "SPECIES", 132, 139]]], ["No IGHG gene was detected in the bowhead whale and little brown bat (Fig. 1) , which may due to the bad genomic assembly of both species considering that IgG subclasses have been identified in other whales (Mancia et al., 2006) and partial sequence encoding of IgG in little brown bat (Myotis lucifugus) was recovered by PCR (Butler et al., 2011) .", [["IGHG", "GENE_OR_GENE_PRODUCT", 3, 7], ["IgG", "GENE_OR_GENE_PRODUCT", 154, 157], ["IgG", "GENE_OR_GENE_PRODUCT", 261, 264], ["brown bat", "ORGANISM", 275, 284], ["Myotis lucifugus", "ORGANISM", 286, 302], ["IGHG gene", "DNA", 3, 12], ["IgG subclasses", "PROTEIN", 154, 168], ["IgG", "PROTEIN", 261, 264], ["Myotis lucifugus", "SPECIES", 286, 302], ["brown bat", "SPECIES", 58, 67], ["brown bat", "SPECIES", 275, 284], ["Myotis lucifugus", "SPECIES", 286, 302], ["IGHG gene", "PROBLEM", 3, 12], ["both species", "PROBLEM", 124, 136], ["IgG subclasses", "PROBLEM", 154, 168], ["IgG in little brown bat", "PROBLEM", 261, 284], ["brown bat", "ANATOMY", 58, 67]]], ["We also failed to retrieve IGHD genes from the genomes of sperm whale, hedgehog, European shrew, little brown bat, black flying fox and elephant despite considerable efforts (Fig. 1) .", [["sperm", "ANATOMY", 58, 63], ["IGHD", "GENE_OR_GENE_PRODUCT", 27, 31], ["sperm whale", "ORGANISM", 58, 69], ["hedgehog", "GENE_OR_GENE_PRODUCT", 71, 79], ["brown bat", "ORGANISM", 104, 113], ["black flying fox", "ORGANISM", 115, 131], ["IGHD genes", "DNA", 27, 37], ["European shrew", "SPECIES", 81, 95], ["brown bat", "SPECIES", 104, 113], ["black flying fox", "SPECIES", 115, 131], ["IGHD genes", "PROBLEM", 27, 37], ["little brown bat", "PROBLEM", 97, 113], ["brown bat", "ANATOMY", 104, 113]]], ["One possible explanation is the poor genome quality, and the an alternative explanation is that the IGHD gene might have really been lost in evolution, similar to the situation in opossums ) and rabbits (Mage et al., 2006) .", [["IGHD", "GENE_OR_GENE_PRODUCT", 100, 104], ["rabbits", "ORGANISM", 195, 202], ["IGHD gene", "DNA", 100, 109], ["rabbits", "SPECIES", 195, 202], ["rabbits", "SPECIES", 195, 202], ["the IGHD gene", "PROBLEM", 96, 109]]], ["Further investigations to recover IGHD transcript by PCR will be needed in the future.", [["IGHD", "GENE_OR_GENE_PRODUCT", 34, 38], ["IGHD transcript", "RNA", 34, 49], ["Further investigations", "TEST", 0, 22], ["IGHD transcript", "TREATMENT", 34, 49]]], ["Despite necessary further verification of IGHC genes in some species(e.g. with transcript evidence), changes in the copy number of IGHC genes among different mammalian lineages might reflect the rapid evolution of Ig genes (Hsu et al., 2006) , corresponding to the marked variability found in the pathogens in different environments.Adaptive evolution of IGHC genes in mammalsTo detect the possible roles of positive selection during the evolution of IGHC genes in mammalian lineages, evolutionary analyses were conducted using a series of selection models implemented in the CODEML program and DataMonkey website.", [["IGHC", "GENE_OR_GENE_PRODUCT", 42, 46], ["IGHC", "GENE_OR_GENE_PRODUCT", 131, 135], ["Ig", "GENE_OR_GENE_PRODUCT", 214, 216], ["IGHC", "GENE_OR_GENE_PRODUCT", 355, 359], ["mammals", "ORGANISM", 369, 376], ["IGHC", "GENE_OR_GENE_PRODUCT", 451, 455], ["IGHC genes", "DNA", 42, 52], ["IGHC genes", "DNA", 131, 141], ["mammalian lineages", "CELL_TYPE", 158, 176], ["Ig genes", "DNA", 214, 222], ["IGHC genes", "DNA", 355, 365], ["IGHC genes", "DNA", 451, 461], ["mammalian lineages", "CELL_TYPE", 465, 483], ["IGHC genes", "PROBLEM", 42, 52], ["some species", "PROBLEM", 56, 68], ["IGHC genes", "PROBLEM", 131, 141], ["the marked variability", "PROBLEM", 261, 283], ["IGHC genes in mammals", "PROBLEM", 355, 376], ["positive selection", "PROBLEM", 408, 426], ["IGHC genes in mammalian lineages", "PROBLEM", 451, 483], ["evolutionary analyses", "TEST", 485, 506], ["selection models", "TREATMENT", 540, 556], ["IGHC genes", "OBSERVATION", 42, 52], ["mammalian lineages", "OBSERVATION", 158, 176], ["rapid", "OBSERVATION_MODIFIER", 195, 200], ["marked", "OBSERVATION_MODIFIER", 265, 271], ["variability", "OBSERVATION", 272, 283], ["IGHC genes", "OBSERVATION", 355, 365], ["positive selection", "OBSERVATION", 408, 426]]], ["Because of the absence of intact IGHD genes in many mammals and the species-specific duplication of IGHG genes, only datasets of the IGHM, IGHE and IGHA genes were used to test the selection.", [["IGHD", "GENE_OR_GENE_PRODUCT", 33, 37], ["IGHG", "GENE_OR_GENE_PRODUCT", 100, 104], ["IGHM", "GENE_OR_GENE_PRODUCT", 133, 137], ["IGHE", "GENE_OR_GENE_PRODUCT", 139, 143], ["IGHA", "GENE_OR_GENE_PRODUCT", 148, 152], ["IGHD genes", "DNA", 33, 43], ["IGHG genes", "DNA", 100, 110], ["IGHM", "DNA", 133, 137], ["IGHE", "DNA", 139, 143], ["IGHA genes", "DNA", 148, 158], ["intact IGHD genes", "PROBLEM", 26, 43], ["the species", "PROBLEM", 64, 75], ["specific duplication of IGHG genes", "PROBLEM", 76, 110], ["IGHE and IGHA genes", "TREATMENT", 139, 158], ["intact", "OBSERVATION_MODIFIER", 26, 32], ["IGHD", "OBSERVATION", 33, 37]]], ["Site model analysis of all mammals revealed that the models incorporating positive selection (M8) fit the data significantly better than the neutral model (M8a) for both the IGHM and IGHA genes, whereas no evidence of positive selection was identified at the IGHE genes (Table 2) .", [["IGHM", "GENE_OR_GENE_PRODUCT", 174, 178], ["IGHA", "GENE_OR_GENE_PRODUCT", 183, 187], ["IGHM and IGHA genes", "DNA", 174, 193], ["IGHE genes", "DNA", 259, 269], ["Site model analysis", "TEST", 0, 19], ["the data", "TEST", 102, 110], ["positive selection", "PROBLEM", 218, 236], ["no evidence of", "UNCERTAINTY", 203, 217], ["positive", "OBSERVATION_MODIFIER", 218, 226], ["selection", "OBSERVATION", 227, 236]]], ["Specially, M8 model detected nine positively selective sites at the IGHM and IGHA genes, whereas a total of 39 codons from the IGHM, IGHE and IGHA genes were also found to be under positive selection using the FEL, REL, and SLAC methods implemented in Datamonkey.", [["IGHM", "GENE_OR_GENE_PRODUCT", 68, 72], ["IGHA", "GENE_OR_GENE_PRODUCT", 77, 81], ["IGHM", "GENE_OR_GENE_PRODUCT", 127, 131], ["IGHE", "GENE_OR_GENE_PRODUCT", 133, 137], ["IGHA", "GENE_OR_GENE_PRODUCT", 142, 146], ["IGHM and IGHA genes", "DNA", 68, 87], ["IGHM, IGHE and IGHA genes", "DNA", 127, 152], ["FEL, REL, and SLAC methods", "DNA", 210, 236], ["the IGHM", "TEST", 123, 131], ["SLAC methods", "TREATMENT", 224, 236]]], ["Eleven codons from three genes (5 in IGHM, 2 in IGHE, 4 in IGHA) were predicted to be robust sites under positive selection identified by at least two ML methods.", [["IGHA", "GENE_OR_GENE_PRODUCT", 59, 63], ["IGHM", "DNA", 37, 41], ["IGHE", "DNA", 48, 52], ["IGHA", "DNA", 59, 63], ["Eleven codons", "PROBLEM", 0, 13], ["codons", "OBSERVATION", 7, 13], ["three genes", "OBSERVATION_MODIFIER", 19, 30], ["positive selection", "OBSERVATION", 105, 123]]], ["Furthermore, TreeSAAP analysis showed that these 11 positively selected sites have undergone radical changes in their physicochemical properties (Table 3) , and this may be regarded as another evidence to support significant positive selection.", [["TreeSAAP", "PROTEIN", 13, 21], ["TreeSAAP analysis", "TEST", 13, 30], ["these 11 positively selected sites", "PROBLEM", 43, 77], ["radical changes", "TREATMENT", 93, 108], ["significant positive selection", "PROBLEM", 213, 243], ["radical", "OBSERVATION", 93, 100]]], ["Then, we marked the putatively selected sites in the alignment and found that 36.4% (4/11) of these sites were located in, or close to, the functionally important regions of IGHC genes (Supplemental Fig. 14) .", [["IGHC", "GENE_OR_GENE_PRODUCT", 174, 178], ["IGHC genes", "DNA", 174, 184], ["IGHC genes", "PROBLEM", 174, 184], ["marked", "OBSERVATION_MODIFIER", 9, 15], ["IGHC genes", "OBSERVATION", 174, 184]]], ["This result suggested that positive selection on mammals may be the major driving force for the evolution of IGHC genes to adapt to environmental pathogens.", [["IGHC", "GENE_OR_GENE_PRODUCT", 109, 113], ["IGHC genes", "DNA", 109, 119], ["positive selection on mammals", "PROBLEM", 27, 56], ["IGHC genes", "TREATMENT", 109, 119], ["environmental pathogens", "PROBLEM", 132, 155]]], ["Besides, for expanded subclasses, such as the 13 IGHA genes of rabbit and multiple copies of IGHG gene in mammals, we tested whether this species-specific expansion has been influenced by positive selection.", [["IGHA", "GENE_OR_GENE_PRODUCT", 49, 53], ["rabbit", "ORGANISM", 63, 69], ["IGHG", "GENE_OR_GENE_PRODUCT", 93, 97], ["13 IGHA genes", "DNA", 46, 59], ["rabbit and multiple copies", "DNA", 63, 89], ["IGHG gene", "DNA", 93, 102], ["rabbit", "SPECIES", 63, 69], ["rabbit", "SPECIES", 63, 69], ["this species", "PROBLEM", 133, 145], ["specific expansion", "PROBLEM", 146, 164]]], ["The site model analysis (M8 vs. M8a, M1a vs. M2a implemented in PAML) showed that the IGHA genes of rabbits were under positive selection with similar positively selected sites (Supplemental Table 3 ).", [["IGHA", "GENE_OR_GENE_PRODUCT", 86, 90], ["rabbits", "ORGANISM", 100, 107], ["M2a", "PROTEIN", 45, 48], ["IGHA genes", "DNA", 86, 96], ["rabbits", "SPECIES", 100, 107], ["rabbits", "SPECIES", 100, 107], ["The site model analysis", "TEST", 0, 23], ["M8a", "TEST", 32, 35], ["M1a", "TEST", 37, 40], ["the IGHA genes of rabbits", "PROBLEM", 82, 107], ["M1a", "ANATOMY", 37, 40]]], ["The branch-site model was used to examine whether some branches leading to gene duplication of IGHG genes (branch a-o) have been positively selected.", [["IGHG", "GENE_OR_GENE_PRODUCT", 95, 99], ["IGHG genes", "DNA", 95, 105], ["some branches", "PROBLEM", 50, 63], ["gene duplication of IGHG genes", "PROBLEM", 75, 105], ["branch", "ANATOMY_MODIFIER", 4, 10], ["gene duplication", "OBSERVATION", 75, 91], ["IGHG genes", "OBSERVATION", 95, 105], ["branch", "OBSERVATION_MODIFIER", 107, 113]]], ["The results showed that signals of positive selection were detected in branches a (Delphinoidea), c (Physeter catodon), e (Bos taurus), f (Sus scrofa), g (Equus caballus), and h (Macaca mulatta) (Supplemental Table 4 , Supplemental Fig. 15 ).", [["Physeter catodon", "ORGANISM", 101, 117], ["Bos taurus", "ORGANISM", 123, 133], ["f (Sus scrofa", "ORGANISM", 136, 149], ["Equus caballus", "ORGANISM", 155, 169], ["Macaca mulatta", "ORGANISM", 179, 193], ["Physeter catodon", "SPECIES", 101, 117], ["Bos taurus", "SPECIES", 123, 133], ["Sus scrofa", "SPECIES", 139, 149], ["Equus caballus", "SPECIES", 155, 169], ["Macaca mulatta", "SPECIES", 179, 193], ["Bos taurus", "SPECIES", 123, 133], ["Sus scrofa", "SPECIES", 139, 149], ["Equus caballus", "SPECIES", 155, 169], ["Macaca mulatta", "SPECIES", 179, 193], ["positive selection", "PROBLEM", 35, 53], ["c (Physeter catodon)", "TREATMENT", 98, 118], ["h (Macaca mulatta)", "TREATMENT", 176, 194], ["Supplemental Table", "TREATMENT", 196, 214], ["positive selection", "OBSERVATION", 35, 53], ["branches", "OBSERVATION_MODIFIER", 71, 79]]], ["Overall, pervasive positive selection was detected on IGHC genes of mammals.Adaptive evolution of IGHC genes in mammalsAs is well known, many physicochemical properties, such as temperature, pressure, illumination and osmotic pressure, are different between water and land environments, possibly causing the difference in the diversity and abundance of pathogens.", [["IGHC", "GENE_OR_GENE_PRODUCT", 54, 58], ["IGHC", "GENE_OR_GENE_PRODUCT", 98, 102], ["IGHC genes", "DNA", 54, 64], ["IGHC genes", "DNA", 98, 108], ["pervasive positive selection", "PROBLEM", 9, 37], ["IGHC genes in mammalsAs", "PROBLEM", 98, 121], ["osmotic pressure", "TREATMENT", 218, 234], ["pathogens", "PROBLEM", 353, 362], ["pervasive", "OBSERVATION_MODIFIER", 9, 18], ["positive selection", "OBSERVATION", 19, 37], ["IGHC genes", "OBSERVATION", 98, 108], ["osmotic pressure", "OBSERVATION", 218, 234], ["possibly causing", "UNCERTAINTY", 287, 303], ["pathogens", "OBSERVATION", 353, 362]]], ["To date, there has been no deterministic conclusion on whether the pathogenic microbes in marine environment or in terrestrial environment are more diverse.", [["no", "UNCERTAINTY", 24, 26], ["terrestrial environment", "OBSERVATION", 115, 138]]], ["Some early studies have supported weaker pathogenic pressure in the water environment (Zhang et al., 2016; Trowsdale et al., 1989; Slade, 1992) , while several recent studies have examined the microbiome of marine mammals, suggesting that although the taxonomic composition of microbial communities in marine mammals is distinct from those of terrestrial mammals, its diversity is not lower than that of terrestrial mammals (Bik et al., 2016; Nelson et al., 2015) .Adaptive evolution of IGHC genes in mammalsTo further test whether marine and terrestrial mammals were subjected to different pathogenic pressures during their evolution, we used the branch model in our study.", [["communities", "ANATOMY", 287, 298], ["IGHC", "GENE_OR_GENE_PRODUCT", 487, 491], ["mammals", "ORGANISM", 501, 508], ["IGHC genes", "DNA", 487, 497], ["Some early studies", "TEST", 0, 18], ["weaker pathogenic pressure in the water environment", "PROBLEM", 34, 85], ["IGHC genes in mammals", "PROBLEM", 487, 508], ["further test", "TEST", 511, 523], ["our study", "TEST", 664, 673], ["weaker", "OBSERVATION_MODIFIER", 34, 40], ["pathogenic", "OBSERVATION_MODIFIER", 41, 51], ["pressure", "OBSERVATION_MODIFIER", 52, 60], ["terrestrial mammals", "OBSERVATION", 343, 362], ["IGHC genes", "OBSERVATION", 487, 497], ["pressures", "OBSERVATION_MODIFIER", 602, 611], ["branch", "ANATOMY_MODIFIER", 648, 654]]], ["The LRTs showed that the free-ratio model fits better than one-ratio model for IGHM, IGHE and IGHA genes, indicating heterogeneous selective pressures on different lineages.", [["IGHM", "GENE_OR_GENE_PRODUCT", 79, 83], ["IGHA", "GENE_OR_GENE_PRODUCT", 94, 98], ["IGHM, IGHE and IGHA genes", "DNA", 79, 104], ["The LRTs", "TEST", 0, 8], ["IGHM", "PROBLEM", 79, 83], ["IGHE and IGHA genes", "PROBLEM", 85, 104], ["heterogeneous selective pressures on different lineages", "PROBLEM", 117, 172], ["heterogeneous", "OBSERVATION_MODIFIER", 117, 130], ["selective", "OBSERVATION_MODIFIER", 131, 140], ["pressures", "OBSERVATION_MODIFIER", 141, 150], ["different", "OBSERVATION_MODIFIER", 154, 163], ["lineages", "OBSERVATION_MODIFIER", 164, 172]]], ["The \u03c9 values greater than 1 are limited to some branches in marine and terrestrial mammals, including the terminal branch of minke whale, the last common ancestral (LCA) branch of baleen whales, the LCA branch of Glires, and the LCA branch of Euarchontoglires at IGHA gene; the terminal branch of bowhead whale, and the LCA branch of Eulipotyphla at IGHE genes; the LCA branch of Laurasiatheria at IGHM gene (Fig. 1) , suggesting similar selective pressures acting on IGHC genes in marine and terrestrial mammals.", [["Euarchontoglires", "GENE_OR_GENE_PRODUCT", 243, 259], ["IGHA", "GENE_OR_GENE_PRODUCT", 263, 267], ["Eulipotyphla", "GENE_OR_GENE_PRODUCT", 334, 346], ["IGHE", "GENE_OR_GENE_PRODUCT", 350, 354], ["IGHM", "GENE_OR_GENE_PRODUCT", 398, 402], ["IGHC", "GENE_OR_GENE_PRODUCT", 468, 472], ["IGHA gene", "DNA", 263, 272], ["IGHE genes", "DNA", 350, 360], ["LCA branch", "DNA", 366, 376], ["IGHM gene", "DNA", 398, 407], ["IGHC genes", "DNA", 468, 478], ["The \u03c9 values", "TEST", 0, 12], ["Eulipotyphla at IGHE genes", "PROBLEM", 334, 360], ["branches", "OBSERVATION_MODIFIER", 48, 56], ["terrestrial mammals", "OBSERVATION", 71, 90], ["terminal", "OBSERVATION_MODIFIER", 106, 114], ["branch", "OBSERVATION_MODIFIER", 115, 121], ["minke whale", "OBSERVATION", 125, 136], ["LCA", "OBSERVATION_MODIFIER", 165, 168], ["branch", "ANATOMY_MODIFIER", 170, 176], ["baleen whales", "OBSERVATION", 180, 193], ["LCA", "OBSERVATION_MODIFIER", 199, 202], ["branch", "OBSERVATION_MODIFIER", 203, 209], ["Glires", "OBSERVATION", 213, 219], ["LCA", "OBSERVATION_MODIFIER", 229, 232], ["branch", "OBSERVATION_MODIFIER", 233, 239], ["terminal", "ANATOMY_MODIFIER", 278, 286], ["branch", "ANATOMY_MODIFIER", 287, 293], ["LCA", "OBSERVATION_MODIFIER", 320, 323], ["branch", "OBSERVATION_MODIFIER", 324, 330], ["LCA", "OBSERVATION_MODIFIER", 366, 369], ["branch", "OBSERVATION_MODIFIER", 370, 376], ["selective", "OBSERVATION_MODIFIER", 438, 447], ["pressures", "OBSERVATION_MODIFIER", 448, 457], ["terrestrial mammals", "OBSERVATION", 493, 512]]], ["This result could provide evidence to support that the diversity and abundance of pathogens in water was comparable to that in land.Adaptive evolution of IGHC genes in mammalsWe also used more stringent branch-site model to predict positive selection acting on specific sites in each lineage.", [["IGHC", "GENE_OR_GENE_PRODUCT", 154, 158], ["mammals", "ORGANISM", 168, 175], ["IGHC genes", "DNA", 154, 164], ["pathogens", "PROBLEM", 82, 91], ["IGHC genes in mammals", "PROBLEM", 154, 175], ["more stringent branch", "TREATMENT", 188, 209], ["IGHC genes", "OBSERVATION", 154, 164], ["branch", "OBSERVATION_MODIFIER", 203, 209]]], ["Almost all signs of positive selection were identified in terrestrial lineages (e.g., artiodactyla, perissodactyla, chiroptera, eulipotyphla, primates, Glires, Fig. 1 .", [["positive selection", "PROBLEM", 20, 38], ["artiodactyla", "TEST", 86, 98], ["positive selection", "OBSERVATION", 20, 38], ["terrestrial lineages", "OBSERVATION", 58, 78]]], ["Positive selection at IGHC genes across the mammal phylogeny and the presence/absence patterns of mammal IGHC genes.", [["IGHC", "GENE_OR_GENE_PRODUCT", 22, 26], ["IGHC", "GENE_OR_GENE_PRODUCT", 105, 109], ["IGHC genes", "DNA", 22, 32], ["mammal IGHC genes", "DNA", 98, 115], ["Positive selection at IGHC genes", "PROBLEM", 0, 32], ["mammal IGHC genes", "PROBLEM", 98, 115], ["selection", "OBSERVATION", 9, 18], ["IGHC genes", "OBSERVATION", 22, 32], ["mammal phylogeny", "OBSERVATION", 44, 60], ["mammal IGHC genes", "OBSERVATION", 98, 115]]], ["A widely accepted phylogeny of mammals was used for selective pressure analysis in the free ratio model and the branch-site model.", [["selective pressure analysis", "TEST", 52, 79], ["widely", "OBSERVATION_MODIFIER", 2, 8], ["branch", "ANATOMY_MODIFIER", 112, 118], ["site model", "OBSERVATION", 119, 129]]], ["The branches indicated by vertical lines or circles show evidence of undergoing positive selection.", [["vertical lines", "CELL_LINE", 26, 40], ["positive selection", "PROBLEM", 80, 98], ["branches", "ANATOMY_MODIFIER", 4, 12], ["vertical lines", "OBSERVATION", 26, 40], ["evidence of", "UNCERTAINTY", 57, 68], ["positive selection", "OBSERVATION", 80, 98]]], ["The red font indicates marine mammals; black font indicates terrestrial mammals.", [["marine mammals", "OBSERVATION", 23, 37], ["terrestrial mammals", "OBSERVATION", 60, 79]]], ["The IGHC genes of corresponding species were listed in the right part of Fig. 1 .", [["right part", "ANATOMY", 59, 69], ["IGHC", "GENE_OR_GENE_PRODUCT", 4, 8], ["IGHC genes", "DNA", 4, 14], ["corresponding species", "PROBLEM", 18, 39], ["corresponding species", "OBSERVATION", 18, 39], ["right", "ANATOMY_MODIFIER", 59, 64], ["Fig", "OBSERVATION", 73, 76]]], ["Each circle represents a gene member; circles represent a complete gene sequence; semicircles indicate a partial gene sequence; red cross means no sequences found by TBLASTN and BLASTN approaches; black cross means the gene really lost; the species highlighted with a black line mean a pseudogene.", [["complete gene sequence", "DNA", 58, 80], ["partial gene sequence", "DNA", 105, 126], ["a complete gene sequence", "TEST", 56, 80], ["a partial gene sequence", "PROBLEM", 103, 126], ["red cross means", "TEST", 128, 143], ["the species", "PROBLEM", 237, 248], ["a black line", "TREATMENT", 266, 278]]], ["By contrast, for marine mammal lineages, only the terminal branch of Florida manatee was subjected to positive selection (Fig. 1, Supplemental Table 4 ).", [["marine mammal lineages", "PROBLEM", 17, 39], ["mammal lineages", "OBSERVATION", 24, 39], ["terminal", "OBSERVATION_MODIFIER", 50, 58], ["branch", "OBSERVATION_MODIFIER", 59, 65]]], ["This result supported that pathogenic pressure was weaker in aquatic environment than in terrestrial environment.", [["pathogenic pressure", "PROBLEM", 27, 46], ["pathogenic", "OBSERVATION_MODIFIER", 27, 37], ["pressure", "OBSERVATION_MODIFIER", 38, 46]]], ["Moreover, recent studies showed a very low number of variable genes that directly binds to antigens in marine mammals, which also supported this conclusion (Olivieri et al., 2014) .", [["antigens", "PROTEIN", 91, 99], ["recent studies", "TEST", 10, 24], ["very", "OBSERVATION_MODIFIER", 34, 38], ["low number", "OBSERVATION_MODIFIER", 39, 49], ["variable genes", "OBSERVATION", 53, 67]]], ["But further study on the variable region will be needed, providing insights to understand whether the difference in selective pressure between marine and terrestrial mammals existed and whether such a difference could respond to the different pathogenic pressure between aquatic and land environments.Adaptive evolution of IGHC genes in mammalsIn the present study, IGHC genes were determined to have undergone positive selection in Chiroptera, which is now known as notorious reservoir hosts for a number of pathogenic viruses, including Nipah, Hendra, Ebola, and severe acute respiratory syndrome (SARS) responsible for severe human and livestock disease outbreaks.", [["Nipah, Hendra, Ebola", "DISEASE", 539, 559], ["acute respiratory syndrome", "DISEASE", 572, 598], ["SARS", "DISEASE", 600, 604], ["human and livestock disease", "DISEASE", 629, 656], ["IGHC", "GENE_OR_GENE_PRODUCT", 323, 327], ["mammals", "ORGANISM", 337, 344], ["IGHC", "GENE_OR_GENE_PRODUCT", 366, 370], ["Chiroptera", "SIMPLE_CHEMICAL", 433, 443], ["Nipah", "ORGANISM", 539, 544], ["Hendra", "ORGANISM", 546, 552], ["Ebola", "ORGANISM", 554, 559], ["human", "ORGANISM", 629, 634], ["IGHC genes", "DNA", 323, 333], ["IGHC genes", "DNA", 366, 376], ["Nipah", "SPECIES", 539, 544], ["Ebola", "SPECIES", 554, 559], ["human", "SPECIES", 629, 634], ["human", "SPECIES", 629, 634], ["further study", "TEST", 4, 17], ["the difference in selective pressure between marine and terrestrial mammals", "PROBLEM", 98, 173], ["IGHC genes in mammals", "PROBLEM", 323, 344], ["the present study", "TEST", 347, 364], ["IGHC genes", "PROBLEM", 366, 376], ["positive selection in Chiroptera", "PROBLEM", 411, 443], ["pathogenic viruses", "PROBLEM", 509, 527], ["Nipah", "PROBLEM", 539, 544], ["Ebola", "PROBLEM", 554, 559], ["severe acute respiratory syndrome", "PROBLEM", 565, 598], ["SARS", "PROBLEM", 600, 604], ["severe human and livestock disease outbreaks", "PROBLEM", 622, 666], ["terrestrial mammals", "OBSERVATION", 154, 173], ["pressure", "OBSERVATION_MODIFIER", 254, 262], ["IGHC genes", "OBSERVATION", 323, 333], ["positive", "OBSERVATION_MODIFIER", 411, 419], ["selection", "OBSERVATION", 420, 429], ["pathogenic", "OBSERVATION_MODIFIER", 509, 519], ["viruses", "OBSERVATION", 520, 527], ["severe", "OBSERVATION_MODIFIER", 565, 571], ["acute", "OBSERVATION_MODIFIER", 572, 577], ["respiratory syndrome", "OBSERVATION", 578, 598], ["livestock disease", "OBSERVATION", 639, 656]]], ["However, they rarely display clinical symptoms (Zhang et al., 2013; Wang, 2009 ).", [["clinical symptoms", "PROBLEM", 29, 46]]], ["The ability of bats to coexist with viruses presents an interesting immunological problem.", [["bats", "ORGANISM", 15, 19], ["viruses", "PROBLEM", 36, 43], ["an interesting immunological problem", "PROBLEM", 53, 89], ["viruses", "OBSERVATION", 36, 43]]], ["Previous studies have founded that some immunoglobulin gene superfamilies underwent expansion in Brandt's bat (Seim et al., 2013) and that some positively selected genes were involved in the immune response (Zhang et al., 2013) .", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 40, 54], ["immunoglobulin gene superfamilies", "DNA", 40, 73], ["Previous studies", "TEST", 0, 16], ["some immunoglobulin gene superfamilies", "PROBLEM", 35, 73], ["expansion", "OBSERVATION_MODIFIER", 84, 93]]], ["Thus, IGHC genes subject to positive selection in chiropterans may be related to the longterm coexistence of bats and viruses.", [["IGHC", "GENE_OR_GENE_PRODUCT", 6, 10], ["chiropterans", "GENE_OR_GENE_PRODUCT", 50, 62], ["IGHC genes", "DNA", 6, 16], ["IGHC genes subject", "PROBLEM", 6, 24]]], ["Evidences for positive selection has also been detected in some domesticated mammals such as pig, horse and cattle.", [["pig", "ORGANISM", 93, 96], ["horse", "ORGANISM", 98, 103], ["cattle", "ORGANISM", 108, 114], ["pig", "SPECIES", 93, 96], ["horse", "SPECIES", 98, 103], ["cattle", "SPECIES", 108, 114], ["pig", "SPECIES", 93, 96], ["horse", "SPECIES", 98, 103], ["cattle", "SPECIES", 108, 114], ["positive selection", "PROBLEM", 14, 32], ["positive selection", "OBSERVATION", 14, 32]]], ["Approximately 200 years ago, selection pressures on livestock increased with the rise of the concept of breeds (Taberlet et al., 2008) .", [["selection pressures", "TEST", 29, 48], ["pressures", "OBSERVATION_MODIFIER", 39, 48], ["increased", "OBSERVATION_MODIFIER", 62, 71]]], ["It has been previously proposed that artificial selection indirectly drove for rapid adaptation of domestic animals and pathogen genes (Smith et al., 2012) .", [["pathogen genes", "DNA", 120, 134], ["artificial selection", "TREATMENT", 37, 57]]], ["Therefore, we postulated that artificial selection resulted in the adaptive evolution observed in IGHC genes of domestic animals.ConclusionsThis study has provided the first characterization of IGHC genes in marine mammals and explored their potential molecular genetic basis in the secondary aquatic adaptation.", [["IGHC", "GENE_OR_GENE_PRODUCT", 98, 102], ["IGHC", "GENE_OR_GENE_PRODUCT", 194, 198], ["IGHC genes", "DNA", 98, 108], ["IGHC genes", "DNA", 194, 204], ["artificial selection", "TREATMENT", 30, 50], ["This study", "TEST", 140, 150], ["secondary aquatic adaptation", "OBSERVATION", 283, 311]]], ["Our analyses revealed that the IGHC genes in marine mammals fit the canonical pattern of their terrestrial relatives.", [["IGHC", "GENE_OR_GENE_PRODUCT", 31, 35], ["IGHC genes", "DNA", 31, 41], ["Our analyses", "TEST", 0, 12], ["the IGHC genes", "PROBLEM", 27, 41]]], ["In addition, different levels of selection were detected between marine and terrestrial mammalian lineages with the branchsite model, suggesting a divergent adaptation to land and aquatic environments probably due to contrasting pathogenic pressures.", [["the branchsite model", "TREATMENT", 112, 132], ["contrasting pathogenic pressures", "PROBLEM", 217, 249], ["terrestrial mammalian lineages", "OBSERVATION", 76, 106], ["pressures", "OBSERVATION_MODIFIER", 240, 249]]], ["Further investigation on the variable region of IgH genes is necessary to improve our understanding of the immune adaptation of marine mammals.Declarations of interestsNone.", [["IgH", "GENE_OR_GENE_PRODUCT", 48, 51], ["IgH genes", "DNA", 48, 57], ["Further investigation", "TEST", 0, 21], ["IgH genes", "PROBLEM", 48, 57]]], ["0.990 0.0526114 P \u03b1 , P \u03b2 , P c , K\u00b0, pK', pH i , P r , \u03b1 c , \u03b1 n , R a , P 11 345 0.0287169 0.0361345 57.5523 P \u03b1 , N s , P r , p, \u03b1 c , R a , H t , P 8 a Radical changes in amino acid properties under categories 6-8 were detected in TreeSAAP.", [["amino acid", "CHEMICAL", 175, 185], ["amino acid", "CHEMICAL", 175, 185], ["amino acid", "AMINO_ACID", 175, 185], ["P \u03b2", "DNA", 22, 25], ["P r , p, \u03b1 c", "DNA", 123, 135], ["H t", "DNA", 144, 147], ["P 8", "DNA", 150, 153], ["P", "TEST", 16, 17], ["\u03b1", "TEST", 18, 19], ["P", "TEST", 22, 23], ["\u03b2", "TEST", 24, 25], ["c", "TEST", 30, 31], ["K\u00b0", "TEST", 34, 36], ["pK", "TEST", 38, 40], ["pH", "TEST", 43, 45], ["i", "TEST", 46, 47], ["c", "TEST", 58, 59], ["P", "TEST", 74, 75], ["P", "TEST", 111, 112], ["\u03b1", "TEST", 113, 114], ["s", "TEST", 119, 120], ["r", "TEST", 125, 126], ["p", "TEST", 129, 130], ["c", "TEST", 134, 135], ["a", "TEST", 140, 141], ["H t", "TEST", 144, 147], ["P", "TEST", 150, 151], ["a Radical changes", "TEST", 154, 171], ["amino acid properties", "TEST", 175, 196], ["categories", "TEST", 203, 213]]], ["P \u03b1 = \u03b1-helical tendencies, N s = Average number of surrounding residues, P \u03b2 = \u03b2-Structure tendencies, B l = Bulkiness, B r = Buriedness, R F = Chromatographic index, P c = Coil tendencies, K\u00b0= Compressibility, pK' = Equilibrium constant of ionization for COOH, C a = Helical contact energy, h = Hydropathy, pHi = Isoelectric point, E l = Long-range non-bonded energy, F = Mean r.m.s. fluctuation displacement, H nc = Normal consensus hydrophobicity, V\u00b0= Partial specific volume, P r = Polar requirement, p = Polarity, \u03b1 c = Power to be C-terminal, \u03b1-helix, \u03b1 m = Power to be middle, \u03b1-helix, \u03b1 n = Power to be N-terminal of an \u03b1-helix, E sm = Short-and medium-range non-bonded energy, R a = Solvent accessible reduction ratio, H p = Surrounding hydrophobicity, H t = Thermodynamic transfer hydrophobicity, E t = Total non-bonded energy, P = Turn tendencies.", [["COOH", "CHEMICAL", 257, 261], ["C", "CHEMICAL", 538, 539], ["N", "CHEMICAL", 612, 613], ["COOH", "PROTEIN", 257, 261], ["C-terminal", "PROTEIN", 538, 548], ["\u03b1-helix", "PROTEIN", 550, 557], ["Power", "PROTEIN", 565, 570], ["\u03b1-helix", "PROTEIN", 585, 592], ["surrounding residues", "PROBLEM", 52, 72], ["B l = Bulkiness", "PROBLEM", 104, 119], ["B r = Buriedness", "PROBLEM", 121, 137], ["Chromatographic index", "TEST", 145, 166], ["Coil tendencies", "TEST", 174, 189], ["K\u00b0", "TEST", 191, 193], ["pK'", "TEST", 212, 215], ["ionization", "TEST", 242, 252], ["COOH", "PROBLEM", 257, 261], ["pHi", "TEST", 309, 312], ["Isoelectric point", "TEST", 315, 332], ["Mean r.m.s. fluctuation displacement", "PROBLEM", 374, 410], ["an \u03b1-helix", "TEST", 626, 636], ["R a = Solvent accessible reduction ratio", "TREATMENT", 687, 727], ["hydrophobicity", "OBSERVATION_MODIFIER", 436, 450], ["middle", "ANATOMY_MODIFIER", 577, 583]]]], "PMC7330279": [["Social Norms and Duty\u2014Bringing Together Two LiteraturesExploring social norms and civic duty together in the context of the coronavirus pandemic is relevant because governments have launched massive campaigns\u2014through discourse and policies\u2014to encourage adherence to public health recommendations.", [["coronavirus pandemic", "DISEASE", 124, 144], ["coronavirus", "ORGANISM", 124, 135], ["the coronavirus pandemic", "PROBLEM", 120, 144]]], ["Experimental and correlational studies have led to agreement\u2014social norms lead to compliance (see Chung and Rimal, 2016, for a full review).", [["correlational studies", "TEST", 17, 38]]], ["The more people realize that a social norm exists, the more they are inclined to follow it (Biccheri, 2005).Social Norms and Duty\u2014Bringing Together Two LiteraturesSimilarly, research on civic duty is compelling with respect to its impact on behaviour.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15]]], ["For example, Blais, Galais and Mayer (2019) find that a duty to be politically informed is less prominent, and that for many who feel a duty to vote, their civic duty does not extend to being informed.", [["less prominent", "OBSERVATION_MODIFIER", 91, 105]]], ["In the current pandemic situation, little is known about whether civic duty includes conforming to behaviours such as physical isolation.Social Norms and Duty\u2014Bringing Together Two LiteraturesWe focus on the roles of social norms and civic duty in compelling compliance with COVID-19 public health recommendations.", [["physical isolation", "TREATMENT", 118, 136]]], ["We suspect each will encourage participation in following health guidelines, but that the effect of social norms will be strongest among those who do not see following the guidelines as a civic duty.Social Norms and Duty\u2014Bringing Together Two LiteraturesTo evaluate these expectations, we make use of questions asked in the 2020 Democracy Checkup (Harell et al., 2020), gathered May 5\u201312, 2020.1 Norms were measured based on people's estimates of the percentage of Canadians who they \u201cthink are abiding by the public health recommendations aimed at slowing the spread of COVID-19\u201d (0% to 100%).", [["people", "ORGANISM", 425, 431], ["people", "SPECIES", 425, 431], ["COVID", "TEST", 571, 576]]], ["Civic duty was measured with a modified version of a question commonly asked about voting (Blais and Achen, 2019), where duty is coded 1 and choice 0:\u2013People have different views about the public health recommendations aimed at slowing the spread of COVID-19.", [["COVID-19", "CHEMICAL", 250, 258], ["People", "ORGANISM", 151, 157], ["People", "SPECIES", 151, 157], ["COVID", "TEST", 250, 255]]], ["For some, adhering to the recommendations is a duty, they feel they should follow them to help protect the health of Canadians.", [["Canadians", "ORGANISM", 117, 126]]], ["For you personally, is adhering to the public health recommendations first and foremost a duty or a choice?2Non-compliance was measured for four of the activities identified by the Government of Canada (2020) to stop the spread of COVID-19.", [["COVID-19", "CHEMICAL", 231, 239], ["COVID", "TEST", 231, 236]]], ["Participants were asked about their behaviour in the previous week, including:\u2013Made non-essential trips in your community\u2013Gathered in groups with people outside your household\u2013Visited someone at higher risk, such as older adults and those in poor health\u2013Been closer than two arms lengths (about two metres) to someone outside your householdResponse categories were no (0), only when necessary (1), and yes (2).", [["people", "ORGANISM", 146, 152], ["Participants", "SPECIES", 0, 12], ["people", "SPECIES", 146, 152]]], ["We combined the responses to the four questions into a single index for analysis (\u03b1 = .63).ResultsA large majority of participants (84%) believe that adhering to recommendations is a duty.", [["participants", "ORGANISM", 118, 130], ["participants", "SPECIES", 118, 130], ["analysis", "TEST", 72, 80], ["large", "OBSERVATION_MODIFIER", 100, 105], ["majority", "OBSERVATION_MODIFIER", 106, 114]]], ["A t-test analysis reveals that the participants who believe it is a duty to follow the guidelines are more likely to report that they did not engage in the four social activities measured (M = 0.39; SD = 0.42) compared to those who believe it is a choice (M = .56, SD = .51) (t(2002) = 6.43, p \u2264 0.001).ResultsTurning to social norms, 77 per cent of the participants believe a majority of Canadians adhere to public health recommendations.", [["Canadians", "ORGANISM", 389, 398], ["participants", "SPECIES", 35, 47], ["participants", "SPECIES", 354, 366], ["A t-test analysis", "TEST", 0, 17], ["SD", "TEST", 265, 267]]], ["Because most people observe at least some compliance, we have recoded this variable into quartiles4 (0\u201360% = 1, 61\u201370% = 2, 71\u201380% = 3, and more than 80% = 4) for subsequent analysis.ResultsTo test whether compliance with public health recommendations varies depending on one's perceptions of civic duty and social norms, we used a moderation analysis conducted with 5,000 bootstraps in PROCESS (Hayes, 2017).", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["subsequent analysis", "TEST", 163, 182], ["a moderation analysis", "TEST", 330, 351]]], ["However, those who see following the rules as a choice (about 16% of our sample) are less likely to report behaviour counter to current health recommendations if they perceive that 71 per cent or more of Canadians are following health guidelines.", [["Canadians", "ORGANISM", 204, 213]]]]}